
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/custom-bootstrap.css">
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/all.min.css">
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/app.css">
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/jquery-3.3.1.slim.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/popper.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/bootstrap.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/moment.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/vanilla-picker.min.js"></script>
<style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/he.js"></script>
<script type="text/javascript" defer="true" src="https://api.manicmarket.com/static/annual-report/js/production.min.js?d=22-10-2021"></script>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style>

 <div class="reboot main-container">
  <div class="reboot d-none" id="back-to-top">
  </div>
  <div class="position-relative" id="dynamic-xbrl-form" style="font: 10pt Times New Roman, Times, Serif">
   <!--?xml version="1.0" encoding="utf-8"?-->
   <title>
   </title>
   <meta content="text/html" http-equiv="Content-Type"/>
   <!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
   <!-- Field: Set; Name: xdx; ID: xdx_030_LCTX_lineagecell.com_20201231 -->
   <!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20201231 -->
   <!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000876343 -->
   <!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
   <!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityFilerCategory_Non%2Daccelerated Filer -->
   <!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DIcfrAuditorAttestationFlag_false -->
   <!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
   <!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
   <!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
   <!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_Y%2D%2D\XBRL OPERATIONS 2020\Lineage Cell Therapeutics, Inc (BioTime, Inc)\20201231 10K FY DFN iXBRL\iXBRL Production\Client\iXBRL\Final Version\form10%2Dk.xdx -->
   <!-- Field: Set; Name: xdx; ID: xdx_070_SO_Y%2D%2D\XBRL OPERATIONS 2020\Lineage Cell Therapeutics, Inc (BioTime, Inc)\20201231 10K FY DFN iXBRL\iXBRL Production\Client\iXBRL\Final Version\form10%2Dk.xdxs -->
   <!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
   <!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
   <!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
   <!-- Field: Set; Name: xdx; ID: xdx_060_Percentage_4_xbrli%2D%2Dpure -->
   <!-- Field: Set; Name: xdx; ID: xdx_06F_Area_0_utr%2D%2Dacre -->
   <!-- Field: Set; Name: xdx; ID: xdx_063_SquareFeet_0_utr%2D%2Dsqft -->
   <!-- Field: Set; Name: xdx; ID: xdx_060_AreaSquareMeter_0_utr%2D%2Dsqm -->
   <!-- Field: Set; Name: xdx; ID: xdx_063_NIS_0_iso4217%2D%2DILS -->
   <!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
   <!-- Field: Set; Name: xdx; ID: xdx_06C_Subsidiary_0_Subsidiary -->
   <div style="display: none">
    <ix:header>
     <ix:hidden>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-0" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityCentralIndexKey" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        0000876343
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:AmendmentFlag" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        false
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-2" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityFilerCategory" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        Non-accelerated Filer
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-3" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:IcfrAuditorAttestationFlag" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        false
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-4" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentFiscalYearFocus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        2020
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-5" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentFiscalPeriodFocus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        FY
       </ix:nonnumeric>
      </span>
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-6" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:CurrentFiscalYearEndDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        --12-31
       </ix:nonnumeric>
      </span>
      <ix:nonfraction id="xdx2ixbrl0064" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0070" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0113" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0124" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0139" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0140" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0145" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0146" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0210" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0246" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0252" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0255" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0312" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0319" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0323" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0325" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0326" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0327" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0330" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0334" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0336" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0337" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0338" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0341" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0345" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0347" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0348" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0349" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0352" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0356" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0358" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0359" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0360" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0363" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0374" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0375" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0377" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0379" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0380" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0381" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0384" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0386" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0388" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0390" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0391" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0392" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0395" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0399" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0401" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0402" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0403" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0406" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0410" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0411" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0413" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0414" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0438" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0439" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0440" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0441" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0445" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0446" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0449" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0452" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0459" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0463" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0470" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0474" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0476" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0477" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0478" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0481" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0485" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0487" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0488" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0489" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0492" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0496" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0498" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0499" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0500" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0503" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0507" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0509" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0510" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0511" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0514" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0516" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0518" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0520" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0521" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0522" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0525" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0529" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0532" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0534" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0535" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0536" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0539" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0540" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0541" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0542" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0546" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0547" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0550" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0553" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0559" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0574" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0577" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0602" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0608" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0611" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0620" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0622" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0644" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0661" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0680" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0685" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0692" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0698" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0700" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0703" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0731" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0733" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0736" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0739" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0742" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0745" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction decimals="INF" id="xdx2ixbrl0750" unitref="Subsidiary">
       3
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0861" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl0939" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonnumeric id="xdx2ixbrl1073">
       P5Y
      </ix:nonnumeric>
      <ix:nonfraction id="xdx2ixbrl1307" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1343" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1345" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1351" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1353" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1357" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1359" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1365" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1367" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1375" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1377" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1383" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1385" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1389" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1391" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1397" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1399" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonnumeric id="xdx2ixbrl1484">
       2022-07-31
      </ix:nonnumeric>
      <ix:nonnumeric id="xdx2ixbrl1497">
       2024-01-31
      </ix:nonnumeric>
      <ix:nonfraction id="xdx2ixbrl1529" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1533" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1535" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1537" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1543" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1551" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1555" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1557" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1561" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1582" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1589" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1592" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1594" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1597" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1638" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1640" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1642" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1648" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1656" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1664" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1670" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1673" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1674" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1675" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1677" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1678" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1679" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1680" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1682" unitref="USDPShares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1686" unitref="Shares" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1712" unitref="Percentage" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1713" unitref="Percentage" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1964" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl1966" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl2042" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl2046" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl2050" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl2147" unitref="USD" xs:nil="true">
      </ix:nonfraction>
      <ix:nonfraction id="xdx2ixbrl2171" unitref="Percentage" xs:nil="true">
      </ix:nonfraction>
     </ix:hidden>
     <ix:references>
      <link:schemaref xlink:href="lctx-20201231.xsd" xlink:type="simple">
      </link:schemaref>
     </ix:references>
     <ix:resources>
      <xbrli:context id="From2020-01-01to2020-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-06-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-06-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2021-03-05">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2021-03-05
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_us-gaap_PreferredStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:PreferredStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:RetainedEarningsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:NoncontrollingInterestMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:AccumulatedOtherComprehensiveIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_PreferredStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:PreferredStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:RetainedEarningsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:NoncontrollingInterestMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:AccumulatedOtherComprehensiveIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:PreferredStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:RetainedEarningsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:NoncontrollingInterestMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:AccumulatedOtherComprehensiveIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:PreferredStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:RetainedEarningsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:NoncontrollingInterestMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:AccumulatedOtherComprehensiveIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:PreferredStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:RetainedEarningsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:NoncontrollingInterestMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:AccumulatedOtherComprehensiveIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationAndAgeXTherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-08-012020-08-31_custom_JuvenescenceLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-08-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-08-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2021-03-05_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2021-03-05
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-07_custom_MergerAgreementMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:MergerAgreementMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-07
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:MergerConsiderationMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AsteriasMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:MergerConsiderationMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember_us-gaap_RestrictedStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:MergerConsiderationMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AsteriasMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          us-gaap:RestrictedStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:MergerConsiderationMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_srt_ParentCompanyMember_us-gaap_CommonStockMember_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_CellCureNeurosciencesLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:CellCureNeurosciencesLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureNeurosciencesLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:CellCureNeurosciencesLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_EsCellInternationalPteLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:EsCellInternationalPteLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_EsCellInternationalPteLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:EsCellInternationalPteLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_OrthocyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:OrthocyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_OrthocyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:OrthocyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-04-282020-05-01_custom_ControlledEquityOfferingMember_custom_SalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ControlledEquityOfferingMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:CantorFitzgeraldAndCoMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-04-28
        </xbrli:startdate>
        <xbrli:enddate>
         2020-05-01
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_srt_ParentCompanyMember_custom_SalesAgreementMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_srt_ParentCompanyMember_custom_SalesAgreementMember_custom_TwentyTwentySalesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:TwentyTwentySalesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember_custom_TwentyTwentySalesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:TwentyTwentySalesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-03-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-03-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-09-092019-09-11">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-09-09
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-09-10_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-09-10
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-09-11_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-09-11
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-09-092019-09-11_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-09-09
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-09-11_custom_OncoCyteCorporationMember_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-09-11
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:StockOptionsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_StockOptionsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:StockOptionsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_LineageWarrantMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:LineageWarrantMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_LineageWarrantMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:LineageWarrantMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_RestrictedStockUnitsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:RestrictedStockUnitsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_RestrictedStockUnitsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
          LCTX:RestrictedStockUnitsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_CreditCardMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          us-gaap:CreditCardMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AlamedaLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AlamedaLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">
          us-gaap:AccountingStandardsUpdate201602Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-01-02
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-01-02_custom_ASU840Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">
          LCTX:ASU840Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-01-02
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MinimumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_GrantMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          us-gaap:GrantMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_GrantMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          us-gaap:GrantMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          LCTX:RoyaltiesFromProductSalesAndLicenseFeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          LCTX:RoyaltiesFromProductSalesAndLicenseFeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_SaleOfResearchProductsAndServicesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          LCTX:SaleOfResearchProductsAndServicesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_SaleOfResearchProductsAndServicesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          LCTX:SaleOfResearchProductsAndServicesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_country_US">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          country:US
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_country_US">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          country:US
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_ForeignMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:ForeignMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_ForeignMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:ForeignMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
          us-gaap:MajorityShareholderMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
          us-gaap:MajorityShareholderMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_RestrictedStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          us-gaap:RestrictedStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_us-gaap_InProcessResearchAndDevelopmentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
          us-gaap:InProcessResearchAndDevelopmentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_RoyaltyContractsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
          LCTX:RoyaltyContractsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_RoyaltyContractsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
          LCTX:RoyaltyContractsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139169281">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_us-gaap_InProcessResearchAndDevelopmentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
          us-gaap:InProcessResearchAndDevelopmentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_CaliforniaInstituteForRegenerativeMedicineMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
          LCTX:CaliforniaInstituteForRegenerativeMedicineMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08_custom_AStClinincalProgramMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:AStClinincalProgramMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_RoyaltyContractsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:RoyaltyContractsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-09-012018-09-30_custom_AsteriasMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AsteriasMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-09-01
        </xbrli:startdate>
        <xbrli:enddate>
         2018-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2016-05-13_us-gaap_CommonStockMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          us-gaap:CommonStockMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2016-05-13
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2016-05-13_custom_AsteriasWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:AsteriasWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2016-05-13
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-04-012019-04-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-04-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-04-012019-04-30_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-04-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-04-30_srt_ParentCompanyMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">
          srt:ParentCompanyMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-04-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-302019-03-31_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-30
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          us-gaap:GeneralAndAdministrativeExpenseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          us-gaap:GeneralAndAdministrativeExpenseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-062019-03-08">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-06
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-08
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_AsteriasBiotherapeuticsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:AsteriasBiotherapeuticsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-07-012019-07-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-07-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-07-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-07-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-07-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-09-082019-09-10_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-09-08
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-10
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-09-082019-09-11_custom_OncoCyteCorporationMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-09-08
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-08-28
        </xbrli:startdate>
        <xbrli:enddate>
         2018-08-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-08-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_ClosingOfTransactionMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:StatementScenarioAxis">
          LCTX:ClosingOfTransactionMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-08-28
        </xbrli:startdate>
        <xbrli:enddate>
         2018-08-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">
          LCTX:PromissoryNoteMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-08-28
        </xbrli:startdate>
        <xbrli:enddate>
         2018-08-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-10-312018-11-02_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-10-31
        </xbrli:startdate>
        <xbrli:enddate>
         2018-11-02
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_PromissoryNoteMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">
          LCTX:PromissoryNoteMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-08-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_PromissoryNoteMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">
          LCTX:PromissoryNoteMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-08-28
        </xbrli:startdate>
        <xbrli:enddate>
         2018-08-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">
          LCTX:PromissoryNoteMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:StockPurchaseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:JuvenescenceLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">
          LCTX:PromissoryNoteMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_EquipmentFurnitureAndFixturesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          LCTX:EquipmentFurnitureAndFixturesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_EquipmentFurnitureAndFixturesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          LCTX:EquipmentFurnitureAndFixturesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          us-gaap:LeaseholdImprovementsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          us-gaap:LeaseholdImprovementsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_RightOfUseAssetsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          LCTX:RightOfUseAssetsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_RightOfUseAssetsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          LCTX:RightOfUseAssetsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-09-30_custom_LineageTerminatedLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:LineageTerminatedLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-09-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-12-012020-12-31_custom_OriginalCellCureLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OriginalCellCureLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-12-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_LineageTerminatedLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:LineageTerminatedLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_InProcessResearchAndDevelopmentOPCOneMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:InProcessResearchAndDevelopmentOPCOneMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_InProcessResearchAndDevelopmentOPCOneMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:InProcessResearchAndDevelopmentOPCOneMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_InProcessResearchAndDevelopmentVACTwoMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:InProcessResearchAndDevelopmentVACTwoMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_InProcessResearchAndDevelopmentVACTwoMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:InProcessResearchAndDevelopmentVACTwoMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_PatentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:PatentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_PatentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:PatentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_RoyaltyContractsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:RoyaltyContractsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_RoyaltyContractsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="LCTX:GoodwillAndIntangibleAssetsByMajorClassAxis">
          LCTX:RoyaltyContractsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          us-gaap:ResearchAndDevelopmentExpenseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          us-gaap:ResearchAndDevelopmentExpenseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CancerResearchMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:CancerResearchMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-04-012020-04-30_custom_AxosBankMember_custom_PaycheckProtectionProgramMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AxosBankMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:PaycheckProtectionProgramMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-04-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-04-30_custom_AxosBankMember_custom_PaycheckProtectionProgramMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AxosBankMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:PaycheckProtectionProgramMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-04-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2021-02-17_us-gaap_SubsequentEventMember_custom_AxosBankMember_custom_PaycheckProtectionProgramMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:AxosBankMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:PaycheckProtectionProgramMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2021-02-17
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_ThreeEmployeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ThreeEmployeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          us-gaap:GeneralAndAdministrativeExpenseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember139172843">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_LineageWarrantsMember139173453">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_CashAndCashEquivalentMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CashAndCashEquivalentMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableSecuritiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:MarketableSecuritiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_LineageWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:LineageWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel1Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel2Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
          us-gaap:FairValueInputsLevel3Member
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-10-012019-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:OncoCyteCorporationAndAgeXTherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-10-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_OfficeSpaceInNewYorkCityMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">
          LCTX:OfficeSpaceInNewYorkCityMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_OfficeSpaceInNewYorkCityMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">
          LCTX:OfficeSpaceInNewYorkCityMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-04-012019-04-30_custom_BroadwoodPartnersLPMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:BroadwoodPartnersLPMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-04-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_BroadwoodPartnersLPMember_custom_NealBradsherMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:BroadwoodPartnersLPMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:NealBradsherMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-07-012019-07-31_custom_BroadwoodPartnersLPMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:BroadwoodPartnersLPMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-07-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-07-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-09-012019-09-30_custom_BroadwoodPartnersLPMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:BroadwoodPartnersLPMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-09-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-01-31_custom_BroadwoodPartnersLPMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:BroadwoodPartnersLPMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-01-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_EmployeeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:EmployeeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_EmployeeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:EmployeeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-05-01_custom_CantorFitzgeraldAndCoMember_custom_TwoThousandSeventeenSalesAgreementMember_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:CantorFitzgeraldAndCoMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:TwoThousandSeventeenSalesAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-05-01
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_SettledInTwentyTwentyOneMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SettledInTwentyTwentyOneMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:ATMSharesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember_custom_SettledInTwentyTwentyOneMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:ATMSharesMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SettledInTwentyTwentyOneMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-03-012021-03-05">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-03-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_CantorFitzgeraldAndCoMember_custom_TwoThousandSeventeenSalesAgreementMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:CantorFitzgeraldAndCoMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:TwoThousandSeventeenSalesAgreementMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139174593">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-09-30_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2017-07-31_custom_HadasitBioHoldingsLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:HadasitBioHoldingsLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2017-07-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2017-07-012017-07-31_custom_HadasitBioHoldingsLtdMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:HadasitBioHoldingsLtdMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2017-07-01
        </xbrli:startdate>
        <xbrli:enddate>
         2017-07-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-09-30_custom_CellCureWarrantsMember_custom_ConsultantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ConsultantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-09-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_srt_MinimumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ConsultantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MinimumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ConsultantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-10-192020-10-20">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-10-19
        </xbrli:startdate>
        <xbrli:enddate>
         2020-10-20
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_custom_RemainingWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:ConsultantsMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:RemainingWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_HadasitBioHoldingsLtdMember_custom_RemainingWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:HadasitBioHoldingsLtdMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:RemainingWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_HadasitBioHoldingsLtdMember_custom_RemainingWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:OwnershipAxis">
          LCTX:HadasitBioHoldingsLtdMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
          LCTX:RemainingWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_CellCureWarrantsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureWarrantsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_OtherLongTermLiabilitiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          LCTX:OtherLongTermLiabilitiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_OtherLongTermLiabilitiesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">
          LCTX:OtherLongTermLiabilitiesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_srt_MaximumMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:RangeAxis">
          srt:MaximumMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_custom_StockOptionPlanOf2012Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:StockOptionPlanOf2012Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:StockOptionPlanOf2012Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlanOf2012Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:StockOptionPlanOf2012Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:StockOptionPlanOf2012Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlanOf2012Member">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:StockOptionPlanOf2012Member
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelvePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_TwoThousandAndTwelvePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelvePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:EmployeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          us-gaap:RestrictedStockUnitsRSUMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">
          LCTX:EmployeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          us-gaap:RestrictedStockUnitsRSUMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-03-08_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-03-08
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-03-09
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:AsteriasTwoThousandThirteenEquityIncentivePlanMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">
          LCTX:AsteriasBiotherapeuticsIncMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_TwoThousandAndTwelvePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelvePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:TwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">
          LCTX:LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_DomesticCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:DomesticCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_DomesticCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:DomesticCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_us-gaap_ForeignCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:ForeignCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_us-gaap_ForeignCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:ForeignCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_ForeignCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:ForeignCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_StateAndLocalJurisdictionMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:StateAndLocalJurisdictionMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_us-gaap_DomesticCountryMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">
          us-gaap:DomesticCountryMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_CaliforniaAgreementMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:CaliforniaAgreementMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-05-31_custom_CarlsbadLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:CarlsbadLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-05-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-05-012019-05-31_custom_CarlsbadLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:CarlsbadLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-05-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-05-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-08-01_custom_CarlsbadLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:CarlsbadLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-08-01
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-08-01_custom_CarlsbadLeaseMember_custom_FirstTwentyFourMonthsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:CarlsbadLeaseMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">
          LCTX:FirstTwentyFourMonthsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-08-01
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2015-12-012015-12-31_custom_AlamedaLeasesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:AlamedaLeasesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2015-12-01
        </xbrli:startdate>
        <xbrli:enddate>
         2015-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2015-12-31_custom_ThousandTenAtlanticPremisesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:ThousandTenAtlanticPremisesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2015-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2015-12-31_custom_ThousandTwentyAtlanticPremisesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:ThousandTwentyAtlanticPremisesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2015-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-02-01_custom_AlamedaLeasesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:AlamedaLeasesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-02-01
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-01-24_custom_AlamedaLeasesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:AlamedaLeasesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-01-24
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-04-30_custom_IndustrialMicrobesIncMember_custom_AlamedaSubleaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:IndustrialMicrobesIncMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
          LCTX:AlamedaSubleaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-04-30
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-09-102020-09-11_custom_AlamedaLeasesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:AlamedaLeasesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-09-10
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-09-102020-09-11_custom_IndustrialMicrobesSubleaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:IndustrialMicrobesSubleaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-09-10
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-09-11_custom_IndustrialMicrobesSubleaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:IndustrialMicrobesSubleaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-09-11
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-04-012020-09-30_custom_IndustrialMicrobesSubleaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:IndustrialMicrobesSubleaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-09-11_custom_ThousandTenAtlanticPremisesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:ThousandTenAtlanticPremisesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-09-11
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-09-102020-09-11_custom_ThousandTenAtlanticPremisesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:ThousandTenAtlanticPremisesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-09-10
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-11
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-09-11_custom_AlamedaLeasesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:AlamedaLeasesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-09-11
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_NISCurrencyExchangeMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:NISCurrencyExchangeMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember_custom_DecemberTwoThousandEighteenExchangeRateMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:DecemberTwoThousandEighteenExchangeRateMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-01-28_custom_CellCureMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-01-28
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-01-272018-01-28_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-01-27
        </xbrli:startdate>
        <xbrli:enddate>
         2018-01-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-01-272018-01-28_custom_CellCureMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-01-27
        </xbrli:startdate>
        <xbrli:enddate>
         2018-01-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-03-302018-04-02_custom_NISCurrencyExchangeMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:NISCurrencyExchangeMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-03-30
        </xbrli:startdate>
        <xbrli:enddate>
         2018-04-02
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-03-302018-04-02_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:OfficeAndLaboratorySpaceJerusalemIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-03-30
        </xbrli:startdate>
        <xbrli:enddate>
         2018-04-02
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-272019-01-28_custom_CellCureMember_custom_NISCurrencyExchangeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:NISCurrencyExchangeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-27
        </xbrli:startdate>
        <xbrli:enddate>
         2019-01-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-272019-01-28_custom_CellCureMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
          LCTX:CellCureMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-27
        </xbrli:startdate>
        <xbrli:enddate>
         2019-01-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2018-01-012018-12-31_custom_JanuaryTwoThousandAndEighteenLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:JanuaryTwoThousandAndEighteenLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2018-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2018-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2018-12-31_custom_JanuaryTwoThousandAndEighteenLeaseMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">
          LCTX:JanuaryTwoThousandAndEighteenLeaseMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2018-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:OperatingLeaseLiabilityMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_OperatingLeaseLiabilityMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:OperatingLeaseLiabilityMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">
          LCTX:FinanceLeaseLiabilityMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-01-05_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:ResearchandOptionAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:OrbitBiomedicalLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-01-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-01-31_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:ResearchandOptionAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:OrbitBiomedicalLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-01-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-08-022019-08-31_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:ResearchandOptionAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:OrbitBiomedicalLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-08-02
        </xbrli:startdate>
        <xbrli:enddate>
         2019-08-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-01-31_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SecondAmendmentMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:GyroscopeTherapeuticsLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-01-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-02-012020-02-29_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember_custom_UponSigningMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SecondAmendmentMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:GyroscopeTherapeuticsLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:UponSigningMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-02-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-02-29
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-11-012020-11-30_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:SecondAmendmentMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:GyroscopeTherapeuticsLimitedMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-11-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-11-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-02-012021-02-28_custom_ThirdAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:ThirdAmendmentMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:GyroscopeTherapeuticsLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-02-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-02-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-08-122019-08-13">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-08-12
        </xbrli:startdate>
        <xbrli:enddate>
         2019-08-13
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-05-042020-05-06_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:LicenseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:GBPPoundSterlingMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-05-04
        </xbrli:startdate>
        <xbrli:enddate>
         2020-05-06
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:LicenseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:GBPPoundSterlingMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-09-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-01-31_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:LicenseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:GBPPoundSterlingMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-01-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-04-012021-04-30_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:LicenseAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
          LCTX:GBPPoundSterlingMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-04-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_FutureYearsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">
          LCTX:FutureYearsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_DomesticMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:DomesticMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_DomesticMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:DomesticMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_ForeignMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:ForeignMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2019-12-31_custom_ForeignMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
          LCTX:ForeignMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2019-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">
          LCTX:RoyaltiesFromProductSalesAndLicenseFeesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="AsOf2020-12-31_custom_ATMSharesMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">
          LCTX:ATMSharesMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:instant>
         2020-12-31
        </xbrli:instant>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_NIHGrantIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:NIHGrantIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_NIHGrantIncomeMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:NIHGrantIncomeMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-12-31_custom_SaleofResearchProductsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:SaleofResearchProductsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-12-31_custom_SaleofResearchProductsMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
          LCTX:SaleofResearchProductsMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-01-012020-03-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-03-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-04-012020-06-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-06-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-07-012020-09-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-07-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2020-10-012020-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2020-10-01
        </xbrli:startdate>
        <xbrli:enddate>
         2020-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-01-012019-03-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-03-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-04-012019-06-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-04-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-06-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-07-012019-09-30">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-07-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-09-30
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2019-10-012019-12-31">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2019-10-01
        </xbrli:startdate>
        <xbrli:enddate>
         2019-12-31
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-02-28_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-02-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-03-042021-03-05_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-03-04
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMShareMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">
          LCTX:ATMShareMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-01-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-03-012021-03-05_custom_ATMShareMember_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">
          LCTX:ATMShareMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-03-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-03-05
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:context id="From2021-02-012021-02-28_custom_ResearchandOptionAgreementMember_custom_GyroscopeTherapeuticsLimitedMember_us-gaap_SubsequentEventMember">
       <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">
         0000876343
        </xbrli:identifier>
        <xbrli:segment>
         <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">
          LCTX:ResearchandOptionAgreementMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="dei:LegalEntityAxis">
          LCTX:GyroscopeTherapeuticsLimitedMember
         </xbrldi:explicitmember>
         <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
          us-gaap:SubsequentEventMember
         </xbrldi:explicitmember>
        </xbrli:segment>
       </xbrli:entity>
       <xbrli:period>
        <xbrli:startdate>
         2021-02-01
        </xbrli:startdate>
        <xbrli:enddate>
         2021-02-28
        </xbrli:enddate>
       </xbrli:period>
      </xbrli:context>
      <xbrli:unit id="USD">
       <xbrli:measure>
        iso4217:USD
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="Shares">
       <xbrli:measure>
        xbrli:shares
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="USDPShares">
       <xbrli:divide>
        <xbrli:unitnumerator>
         <xbrli:measure>
          iso4217:USD
         </xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
         <xbrli:measure>
          xbrli:shares
         </xbrli:measure>
        </xbrli:unitdenominator>
       </xbrli:divide>
      </xbrli:unit>
      <xbrli:unit id="Percentage">
       <xbrli:measure>
        xbrli:pure
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="Area">
       <xbrli:measure>
        utr:acre
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="SquareFeet">
       <xbrli:measure>
        utr:sqft
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="AreaSquareMeter">
       <xbrli:measure>
        utr:sqm
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="NIS">
       <xbrli:measure>
        iso4217:ILS
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="GBP">
       <xbrli:measure>
        iso4217:GBP
       </xbrli:measure>
      </xbrli:unit>
      <xbrli:unit id="Subsidiary">
       <xbrli:measure>
        LCTX:Subsidiary
       </xbrli:measure>
      </xbrli:unit>
      <ix:relationship fromrefs="Fact000779" torefs="Footnote000788">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000832" torefs="Footnote000839">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000834" torefs="Footnote000839">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000953" torefs="Footnote000960">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000955" torefs="Footnote000960">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000978" torefs="Footnote001005">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000980" torefs="Footnote001005">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000988" torefs="Footnote001010">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001000" torefs="Footnote001010">
      </ix:relationship>
      <ix:relationship fromrefs="Fact000990" torefs="Footnote001013">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001205" torefs="Footnote001216">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001207" torefs="Footnote001216">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001239" torefs="Footnote001270">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001241" torefs="Footnote001270">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001243" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001245" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001247" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001249" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001255" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact001257" torefs="Footnote001271">
      </ix:relationship>
      <ix:relationship fromrefs="Fact002115" torefs="Footnote002122">
      </ix:relationship>
      <ix:relationship fromrefs="Fact002117" torefs="Footnote002122">
      </ix:relationship>
      <ix:relationship fromrefs="Fact002128" torefs="Footnote002135">
      </ix:relationship>
      <ix:relationship fromrefs="Fact002130" torefs="Footnote002135">
      </ix:relationship>
     </ix:resources>
    </ix:header>
   </div>
   <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">
   </p>
   <!-- Field: Rule-Page -->
   <div style="width: 100%">
    <div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">
    </div>
   </div>
   <!-- Field: /Rule-Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 18pt Times New Roman, Times, Serif">
     <b>
      UNITEDSTATES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 18pt Times New Roman, Times, Serif">
     <b>
      SECURITIESAND EXCHANGE COMMISSION
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 12pt Times New Roman, Times, Serif">
     <b>
      Washington,D.C. 20549
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 18pt Times New Roman, Times, Serif">
     <b>
      FORM
      <span id="xdx_90B_edei--DocumentType_c20200101__20201231_z5EPrwBnFZy5">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-7" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentType" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         10-K
        </ix:nonnumeric>
       </span>
      </span>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span id="xdx_903_edei--DocumentAnnualReport_c20200101__20201231_zIOnmxIEM8x1">
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleantrue" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-8" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentAnnualReport" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       ☒
      </ix:nonnumeric>
     </span>
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     ANNUALREPORT PURSUANT TO SECTION 13 OR 15(d)
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OFTHE SECURITIES EXCHANGE ACT OF 1934
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe fiscal year ended
     <span id="xdx_902_edei--DocumentPeriodEndDate_c20200101__20201231_zQKMHJshgHDb">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-9" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentPeriodEndDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        December 31, 2020
       </ix:nonnumeric>
      </span>
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OR
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span id="xdx_906_edei--DocumentTransitionReport_c20200101__20201231_ziTmUmN5dYLl">
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-10" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentTransitionReport" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       ☐
      </ix:nonnumeric>
     </span>
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     TRANSITIONREPORT PURSUANT TO SECTION 13 OR 15(d)
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OFTHE SECURITIES EXCHANGE ACT OF 1934
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe transition period from___________ to __________
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Commissionfile number
     <span id="xdx_905_edei--EntityFileNumber_c20200101__20201231_zLwcFDtWwExc">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-11" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityFileNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        001-12830
       </ix:nonnumeric>
      </span>
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 18pt Times New Roman, Times, Serif">
     <b>
      <span id="xdx_908_edei--EntityRegistrantName_c20200101__20201231_zf5z5wYyBFK4">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-12" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityRegistrantName" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         LineageCell Therapeutics, Inc.
        </ix:nonnumeric>
       </span>
      </span>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (Exactname of registrant as specified in its charter)
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20200101__20201231_zpap3KmBbCKe">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:stateprovnameen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-13" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityIncorporationStateCountryCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            California
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="xdx_905_edei--EntityTaxIdentificationNumber_c20200101__20201231_zQcZ4GzEJ4J7">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-14" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityTaxIdentificationNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            94-3127919
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (State    or other jurisdiction of
        <br/>
        incorporation or organization)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (I.R.S.    Employer
        <br/>
        Identification No.)
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="xdx_90B_edei--EntityAddressAddressLine1_c20200101__20201231_zEsFyXqKWZd">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-15" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressAddressLine1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         2173Salk Avenue
        </ix:nonnumeric>
       </span>
      </span>
      ,
      <span id="xdx_90E_edei--EntityAddressAddressLine2_c20200101__20201231_zB1l2Rxx6smf">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-16" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressAddressLine2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         Suite 200
        </ix:nonnumeric>
       </span>
      </span>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="xdx_902_edei--EntityAddressCityOrTown_c20200101__20201231_zwn85X0fAU09">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-17" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressCityOrTown" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         Carlsbad
        </ix:nonnumeric>
       </span>
      </span>
      ,
      <span id="xdx_904_edei--EntityAddressStateOrProvince_c20200101__20201231_zKLno8HswRre">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:stateprovnameen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-18" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressStateOrProvince" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         California
        </ix:nonnumeric>
       </span>
      </span>
      <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20200101__20201231_zRyQwZxSn0gj">
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-19" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressPostalZipCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         92008
        </ix:nonnumeric>
       </span>
      </span>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (Addressof principal executive offices) (Zip Code)
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Registrant’stelephone number, including area code
     <b>
      <span>
       <span id="xdx_907_edei--CityAreaCode_c20200101__20201231_zIJdyp2e4103">
        <span>
         <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-20" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:CityAreaCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          (442)
         </ix:nonnumeric>
        </span>
       </span>
       <span id="xdx_90F_edei--LocalPhoneNumber_c20200101__20201231_z7UoIL19jmKe">
        <span>
         <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-21" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:LocalPhoneNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          287-8990
         </ix:nonnumeric>
        </span>
       </span>
      </span>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Securitiesregistered pursuant to Section 12(b) of the Act
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Title    of each class
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Trading    Symbol(s)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Name    of each exchange on which registered
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="xdx_90D_edei--Security12bTitle_c20200101__20201231_zK43hWRbKeH3">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-22" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:Security12bTitle" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            Common    stock
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="xdx_90D_edei--TradingSymbol_c20200101__20201231_zBlQT7w4Y3fd">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-23" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:TradingSymbol" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            LCTX
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span>
          <span id="xdx_90D_edei--SecurityExchangeName_c20200101__20201231_zKE1dh3zSln8">
           <span>
            <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:exchnameen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-24" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:SecurityExchangeName" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             NYSE
            </ix:nonnumeric>
           </span>
          </span>
          American
         </span>
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Securitiesregistered pursuant to Section 12(g) of the Act:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      None
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
     <b>
      ☐
     </b>
     <span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20200101__20201231_zlY5coQeXtm3">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-25" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityWellKnownSeasonedIssuer" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
     </span>
     <b>
      ☒
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes
     <b>
      ☐
     </b>
     <span id="xdx_90C_edei--EntityVoluntaryFilers_c20200101__20201231_zr2xNBvz6IC9">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-26" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityVoluntaryFilers" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
     </span>
     <b>
      ☒
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.
     <span id="xdx_906_edei--EntityCurrentReportingStatus_c20200101__20201231_zjvM8z6rsSB4">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-27" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityCurrentReportingStatus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        Yes
       </ix:nonnumeric>
      </span>
     </span>
     ☒ No
     <b>
      ☐
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).
     <span id="xdx_909_edei--EntityInteractiveDataCurrent_c20200101__20201231_zFLUcPgGixN">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-28" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityInteractiveDataCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        Yes
       </ix:nonnumeric>
      </span>
     </span>
     ☒ No
     <b>
      ☐
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Large    accelerated filer
        <b>
         ☐
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Accelerated    filer
        <b>
         ☐
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span>
         Non-accelerated    filer
        </span>
        ☒
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Smaller    reporting company
        <b>
         <span id="xdx_904_edei--EntitySmallBusiness_c20200101__20201231_zVl0vTA3dOo1">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleantrue" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-29" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntitySmallBusiness" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            ☒
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Emerging    growth company
        <b>
         <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20200101__20201231_zGN5DKalxcX7">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-30" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityEmergingGrowthCompany" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            ☐
           </ix:nonnumeric>
          </span>
         </span>
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. ☐
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.
     <b>
      ☐
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐
     <span id="xdx_909_edei--EntityShellCompany_c20200101__20201231_zuDF9oHrEVcl">
      <span>
       <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-31" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityShellCompany" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
     </span>
     <b>
      ☒
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof June 30, 2020, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregatemarket value of the registrant’s voting and non-voting common equity held by non-affiliates of the registrant was approximately
     <span id="xdx_90D_edei--EntityPublicFloat_iI_pn5n6_c20200630_zcS16Unn4qL7" title="Entity Public Float">
      $
      <span>
       <ix:nonfraction contextref="AsOf2020-06-30" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-32" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="dei:EntityPublicFloat" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
        93.9
       </ix:nonfraction>
      </span>
     </span>
     million.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thenumber of common shares outstanding as of March 5, 2021 was
     <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_pii_c20210305_zHJ6SypAbe48" title="Entity Common Stock, Shares Outstanding">
      <span>
       <ix:nonfraction contextref="AsOf2021-03-05" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-33" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="dei:EntityCommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
        161,637,890
       </ix:nonfraction>
      </span>
     </span>
     .
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
   </p>
   <!-- Field: Rule-Page -->
   <div style="width: 100%">
    <div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">
    </div>
   </div>
   <!-- Field: /Rule-Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 1 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="width: 100%">
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <table cellpadding="0" cellspacing="0" style="width: 100%">
     <tbody>
      <tr>
       <td style="text-align: center; width: 100%">
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LineageCell Therapeutics, Inc.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Tableof Contents
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.65in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Page
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Number
         </b>
        </span>
       </p>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_001" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Part    I.
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    1
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_002" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Business
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         3
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    1A
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_003" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Risk    Factors
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         26
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    1B
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_004" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Unresolved    Staff Comments
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         53
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    2
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_005" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Properties
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         54
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    3
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_006" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Legal    Proceedings
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         54
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    4
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_007" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Mine    Safety Disclosures
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         54
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_008" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Part    II.
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    5
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_009" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Market    for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         55
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    6
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_010" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Selected    Financial Data
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         55
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    7
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_011" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Management’s    Discussion and Analysis of Financial Condition and Results of Operations
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         56
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    7A
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_012" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Quantitative    and Qualitative Disclosures about Market Risk
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         65
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    8
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_013" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Financial    Statements and Supplementary Data
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         66
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    9
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_014" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Changes    in and Disagreements with Accountants on Accounting and Financial Disclosure
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         109
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    9A
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_015" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Controls    and Procedures
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         109
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    9B
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_016" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Other    Information
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         109
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_017" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Part    III.
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    10
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_018" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Directors,    Executive Officers, and Corporate Governance
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         110
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    11
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_019" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Executive    Compensation
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         113
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    12
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_020" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Security    Ownership of Certain Beneficial Owners and Management, and Related Stockholder Matters
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         119
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    13
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_021" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Certain    Relationships and Related Transactions, and Director Independence
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         122
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    14
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_022" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Principal    Accounting Fees and Services
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         123
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_023" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Part    IV.
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    15
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_024" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Exhibits,    Financial Statement Schedules
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         124
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Item    16
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_025" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Form    10-K Summary
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         126
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
      <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <a href="#a_026" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Signatures
         </b>
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         127
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 2 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="width: 100%">
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <table cellpadding="0" cellspacing="0" style="width: 100%">
     <tbody>
      <tr>
       <td style="text-align: center; width: 100%">
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_001">
      </span>
      PARTI
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      FORWARD-LOOKINGSTATEMENTS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ThisAnnual Report on Form 10-K (this “Report”) contains forward-looking statements within the meaning of Section 27A ofthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in PartI, Item 1. “Business,” Part I, Item 1A. “Risk Factors,” and Part II, Item 7. “Management’sDiscussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere in this Report.In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,”“could,” “would,” “should,” “expect,” “intend,” “plan,”“objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,”“potential,” “continue” and “ongoing,” or the negative of these terms, or other comparableterminology intended to identify statements about the future. These statements involve known and unknown risks, uncertaintiesand other factors that may cause our actual results, levels of activity, performance or achievements to be materially differentfrom the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basisfor each forward-looking statement contained in this Report, we caution you that these statements are based on a combination offacts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-lookingstatements include statements about:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    plans to research, develop and commercialize our product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    initiation, progress, success, cost and timing of our clinical trials and product development activities;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete, clinical    trials;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing    and costs of such manufacture;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    performance of third parties in connection with the development and manufacture of our product candidates, including third    parties conducting our clinical trials as well as third-party suppliers and manufacturers;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    potential of our cell therapy platform, and our plans to apply our platform to research, develop and commercialize our product    candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our    product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    size and growth of the potential markets for our product candidates and our ability to serve those markets;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    potential scope and value of our intellectual property rights;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting    our product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary    rights of third parties;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    ability to recruit and retain key personnel;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    effects of the COVID-19 pandemic on our operations; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        other    risks and uncertainties, including those described under Part I, Item 1A. Risk Factors of this Report.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 3; Options: NewSection -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        1
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Youshould refer to “Item 1A. Risk Factors” in this Report for a discussion of important factors that may cause our actualresults to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors,we cannot assure you that the forward-looking statements in this Report will prove to be accurate. Furthermore, if our forward-lookingstatements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-lookingstatements, you should not regard these statements as a representation or warranty by us or any other person that we will achieveour objectives and plans in any specified time frame, or at all. The forward-looking statements in this Report represent our viewsas of the date of this Report. We anticipate that subsequent events and developments may cause our views to change. However, whilewe may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly updateany forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to thedate of this Report.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.4pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Youshould read this Report and the documents that we reference in this Report completely and with the understanding that our actualfuture results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionarystatements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.4pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ThisReport also contains market data, industry forecasts and other data made by independent parties and by us relating to market sizeand growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautionednot to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance andthe future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.4pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Allbrand names or trademarks appearing in this Report are the property of their respective owners. Solely for convenience, the trademarksand trade names in this Report are referred to without the symbols
     <sup>
      ®
     </sup>
     and
     <sup>
      TM
     </sup>
     , but such references shouldnot be construed as any indication that their respective owners will not assert, to the fullest extent under applicable law, theirrights thereto.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.4pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Unlessthe context requires otherwise, references in this report to “Lineage,” “we,” “us,” and “our”refer to Lineage Cell Therapeutics, Inc. and its consolidated subsidiaries.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RISKFACTOR SUMMARY
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Belowis a summary of the material factors that make an investment in our stock speculative or risky. This summary does not addressall of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks thatwe face, can be found below under the heading “Risk Factors” in Item 1A of Part I of this Report and should be carefullyconsidered, together with other information in this Report and our other filings with the Securities and Exchange Commission beforemaking investment decisions regarding our common shares.
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    have incurred operating losses since inception, and we do not know if or when we will attain profitability.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    will continue to spend a substantial amount of our capital on research and development, but we might not succeed in developing    products and technologies that are useful in medicine.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    amount and pace of research and development work that we can do or sponsor, and our ability to commence and complete clinical    trials required to obtain regulatory approval to market our therapeutic and medical device products, depends upon the amount    of funds we have.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    will need to issue additional equity or debt securities in order to raise additional capital needed to pay our operating expenses.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, including anti-kickback and    false claims laws, transparency laws, and health information privacy and security laws. If we are unable to comply, or have    not fully complied, with such laws, we could face substantial penalties.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        If    we do not receive regulatory approvals, we will not be permitted to sell our therapeutic and medical device products.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 4 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        2
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Government-imposed    bans or restrictions and religious, moral, and ethical concerns about the use of hES cells could prevent us from developing    and successfully marketing stem cell products.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    expect that the commercial opportunity for some of our products may depend on our ability to obtain reimbursement and continued    coverage from various payors, including government entities and insurance companies.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Clinical    studies are costly, time consuming and are subject to risks that could delay or prevent commercialization of our current or    future product candidates.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Clinical    and preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of early    preclinical trials and clinical trials of our product candidates are not necessarily predictive of future results. Our product    candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval on a timely basis,    if at all.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Interim,    topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient    data become available and are subject to audit and verification procedures that could result in material changes in the final    data.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Our    intellectual property may be insufficient to protect our products.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        If    we are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete with    us, which could limit opportunities for us to generate revenues by licensing our technology and selling products.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    may become dependent on possible future collaborations to develop and commercialize many of our product candidates and to    provide the regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Because    we are engaged in the development of pharmaceutical and stem cell therapy products, the price of our common shares may rise    and fall rapidly.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Current    economic and stock market conditions may adversely affect the price of our common shares.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_002">
         </span>
         ITEM    1.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         BUSINESS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Overview
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Our focus is to develop therapiesfor degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting andcombating cancer. Specifically, Lineage is testing therapies to treat dry age-related macular degeneration, spinal cord injuries,and non-small cell lung cancer. Our programs are based on our proprietary cell-based therapy platform and associated developmentand manufacturing capabilities. From this platform, we develop and manufacture specialized, terminally or functionally differentiatedhuman cells from established and well-characterized pluripotent cell lines. These differentiated cells are transplanted into apatient either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, orare administered as a means of helping the body mount an effective immune response to cancer.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      ProductCandidates &amp; Other Programs
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave three allogeneic, or “off-the-shelf,” cell therapy programs in clinical development:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         OpRegen
         <sup>
          ®
         </sup>
        </i>
        ,    a retinal pigment epithelium (“RPE”) cell replacement therapy currently in a Phase 1/2a multicenter clinical trial    for the treatment of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy (“GA”).    There currently are no therapies approved by the U.S. Food and Drug Administration (“FDA”) for dry AMD, which    accounts for approximately 85-90% of all AMD cases and is the leading cause of blindness in people over the age of 60.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 5 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        3
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         OPC1
        </i>
        ,    an oligodendrocyte progenitor cell therapy currently in the long-term follow-up portion of a Phase 1/2a multicenter clinical    trial for acute spinal cord injuries (“SCI”). This clinical trial has been partially funded by the California    Institute for Regenerative Medicine.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         VAC2
        </i>
        ,    an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 clinical trial in non-small    cell lung cancer. This clinical trial is being funded and conducted by Cancer Research UK, the world’s largest independent    cancer research charity.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition to seeking to create value for shareholders by developing product candidates and other technologies through our clinicaldevelopment programs, we also seek to create value from our technologies through partnering and strategic transactions. We foundedtwo companies that later became publicly traded companies: OncoCyte Corporation (“OncoCyte”) and AgeX Therapeutics,Inc. (“AgeX”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Duringthe year ended December 31, 2020, we received approximately $12.6 million in gross proceeds in connection with our sale of sharesof OncoCyte and AgeX.
    </span>
    In August 2020, we also received $24.6 million from Juvenescence Limited (“Juvenescence”),representing principal and accrued interest under a promissory note we received in connection with our sale of AgeX shares toJuvenescence in August 2018.
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weno longer hold any common stock in AgeX. The value of our OncoCyte holdings as of March 5, 2021, was approximately $4.2million, based on the closing price of its common stock on that date. In this Report, see Part I, Item 1A, “Risk Factors—RisksRelated to Our Business Operations and Capital Requirements—The value of our investments in public companies fluctuatesbased on their respective stock prices and could be negatively affected by poor business performance.”
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thoughour principal focus is on advancing our three cell therapy programs currently in clinical development, we may seek to create additionalvalue through corporate transactions, as we have in the past, or by initiating new programs using our protocols or with new protocolsand cell lines.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      CorporateInformation
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineageis incorporated in the State of California. Our common shares trade on the NYSE American and the Tel Aviv Stock Exchange underthe symbol “LCTX.” Our principal executive offices are at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008, and ourphone number at that address is (442) 287-8990. Our website address is www.lineagecell.com. The information on, or that can beaccessed through our website is not part of this Report. Lineage routinely uses its website as a means of disclosing materialnon-public information and for complying with its disclosure obligations under Regulation FD. We also make available, free ofcharge through our website, our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form8-K and any amendments to those reports as soon as reasonably practicable after the reports are electronically filed with or furnishedto the Securities and Exchange Commission.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      2020Highlights
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weachieved numerous strategic accomplishments during 2020, including advancing clinical trials and product development in severalkey programs.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        In    May 2020, we announced the early exercise of our option with Cancer Research UK to bring the VAC immuno-oncology platform    in-house.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        In    June 2020, we announced the first known finding of retinal tissue restoration in a patient who received an RPE cell    transplant.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        In    October 2020, we reported encouraging preliminary Phase 1 clinical study results with VAC2 for the treatment of non-small    cell lung cancer with high levels of antigen-specific immunogenicity observed.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        In    November 2020, we completed enrollment in a 24 patient Phase 1/2a clinical study of OpRegen for the treatment of dry AMD with    GA with encouraging preliminary signs of tolerability and efficacy.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        In    December 2020, we announced that we had been able to make significant manufacturing improvements to our OPC1 acute SCI program,    including better controlled processes, enhanced purity, potency, and scale, and to the development of a “ready-to-inject”    formulation, substantially decreasing logistical burden at the point of care and enabling use at a much larger number of treatment    centers.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 6 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        4
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      BusinessStrategy
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourgoal is to become a leading cell therapy company by developing allogeneic, or “off-the-shelf,” treatments that arecomprised of differentiated cells derived from pluripotent cell lines, which have been directed to become specific cell typesand use those cells as treatments to restore diseased or diminished functions, such as impaired vision, loss of movement and sensation,or to increase immune response to tumors. Significant near-term activities that underlie our business strategy include:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Presenting    new and accumulated OpRegen data from the ongoing Phase 1/2a clinical study on two occasions during the first and second quarters    of 2021;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Completing    VAC2 patient enrollment in the ongoing Phase 1 clinical study for the treatment of non-small cell lung cancer by the end of    the first half of 2021;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Evaluating    delivery improvements for our OPC1 program, which combined with our “ready-to-inject” formulation, will enable    access to a greater number of clinical sites, currently ongoing and throughout 2021;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Meeting    with the FDA to discuss further development of the OPC1 program, including a late-stage clinical study, during the second    half of 2021;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Evaluating    opportunities for new VAC product candidates based on manufacturing improvements and product improvements, including newly    discovered tumor antigens/neoantigens, throughout 2021; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Evaluating    partnership opportunities and expansion of existing external collaborations and identification of new collaborations for OpRegen,    OPC1 and VAC2, currently ongoing and throughout 2021.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CellTherapy Technology
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve we are a leader in pluripotent, cell-based asset development based on directed lineage derivation protocols and wholecell manufacturing capabilities. Pluripotent cells, which are widely published as capable of becoming any human cell type, havepotential applications in many areas of medicine with large unmet patient needs, including certain age-related degenerative diseasesand degenerative conditions for which there presently are no cures. We currently are focused on developing pluripotent cells intoRPE cells, oligodendrocyte progenitor cells and dendritic cells.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      PluripotentStem Cells
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <img alt="" data-src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_001.jpg" src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_001.jpg" style="height: 271px; width: 326px"/>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 7 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        5
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Unlikepharmaceuticals that require a narrowly defined molecular target, cellular therapies are often aimed at regenerating or replacingthe entire affected cell or tissue and therefore, may have broader or more suitable applicability than many traditional pharmaceuticalproducts. Small molecules and biologic therapies that require systemic delivery into the body often have unexpected results, orside effects, that can limit their usefulness. When cell replacement is locally administered, particularly to anatomical compartments,systemic side effects are usually not the primary concern. The risk profile of cell therapy more closely resembles that of transplantmedicine, focused more on whether the transplanted cells are rejected by the body and whether the cells function as expected.We currently are using our pluripotent stem cells as starting material from which we derive three separate and specific cell types,each of which are product candidates currently in clinical testing.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemaintain an innovative cell therapy manufacturing facility in the Bio Park on the campus of the Hadassah University Hospital inJerusalem, Israel. The facility includes process development laboratories and a state-of-the-art, cGMP manufacturing facility.It is designed and equipped to enable simultaneous cGMP processes and to produce a range of cell therapy products for human usein clinical trials as well as developing scale suitable for commercial launch. All cGMP manufacturing processes, including cellbanks and product manufacturing for our cell therapy product candidates, are conducted in this facility.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CellTherapy Product Candidates
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <img alt="" data-src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_002.jpg" src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_002.jpg" style="height: 274px; width: 549px"/>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OpRegen
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OpRegenis our lead ophthalmic product candidate (currently in a Phase 1/2a clinical trial) for the treatment of advanced dry AMD withGA. AMD is a gradual, progressive, deterioration of the macula, the small sensitive area in the center of the retina that providesclear, high definition central vision. AMD affects over 30 million people worldwide and approximately 1.6 million people are diagnosedannually in the United States. It is a leading cause of vision loss in people over the age of 65 in the developed world. As thearea of atrophy begins to include the fovea (the center of the macula), patients lose their central vision, making facial recognition,reading and driving difficult or impossible, and often resulting in legal blindness. The exact cause of dry AMD is unknown, butis thought to result from multiple factors, such as genetics, age and environmental effects. There are two clinical presentationsof AMD, the dry form and the wet form, or neovascular form (growth of abnormal new blood vessels). Dry AMD typically advancesslowly toward GA in which RPE cells and photoreceptors deteriorate over time. RPE cells support and nourish the retina by metabolizingwaste by-products and producing a number of components useful for photoreceptor health and function. If the metabolic waste productsaccumulate, lesions known as drusen are generated. Approximately 85-90% of AMD patients suffer from dry AMD, for which there isno FDA-approved medical therapies. Dry AMD may also lead to wet AMD, a condition for which there are several FDA-approved treatmentsadministered locally to inhibit the growth of new blood vessels, but these treatments are not effective nor approved for the treatmentof dry AMD. Physicians often recommend a healthy diet, exercise and/or nutritional supplements for dry AMD, but nutritional supplementshave shown limited efficacy in delaying the onset of more progressive disease in longer-term studies. The schematics below showa representation of the process of drusen formation and the goal of cell replacement therapy.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 8 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        6
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <img alt="" data-src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_003.jpg" src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_003.jpg" style="height: 245px; width: 245px"/>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      DryAMD involves the loss of retina cells, creating an area of geographic atrophy (GA), which causes impaired vision and blindness
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve one of the most promising approaches to treat dry AMD is to replace the layer of damaged RPE cells with new, healthy andfunctional RPE cells manufactured from a well-characterized cell line. OpRegen is a cell replacement therapy derived from ourpluripotent cell technology in which our proprietary directed-differentiation methods convert pluripotent stem cells into nearlypure populations of RPE cells. Using this method, OpRegen is grown free of any animal products and consists of human RPE cellswith high yield and purity that can be transplanted directly into the patient’s eye, where the patient’s own RPE cellsare missing or dysfunctional. The OpRegen therapeutic approach is designed to replace damaged or lost RPE cells with the goalof slowing disease progression to preserve and/or restore visual function.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <img alt="" data-src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_004.jpg" src="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/form10-k_004.jpg" style="height: 252px; width: 295px"/>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      OpRegenis an injection of RPE cells delivered to the retina, to replace lost retinal cells and preserve or restore vision
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Preclinicalstudies in the Royal College of Surgeons (RCS) rat model have shown that following a single subretinal injection, OpRegenas a suspension of cells rapidly organized into their natural monolayer structure and survived until the end of the study, whichwe believe is critical to the potential success of OpRegen in humans. Additionally, rats receiving OpRegen had objective evidenceof improved optomotor tracking, indicating functional visual improvement compared to control animals.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OpRegenis intended to be an allogeneic, or “off-the-shelf,” product provided to retinal surgeons in an “easy-to-use”form for transplantation. We believe OpRegen could have a lasting benefit from a single administration, or once every severalyears. This approach differs from other investigational drugs for Dry AMD and approved agents currently marketed for wet AMD,such as Ranibizumab (Lucentis
     <sup>
      ®
     </sup>
     ) and Aflibercept (Eylea
     <sup>
      ®
     </sup>
     ), that require multiple, frequent intravitrealinjections into the eye.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 9 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        7
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thepatients in our ongoing Phase 1/2a clinical trial are 50 years of age or older, whose dry AMD has advanced to the GA stage, withabsence of additional concomitant ocular disorders. The eye in which the disease has progressed the most is treated, while theirother eye serves as a measure of disease progression. Following injection, the patients are followed for 12 months at specifiedintervals to evaluate the safety and tolerability of OpRegen.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Followingthe initial 12-month period, patients are evaluated at longer intervals for up to an additional five years following administration.A secondary objective of the clinical trial is to examine the ability of transplanted OpRegen to engraft, survive, and modulatedisease progression in the patients. In addition to thorough characterization of visual function, several vision tests are usedto quantify stabilization or improvements in visual function. We also perform anatomical evaluation imaging to assess the restorationof the structure of the retina.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Interimdata from the first 12 subjects in Cohorts 1-3 have been encouraging and suggest that OpRegen RPE cells are generally well-toleratedwhen administered by subretinal injection in these legally blind patients with large areas of GA that have encompassed the fovealarea. The surgical procedures were generally well-tolerated, with spectral domain optical coherence tomography (SD-OCT) imagesshowing absorption of the subretinal fluid in the bleb less than 48 hours after surgery and healing of the site of retinal penetrationby the cannula within a few weeks. Initial findings using a variety of imaging modalities suggest presence of cells in the subretinalspace, an observation consistent with, and supported by, the data from preclinical studies of OpRegen. Findings on clinical examinationby different imaging modalities show potential improvements in retinal structure, which could precede visual functional improvements.Though it is not definitively known at this time whether these changes represent engraftment and survival of the transplantedcells, data from the preclinical animal studies suggest this is the most likely scenario.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Importantly,in this safety-focused aspect of the trial, no unexpected ocular adverse events have been observed and those events expected tooccur based on the procedures involved in OpRegen administration, such as vitrectomy, have been predominately mild in severity.The majority of these subjects had pre-existing epiretinal membranes (ERMs) at the time of trial enrollment and in most cases,experienced new or worsening ERMs following the surgical procedure, which is believed to be partially attributable to the routeof administration via pars plana vitrectomy (PPV) and retinotomy. The majority were mild to moderate in severity, though two patientswith severe ERM were successfully treated via a routine surgical procedure. These subjects are being monitored during trial follow-up.One instance of retinal detachment occurred in a patient who was legally blind prior to treatment. The event was not assignedas related to treatment, procedure or to the combination. The patient continued for a period of time in the trial following successfulsurgical repair but has since withdrawn due to other unrelated health issues. The independent data safety monitoring board approvedmoving to Cohort 4 based on the safety data from the Cohorts 1-3. Cohort 4 incorporates an additional variety of objective andsubjective assessments to look for signs of potential efficacy as well as potential anatomical changes indicative of OpRegen cellfunction following implantation.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asdescribed above, many of the adverse events (AEs) observed in subretinal procedures are likely related to the delivery techniqueutilized during the surgery. As previously described, in January 2019, we announced an exclusive partnership with Orbit Biomedical(now Gyroscope Therapeutics, Ltd.) to assess its FDA-cleared Orbit Subretinal Delivery System (SDS), a single-use vitrectomy-freedelivery device designed to deliver products to the subretinal space for the administration of OpRegen within the ongoing clinicaltrial. The device allows for access to the subretinal space via a sclerotomy and suprachoroidal approach, which means that thereare no openings created into the vitreous chamber. This could eliminate the possibilities of new or worsening epiretinal membranesand exacerbation or generation of a cataract, both known issues with the older standard method of delivery. We believe that theuse of this device could significantly decrease the number of adverse events and improve retention and dose control of OpRegenin our clinical trials.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wecompleted enrollment in Cohorts 1-3 (12 patients) in the middle of 2018 and as previously reported, OpRegen was well toleratedwith no unexpected systemic serious adverse events (SAEs) or ocular AEs. Importantly, there were several patients that exhibitedimproved retinal structure, reduction in drusen, alterations in the pattern of GA progression and indications of long-term survivalof the OpRegen cells. We began enrollment of Cohort 4 (targeted for an additional 12 patients) shortly thereafter and treatedthree patients via the traditional route of administration. In 2019, we amended our clinical protocol to incorporate the OrbitSDS and our new thaw and inject formulation into our Phase 1/2a clinical trial. In February 2020, we announced that after reviewingpromising preliminary data from the ongoing OpRegen Phase 1/2a clinical trial, our independent data safety monitoring board removedthe protocol-mandated treatment stagger. The COVID pandemic slowed the rate of patient accrual but study enrollment was completedon November 10, 2020, with the treatment of the twelfth Cohort 4 patient, seven via the Orbit SDS and five via PPV/retinotomy.Five different surgeons at four centers successfully delivered OpRegen using the Orbit SDS and there were no unexpected AEs. Encouragingstructural and clinical changes in these better vision patients, including better visual acuity and increased reading speed, arebeing followed and updates will be provided at major medical meetings or as findings merit.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 10 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        8
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InJune 2020, we were able to report the first known example of retinal restoration following OpRegen administration in aCohort 4 patient who was treated via the PPV/retinotomy route, with the findings confirmed by several independent reviewers. Itis hypothesized that photoreceptor cells in the transition areas at the boundary of the GA are dysfunctional and dying, but notcompletely lost. The addition of new RPE cells may restore the microenvironment in surrounding tissue and contribute to the possibilityof restoring function to existing cells that otherwise, if left untreated, would inevitably progress to further expansion of theatrophic region. Specifically, in this patient, the area of GA assessed at nine months following OpRegen treatment wasapproximately 25% smaller than the patient’s pre-treatment baseline. As reported in November at the 2020 American Academyof Ophthalmology (AAO) Annual Meeting, this patient continues to show signs of a smaller area of GA and improved visual acuity.This unprecedented finding supports the view that dry AMD is not an irreversible, degenerative condition and that some portionof diseased retinal tissue may be recoverable in atrophic end-stage disease patients.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Withenrollment complete, patients are being followed for safety and efficacy as per protocol. We plan to present OpRegen data to theFDA in the third quarter of 2021 for discussion about a subsequent, comparative clinical trial.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OPC1
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OPC1is our lead product candidate for the treatment of acute spinal cord injury (“SCI”). SCI occurs when the spinal cordis subjected to a severe crush or contusion injury, such as that caused by a car or motorcycle accident and typically resultsin severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder and sexual function. Thereare approximately 18,000 new spinal cord injuries annually in the U.S. (NSCIC SCI Facts and Figures at a Glance (2019)), and thereare currently no FDA-approved drugs specifically for the treatment of SCI, although methylprednisolone, a corticosteroid generallyused as an anti-inflammatory drug, is sometimes prescribed on an off-label basis to reduce acute inflammation in the injured spinalcord immediately after injury. It is believed that to effect substantial benefit in treating this complex injury, multiple mechanismsof action are required, such as introduction of biologics that preserve surviving neurons and stimulate new nerve axon outgrowth,suppression of lesion formation at the injury site, generation of new blood vessels to repair the ischemic damage from injury,and myelination of the demyelinated and newly formed nerve axons. A key therapeutic target in SCI is replacement of oligodendrocytesthat are selectively lost at the injury site. As the sole source of the insulating protein myelin in the brain and spinal cord,oligodendrocytes wrap around nerve axons and allow conduction of electrical impulses throughout the central nervous system (“CNS”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OPC1is an oligodendrocyte progenitor cell therapy derived from our pluripotent cell technology under Current Good Manufacturing Practice(“cGMP”) conditions using a directed differentiation method. These cells are stored frozen until ready for use andprepared for direct administration into the injured spinal cord. Based on preclinical studies, when OPC1 is transplanted intothe injured spinal cord, the cells undergo further maturation to generate a replacement population of oligodendrocytes at theinjury site that are capable of remyelinating denuded and newly formed nerve axons. Prior to their maturation, the transplantedoligodendrocyte progenitor cells stimulate additional reparative processes, including promotion of neuron survival and nerve axonoutgrowth, and induction of blood vessel formation in and around the injury site. In addition, OPC1 cells rapidly migrate fromthe injection point to the injury site where they generate a supportive tissue matrix and suppress cavitation. Cavitation is adestructive process that occurs within the spinal cord following SCI, and typically results in permanent loss of motor and sensoryfunction. A patient with cavitation can develop a condition known as syringomyelia, which results in additional neurological andfunctional damage to the patient and can result in chronic pain. Based on the multiple reparative properties associated with OPC1,we believe this candidate cell therapy product is ideally suited to treat neurological conditions such as SCI and other demyelinationand demyelination disorders of the CNS.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Undera grant for clinical development, the development of OPC1 has been supported by $14.3 million in funds from the California Institutefor Regenerative Medicine (“CIRM”), from 2014 through the date of this Report. We intend to apply for additional grantsfrom CIRM for the program’s continued development.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 11 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        9
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Priorto its acquisition, Asterias tested OPC1 in two clinical trials: a five patient Phase 1 safety trial and a 25-patient Phase 1/2adose escalation trial, which we call the SCiStar trial. The SCiStar trial was an open-label, single-arm trial testing three sequentialescalating doses of OPC1 administered at up to 20 million OPC1 cells with subacute, C-4 to C-7, motor complete (AIS-A or AIS-B)cervical SCI. These individuals have essentially lost all movement below their injury site and experience severe paralysis ofthe upper and lower limbs. AIS-A patients have lost all motor and sensory function below their injury site, while AIS-B patientshave lost all motor function but may retain some minimal sensory function below their injury site. OPC1 was administered 21 to42 days post-injury. Patients continue to be followed by neurological exams and imaging procedures to assess the safety and activityof the product. Enrollment was completed in December 2017 and consisted of five cohorts:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Cohort
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Injury    Type; OPC1 Dose
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         #    of Patients
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Cohort    1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        AIS-A;    2 million OPC1 cells (low dose for safety evaluation)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Cohort    2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        AIS-A;    10 million OPC1 cells
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        6
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Cohort    3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        AIS-A;    20 million OPC1 cells*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        6
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Cohort    4
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        AIS-B;    10 million OPC1 cells
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        6
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Cohort    5
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        AIS-B;    20 million OPC1 cells*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        4
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     *One patient from Cohort 3 and one patient from Cohort 5 were administered 10 million cells.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InJanuary 2019, top-line 12-month data from the SCiStar trial were announced by Asterias, which included the following key findings:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span style="text-decoration: underline">
         Positive    Safety Profile
        </span>
        . Magnetic resonance imaging (“MRI”) scans at 12 months post-injection of OPC1 showed no evidence    of adverse changes in any of the 25 patients.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span style="text-decoration: underline">
         Cell    Engraftment
        </span>
        . All three patients in Cohort 1 and 21 of the 22 patients in Cohorts 2-5 had MRI scans at 12 months consistent    with the formation of a tissue matrix at the injury site, which is encouraging evidence that OPC1 cells had engrafted at the    injury site and helped to prevent cavitation.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span style="text-decoration: underline">
         Improved    Motor Function
        </span>
        . At 12 months, 21 of the 22 patients who were administered either 10 million or 20 million cells of OPC1    (Cohorts 2-5) recovered at least one motor level on at least one side, and seven of the 22 patients recovered two or    more motor levels on at least one side. Motor level recovery was based on the upper extremity motor score (“UEMS”),    as measured by the International Standards for Neurological Classification of Spinal Cord Injury (“ISNCSCI”).    None of these patients saw decreased motor function following administration of OPC1, and patients consistently retained the    motor function recovery seen through six months or saw further motor function recovery from six to 12 months.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InNovember 2019, we provided an update on the SCiStar trial that highlighted, among other things:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span style="text-decoration: underline">
         Positive    Safety Profile
        </span>
        . For the 21 SCiStar trial patients who had follow-up visits at 24 months post-injection of OPC1, MRI scans    showed no evidence of adverse changes, and none of the patients had a decline in their motor function from their 12-month    follow-up visit. There were no unexpected serious adverse events to date in any of these patients.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <span style="text-decoration: underline">
         Improved    Motor Function
        </span>
        . All 3 Cohort 1 patients continued to be stable 2-4 years out post treatment. At 24 months, five    of the six Cohort 2 patients recovered at least two motor levels on at least one side, and one Cohort 2 patient    recovered three motor levels, which has been maintained through that patient’s 36-month follow-up visit. Motor level    recovery was based on the UEMS as measured by the ISNCSCI.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InNovember 2020, the formal Clinical Study Report for the SCiStar study with the above supporting data was submitted to the FDA.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheFDA designated OPC1 as a Regenerative Medicine Advanced Therapy (“RMAT”), for the treatment of acute SCI and grantedit Orphan Drug Designation, which includes the ability for increased interfacing with the FDA during clinical development, anda pathway to possible market exclusivity.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 12 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        10
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     In2019, we transferred all cGMP manufacturing processes, including the establishment of cell banks and the OPC1 process developmentand manufacturing for clinical studies, to our cell therapy manufacturing facility in Jerusalem, Israel. Improvements to the manufacturingprocess were completed in 2020 and include enhancements to the production process to ensure robust, controlled reproducible andcommercially viable scale, and purity of OPC1. We also developed a thaw and inject formulation of OPC1 to facilitate logisticsand handling at the point of care with the elimination of the dose preparation at the clinical site. An information amendmentdescribing the new process, an improved analytical plan, and a proposed comparability plan has been filed with FDA. A meetingwith the FDA is planned during the second half of 2021 to discuss our manufacturing improvements and the further developmentof OPC1 in SCI to best set the program up for success moving forward. Concurrently, we have announced a new partnership for theintroduction of a novel delivery device for OPC1. Preliminary assessment of prototypes revealed promising compatibility with OPC1product while simplifying the surgical procedure by providing surgeons with an instrument that is small, simple to use and wouldnot require stopping the patient’s ventilator to perform the injection, allowing far more flexibility for accurate deliveryto the injury site. We intend to complete development activities in the first half of 2021, then discuss with FDA the introductionof the new delivery device in our IND if supported by the collected data. We continue work to expand our partnerships with SCIadvocacy and support organizations to support their mission to accelerate stem cell treatments to patients with unmet medicalneeds and fast-track the development of the most promising stem cell technologies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      VAC2
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     VAC2is our lead product candidate for the treatment of cancer. Cancer afflicts millions worldwide and is one of the largest unmetclinical needs with current treatment options providing limited efficacy and a wide range of debilitating side effects. To providea more effective and targeted treatment, we are developing VAC2 as an allogeneic, or non-patient specific, cancer vaccine candidatedesigned to stimulate patient immune responses to an antigen hTERT, which is commonly expressed in cancerous cells but not innormal adult cells. VAC2, is produced by our pluripotent cell technology using a directed differentiation method, and is comprisedof a population of mature dendritic cells to which the hTERT antigen was introduced. As the most potent type of antigen presentingcell in the body, dendritic cells instruct our body’s immune system to attack and eliminate harmful pathogens and unwantedcells. To target cancerous cells, VAC2 is engineered to express the tumor-selective antigen telomerase, which is found in over85% of all cancers. The tumor antigen is loaded exogenously into the dendritic cells. The VAC1 autologous program,which preceded VAC2, serves as an effective and encouraging proof of concept behind our approach to dendritic cell vaccinestargeting telomerase, which is the backbone of the VAC2 program.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Usingpluripotent cells as the starting material for VAC2 production adds several additional advantages to this therapeutic candidate.Compared to technologies that rely on the use of a patient’s own blood, our pluripotent cell technology provides a scalablesystem for production of a large number of vaccine doses in a single lot, lower manufacturing costs, greater product consistency,and more notably, off-the-shelf availability to provide broader and immediate access to patients. In addition, we believe thatas an allogeneic therapy, VAC2 has the potential to stimulate a more robust immune response through an adjuvant effect resultingfrom the partial immune mismatch between the VAC2 cells and patients receiving the therapy. We believe that VAC2 can be used asa platform technology that can be modified to carry any antigen, including patient-specific tumor neo-antigens.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InSeptember 2014, Asterias initiated clinical development of VAC2 by entering into a Clinical Trial and Option Agreement (the “CRUKAgreement”) with Cancer Research UK (“CRUK”) and Cancer Research Technology Limited (“CRT”), a whollyowned subsidiary of CRUK, under which CRUK agreed to fund Phase 1 clinical development of VAC2 in non-small cell lung cancer.CRUK is responsible, at its own cost, for manufacturing clinical grade VAC2 and for carrying out the Phase 1 clinical trial ofVAC2. Patient enrollment began in June 2018 and six patients have now completed dosing in the initial aspect of the trial.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InMay 2020, Lineage and its wholly owned subsidiary Asterias entered into a Second Amendment to Clinical Trial and Option Agreement(the “CTOA Amendment”) with CRUK and CRT, which amends the Clinical Trial and Option Agreement entered into betweenAsterias, CRUK and CRT dated September 8, 2014, as amended September 8, 2014. Pursuant to the CTOA Amendment, Lineage assumedall obligations of Asterias and exercised early its option to acquire data generated in the Phase 1 clinical trial of VAC2 innon-small cell lung cancer being conducted by CRUK. CRUK will continue conducting the VAC2 study.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 13 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        11
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineageand CRT effectuated the option by simultaneously entering into a license agreement (the “License Agreement”) pursuantto which Lineage agreed to pay the previously agreed signature fee of £1,250,000 (approximately $1.6 million). In considerationof Lineage’s agreement to exercise the option prior to completion of the study, the parties agreed to defer the signaturefee as follows: £500,000 in September 2020, £500,000 in January 2021 and £250,000 in April 2021. For the primarylicensed product for the first indication, the License Agreement provides for milestone fees of up to £8,000,000 based uponinitiation of a Phase 3 clinical trial and the filing for regulatory approval and up to £22,500,000 in sales-based milestonespayments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications, andmid-single-digit royalty payments are payable on sales of commercial products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wecompleted the transfer of all cGMP manufacturing processes, including the establishment of cell banks and the VAC2 process developmentand manufacturing for clinical studies, to our cell therapy manufacturing facility in Jerusalem, Israel. In 2021, we will focuson updating and optimizing the manufacturing process for VAC to ensure reliable supply for future clinical studies and possiblecommercial development. An improved VAC manufacturing process will be the subject of a key interaction with FDA in the futureto introduce VAC in an IND.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theallogeneic VAC2 program was preceded by the autologous VAC1 program which isolated dendritic cells from a patient’s ownblood, modified those cells to stimulate immune responses to telomerase and then administered those cells back to the patientas a therapeutic modality. VAC1 was studied for the treatment of acute myeloid leukemia, the most common form of acute leukemiain adults. A Phase 2 clinical trial of VAC1 demonstrated that it successfully manufactured and released in 24 out of the 33 patientsenrolled in the trial. Twenty-one patients received VAC1 in the trial, including 19 in clinical remission and two in early relapse.VAC1 was found to have a favorable safety and tolerability profile. Asterias performed follow-up data collection on the 19 patientstreated while in complete remission to determine the long-term effects of the VAC1 administration on remission duration and disease-freesurvival.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     VAC1utilized an autologous approach where the cellular vaccine needs to be created specifically for each patient. This results ina longer time prior to administration of therapy as compared to the allogeneic approach of the VAC2 program, which is disadvantageousin advanced cancer patients given the rapidity of disease progression. The VAC1 autologous program which preceded VAC2 servesas an effective and encouraging proof of concept behind our approach to dendritic cell vaccines targeting telomerase, which isthe backbone of the VAC2 program.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      ResearchPrograms
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Visionrestoration
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     In2017, we expanded our ophthalmology portfolio by acquiring exclusive global rights to technology that allows the generation ofthree-dimensional human retinal tissue derived from human pluripotent cells. This tissue contains all the cell types and layersof the human retina and has shown evidence of functional integration in proof of concept animal models for advanced retinal degeneration.The technology is being developed to potentially treat or prevent a variety of retinal degenerative diseases and injuries. In2017, the National Institutes of Health (“NIH”) awarded us a grant of up to $1.6 million to further develop this innovative,next generation vision restoration program for retinal diseases and injuries, which severely impact the quality of life for millionsof people who have limited treatment options. In 2019, we received an additional grant of $0.7 million to continue work on thisprogram. We completed work under this grant in 2020 and submitted final reports to the NIH.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     In2020, the Israeli Innovation Authority approved a budgeted grant of approximately $0.6 million for us to manufacture novelretinal implants aimed to treat patients with severe retinal impairment such as retinitis pigmentosa. We are eligible for 60%reimbursement of our costs under this grant. This program allows us to combine our knowledge in manufacturing RPE cells andphotoreceptors with 3D printing technology.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Demyelination
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OPC1exhibits multiple reparative properties that may have broad applicability to neurological injury and disease, particularly asa treatment for demyelination. Past research efforts investigated the potential development of OPC1 as a candidate treatment forcertain forms of ischemic stroke and multiple sclerosis (“MS”), two severely debilitating conditions for which demyelinationis a central component to their pathology.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 14 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        12
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Todevelop OPC1 as a treatment for MS, initial proof-of-concept efficacy data has been demonstrated in collaboration with Yale Universityusing a non-human primate model of MS. Results of this study showed OPC1 engraftment that was associated with substantial remyelinationof the lesioned primate spinal cord up to five months post-treatment. Subsequently, we initiated a collaboration with Universityof California Irvine to assess OPC1 efficacy in additional mouse models of MS that better recapitulate the autoimmune componentsof the disease. Preliminary results indicated that in addition to OPC1’s capacity to remyelinate the lesioned spinal cord,the cells may also help stimulate proliferation of a distinct class of immune cells known as regulatory T cells that can helpreduce or eliminate autoimmunity.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forischemic stroke, initial proof-of-concept efficacy data for OPC1 has been demonstrated in a collaborative study with the Universityof California Los Angeles using a mouse model of white matter ischemic stroke. Results of this study demonstrated that withinthe stroke injury site, OPC1 cells engrafted, reduced lesion formation and inflammation, and increased myelination, culminatingin improved functional recovery. A second preclinical study was completed in collaboration with the University of South Floridato test two different doses of OPC1 in a rat model of ischemic subcortical and white matter stroke. Results from this study demonstratedthe ability of OPC1 to impact the restoration of motor function in a rat model of white matter stroke. Further, histological assessmentsshowed a treatment-associated reduction in stroke lesion size, including in the white matter, as well as reduced inflammationand sustained OPC1 engraftment in the injured brain.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Whilewe are not actively pursuing OPC1 for MS and ischemic stroke at this time, we may use the results of these studies to seek additionalfunding and guide further preclinical development of OPC1 for these or other conditions of demyelination.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Productsfor Other Indications
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wealso have rights to intellectual property applicable to other indications such as for producing cardiomyocytes, pancreatic isletcells, hepatocytes, chondrocytes, osteoblasts and other cell types for which development of new therapies represent significantcommercial opportunities. We may elect to pursue these or other programs at any time.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      OtherProducts
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wealso have rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix, the structural networkof molecules surrounding cells in organs and tissues essential to cellular function and tissue structure. HyStem may be usefulas a scaffold for cell replacement and retention. We sold HyStem-related assets and licensed the applicable technology in late2019, but retained the rights for other uses, including for Renevia, our facial aesthetics product, which received a ConformitéEuropéenne (CE) Mark in September 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Investmentsand subsidiaries:
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing tables show the companies in which we have a direct or indirect ownership, their respective principal fields of business,our percentage ownership as of March 5, 2021, and the country where their principal business is located:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Investments:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold">
       Company
      </td>
      <td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; width: 40%; font-weight: bold">
       Field of Business
      </td>
      <td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Lineage                                         Ownership
        </b>
       </span>
      </td>
      <td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">
      </td>
      <td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">
       Country
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td>
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
       <span style="font: 10pt Times New Roman, Times, Serif">
        OncoCyte Corporation
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: justify">
       Cancer diagnostics
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ~1
       </span>
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: center">
       USA
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Hadasit Bio-Holdings    Ltd.
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
       Owns a portfolio of R&amp;D based companies
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        &lt;2
       </span>
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: center">
       Israel
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 15 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        13
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Significantsubsidiaries:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       Company
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       Field of Business
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Lineage Ownership
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Country
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Cell Cure Neurosciences Ltd.
      </td>
      <td>
      </td>
      <td style="text-align: justify">
       Development and manufacturing of Lineage’s cell replacement platform technology
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        99
       </span>
      </td>
      <td style="text-align: left">
       %
       <sup>
        (2)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: center">
       Israel
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; width: 30%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    Biotherapeutics, Inc.
        <sup>
         (3)
        </sup>
       </span>
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 39%; text-align: left">
       Cell based therapeutics to treat neurological conditions
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 10%; text-align: right">
       100
      </td>
      <td style="width: 4%; text-align: left">
       %
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 10%; text-align: center">
       USA
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ES Cell International    Pte. Ltd
        <sup>
         (4)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: justify">
       Research and clinical grade cell lines
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       100
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: center">
       Singapore
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
       <span style="font: 10pt Times New Roman, Times, Serif">
        OrthoCyte Corporation
        <sup>
         (4)(5)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: justify">
       Research in orthopedic diseases and injuries
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       99.8
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: center">
       USA
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        These    are publicly traded companies. See Notes to Consolidated Financial Statements: Note 4. Equity Method of Accounting for Common    Stock of OncoCyte, at Fair Value.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes    shares owned by Lineage and ES Cell International Pte. Ltd. (“ESI”).
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    was acquired by Lineage in March 2019. See Notes to Consolidated Financial Statements: Note 3. Asterias Merger.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    operating activities and fields of business listed under these subsidiaries are conducted primarily by Lineage as the parent    company.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (5)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        OrthoCyte    Corporation (“OrthoCyte”) adopted a stock option plan under which it may issue up to 4,000,000 shares of its common    stock to officers, directors, employees, and consultants of OrthoCyte and Lineage employees, including officers. As of December    31, 2020, no options to purchase OrthoCyte common stock were outstanding.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Patentsand Trade Secrets
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weseek to protect and rely on our proprietary cell-based therapy platform and associated development and manufacturing capabilitiesand derived product candidates through a variety of methods, including seeking and maintaining patents intended to cover our productsand compositions, their methods of use and processes for their manufacture, our platform technologies and any other inventionsthat are commercially important to the development of our business. We also rely on contractual obligations with employees andthird parties to protect our proprietary rights. For example, in addition to protecting our proprietary rights with patents, werely on unpatented trade secrets, improvements, know-how and innovation, and we take steps necessary to protect these rights,including through confidentiality agreements with our corporate partners, employees, consultants and vendors. We have sought,and intend to continue to seek, appropriate patent protection for important and strategic components of our proprietary technologiesby filing patent applications in the U.S. and internationally. We may also file additional patent applications, when appropriate,to cover improvements on our clinical products, clinical product candidates, and related technologies. There are no assurancesthat any of our intellectual property rights will guarantee complete or adequate protection or market exclusivity for our productsand product candidates. We also enter into collaborative and other similar arrangements with third parties, such as license agreements,to in-license and/or out-license intellectual property rights. Our financial success will be dependent, in part, on our abilityto obtain rights to commercially valuable patents, to protect and enforce our intellectual property rights and to operate withoutinfringing any intellectual property rights of others. From time to time, we assess our patents and pending applications coveringour products and product candidates. If we determine that any patents or patent applications no longer provide adequate or necessaryprotection, we may transfer or abandon such patents and patent applications to avoid incurring unnecessary costs.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weown or license, directly  or through our subsidiaries, several patent families that include hundreds of U.S. and internationalpatents and patent applications. We cannot be certain that issued patents will be enforceable or provide adequate protection orthat pending applications will result in issued patents.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OpRegen
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weand our subsidiary, Cell Cure, have rights to issued U.S. and international patents and pending patent applications covering OpRegen.The issued patents have expiration dates ranging from 2028 to 2036. The pending applications if issued, will have estimated expirationdates ranging from 2028 to 2041. These U.S. and international issued patents and pending applications also include those in-licensedfrom Hadasit Medical Research Services and Development Ltd. (“Hadasit”), the commercial arm and a wholly owned subsidiaryof Hadassah Medical Organization. We also solely own pending U.S. and Patent Cooperation Treaty (“PCT”) patent applicationsrelating to cryopreserving the cell population and then shipping it to the clinical trial site so the cells can be immediatelythawed and delivered to the patient without further processing. The U.S. patent applications, and any filed international patentapplications based on the PCT applications, if issued, will have estimated expiration dates in 2038.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 16 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        14
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     CellCure was a party to two pending opposition proceedings in the European Patent Office (“EPO”) involving EP Patent Numbers2147094 (issued 08-Oct-2014) and 2554661 (issued 19-Nov-2014), both entitled, “Stem Cell-Derived Retinal Pigment EpithelialCells”. The oral proceedings took place on March 16, 2017 and March 17, 2017, respectively. Both patents were upheld bythe EPO and the patents issued as amended during the opposition proceedings. Both patents cover OpRegen until 2028.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OPC1
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave numerous U.S. and international issued patents and pending patent applications that are relevant to neural cells, such asoligodendrocyte progenitor cells, including patent families acquired from Geron Corporation (“Geron”) that are directedto the differentiation of pluripotent stem cells, including human embryonic stem (“hES”) cells, into various neuralcell types, as well as various culture and purification methods. These U.S. and international issued patents and pending patentapplications also include those in-licensed from the Regents of the University of California. Additionally, there are four patentfamilies with pending patent applications owned by us directed to improved methods of producing oligodendrocyte progenitor cells,oligodendrocyte progenitor cell compositions and methods of treatment of spinal cord injury using oligodendrocyte progenitor cells.There is also a patent family directed to improved methods of producing oligodendrocyte progenitor cells, oligodendrocyte progenitorcell compositions and methods for the treatment of stroke using oligodendrocyte progenitor cells which is jointly owned with theRegents of the University of California. The expiration dates of the patents and pending patent applications acquired from Geronand in-licensed from the Regents of the University of California range from 2023 to 2036. The estimated expiration dates of thefour patent families with pending applications owned by us range from 2036 to 2040. The commercial success of OPC1 depends, inpart, upon our ability to exclude competition for this product with the existing patent portfolio, regulatory exclusivity, undisclosedknow-how and/or trade secrets, or a combination of these barriers to entry.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      VAC1and VAC2
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave numerous U.S. and international issued patents and pending patent applications that are relevant to dendritic cells, includingpatent families acquired from Geron or in-licensed from third parties that are directed to the differentiation of pluripotentstem cells, including hES cells, into hematopoietic progenitor cells and immature and mature dendritic cells. In addition, thesepatent rights include a patent family with claims directed to immunogenic compositions comprising antigen-presenting dendriticcells and methods of eliciting an anti-telomerase immune response in a subject by administering to the subject such compositions.The expiration dates of the patents, and the estimated expiration dates of the pending applications, acquired from Geron or in-licensedto us range from 2022 to 2041. The commercial success of VAC1 and VAC2 products depends, in part, upon our ability to excludecompetition in these products with this patent portfolio, regulatory exclusivity, undisclosed know-how and/or trade secrets, ora combination of these barriers to entry.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OtherPatents and Patent Applications
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave U.S. and international issued patents and pending patent applications related to producing cardiomyocytes, pancreatic isletcells, hepatocytes, chondrocytes and osteoblasts. The expiration dates of these patents and pending patent applications rangefrom 2020 to 2032. In addition, we have U.S. and international issued patents and pending patent applications related to suspensioncultures and feeder-free cultures for culturing and proliferating pluripotent stem cells. The expiration dates for these patentsand pending patent applications range from 2021 to 2026.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wealso have U.S. and international issued patents and pending applications covering Renevia, include those in-licensed from theUniversity of Utah Research Foundation (“UURF”) having expiration dates ranging from 2023 to 2027, and a pending patentapplication in Europe having an estimated expiration date of 2024. We also solely own pending U.S. and European patent applicationsfiled in 2018 that, if issued, will have estimated expiration dates in 2038.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 17 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        15
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      GeneralRisks Related to Obtaining and Enforcing Patent Protection
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Becausepatent applications are confidential until a patent is issued, we may not know if our competitors have filed patent applicationsfor technology covered by our pending applications or if we were the first to invent or first to file an application directedtoward the technology that is the subject of our patent applications. Competitors may have filed patent applications or receivedpatents and may obtain additional patents and proprietary rights that block or compete with our products. In addition, if competitorsfile patent applications covering our technology, we may have to participate in interference/derivation proceedings or litigationto determine the right to a patent. Litigation and interference/derivation proceedings are unpredictable and expensive, such that,even if we are ultimately successful, our results of operations may be adversely affected by such events. Accordingly, there isa risk that any patent applications that we file and any patents that we hold or later obtain could be challenged by third partiesand be declared invalid in view of third party patent applications and/or patents. Litigation, interferences, oppositions, interpartes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validityand scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement ofcertain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. We may also facechallenges to our patent and regulatory protections covering our products by third parties, including manufacturers of genericsand biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatoryexclusivity. Litigation, interference, oppositions, inter partes reviews, administrative challenges or other similar types ofproceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedingscould adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture andmarket our products, require us to seek a license for the infringed product or technology or result in the assessment of significantmonetary damages against us that may exceed any amounts that we may accrue on our financial statements as a reserve for contingentliabilities. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses couldprevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain wouldreduce our profits derived from the covered products and services.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theenforcement of patent rights often requires litigation against third-party infringers, and such litigation can be costly to pursue.Even if we succeed in having new patents issued or in defending any challenge to issued patents, there is no assurance that ourpatents will be comprehensive enough to provide us with meaningful patent protection against our competitors.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Employees
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, we had 55 employees, of which 20 were Lineage employees and 35 were employees of Cell Cure in Israel andof which 49 were employed on a full-time basis and six were employed on a part-time basis. Ten employees hold Ph.D.degrees in one or more fields of science. None of our employees are covered by a collective bargaining agreement.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Manufacturing
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemaintain an innovative cell therapy manufacturing facility in the Bio Park on the campus of the Hadassah University Hospital inJerusalem, Israel. The facility includes process development laboratories and a state-of-the-art, cGMP manufacturing facility.It is designed and equipped to enable simultaneous cGMP processes and to produce a range of cell therapy products for human usein clinical trials as well as at a scale suitable for commercial launch. All cGMP manufacturing processes, including cell banksand product manufacturing for our cell therapy product candidates are conducted in this facility.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weobtain key components required for the manufacture of our cell therapy product candidates from third-party manufacturers and suppliers,which include, in some instances, sole source manufacturers and suppliers. We do not currently have long-term commitments or supplyagreements in place to obtain certain key components used in the manufacture of our cell therapy product candidates.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LicensedTechnology and Product Development Agreements
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineagehas obtained the right to use technology that we believe has great potential in our product development efforts, and that maybe useful to other companies that are engaged in the research and development of products for human therapeutic and diagnosticuse.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 18 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        16
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      SecondAmendment to Clinical Trial and Option Agreement and License Agreement with Cancer Research UK
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnMay 6, 2020, Lineage and its wholly owned subsidiary Asterias entered into a Second Amendment to Clinical Trial and Option Agreement(the “CTOA Amendment”) with Cancer Research UK (“CRUK”) and Cancer Research Technology Limited (“CRT”),which amends the Clinical Trial and Option Agreement entered into between Asterias, CRUK and CRT dated September 8, 2014, as amendedSeptember 8, 2014. Pursuant to the CTOA Amendment, Lineage assumed all obligations of Asterias and exercised early its optionto acquire data generated in the Phase 1 clinical trial of VAC2 in non-small cell lung cancer being conducted by CRUK. CRUK iscontinuing to conduct the VAC2 study.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineageand CRT effectuated the option by simultaneously entering into a license agreement (the “CRT License Agreement”) pursuantto which Lineage agreed to pay the previously agreed signature fee of £1,250,000 (approximately $1.6 million). In considerationof Lineage’s agreement to exercise the option prior to completion of the study, the parties agreed to defer the signaturefee as follows: £500,000 in September 2020, £500,000 in January 2021 and £250,000 in April 2021. For the primarylicensed product for the first indication, the CRT License Agreement provides for milestone fees of up to £8,000,000 basedupon initiation of a Phase 3 clinical trial and the filing for regulatory approval and up to £22,500,000 in sales-basedmilestones payments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications,and mid-single-digit royalty payments are payable on sales of commercial products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Eitherparty may terminate the CRT License Agreement for the uncured material breach of the other party. CRT may terminate the CRT LicenseAgreement in the case of Lineage’s insolvency or if Lineage ceases all development and commercialization of all productsunder the CRT License Agreement.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      HadasitResearch and License Agreement
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InJune 2017, Cell Cure entered into a Second Amended and Restated License Agreement with Hadasit (the “Hadasit License Agreement”).Pursuant to the Hadasit License Agreement, Hadasit granted Cell Cure an exclusive, worldwide, royalty-bearing license (with theright to grant sublicenses) in its intellectual property portfolio of U.S. and international issued patents and pending patentapplications relevant to materials and technology related to human stem cell derived photoreceptor cells and RPE cells, to use,commercialize and exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of: (i)human stem cell derived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatmentof eye disorders; and (ii) human stem cell derived RPE cells, solely for use in cell therapy for the diagnosis, amelioration,prevention and treatment of eye disorders. This intellectual property licensed includes patents and pending applications havingexpiration dates, and estimated expiration dates, respectively, ranging from 2025 to 2028. Cell Cure and Hadasit also jointlyown U.S. and international issued patents and patent applications directed to methods of selecting RPE cells, which patents andpatent applications will expire in 2033.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Pursuantto the Hadasit License Agreement, Cell Cure paid a small one-time lump sum payment for reimbursement of intellectual propertyrelated expenses and will pay a royalty in the mid-single digits of net sales from sales of licensed intellectual property byany invoicing entity and a royalty of 21.5% on sublicensing receipts. In addition, Cell Cure will pay Hadasit an annual minimalnon-refundable royalty, which will become due and payable the first January 1 following the completion of services to Cell Cureby a research laboratory.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     CellCure agreed to pay Hadasit non-refundable milestone payments upon the recruitment of the first patient for the first Phase 2bclinical trial, upon the enrollment of the first patient in the first Phase 3 clinical trials, upon delivery of the report forthe first Phase 3 clinical trials, upon the receipt of an NDA or marketing approval in the EU, whichever is the first to occur,and upon the first commercial sale in the United States or EU, whichever is the first to occur. Such milestones, in the aggregate,may be up to $3.5 million. As of December 31, 2020, Cell Cure had not accrued any of these milestone payments.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheHadasit License Agreement terminates upon the expiration of Cell Cure’s obligation to pay royalties for all licensed products,unless earlier terminated. In addition, the Hadasit License Agreement may be terminated by (i) Hadasit if, among other reasons,Cell Cure fails to continue the clinical development of the licensed intellectual property or fails to take actions to commercializeor sell the licensed intellectual property over any consecutive 12-month period, and (ii) by either party for: (a) a materialbreach which remains uncured following a cure period; or (b) the granting of a winding-up order in respect of the other party,or upon an order being granted against the other party for the appointment of a receiver or a liquidator in respect of a substantialportion of such other party’s assets. The Hadasit License Agreement also contains customary indemnification obligationsof Cell Cure.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 19 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        17
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      LicenseAgreement with University of California
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare party to an exclusive license agreement with The Regents of the University of California dated February 20, 2003 (the “UCLicense Agreement”) for U.S. and international issued patents and pending patent applications covering a method for directingthe differentiation of pluripotent cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytesfor remyelination and treatment of spinal cord injury. Under the UC License Agreement, we have an exclusive worldwide licenseunder such patents, including the right to grant sublicenses, to create products for biological research, drug screening, andhuman therapy using the licensed patents. These issued patents and pending applications have expiration dates ranging from 2023to 2024.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Underthe UC License Agreement, we will pay the university a royalty of 1% from sales of products that are covered by the licensed patentrights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensedpatent rights occurs and continuing for the life of the applicable patent right under the agreement. Under certain conditions,we will pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements,that we receive from sublicensees.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheUC License Agreement terminates on the expiration of the last-to-expire of the university’s issued licensed patents. Ifno further patents covered by the UC License Agreement are issued, it will terminate in 2024. The university may terminate theUC License Agreement if we breach it, and we can terminate with 60 days’ notice.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      WARFAgreements
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave rights to certain U.S and international issued patents, pending patent applications and stem cell lines with the WisconsinAlumni Research Foundation (“WARF”) under a Commercial License and Option Agreement entered into between Lineage andWARF in January 2008 and a Non-Exclusive License Agreement entered into between Asterias and WARF in October 2013 (collectively,the “WARF Agreements”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Underthe WARF Agreements, we have a worldwide non-exclusive license under certain WARF patents and WARF-owned primate (including human)stem cell lines covered by such patents for use in internal research, and to make, use and sell products that are used as researchtools and products that are discovered or developed through our internal research using such patents and stem cells. We paid upfrontlicense fees and have agreed to additional payments upon the attainment of specified clinical development milestones, royaltieson sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that we may receive fromany sublicenses that we may grant to use the licensed patents or stem cell lines.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheWARF Agreements will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire andwith respect to licensed cell lines until terminated by a party. We may terminate the WARF Agreements at any time with prior writtennotice, and WARF may terminate the WARF Agreements upon a breach. We have agreed to indemnify WARF and certain other designatedaffiliated entities from liability arising out of or relating to the death or injury of any person or damage to property due tothe sale, marketing, use or manufacture of products that are covered by the licensed patents, licensed stem cell lines or inventionsor materials developed or derived from the licensed patents or stem cell lines.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      RoyaltyAgreement with Geron
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inconnection with Asterias’s acquisition of Geron’s stem cell assets, in October 2013, we entered into a royalty agreementwith Geron (the “Royalty Agreement”) pursuant to which we agreed to pay Geron a 4% royalty on net sales (as definedin the Royalty Agreement) by us or any of our affiliates or sales agents of any products that we develop and commercialize thatare covered by the patents Geron contributed to us. In the case of sales of such products by a person other than us or one ofour affiliates or sales agents, we will be required to pay Geron 50% of all royalties and cash payments received by us or by ouraffiliate in respect of a product sale. Royalty payments will be subject to proration in the event that a product covered by apatent acquired from Geron is sold in combination with another product that is not covered by a patent acquired from Geron. TheRoyalty Agreement will terminate at the expiration or termination date of the last issued patent contributed by Geron under theRoyalty Agreement. We estimate that the latest patent expiration date will be in 2032.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 20 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        18
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      GovernmentRegulation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Governmentauthorities at the federal, state and local level, and in other countries, extensively regulate among other things, the development,testing, manufacture, quality, approval, safety, efficacy, distribution, labeling, packaging, storage, record keeping, marketing,import/export and promotion of drugs, biologics, and medical devices. Authorities also heavily regulate many of these activitiesfor human cells, tissues, and cellular and tissue-based products (“HCT/Ps”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      FDAand Foreign Regulation of Therapeutic Products
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheFDA and foreign regulatory authorities will regulate our proposed products as drugs, biologics or medical devices, depending uponsuch factors as the use to which the product will be put, the chemical composition, and the interaction of the product with thehuman body. In the United States, the FDA regulates drugs and biologics under the Federal Food, Drug and Cosmetic Act (“FDCA”),the Public Health Service Act (“PHSA”), and implementing regulations. In addition, establishments that manufacturehuman cells, tissues, and HCT/Ps are subject to additional registration and listing requirements, including current good tissuepractice regulations. Certain cell therapy proposed products will be reviewed by the FDA staff in its Center for Biologics Evaluationand Research Office of Cellular, Tissue and Gene Therapies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourdomestic human drug and biologic products will be subject to rigorous FDA review and approval procedures. After testing in animalsto evaluate the potential efficacy and safety of the product candidate, an investigational new drug (“IND”) submissionmust be made to the FDA to obtain authorization for human testing. Extensive clinical testing, which is generally done in threephases, must then be undertaken to demonstrate optimal use, safety, and efficacy of each product in humans. Each clinical trialis conducted under the auspices of an independent Institutional Review Board (“IRB”). The IRB will consider, amongother things, ethical factors, the safety of human subjects, and the possible liability of the institution.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Phase1 clinical trials are conducted in a small number of healthy volunteers or volunteers with the target disease or condition toassess safety. Phase 2 clinical trials are conducted with groups of patients afflicted with the target disease or condition inorder to determine preliminary efficacy, optimal dosages and expanded evidence of safety. In some cases, an initial trial is conductedin diseased patients to assess both preliminary efficacy and preliminary safety, in which case it is referred to as a Phase 1/2clinical trial. Phase 3 clinical trials are large-scale, multi-center, comparative trials and are conducted with patients afflictedwith the target disease or condition in order to provide enough data to demonstrate the efficacy and safety required by the FDA.The FDA closely monitors the progress of each of the three phases of clinical testing and may, at its discretion, re-evaluate,alter, suspend or terminate the clinical trial based upon the data which have been accumulated to that point and its assessmentof the risk/benefit ratio to the intended patient population. All adverse events must be reported to the FDA. Monitoring of allaspects of the trial to minimize risks is a continuing process.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Noaction can be taken to market any therapeutic product in the U.S. until an appropriate New Drug Application (“NDA”)or Biologics License Application (“BLA”) has been approved by the FDA. Submission of the application is not a guaranteethat the FDA will find it complete and accept it for filing. If an application is accepted for filing, following the FDA’sreview, the FDA may grant marketing approval, request additional information or deny the application by way of a Complete ResponseLetter if it determines that the application does not provide an adequate basis for approval. FDA regulations also restrict theexport of therapeutic products for clinical use prior to FDA approval. Before approving a BLA, the FDA will inspect the facilitiesat which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processesand facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within requiredspecifications including gene therapy products (“GTPs”) to the extent applicable. These are FDA regulations and guidancedocuments that govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps. The primary intentof the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent theintroduction, transmission and spread of communicable disease. FDA regulations also require HCT/P establishments to register andlist their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approvinga BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliancewith IND trial requirements and GCP requirements. To maintain compliance with CGMPs, GTPs, and GCPs, an applicant must incur significantexpenditure of time, money and effort in the areas of training, record keeping, production, and quality control.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 21 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        19
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Todate, the FDA has not granted marketing approval to any pluripotent stem-based therapeutic products and it is possible that theFDA or foreign regulatory agencies may subject our product candidates to additional or more stringent review than drugs or biologicsderived from other technologies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheFDA offers several programs to expedite development of products that treat serious or life-threatening illnesses and that providemeaningful therapeutic benefits to patients over existing treatments. A drug is eligible for designation as an RMAT if: the drugis a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell andtissue product or any combination product using such therapies or products, except for those regulated solely under certain othersections; the drug is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition; and preliminaryclinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. Someof our current and future products may be eligible for RMAT designation.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Underthe Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition,which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000individuals in the United States, there is no reasonable expectation that the cost of developing and making available a drug orbiologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphandrug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identityof the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does notconvey any advantage in, or shorten the duration of, the regulatory review or approval process.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifa product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has suchdesignation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications,including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, suchas a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDAfrom approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different diseaseor condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLAapplication fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broaderthan the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States maybe lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unableto assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      CombinationProducts
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe develop any products that are used with medical devices, they may be considered combination products, which are defined bythe FDA to include products comprised of two or more regulated components or parts such as a biologic and a device. For example,our HyStem hydrogel products may be used to administer one or more pluripotent stem cell-based therapy products. When regulatedindependently, biologics and devices each have their own regulatory requirements. However, the regulatory requirements for a combinationproduct comprised of a biologic administered with a delivery device can be more complex, because in addition to the individualregulatory requirements for each component, additional combination product regulatory requirements may apply. The Office of CombinationProducts at the FDA coordinates the review of such products and determines the primary mode of action of a combination product.The definition and regulatory requirements for combination products may differ significantly among countries in which we may seekapproval of our product candidates.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      FDARegulation of Manufacturing
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheFDA regulates the manufacturing process of pharmaceutical products, human tissue and cell products, and medical devices, requiringthat they be produced in compliance with cGMP. See “Manufacturing.” The FDA regulates and inspects equipment, facilities,laboratories and processes used in the manufacturing and testing of products prior to providing approval to market products. Ifafter receiving approval from the FDA, a material change is made to manufacturing equipment or to the location or manufacturingprocess, additional regulatory review may be required. The FDA also conducts regular, periodic visits to re-inspect the equipment,facilities, laboratories and processes of manufacturers following an initial approval. If, as a result of those inspections, theFDA determines that equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditionsof product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against the manufacturer, includingsuspension of manufacturing operations. Issues pertaining to manufacturing equipment, facilities or processes may also delay theapproval of new products undergoing FDA review.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 22 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        20
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      FDARegulation of Advertising and Product Promotion
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheFDA also regulates the content of advertisements used to market pharmaceutical and biologic products. Claims made in advertisementsconcerning the safety and efficacy of a product, or any advantages of a product over another product, must be supported by clinicaldata filed as part of an NDA, a BLA, or an amendment to an NDA or a BLA, and must beconsistent with the FDA-approved labeling and dosage information for that product.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Pharmaceuticaland biologic products may be promoted only for the approved indications in accordance with the approved label. The FDA and otheragencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found tohave improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medicaljudgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in theirchoice of treatments but the FDA does restrict manufacturer’s communications on the subject of off-label use of their products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      ForeignRegulation
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Salesof pharmaceutical products outside the U.S. are subject to foreign regulatory requirements that vary widely from country to country.Even if FDA approval has been obtained, approval of a product by comparable regulatory authorities of foreign countries must beobtained prior to the commencement of marketing the product in those countries. The time required to obtain such approval maybe longer or shorter than that required for FDA approval.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      FederalFunding and State Regulations
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     EffectiveJuly 7, 2009, the National Institutes of Health (“NIH”) adopted guidelines on the use of hES cells in federally fundedresearch. The central focus of the guidelines is to assure that hES cells used in federally funded research are derived from humanembryos that were created for reproductive purposes, are no longer needed for this purpose, and are voluntarily donated for researchpurposes with the informed written consent of the donors. hES cells that were not derived in compliance with the guidelines, arenot eligible for use in federally funded research.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thestate of California has adopted legislation and regulations that require institutions that conduct stem cell research to notify,and in certain cases obtain approval from, a Stem Cell Research Oversight Committee (“SCRO Committee”) before conductingthe research. Under certain California regulations, all hES cell lines used in our research must be acceptably derived. Californiaregulations further require certain records to be maintained with respect to stem cell research and the materials used. Lineageprograms that involve the use of stem cells have been reviewed by a SCRO Committee to confirm compliance with federal and stateguidelines.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ThehES cell lines that we use are all on the NIH registry of lines that have been reviewed and meet standards for federal fundinggrants. All of our research programs utilize stem cells from established and well-characterized cell lines and which are capableof self-renewal and expansion through normal cellular division (mitosis). Our research programs do not require new tissue or cellsfrom donors of any kind.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      HealthInsurance Portability and Accountability Act and Other Health Information Privacy and Security Laws
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheHealth Insurance Portability and Accountability Act (“HIPAA”), as amended by the Health Information Technology forEconomic and Clinical Health Act (“HITECH”), and their respective implementing regulations impose obligations on “coveredentities,” including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective“business associates” that create, receive, maintain or transmit individually identifiable health information foror on behalf of a covered entity, and their subcontractors that use, disclose, access, or otherwise process individually identifiableprotected health information, with respect to protecting the privacy, security, and transmission of protected health information.HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization ofidentifiers for covered health plans and providers. Penalties for violations of HIPAA regulations include civil and criminal penalties.Additionally, HITECH created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directlyapplicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctionsin U.S. federal courts to enforce HIPAA and seek attorneys’ fees and costs associated with pursuing federal civil actions.In addition, certain state and foreign laws also govern the privacy and security of health information in some circumstances,many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 23 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        21
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Federaland State Fraud and Abuse Laws
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Avariety of federal and state laws prohibit fraud and abuse. These laws are interpreted broadly and enforced aggressively by variousstate and federal agencies, including the Centers for Medicare &amp; Medicaid Services (“CMS”), the Department ofJustice, the Office of Inspector General for HHS, and various state agencies. In addition, the Medicare and Medicaid programsincreasingly use a variety of contractors to review claims data and to identify improper payments as well as fraud and abuse.These contractors include Recovery Audit Contractors, Medicaid Integrity Contractors and Zone Program Integrity Contractors. Inaddition, CMS conducts Comprehensive Error Rate Testing audits, the purpose of which is to detect improper Medicare payments.Any overpayments identified must be repaid unless a favorable decision is obtained on appeal. In some cases, these overpaymentscan be used as the basis for an extrapolation, by which the error rate is applied to a larger universe of claims, and which canresult in even higher repayments.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefederal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, receiving,or providing remuneration, directly or indirectly, to induce or in return for either the referral of an individual, or the furnishing,recommending, or arranging for the purchase, lease or order of any health care item or service reimbursable, in whole or in part,under a federal health care program. The definition of “remuneration” has been broadly interpreted to include anythingof value, including gifts, discounts, credit arrangements, payments of cash, ownership interests and providing anything at lessthan its fair market value. Recognizing that the federal Anti- Kickback Statute is broad and may prohibit certain common activitieswithin the health care industry, the Office of Inspector General for HHS has issued a series of statutory exceptions and regulatory“safe harbors.” However, these exceptions and safe harbors are drawn narrowly and require strict compliance in orderto offer protection from prosecution under the federal Anti-Kickback Statute. Although full compliance with these provisions ensuresagainst prosecution under the federal Anti-Kickback Statute, the failure of a transaction or arrangement to fit within a specificsafe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-KickbackStatute will be pursued. However, conduct and business arrangements that do not fully satisfy all requirements of an applicablesafe harbor may result in increased scrutiny by government enforcement authorities and would be evaluated on a case-by-case basisbased on a cumulative review of their facts and circumstances. Additionally, the Patient Protection and Affordable Care Act, asamended by the Health Care and Education Reconciliation Act (collectively, the “ACA”) codified case law that a claimincluding items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulentclaim for purposes of the federal False Claims Act.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefederal civil and criminal false claims laws, including the federal False Claims Act, which can be enforced by private citizenson behalf of the government, through civil whistleblower or qui tam actions, and civil monetary penalty laws, which prohibit,among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare,Medicaid, or other third-party payors that are false or fraudulent. Pharmaceutical and other health care companies have been prosecutedunder these laws for alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing informationsubmitted to the government for government price reporting purposes, and allegedly providing free product to customers with theexpectation that the customers would bill federal healthcare programs for the product. As a result of a modification made by theFraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presentedto the U.S. government. In addition, manufacturers can be held liable under the federal False Claims Act even when they do notsubmit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     HIPAAalso created new federal crimes, including health care fraud and false statements relating to health care matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, includingprivate third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or coveringup a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or paymentfor health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need tohave actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 24 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        22
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefederal Physician Payments Sunshine Act which require certain manufacturers of drugs, devices, biologics and medical suppliesfor which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions)to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors,dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interestsheld by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to reportinformation regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners,clinical nurse specialists, certified nurse anesthetists and anesthesiologist assistants, and certified nurse-midwives.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Manystates have laws similar to the federal laws described above and the state laws may be broader in scope and may apply regardlessof payor, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involvinghealthcare items or services reimbursed by non-governmental third party payors, including private insurers, or that apply regardlessof payor, state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary complianceguidelines and the relevant compliance guidance promulgated by the federal government, state and local laws that require drugmanufacturers to report information related to payments and other transfers of value to physicians and other healthcare providersor marketing expenditures, state laws that require the reporting of information related to drug pricing, and state and local lawsrequiring the registration of pharmaceutical sales representatives.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Additionally,the U.S. Foreign Corrupt Practices Act (“FCPA”) prohibits U.S. corporations and their representatives from offering,promising, authorizing or making payments to any foreign government official, government staff member, political party or politicalcandidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcareprofessionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifour operations are found to be in violation of any of the laws described above, or any other governmental regulations that applyto us, we may be subject significant civil, criminal and administrative penalties, including sanctions, damages, disgorgement,monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment,integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings,and curtailment or restructuring of our operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Coverageand Reimbursement
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Patientsgenerally rely on third-party payors to reimburse part or all of the costs associated with medical products. Accordingly, marketacceptance of medical products can depend on the extent to which third-party coverage and reimbursement is available from governmenthealth administration authorities, private healthcare insurers and other healthcare funding organizations. No uniform policy forcoverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor topayor. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursementto be provided are made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitationsin setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations.As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientificand clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequatereimbursement will be applied consistently or obtained in the first instance. Pharmaceutical companies may be required to providespecified rebates or discounts on the products it sells to certain government funded programs, including Medicare and Medicaid,and those rebates or discounts have increased over time. The ACA increased many of these mandatory discounts and rebates requiredand imposed a new branded prescription pharmaceutical manufacturers and importers fee payable each year by certain pharmaceuticalcompanies and manufacturers.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Outsideof the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governingdrug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the rangeof medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinalproducts for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a systemof direct or indirect controls on the profitability of the company placing the medicinal product on the market. Historically,products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 25 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        23
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      HealthcareReform
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheUnited States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcaresystem. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcarecosts, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus ofthese efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limitthe pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-fundedhealth care programs, and increased governmental control of drug pricing.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InMarch 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and privateinsurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisionsof particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollmentin federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Programare calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceuticalcompanies’ share of sales to federal health care programs. Since its enactment, there have been judicial, Congressional,and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendmentsto the ACA in the future. For example, the 2020 federal spending package permanently eliminated, effective January 1, 2020, theACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effectiveJanuary 1, 2021, also eliminated the health insurer tax. In addition, legislation enacted in 2017, informally known as the TaxCuts and Jobs Act (the “2017 Tax Act”), among other things, removes penalties for not complying with ACA’sindividual mandate to carry health insurance. Since the enactment of the 2017 Tax Act, there have been additional amendments tocertain provisions of the ACA. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled thatthe individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the2017 Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December 18, 2019, the U.S. Court of Appealsfor the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case backto the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court iscurrently reviewing the case, although it is unknown when or how the Supreme Court will rule. Accordingly, it is unclear how thisdecision, future decisions, subsequent appeals, if any, and other efforts to repeal and replace the ACA will impact the ACA.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Moreover,there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketedproducts, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designedto, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patientprograms, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration’sbudget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drugprices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic andbiosimilar drugs. Further, the Trump administration released a “Blueprint”, or plan, to lower drug prices and reduceout of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiatingpower of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reducethe out of pocket costs of drug products paid by consumers. The likelihood of implementation of any of these, or the other Trumpadministration reform initiatives is uncertain, particularly in light of the new presidential administration. At the state level,legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing,including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosureand transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further,it is possible that additional governmental action is taken in response to the COVID-19 pandemic.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <!-- Field: Page; Sequence: 26 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        24
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      MajorCustomers and Sources of Revenues
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      MajorSources of Revenues
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows our major sources of revenues, as a percentage of total revenues, that were recognized during the yearsended December 31, 2020 and 2019:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       Sources of Revenues
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 60%; text-align: left">
       NIH grant income
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 16%; text-align: right">
       21.2
      </td>
      <td style="width: 1%; text-align: left">
       %
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 16%; text-align: right">
       17.5
      </td>
      <td style="width: 1%; text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       IIA grant income (Cell Cure Neurosciences Ltd, Israel)
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       36.5
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       40.5
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Royalties from product sales and licenses fees
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       42.3
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       34.7
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Sale of research products
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       7.3
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      GeographicArea
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 60%; text-align: left">
       United States
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 16%; text-align: right">
       1,160
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 16%; text-align: right">
       2,092
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-bottom: 1.5pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Foreign
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       666
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       1,423
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 2.5pt">
       Total revenues
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       1,826
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       3,515
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (1)Foreign revenues are primarily generated from grants in Israel.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Marketing
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif; color: Black">
     <i>
      TherapeuticProducts and Medical Devices
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Becauseour planned therapeutic products and medical devices are still in the research and development stage, we will not initially needto have our own marketing personnel. If we or our subsidiaries are successful in developing marketable therapeutic products andmedical devices, we will need to build our own marketing and distribution capability for those products, which would require theinvestment of significant financial and management resources, or we and our subsidiaries will need to find collaborative marketingpartners, independent sales representatives, or wholesale distributors for the commercial sale of those products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe market products through arrangements with third parties, we may pay sales commissions to sales representatives or we may sellor consign products to distributors at wholesale prices. This means that our gross profit from product sales may be less thanwould be the case if we were to sell our products directly to end users at retail prices through our own sales force. On the otherhand, selling to distributors or through independent sales representatives would allow us to avoid the cost of hiring and trainingour own sales employees. There can be no assurance we will be able to negotiate distribution or sales agreements with third partieson favorable terms to justify our investment in our products or achieve sufficient revenues to support our operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Competition
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weface substantial competition in all fields of business in which we engage. That competition is likely to intensify as new productsand technologies reach the market. Superior new products are likely to sell for higher prices and generate higher profit marginsif acceptance by the medical community is achieved. Those companies that are successful at being the first to introduce new productsand technologies to the market may gain significant economic advantages over their competitors in the establishment of a customerbase and track record for the performance of their products and technologies. Such companies will also benefit from revenues fromsales that could be used to strengthen their research and development, production, and marketing resources. Companies engagedin the medical products industry face the risk of obsolescence of their products and technologies as more advanced or cost-effectiveproducts and technologies are developed by competitors. As the industry matures, companies will compete based upon the performanceand cost-effectiveness of their products. Specific efforts in the development of treatments for dry AMD include, but are not limitedto, neuroprotection, reducing by-product accumulation, and suppressing inflammation. Specific approaches include small molecules,antibodies, and cell therapies. Some of these efforts have reached clinical development and at least one approach, complementinhibition, is currently in a Phase 3 clinical trial. We believe that replacing the entire cell rather than attempts to fix oneaberrant pathway or signal confer a greater probability of success for individuals suffering with dry AMD.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 27 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        25
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Productsfor Regenerative Medicine
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thecell therapy industry is characterized by rapidly evolving technology and intense competition. Our competitors include major multinationalpharmaceutical companies, specialty biotechnology companies, and chemical and medical products companies operating in the fieldsof regenerative medicine, cell therapy, tissue engineering, and tissue regeneration. Many of these companies are well establishedand possess technical, research and development, financial, and sales and marketing resources significantly greater than ours.In addition, certain smaller biotech companies have formed strategic collaborations, partnerships, and other types of joint ventureswith larger, well-established industry competitors that afford the smaller companies’ potential research and developmentas well as commercialization advantages. Academic institutions, governmental agencies, and other public and private research organizationsare also conducting and financing research activities, which may produce products directly competitive to those we are developing.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve that some of our competitors are trying to develop pluripotent cells and human embryonic progenitor cell-based technologiesand products that may compete with our stem cell products based on efficacy, safety, cost, and intellectual property positions.Ocata Therapeutics, Inc. (“Ocata”), which was acquired by a subsidiary of Astellas Pharma Inc. for approximately $379million in 2016, and Retinal Patch Technologies Inc. have conducted clinical trials of hES cell products designed to treat dryAMD. If their products are proven to be safe and effective, they may reach the market ahead of OpRegen.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemay also face competition from companies that have filed patent applications relating to the propagation and differentiation ofstem cells. Those companies include Ocata, which in 2015 had certain U.S. patents issue with claims directed to methods of producingRPE cells and isolating and purifying such cells. We may be required to seek licenses from these competitors in order to commercializecertain products proposed by us, and such licenses may not be granted.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_003">
         </span>
         ITEM    1A.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         RISK    FACTORS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourbusiness is subject to various risks, including those described below. You should consider the following risk factors, togetherwith all of the other information included in this report, which could materially adversely affect our proposed operations, ourbusiness prospects, and financial condition, and the value of an investment in our business. There may be other factors that arenot mentioned here or of which we are not presently aware that could also affect our business operations and prospects.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksRelated to Our Business Operations and Capital Requirements
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wehave incurred operating losses since inception, and we do not know if or when we will attain profitability.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourtotal operating losses for the fiscal years ended December 31, 2020 and 2019 were $26.4 million and $38.9 million, respectively,and we had an accumulated deficit of $294.1 million as of December 31, 2020. Since inception, we have incurred significant operatinglosses and have funded our operations primarily through sales of our equity securities and the equity securities of former subsidiaries,receipt of research grants, royalties on product sales, license revenues, sales of research products, and revenues from subscriptionfees and advertising revenue from database products of a former subsidiary. Substantially all of our losses have resulted fromexpenses incurred in connection with our research and development programs and from general and administrative costs associatedwith our operations. All of our product candidates will require substantial additional development time and resources before wewould be able to apply for or receive regulatory approvals. We expect to continue to incur losses for the foreseeable future,and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for andpotentially commercialize any of our product candidates and seek to identify, assess, acquire, in-license or develop additionalproduct candidates.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Tobecome and remain profitable, we must succeed in developing and eventually commercializing products that generate significantrevenue. This will require us to be successful in a range of challenging activities, including completing clinical trials andpreclinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketingand selling any products for which we may obtain regulatory approval. In addition, we are attempting to develop new medical productsand technology. We may never succeed in these activities and, even if we do, may never generate revenues that are significantenough to achieve profitability.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 28 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        26
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wewill continue to spend a substantial amount of our capital on research and development, but we might not succeed in developingproducts and technologies that are useful in medicine.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare attempting to develop new medical products and technology. These new products and technologies might not prove to be safeand efficacious in the human medical applications for which they are being developed. Our research and development activitiesare costly, time consuming, and their results are uncertain. We incurred research and development expenses amounting to approximately$12.3 million and $17.9 million during the fiscal years ended December 31, 2020 and 2019, respectively. If we successfullydevelop a new technology or product, refinement of the new technology or product and definition of the practical applicationsand limitations of the technology or product may take years and require large sums of money. Clinical trials of new therapeuticproducts, particularly those products that are regulated as biologics, drugs, or devices, are very expensive and take years tocomplete. We may not have the financial resources to fund clinical trials on our own and we may have to enter into licensing orcollaborative arrangements with others. Any such arrangements may be dilutive to our ownership or economic interest in the productswe develop, and we might have to accept royalty payments on product sales rather than receiving the gross revenues from productsales. In addition, we may discontinue one or more of the research or product development programs. Our product and technologydevelopment programs may be delayed or discontinued should adequate funding on acceptable terms not be available.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Theamount and pace of research and development work that we can do or sponsor, and our ability to commence and complete clinicaltrials required to obtain regulatory approval to market our therapeutic and medical device products, depends upon the amount offunds we have.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     AtDecember 31, 2020, we had $41.6 million of cash, cash equivalents and marketable equity securities. There can be no assurancethat we will be able to raise additional funds on favorable terms or at all, or that any funds raised will be sufficient to permitus to develop and market our products and technology, if and when approved. Our ability to raise additional funds may be adverselyimpacted by deteriorating global economic conditions and the disruptions to and volatility in the credit and financial marketsin the United States and worldwide resulting from the ongoing COVID-19 pandemic. Unless we are able to generate sufficient revenueor raise additional funds when needed, it is likely that we will be unable to continue our planned activities, even if we makeprogress in our research and development projects. We may have to postpone or limit the pace of our research and development workand planned clinical trials of our product candidates unless our cash resources increase through a growth in revenues, royalties,license fees, equity financings or borrowings.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wewill need to issue additional equity or debt securities in order to raise additional capital needed to pay our operating expenses.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weexpect to continue to incur substantial research and product development expenses and will need to raise additional capital topay operating expenses until we are able to generate sufficient revenues from product sales, royalties and license fees. Our abilityto raise additional equity or debt capital will depend, not only on progress made in developing new products and technologies,but also on access to capital and conditions in the capital markets. We believe that our cash, cash equivalents and marketablesecurities as of December 31, 2020 will be sufficient to fund our planned operations for at least the next 12 months. We havebased these estimates on assumptions that may prove to be wrong, and we may use our capital resources sooner than we currentlyexpect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown tous, and we may need to seek additional funds sooner than planned. Any equity capital raise could result in the dilution of theinterests of shareholders or may otherwise limit our ability to finance further in the future, which may negatively impact ourbusiness and operations. Any debt capital financing may involve covenants that restrict our operations, including limitationson additional borrowing and on the use of our assets. If we raise capital through licensing arrangements, it may be necessaryto grant licenses on terms that are not favorable to us. There can be no assurance that we will be able to raise capital on favorableterms, or at all, or at times and in amounts needed to successfully finance product development, clinical trials, and generaloperations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Lawsuitshave been filed and other lawsuits may be filed against Lineage and certain members of the Lineage and Asterias Biotherapeutics,Inc. (“Asterias”) boards of directors relating to our acquisition of Asterias (the “Asterias Merger”).An adverse ruling in any such lawsuit may result in additional payments and costs.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Aputative class action lawsuit alleging breach of fiduciary duties in connection with the Asterias Merger is pending in the DelawareChancery Court. As of December 31, 2020, the defendants are certain former members of Asterias’ board of directors and Lineage.The complaint alleges that the merger process was conflicted, that the consideration was inadequate, and that the proxy statementfiled by Asterias was misleading. The complaint seeks, among other things, certification of a class, rescission of the mergeror monetary damages, and attorneys’ fees and costs.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 29 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        27
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thedefendants specifically deny all allegations in the litigation and intend to defend it vigorously. However, any adverse rulingin this case could result in additional payments. Additional lawsuits arising out of or relating to the merger agreement and/orthe merger may be filed in the future.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Changesin tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business,cash flow, financial condition or results of operations.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Newincome, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adverselyaffect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinancescould be interpreted, changed, modified or applied adversely to us. For example, the 2017 Tax Act, enacted many significant changesto the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the 2017 TaxAct may affect us, and certain aspects of the 2017 Tax Act could be repealed or modified in future legislation. For example, theCoronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and the Consolidated Appropriations Act, 2021(CA) modified certain provisions of the 2017 Tax Act. In addition, it is uncertain if and to what extent various states will conformto the 2017 Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realizationof net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses underthe 2017 Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could resultin significant one-time charges, and could increase our future U.S. tax expense.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourability to use net operating losses and other tax attributes to offset future taxable income or taxes may be subject to limitations.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, we had net operating loss (“NOL”) carryforwards for U.S. federal and state tax purposes of approximately$169.9 million and $118.6 million, respectively. Included in these amounts are NOLs acquired through the merger with Asterias(see below). A portion of the federal and state NOL carryforwards will begin to expire, if not utilized, in varying amounts between2027 and 2037. NOLs that expire unused will be unavailable to offset future income tax liabilities. Under federal income tax law,federal NOLs incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibilityof such NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to whatextent various states that we may operate in will conform to the federal tax law. In addition, under Sections 382 and 383 of theInternal Revenue Code of 1986, as amended (the “IRC”), and corresponding provisions of state law, if a corporationundergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equityownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-changetax attributes to offset its post-change income or taxes may be limited. We may experience ownership changes in the future asa result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occursand our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectivelyincreasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operatingloss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example,in 2020 California enacted A.B. 85 which imposed limits on the usability of California state net operating losses and certaintax credits in tax years beginning after 2019 and before 2023.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Aspart of the merger with Asterias, we acquired various tax attribute carryforwards including federal and California NOLs of $52.8million and $41.9 million, respectively, as well as California research and development credits of $2.4 million. As a result ofthe merger, Asterias incurred an ownership change under Section 382 of the IRC, which places annual limits on the amount of theseNOLs that are available to offset income. Because of the annual limitation, the total amount of these NOLs is not immediatelyavailable to offset future income. The California research and development credit of $2.4 million has no expiration date.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 30 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        28
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Taxingauthorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax liability.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare organized in the United States, and currently have subsidiaries in Israel and Singapore. If we succeed in growing our business,we expect to conduct increased operations through subsidiaries in various tax jurisdictions pursuant to transfer pricing arrangementsbetween us and our subsidiaries. If two or more affiliated companies are located in different countries, the tax laws or regulationsof each country generally will require that such arrangements be priced the same as those between unrelated companies dealingat arm’s length and that appropriate documentation is maintained to support the value of such arrangements. Our transferpricing policies were formulated with the assistance of third-party experts. We are in the process of obtaining a formal transferpricing report. However, after we receive such report, we do not intend to amend our returns for prior years. Whether we obtaina formal transfer pricing study with outside experts or not, our transfer pricing procedures will not be binding on applicabletax authorities.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Iftax authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm’s lengthtransactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transferprices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated doesnot agree with the reallocation, both countries could tax the same income, resulting in double taxation. If tax authorities wereto allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it wouldincrease our tax liability, which could adversely affect our financial condition, results of operations and cash flows.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourbusiness and operations could suffer in the event of system failures.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Despitethe implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerableto damage from computer viruses, unauthorized access, natural disasters including earthquakes and tsunamis, terrorism, war, andtelecommunication and electrical failures. Such events could cause significant interruption of our operations and developmentprograms. For example, the loss of data for our product candidates could result in delays in our regulatory filings and developmentefforts and significantly increase our costs. To the extent that any disruption or security breach was to result in a loss ofor damage to our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and thedevelopment of our product candidates could be delayed.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, our product candidates are manufactured by starting with cells that are stored in a cryopreserved master cell bank.While we believe we have adequate backup should any cell bank be lost in a catastrophic event, we or our third-party suppliersand manufacturers could lose multiple cell banks, which would severely affect our manufacturing activities. We cannot assure youthat any stability or other issues relating to the manufacture of any of our product candidates or products will not occur inthe future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinicaltrials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, requireus to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affectingclinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages,lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates or products. Accordingly,failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the developmentand commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects,financial condition and results of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Significantdisruptions of information technology systems or data security breaches could adversely affect our business.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary courseof our business, we collect, store, process and transmit large amounts of confidential information, including intellectual property,proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality,integrity and availability of such information. We have also outsourced some of our operations (including parts of our informationtechnology infrastructure) to a number of third-party vendors who may have, or could gain, access to our confidential information.In addition, many of those third parties, in turn, subcontract or outsource some of their responsibilities to third parties.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 31 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        29
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourinformation technology systems are large and complex and store large amounts of confidential information. The size and complexityof these systems make them potentially vulnerable to service interruptions or to security breaches from inadvertent or intentionalactions by our employees, third party vendors and/or business partners, or from cyber-attacks by malicious third parties. Attacksof this nature are increasing in frequency, persistence, sophistication and intensity, and are being conducted by sophisticatedand organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise,including organized criminal groups, “hacktivists,” nation states and others. In addition to the extraction of importantinformation, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineeringand other means to affect service reliability and threaten the confidentiality, integrity and availability of our information.Although the aggregate impact on our operations and financial condition has not been material to date, we have been the targetof events of this nature and expect them to continue.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Significantdisruptions of our, our third party vendors’ and/or business partners’ information technology systems or securitybreaches could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access,use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectualproperty, proprietary business information and personal information), and could result in financial, legal, business and reputationalharm to us. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal informationregarding our patients or employees, could harm our reputation, compel us to comply with federal and/or state breach notificationlaws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of databasecontents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information,which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant legal and financialexposure. In addition, security breaches and other inappropriate access can be difficult to detect, and any delay in identifyingthem may further harm us. Moreover, the prevalent use of mobile devices to access confidential information increases the riskof security breaches. While we have implemented security measures to protect our information technology systems and infrastructure,there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affectour business. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurityin general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourbusiness could be adversely affected if we lose the services of the key personnel upon whom we depend or if we fail to attractsenior management and key scientific personnel.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve that our continued success depends to a significant extent upon our efforts and ability to retain highly qualified personnel,including our Chief Executive Officer, Brian Culley. All of our officers and other employees are at-will employees and may terminatetheir employment with us at any time with no advance notice. The loss of the services of Mr. Culley or other members of our seniormanagement could have a material adverse effect on us. Further, the replacement of any of such individuals likely would involvesignificant time and costs and may significantly delay or prevent the achievement of our business and clinical objectives andwould harm our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, we could experience difficulties attracting qualified employees in the future. For example, competition for qualifiedpersonnel in the biotechnology and medical device field is intense due to the limited number of individuals who possess the skillsand experience required by our industry. We will need to hire additional personnel, including experienced sales representatives,as we expand our clinical development and commercial activities. We may not be able to attract quality personnel on acceptableterms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they havebeen improperly solicited or that they have divulged proprietary or other confidential information or that their former employersown their research output.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Thevalue of our investments in public companies fluctuates based on their respective stock prices and could be negatively affectedby business, regulatory and other risks applicable to them.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, we had an equity investment in OncoCyte, a U.S. publicly traded company. As of December 31, 2020, the valueof our investment in OncoCyte was approximately $8.7 million based on its closing stock price as of that date. If OncoCyte wereto have delays in clinical trials or commercialization activities or otherwise realize the specific business, regulatory and otherrisks applicable to them, the value of its common stock and the valuation of our investment could be negatively affected. If OncoCytewere to fail and ultimately cease operations, we may lose the entire value of our investment. In addition, the value of our marketableequity securities may be significantly and adversely impacted by deteriorating global economic conditions and the disruptionsto and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 32 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        30
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Failureof our internal control over financial reporting could harm our business and financial results.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting. Because of itsinherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatementof our financial statements would be prevented or detected. Our growth and entry into new products, technologies and markets willplace significant additional pressure on our system of internal control over financial reporting. Any failure to maintain an effectivesystem of internal control over financial reporting could limit our ability to report our financial results accurately and timelyor to detect and prevent fraud. Operating our business through subsidiaries, some of which are located in foreign countries, alsoadds to the complexity of our internal control over financial reporting and adds to the risk of a system failure, an undetectedimproper use or expenditure of funds or other resources by a subsidiary, or a failure to properly report a transaction or financialresults of a subsidiary. We allocate certain expenses among Lineage itself and one or more of our subsidiaries, which createsa risk that the allocations we make may not accurately reflect the benefit of an expenditure or use of financial or other resourcesby Lineage as the parent company and the subsidiaries among which the allocations are made. An inaccurate allocation may impactour consolidated financial results, particularly in the case of subsidiaries that we do not wholly own since our financial statementsinclude adjustments to reflect the minority ownership interests in our subsidiaries held by others.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirementsof Section 404 of the Sarbanes-Oxley Act in a timely manner or assert that our internal control over financial reporting is effective,or if our independent registered public accounting firm is unable to express an opinion or expresses a qualified or adverse opinionabout the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completenessof our financial reports and the market price of our common shares could be negatively affected. In addition, we could becomesubject to investigations by the NYSE American, the Securities and Exchange Commission, and other regulatory authorities, whichcould require additional financial and management resources.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wereceived a loan under the Paycheck Protection Program of the CARES Act, and all or a portion of the loan may not be forgivable.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InApril 2020, we received a loan for $523,305 from Axos Bank under the Paycheck Protection Program (“PPP”) containedwithin the new CARES Act. The PPP loan has a term of two years, is unsecured, and is guaranteed by the U.S. Small Business Administration(SBA). The loan carries a fixed interest rate of one percent per annum, with the first six months of interest deferred. Underthe CARES Act and Paycheck Protection Program Flexibility Act, we are eligible to apply for forgiveness of all loan proceeds usedto pay payroll costs, rent, utilities and other qualifying expenses during the 24-week period following receipt of the loan, providedthat we maintain our number of employees and compensation within certain parameters during such period. Not more than 40% of theforgiven amount may be for non-payroll costs. If the conditions outlined in the PPP loan program are adhered to by us, all orpart of such loan could be forgiven. However, we cannot provide any assurance that any amount of the PPP loan will ultimatelybe forgiven by the SBA. Any forgiven amounts will not be included in our taxable income. We applied for full forgiveness of thePPP loan on September 30, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksRelated to Government Regulation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wemay be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, including anti-kickback and falseclaims laws, transparency laws, and health information privacy and security laws. If we are unable to comply, or have not fullycomplied, with such laws, we could face substantial penalties.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourcurrent and future operations may be subject to various federal and state fraud and abuse laws, including, without limitation,the federal Anti-Kickback Statute, the federal False Claims Act, and healthcare professional transparency laws and regulations.These laws may impact, among other things, our research activities and our proposed sales, marketing, and education programs.In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conductour business. The laws that may affect our ability to operate include:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,    offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an    item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 33 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        31
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        federal    civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which prohibit,    among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from    Medicare, Medicaid, or other third-party payors that are false or fraudulent;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal    statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false    statements relating to healthcare matters;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        HIPAA,    as amended by the Health Information Technology for Economic and Clinical Health Act, (“HITECH”) and their implementing    regulations, which imposes certain requirements on covered entities,” including certain healthcare providers, health    plans, and healthcare clearinghouses, as well as their respective “business associates” that create, receive,    maintain or transmit individually identifiable health information for or on behalf of a covered entity, and their subcontractors    that use, disclose, access, or otherwise process individually identifiable protected health information, relating to the privacy,    security, and transmission of individually identifiable health information;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    Physician Payments Sunshine Act which requires manufacturers of drugs, devices, biologics, and medical supplies to report    annually to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists,    optometrists, podiatrists, and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians    and other healthcare providers and their immediate family members and applicable group purchasing organizations, and, beginning    in 2020 will require applicable manufacturers to report information regarding payments and other transfers of value provided    during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists    and anesthesiologist assistants, and certified nurse-midwives; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        state    law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or    services reimbursed by any third-party payors, including commercial insurers, state laws that require pharmaceutical companies    to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated    by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral    sources; state laws that require drug manufacturers to report information related to payments and other transfers of value    to physicians and other healthcare providers, marketing expenditures, or drug pricing, state and local laws that require the    registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information    in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus    complicating compliance efforts.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Becauseof the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possiblethat some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifour operations are found to be in violation of any of the laws described above or any other governmental regulations that apply,we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement,exclusion from participation in government health care programs, such as Medicare and Medicaid, integrity oversight and reportingobligations, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our abilityto operate our business and our results of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 34 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        32
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe do not receive regulatory approvals, we will not be permitted to sell our therapeutic and medical device products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thetherapeutic and medical device products that we and our subsidiaries develop cannot be sold until the FDA and corresponding foreignregulatory authorities approve the products for medical use. The need to obtain regulatory approval to market a new product meansthat:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    will have to conduct expensive and time-consuming clinical trials of new products. The full cost of conducting and completing    clinical trials necessary to obtain FDA and foreign regulatory approval of a new product cannot be presently determined but    could exceed our current financial resources.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Clinical    trials and the regulatory approval process for a pharmaceutical or cell-based product can take several years to complete.    As a result, we will incur the expense and delay inherent in seeking FDA and foreign regulatory approval of new products,    even if the results of clinical trials are favorable.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Data    obtained from preclinical and clinical studies is susceptible to varying interpretations and regulatory changes that could    delay, limit, or prevent regulatory agency approvals.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Because    the therapeutic products we are developing with pluripotent stem cell technology involve the application of new technologies    and approaches to medicine, the FDA or foreign regulatory agencies may subject those products to additional or more stringent    review than drugs or biologics derived from other technologies.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        A    product that is approved may be subject to restrictions on use.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    FDA can recall or withdraw approval of a product, if it deems necessary.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    will face similar regulatory issues in foreign countries.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Government-imposedbans or restrictions and religious, moral, and ethical concerns about the use of hES cells could prevent us from developing andsuccessfully marketing stem cell products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Government-imposedbans or restrictions on the use of embryos or hES cells in research and development in the United States and abroad could generallyconstrain stem cell research, thereby limiting the market and demand for our products. During March 2009, President Obama liftedcertain restrictions on federal funding of research involving the use of hES cells, and in accordance with President Obama’sExecutive Order, the National Institutes of Health (“NIH”) has adopted guidelines for determining the eligibilityof hES cell lines for use in federally funded research. The central focus of the guidelines is to assure that hES cells used infederally funded research were derived from human embryos that were created for reproductive purposes, were no longer needed forthis purpose, and were voluntarily donated for research purposes with the informed written consent of the donors. The hES cellsthat were derived from embryos created for research purposes rather than reproductive purposes, and other hES cells that werenot derived in compliance with the guidelines, are not eligible for use in federally funded research. California law requiresthat stem cell research be conducted under the oversight of a stem cell review oversight committee (“SCRO”). Manykinds of stem cell research, including the derivation of new hES cell lines, may only be conducted in California with the priorwritten approval of the SCRO. A SCRO could prohibit or impose restrictions on the research that we plan to do. The use of hEScells may give rise to religious, moral, and ethical issues. These considerations could lead to more restrictive government regulationsor could generally constrain stem cell research, thereby limiting the market and demand for our products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Weexpect that the commercial opportunity for some of our products may depend on our ability to obtain reimbursement and continuedcoverage from various payors, including government entities and insurance companies.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifthese third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover ourproducts as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our productson a profitable basis.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 35 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        33
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forexample, in the United States, healthcare providers are reimbursed for covered services and products they deliver through Medicare,Medicaid and other government healthcare programs, as well as through private payers. No uniform policy for coverage and reimbursementexists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Decisions regardingwhether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be providedare made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in settingtheir own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result,the coverage determination process is often a time-consuming and costly process that will require us to provide scientific andclinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequatereimbursement will be applied consistently or obtained in the first instance. We may be required to provide specified rebatesor discounts on the products we sell to certain government funded programs, including Medicare and Medicaid, and those rebatesor discounts have increased over time. The Patient Protection and Affordable Care Act, as amended by the Health Care and EducationReconciliation Act (collectively, the “ACA”), enacted in 2010, increased many of the mandatory discounts and rebatesand imposed a new branded prescription pharmaceutical manufacturers and importers fee payable each year by certain manufacturers.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weface similar issues outside of the United States. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approvedbefore it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example,the EU provides options for its member states to restrict the range of medicinal products for which their national health insurancesystems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specificprice for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the companyplacing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursementlimitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically,products launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Disruptionsat the FDA and other government agencies caused by funding shortages or global health concerns could negatively impact our business.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theability of the FDA to review and approve proposed clinical trials or new product candidates can be affected by a variety of factors,including, but not limited to, government budget and funding levels, ability to hire and retain key personnel and accept the paymentof user fees, statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA’s ability toperform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, governmentfunding of other government agencies that fund research and development activities is subject to the political process, whichis inherently fluid and unpredictable.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Disruptionsat the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessarygovernment agencies, which would adversely affect our business. For example, over the last several years, including for 35 daysbeginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA,have had to furlough critical FDA employees and stop critical activities.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Separately,in response to the global COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most foreign inspectionsof manufacturing facilities and temporarily postponed routine surveillance inspections of domestic manufacturing facilities.In July 2020 domestic inspections restarted only on a risk-based basis. Regulatory authorities outside the United Statesmay adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdownoccurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regularinspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatoryauthorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      TheACA and future changes to that law may adversely affect our business.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asa result of the adoption of the ACA, in the United States, substantial changes have been made to the system for paying for healthcarein the United States. Among the ACA’s provisions of importance to our industry are that it:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        created    the branded prescription pharmaceutical manufacturers and importers annual fee;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        increased    the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average    manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs    at 100% of the Average Manufacturer Price;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 36 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        34
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        created    new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs    and biologics that are inhaled, infused, instilled, implanted or injected;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        extended    manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed    care organizations;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        expanded    eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional    individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal    poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        expanded    the entities eligible for discounts under the Public Health program;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        created    a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness    research, along with funding for such research;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        established    a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services (“CMS”) to    test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription    drug spending; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        created    a licensure framework for follow on biologic products.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereremain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration torepeal or replace certain aspects of the ACA. Since January 2017, President Trump signed Executive Orders and other directivesdesigned to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation thatwould repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, ithas enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complyingwith the ACA’s individual mandate to carry health insurance, and eliminating the implementation of certain ACA-mandatedfees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the“individual mandate” was repealed by Congress as part of the 2017 Tax Act. Additionally, on December 18, 2019, theU.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional andremanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. TheU.S. Supreme Court is currently reviewing the case, although it is uncertain when or how the Supreme Court will rule. It is unclearhow such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, theBudget Control Act of 2011, includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effecton April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exceptionof a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. On January2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments toseveral providers, including hospitals, and increased the statute of limitations period for the government to recover overpaymentsto providers from three to five years.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 37 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        35
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Further,there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the risingcost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed andenacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review therelationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies forproducts. At the federal level, the Trump administration’s budget proposal for fiscal year 2021 includes a $135 billionallowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costsfor patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administrationsent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap MedicarePart D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocketexpenses, and place limits on pharmaceutical price increases. In addition, the Trump administration previously released a “Blueprint”to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition,increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of theirproducts, and reduce the out-of-pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measuresand has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantageplans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy changethat was effective January 1, 2019. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protectionfor price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefitmanagers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflectedat the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.The likelihood of implementation of any of the other Trump administration reform initiatives is uncertain, particularly in lightof the new presidential administration. On November 20, 2020, CMS issued an interim final rule implementing President Trump’sMost Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to thelowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United StatesDistrict Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule.The likelihood of implementation of any of the other Trump administration reform initiatives is uncertain, particularly in lightof the new presidential administration. At the state level, legislatures have increasingly passed legislation and implementedregulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts,restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed toencourage importation from other countries and bulk purchasing.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, it is possible that additional governmental action is taken to address the COVID-19 pandemic.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increasedcosts, penalties and a loss of business.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ouractivities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive governmentregulation and oversight both in the U.S. and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictionswill directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies,product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Ourinteractions in the U.S. or abroad with physicians and other health care providers that may prescribe or purchase our productsare also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greaterrestrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of theirrelationships with health care providers from anti-corruption enforcement officials. In addition, health care companies have beenthe target of lawsuits and investigations alleging violations of government regulation, including claims asserting submissionof incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influencethe referral of health care business, submission of false claims for government reimbursement, antitrust violations or violationsrelated to environmental matters. Risks relating to compliance with laws and regulations may be heightened as we bring productsto the market globally.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Regulationsgoverning the health care industry are subject to change, with possibly retroactive effect, including:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        new    laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health    care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method    of delivery, payment for health care products and services, compliance with health information and data privacy and security    laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals,    extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product    take-back requirements;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        changes    in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in    lost market opportunity;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 38 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        36
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        requirementsthat provide for increased transparency of clinical trial results and quality data, such as the EMA’s clinical transparencypolicy, which could impact our ability to protect trade secrets and competitively sensitive information contained in approvalapplications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business;and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        changes    in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution    or use, or other measures after the introduction of our products to market, which could increase our costs of doing business,    adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Violationsof governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penaltiesand exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeingour business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we receivedfrom government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information wehave submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instanceprotect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the lawsor regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into allegedunlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affectour business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Evenif we receive approval for our products, we may be subject to extensive regulatory obligations in order to commercialize our products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Evenafter initial FDA or foreign regulatory agency approval has been obtained, further studies may be required to provide additionaldata on safety or to gain approval for the use of a product as a treatment for clinical indications other than those initiallytargeted. Use of a product during testing and after marketing could reveal side effects that could delay, impede, or prevent marketingapproval, result in a regulatory agency-ordered product recall, or in regulatory agency-imposed limitations on permissible usesor in withdrawal of approval. For example, if the FDA or foreign regulatory agency becomes aware of new safety information afterapproval of a product, it may require us to conduct further clinical trials to assess a known or potential serious risk and toassure that the benefit of the product outweigh the risks. If we are required to conduct such a post-approval study, periodicstatus reports must be submitted to the FDA or foreign regulatory agency. Failure to conduct such post-approval studies in a timelymanner may result in substantial civil or criminal penalties. Data resulting from these clinical trials may result in expansionsor restrictions to the labeled indications for which a product has already been approved. Any of these requirements or actionsmay negatively impact our business or operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe are deemed to be an investment company, we may have to institute burdensome compliance requirements and our activities maybe restricted.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Anentity that, among other things, is or holds itself out as being engaged primarily, or proposes to engage primarily, in the businessof investing, reinvesting, owning, trading or holding certain types of securities would be deemed an investment company underthe Investment Company Act of 1940, as amended (the “1940 Act”). Based on the securities we hold, including our equityownership in publicly traded companies, we may not meet the requirements for an exemption promulgated under the 1940 Act. If weare deemed to be an investment company under the 1940 Act, we would be subject to additional limitations on operating our business,including limitations on the issuance of securities, which may make it difficult for us to raise capital.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksRelated to Our Clinical Development and Commercial Operations
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Clinicalstudies are costly, time consuming and are subject to risks that could delay or prevent commercialization of our current or futureproduct candidates.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wecannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of oneor more clinical studies can occur at any stage of development. Events that may prevent successful or timely completion of clinicaldevelopment include but are not limited to:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        inability    to generate satisfactory preclinical, toxicology, or other
        <i>
         in vivo
        </i>
        or
        <i>
         in vitro
        </i>
        data or diagnostics to support    the initiation or continuation of clinical studies necessary for product approval;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 39 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        37
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    in securing clinical investigators and agreeing on acceptable terms with contract research organizations (“CROs”)    and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among CROs    and clinical trial sites;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    in obtaining required Institutional Review Board (“IRB”) approval at each clinical trial site;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        failure    to obtain permission from regulatory authorities to conduct a clinical trial after review of an investigational new drug (“IND”)    or equivalent foreign application or amendment;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        slower    than anticipated rates of patient recruitment and enrollment (including as a result of actual or threatened public health    emergencies and outbreaks of disease such as the current COVID-19 pandemic), failing to reach the targeted number of patients    due to competition for patients from other trials, or patients dropping out of our clinical studies once enrolled;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        failure    by clinical sites or our CROs or other third parties to adhere to clinical trial requirements or report complete findings;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        failure    to perform the clinical studies in accordance with the FDA’s good clinical practices requirements or applicable foreign    regulatory guidelines;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        occurrence    of adverse events associated with our product candidates or with product candidates of third parties that may have characteristics    similar to or perceived to be similar to our product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        negative    or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct    additional clinical studies or to curtail or abandon development programs for a product candidate;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        unforeseen    side effects, possibly resulting in the FDA or other regulatory authorities denying approval of our product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        approval    and introduction of new therapies or changes in standards of practice or regulatory guidance that render our clinical trial    endpoints or the targeting of our proposed indications obsolete;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        inability    to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial    protocols;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        inability    or unwillingness of medical investigators to follow our clinical protocols;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        unavailability    of clinical trial supplies;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        inability    to use clinical trial results from foreign jurisdictions to support U.S. regulatory approval;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        changes    in regulatory requirements and guidance that require amending or submitting new clinical protocols;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    cost of clinical studies of our product candidates; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    in agreeing on acceptable terms with third-party manufacturers and the time for manufacture of sufficient quantities of our    product candidates for use in clinical studies.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Anyinability to successfully complete clinical development and obtain regulatory approval could result in additional costs to usor impair our ability to generate revenue. Clinical trial delays could also shorten any periods during which our products havepatent protection and may allow competitors to develop and bring products to market before we do and may harm our business andresults of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 40 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        38
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Clinicaland preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of early preclinicaltrials and clinical trials of our product candidates are not necessarily predictive of future results. Our product candidatesmay not have favorable results in later clinical trials, if any, or receive regulatory approval on a timely basis, if at all.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Clinicaland preclinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Ourclinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time duringthe preclinical trial or clinical trial process. All of our product candidates will require substantial additional development,and no assurances can be given that the development of any of our product candidates will ultimately be successful. Although wemay from time to time disclose results from preclinical testing or preliminary data or interim results from our clinical studiesof our product candidates, and earlier clinical studies, including clinical studies with similar product candidates, these arenot necessarily predictive of future results, including clinical trial results. The historical failure rate for product candidatesin our industry is high.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theresults of our current and future clinical trials may differ from results achieved in earlier preclinical and clinical studiesfor a variety of reasons, including:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        we    may not demonstrate the potency and efficacy benefits observed in previous studies;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    efforts to improve, standardize and automate the manufacture of our product candidates, including OpRegen, OPC1 and VAC2,    and any resulting deviations in the manufacture of our product candidates, may adversely affect the safety, purity, potency    or efficacy of such product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        differences    in trial design, including differences in size, eligibility criteria, and patient populations;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        advancements    in the standard of care may affect our ability to demonstrate efficacy or achieve trial endpoints in our current or future    clinical trials;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        safety    issues or adverse events in patients that enroll in our current or future clinical trials; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        results    in preclinical and clinical tests may not be repeated in subsequent tests or be predictive of future results.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inparticular, data presented from the Phase 1/2a open-label trial showed that both the surgical procedure and the OpRegen cellswere generally well tolerated, with no treatment-related systemic serious adverse events reported to date in the first nine patients.The best corrected visual acuity of these patients remained relatively stable. In addition, the imaging of patients 8 and 9 suggestedearly signs of structural improvement within the retina. However, we do not know how OpRegen will perform in future clinical trials.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Itis not uncommon to observe results in clinical trials that are unexpected based on preclinical trials and early clinical trials,and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical datamay be susceptible to varying interpretations and analyses. A number of companies in the biotechnology industry have sufferedsignificant setbacks in clinical development even after achieving promising results in earlier studies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Further,as a result of the COVID-19 pandemic, if patients drop out of our clinical trials, miss scheduled doses or follow-up visits orotherwise fail to follow clinical trial protocols, or if our clinical trials are otherwise disrupted due to COVID-19 or actionstaken to slow its spread, the integrity of data from our clinical trials may be compromised or not accepted by the FDA or otherregulatory authorities, which would represent a significant setback for the applicable program.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Evenif our current and planned clinical trials are successful, we will need to conduct additional clinical trials, which may includeregistrational trials, trials in additional patient populations or under different treatment conditions, and trials using differentmanufacturing protocols, processes, materials or facilities or under different manufacturing conditions, before we are able toseek approvals for our product candidates from the FDA and regulatory authorities outside the United States to market and sellthese product candidates. Our failure to meet the requirements to support marketing approval for our product candidates in ourongoing and future clinical trials would substantially harm our business and prospects. For the foregoing reasons, our ongoingand planned clinical trials may not be successful, which could have a material adverse effect on our business, financial conditionand results of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 41 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        39
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Interim,topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patientdata become available and are subject to audit and verification procedures that could result in material changes in the finaldata.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Fromtime to time, we may publicly disclose preliminary or topline data from our clinical trials, which is based on a preliminary analysisof then-available data, and the results and related findings and conclusions are subject to change following a more comprehensivereview of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as partof our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result,the topline results that we report may differ from future results of the same studies, or different conclusions or considerationsmay qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to auditand verification procedures that may result in the final data being materially different from the preliminary data we previouslypublished. As a result, topline data should be viewed with caution until the final data are available. From time to time, we mayalso disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to therisk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomeavailable. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Further,others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analysesor may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvabilityor commercialization of the particular product candidate or product and our company in general. In addition, the information wechoose to publicly disclose regarding a particular trial is based on what is typically extensive information, and you or othersmay not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and anyinformation we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,activities or otherwise regarding a particular product candidate or our business. If the topline data that we report differ fromactual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approvalfor, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financialcondition.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Becausewe have multiple cell therapy programs in clinical development, we may expend our limited resources to pursue a particular productcandidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihoodof success.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave three cell therapy programs in clinical development. OpRegen is currently in a Phase 1/2a multicenter clinical trial forthe treatment of dry AMD, OPC-1 is currently in a Phase 1/2a clinical trial for acute spinal cord injuries, and VAC2 is in a Phase1 clinical trial in non-small cell lung cancer. As a result of these and other future clinical trials for these product candidatesor any of our future product candidates may make our decision as to which product candidates to focus on more difficult and wemay forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential orlikelihood of success.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourresource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.Our spending on current and future research and development programs and product candidates may not yield any commercially viableproducts. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we mayrelinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements incases in which it would have been more advantageous for us to retain sole development and commercialization rights to such productcandidate.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Additionally,we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk tous. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resourcesexpertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentiallyresulting in a diversion of our management’s time and the expenditure of our resources with no resulting benefit. For example,if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capitaland other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 42 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        40
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Thecommercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians,patients, third-party payors, other health care providers and others in the medical community.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Evenif a product candidate obtains regulatory approval, its commercial success will depend in part on physicians, patients, third-partypayors, other health care providers and others in the medical community accepting our product candidates as medically useful,cost-effective, and safe. Any product we bring to the market may not gain market acceptance by such parties. The degree of marketacceptance of any of our products will depend on several factors, including without limitation:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    efficacy of the product as demonstrated in clinical trials and potential advantages over competing treatments;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    prevalence and severity of the disease and any side effects;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    clinical indications for which approval is granted, including any limitations or warnings contained in a product’s approved    labeling;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    convenience and ease of administration;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    cost of treatment, particularly as additive to existing treatments;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    willingness of the patients and physicians to accept and use these therapies;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    marketing, sales and distribution support for the products;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    publicity concerning our products or competing products and treatments; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    pricing and availability of coverage and adequate reimbursement by third-party payors and government authorities.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Evenif a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product will be uncertain.Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investmentand resources and may never succeed. If our products fail to achieve an adequate level of acceptance by physicians, patients,third-party payors, other health care providers and others in the medical community, we will not be able to generate sufficientrevenue to become or remain profitable.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifthe market opportunities for our product candidates are smaller than we believe and estimate they are, we may not meet our revenueexpectations and our business may suffer.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourprojections of the number of potential users in the markets we are attempting to address are based on our beliefs and estimates.Our estimates have been derived from a variety of sources, including market research and publications and scientific literatureestimating the total number of potential patients and currently approved or used therapies. Our estimates are also based on assumptionsregarding the potential size of the market assuming broad regulatory approval or potential usage by physicians beyond the approvedlabel. Any of our estimates may prove to be incorrect. The scope of approval and potential use of any product candidate may besignificantly narrower, and the number of patients may turn out to be lower than expected. Competitive products or approachesmay be approved or come into use and the potentially addressable patient population for each of our product candidates may belimited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult toidentify or gain access to, any which could adversely affect our results of operations and our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Salesof the products we may develop will be adversely affected by the availability of competing products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourproducts and product candidates will face substantial competition, whether through the development of safer and more effectivealternatives to our products, lower costs to administer than our products or other forms of competition such as more favorabledistribution, reimbursement and pricing or formulary and health care provider acceptance.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 43 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        41
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thecell therapy industry is characterized by rapidly evolving technology and intense competition. Our competitors include major multinationalpharmaceutical companies, specialty biotechnology companies, and chemical and medical products companies operating in the fieldsof regenerative medicine, cell therapy, tissue engineering, and tissue regeneration. Many of these companies are well establishedand possess technical, research and development, financial, and sales and marketing resources significantly greater than ours.In addition, certain smaller biotechnology companies have formed strategic collaborations, partnerships, and other types of jointventures with larger, well-established industry competitors that afford the smaller companies’ potential research and developmentas well as commercialization advantages. Academic institutions, governmental agencies, and other public and private research organizationsare also conducting and financing research activities, which may produce products directly competitive to those we are developing.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve that some of our competitors are trying to develop pluripotent cells and human embryonic progenitor cell (“hEPC”)based technologies and products that may compete with our stem cell products based on efficacy, safety, cost, and intellectualproperty positions. Ocata, which was acquired by a subsidiary of Astellas Pharma Inc., and Retinal Patch Technologies Inc. areconducting clinical trials of hES cell products designed to treat age-related macular degeneration. If their products are provento be safe and effective, they may reach the market ahead of OpRegen.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemay also face competition from companies that have filed patent applications relating to the propagation and differentiation ofstem cells. Those companies include Ocata, which in 2015 had certain U.S. patents issue with claims directed to methods of producingRPE cells and isolating and purifying such cells. We may be required to seek licenses from these competitors in order to commercializecertain products proposed by us, and such licenses may not be granted.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Competitiveproducts may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializingour product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our productswe may develop, if approved, could be adversely affected.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wewill face risks related to our own manufacturing capabilities and those related to our reliance on third parties to manufactureproducts, including those related to product acquisition costs, production delays, and supply shortages that could impair ourability to complete the development and commercialization of our product candidates.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Themanufacture of medical products is complex and requires significant expertise and capital investment, including the developmentof advanced manufacturing techniques and process controls. Although we have manufacturing capability through Cell Cure for OpRegen,OPC1, and VAC2 in Israel, we will need greater manufacturing capacity if we are to successfully commercialize our products. Unlesswe can raise the capital required to construct our own commercial scale manufacturing facilities and can develop the expertiseto manage and operate a manufacturing facility of our own, we may need to rely on third-party manufacturers to manufacture anyproducts we develop. There is no assurance that we will be able to identify manufacturers on acceptable terms or at all. Regardlessof whether we do our own manufacturing or rely on third parties to manufacture products for us, we will face risks related tothe manufacture of our products including these risks:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    or any third-party manufacturers might not timely formulate and manufacture our products or produce the quantity and quality    required to meet our clinical and commercial needs, if any.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    or any third-party manufacturers may not execute our manufacturing procedures appropriately.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Any    third-party manufacturers we engage may not perform as agreed or may not remain in the contract manufacturing business for    the time required to supply our clinical trials or to successfully produce, store and distribute our products on a commercial    scale.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    or any third-party manufacturers will be subject to ongoing periodic unannounced inspection by the FDA and corresponding state    agencies to ensure strict compliance with current good manufacturing practices (“cGMP”), and other government    regulations and corresponding foreign standards. We will not have control over third-party manufacturers’ compliance    with applicable regulations and standards.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 44 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        42
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers    in the manufacturing process for our product candidates.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    may not obtain licenses for third-party intellectual property rights needed by manufacturers to produce our products.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Third-party    manufacturers could breach or terminate their agreements with us.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        We    or third-party manufacturers may experience manufacturing difficulties as a result of resource constraints, labor disputes,    unstable political environments, natural disasters, public health crises such as pandemics and epidemics, political crises    such as terrorism, war, political insecurity or other conflict, or other events outside of our or our third-party manufacturers    control (including as a result of actual or threatened public health emergencies and outbreaks of disease such as the current    COVID-19 pandemic). This may result in business closures that affect us and our third-party manufacturers.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, we may rely on third parties to perform release testing on our product candidates prior to delivery to patients. Ifthese tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm whichcould result in product liability suits.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe or any third-party manufacturers we may engage were to encounter any of these difficulties, our ability to provide our productcandidates to patients in clinical trials or to the medical market place would be jeopardized. Any delay or interruption in thesupply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintainingclinical trial programs and, depending upon the period of delay, could require us to either commence new clinical trials at additionalexpense or terminate clinical trials completely. Each risk could delay our clinical trials, any approval of our product candidatesby the FDA, or the commercialization of our product candidates, and could result in higher costs or deprive us of potential productrevenue.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Anycell-based products that receive regulatory approval may be difficult and expensive to manufacture profitably.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Cell-basedproducts are among the more expensive biologic products to manufacture in accordance with cGMP. We do not yet have sufficientinformation to reliably estimate the cost of commercially manufacturing any of our product candidates. Excessive manufacturingcosts could make our product candidates too expensive to compete in the medical market place with alternative products manufacturedby our competitors or might result in third party payors such as health insurers and Medicare, declining to cover our productsor setting reimbursement levels too low for us to earn a profit from the commercialization of one or more of our products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wemay not secure a commercialization partner for Renevia.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InSeptember 2019, Renevia was granted a CE Mark and Class III classification with an intended use in adults as a resorbable matrixfor the delivery of autologous adipose tissue preparations to restore and/or augment facial volume after subcutaneous fat volumeloss for the treatment of facial lipoatrophy. The CE Mark provides us, or our authorized agent, the authority to market and distributeRenevia throughout the European Union (“EU”) and in other countries that recognize the CE Mark.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     However,because we have no commercial infrastructure, we are seeking a commercialization partner in the EU. We can give no assurance thatwe will secure a commercialization partner for Renevia or otherwise commercialize Renevia.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Theongoing COVID-19 pandemic may adversely affect our operations, including the conduct of our clinical trials.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InDecember 2019, a novel strain of coronavirus and the resulting illness known as COVID-19 emerged in Wuhan, China. The outbreakhas now spread to other countries and has been declared a pandemic by the World Health Organization.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 45 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        43
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheCOVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including a Californiaexecutive order and several other state and local orders across the country, which, among other things, direct individuals toshelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physicallocations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. In response to these publichealth directives and orders, we have implemented work-from-home policies for our employees. The effects of the executive order,the shelter-in-place order and our work-from-home policies may negatively impact productivity, disrupt our business and delayour clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictionsand other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe,disruptions in our operations could negatively impact our business, operating results and financial condition.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     AsCOVID-19 continues to spread in the United States and Israel, we have experienced and may continue to experience disruptions thatcould adversely affect our operations and clinical trials, including:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    or difficulties in enrolling, or conducting follow-up visits with, patients in our clinical trials, particularly patients    for our OpRegen Phase 1/2a clinical trial, who are older and who may be at higher risk of complications from COVID-19;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and staff;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        diversion    of healthcare resources away from the conduct of clinical trials;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        interruption    of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        limited    availability of our employees and the staff of our current clinical sites due to sickness or social distancing measures;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        manufacturing    difficulties for us and our suppliers of raw materials caused by business closures;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        delays    in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global    shipping that may affect the transport of clinical trial materials;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        changes    in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical    trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        interruption    or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        risk    that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact    the results of the clinical trial, including by increasing the number of observed adverse events; and;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
         refusalof the FDA to accept data from clinical trials in affected geographies;
        </span>
       </p>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theseand other disruptions in our operations and the global economy could negatively impact our business, operating results and financialcondition. The extent to which the COVID-19 pandemic affects our operations will depend on future developments, which are highlyuncertain and cannot be predicted with confidence, including the duration and severity of the pandemic, and the actions that maybe required to contain the COVID-19 pandemic or treat its impact.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourclinical trials have been, and may in the future be, affected by the COVID-19 pandemic. For example, the COVID-19 pandemic hasimpacted patient enrollment in our OpRegen Phase 1/2a multicenter clinical trial and the VAC2 Phase 1 multicenter clinical trial.In particular, some sites have paused enrollment to focus on, and direct resources to, the COVID-19 pandemic, while at other sites,patients are choosing not to enroll or continue participating in the clinical trial as a result of the pandemic. We are unableto predict with confidence the duration of such patient enrollment delays and difficulties. If patient enrollment is delayed foran extended period of time, such clinical trials could be delayed or otherwise adversely affected. Our inability to enroll a sufficientnumber of patients for any of our current or future clinical trials could result in significant delays or may require us to abandonone or more clinical trials altogether. As a result, we may experience new or additional delays and difficulties in enrollment,which would result in the delay of completion of such trials beyond our expected timelines.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 46 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        44
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourongoing or planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparableforeign regulatory agencies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or otherrestrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impactpersonnel at our CROs or third-party manufacturing facilities upon which we rely, or the availability or cost of materials, whichcould disrupt the supply chain for our product candidates. To the extent our suppliers and service providers are unable to complywith their obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goodsand services to us due to the COVID-19 pandemic, our ability to continue meeting clinical supply demand for our product candidatesor otherwise advancing development of our product candidates may become impaired.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thespread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. While the potential economicimpact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, there could be a significantdisruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect ourliquidity and financial position. In addition, the trading prices for other biotechnology companies have been highly volatileas a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common sharesor such sales may be on unfavorable terms.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     COVID-19and actions taken to reduce its spread continue to rapidly evolve. The extent to which COVID-19 may impede the development ofour product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduceour access to capital or limit our business development activities, will depend on future developments, which are highly uncertainand cannot be predicted with confidence.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also havethe effect of heightening many of the other risks and uncertainties described in this ‘‘Risk Factors’’section.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Thewithdrawal of the United Kingdom (the “U.K.”) from the EU, commonly referred to as “Brexit,” may adverselyimpact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition oftaxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order todevelop, manufacture and commercialize our product candidates in the EU.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnJune 23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. toleave the EU. The U.K. formally left the EU on January 31, 2020, which is commonly referred to as Brexit, with a transitionperiod that ended December 31, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 47 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        45
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Sincea significant proportion of the regulatory framework in the U.K. applicable to our business and our product candidates is derivedfrom EU directives and regulations, Brexit and the new Trade and Cooperation Agreement between the European Union and the U.K.that took provisional effect on January 1, 2021 could materially impact the regulatory regime with respect to the development,manufacture, importation, approval and commercialization of our product candidates in the U.K. or the EU. For example, theU.K. is no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the European MedicinesAgency and a separate process for authorization of drug products, including our product candidates, will be required in the U.K.
     <span style="background-color: white">
      It is currently unclear whether the Medicines &amp; Healthcare products Regulatory Agencyin the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likelyto receive.
     </span>
     <span style="background-color: white">
     </span>
     Any delay in obtaining, or an inability to obtain, any marketingapprovals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. or theEU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to paytaxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU, orwe may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of theseoutcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. or the EU for our productcandidates, or incur significant additional expenses to operate our business, which could significantly and materially harm ordelay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariffand import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barrierson us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular,trade between the affected nations and the U.K. It is also possible that Brexit may negatively affect our ability to attract andretain employees, particularly those from the EU.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Weface potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.If the use or misuse of our products or product candidates harm patients or is perceived to harm patients even when such harmis unrelated to our products or product candidates, our regulatory approvals could be revoked, suspended or otherwise negativelyaffected, and we could be subject to costly and damaging product liability claims.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weface the risk of incurring liabilities to clinical trial patients if they are injured as a result of their participation in ourclinical trials. In the event we commercialize Renevia in the EU or in other countries that recognize the CE Mark, we will alsoface product liability risks associated with the use of Renevia by consumers. If any claims are made and if liability can be established,the amount of any liability we or our affiliates may incur, could exceed any insurance coverage in effect, and the amount of theliability could be material to our financial condition.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theuse or misuse of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval,including Renevia, exposes us to the risk of product liability claims. Product liability claims might be brought against us byconsumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products.There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liabilityclaims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liabilityclaims may result in:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 36px">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        impairment    of our business reputation;
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        initiation    of investigations by regulators;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        withdrawal    of clinical trial participants;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        costs    due to related litigation;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        distraction    of management’s attention from our primary business;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        substantial    monetary awards to patients or other claimants;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    inability to commercialize our product candidates;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        product    recalls, withdrawals or labeling, marketing or promotional restrictions; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        decreased    demand for our product candidates, if approved for commercial sale.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 48 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        46
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve our current product liability insurance coverage is appropriate in light of our clinical programs; however, we may notbe able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.If and when we obtain marketing approval for product candidates, we intend to increase our insurance coverage to include the saleof commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or inadequate amounts. Significant damages have been awarded in class action lawsuits based on drugs or medical treatments that hadunanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stockprice to decline and, if the amount of damages exceeds our insurance coverage, could adversely affect our results of operationsand business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CellCure has received Israeli government grants for certain of its research and development activities. The terms of these grantsmay require Cell Cure to seek approvals and to satisfy specified conditions to manufacture products and transfer or license grant-supportedtechnologies outside of Israel. In the context of such approvals, Cell Cure will be required to pay penalties in addition to therepayment of the grants. Such grants are applied for on a yearly basis and may not be available or only partially granted in thefuture, which would increase our costs.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     CellCure has received Israeli government grants for certain of its research and development activities. The terms of these grantsrequire prior approval and the satisfaction of specified conditions to manufacture products and transfer or license technologiesoutside of Israel.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Underthe Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Lawfor the Encouragement of Research and Development in Industry 5744-1984), and the regulations, guidelines, rules, procedures andbenefit tracks thereunder (collectively, the “Innovation Law”), annual research and development programs that meetspecified criteria and are approved by a committee of the Israel Innovation Authority (“IIA”) are eligible for grants.The grants awarded are typically up to 50% of the project’s expenditures, as determined by the IIA committee and subjectto the benefit track under which the grant was awarded. A company that receives a grant from the IIA (a “Grant Recipient”),is typically required to pay royalties to the IIA on income generated from products incorporating know-how developed using suchgrants (including income derived from services associated with such products) or on all revenues of the Grant Recipient (dependingupon the terms of the approval letters issued by the IIA), until 100% of the U.S. dollar-linked grant plus annual LIBOR interestis repaid. In general, the rate of such royalties varies between 3% to 5%.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theobligation to pay royalties is contingent on actual revenues being generated from such products and services or actual revenuesbeing generated by the Grant Recipient in general (as the case may be). In the absence of such revenues, no payment of royaltiesis required. It should be noted that the restrictions under the Innovation Law will continue to apply even after the repaymentof such royalties in full by the Grant Recipient including restrictions on the sale, transfer or licensing to a foreign entityof know-how developed as part of the programs under which the grants were given.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theterms of the grants under the Innovation Law also (generally) require that the products developed as part of the programs underwhich the grants were given be manufactured in Israel and that the know-how developed thereunder may not be transferred outsideof Israel, unless prior written approval is received from the IIA (such approval is not required for the transfer of a portionof the manufacturing capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outsideof Israel in the applications for funding (in which case only notification is required), and additional payments are requiredto be made to IIA). It should be noted that this does not restrict the export of products that incorporate the funded know-how.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheInnovation Law restricts the ability to transfer or license know-how funded by IIA outside of Israel. Transfer of IIA-funded know-howoutside of Israel requires prior approval and is subject to approval and payment of a redemption fee to the IIA calculated accordingto the relevant formulas provided under the Innovation Law. A transfer or license for the purpose of the Innovation Law are generallyinterpreted very broadly and include, inter alia, any actual sale or assignment of the IIA-funded know-how, any license to furtherdevelop or otherwise exploit the IIA-funded know-how or the products resulting from such IIA-funded know-how or any other transaction,which, in essence, constitutes a transfer of the IIA-funded know-how. Generally, a mere license solely to market or distributeproducts resulting from the IIA-funded know-how would not be deemed a transfer or license for the purpose of the Innovation Law.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Partof Cell Cure’s research and development efforts have been financed, partially, through grants that it has received fromthe IIA and when we acquired our holdings in Cell Cure, we undertook in writing, vis-à-vis the IIA, to abide by, and toensure the abidance of Cell Cure to, the Innovation Law. We therefore must comply with the requirements of the Innovation Lawand related regulations. As of December 31, 2020, we received approximately $15.4 million of such grants.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 49 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        47
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Therestrictions under the Innovation Law may impair our ability to enter into agreements which involve IIA-funded products or know-howwithout the approval of IIA. We cannot be certain that any approval of IIA will be obtained on terms that are acceptable to us,or at all. We may not receive the required approvals should we wish to transfer or license IIA-funded know-how, manufacturingand/or development outside of Israel in the future. Furthermore, in the event that we undertake a transaction involving the transferto a non-Israeli entity of know-how developed with IIA-funding pursuant to a merger or similar transaction, the considerationavailable to our shareholders may be reduced by the amounts we are required to pay to the IIA. Any approval, if given, will generallybe subject to additional financial obligations. Failure to comply with the requirements under the Innovation Law may subject CellCure to mandatory repayment of grants received by it (together with interest and penalties), as well as expose its directors andmanagement to criminal proceedings. In addition, the IIA may from time to time conduct royalty audits. Further grants may notbe approved or reduced in the future, which would increase our costs. IIA approval is not required for the marketing or distributionof products resulting from the IIA-funded research or development in the ordinary course of business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourinternational business exposes us to business, regulatory, political, operational, financial and economic risks associated withdoing business outside of the United States.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     CellCure is our 99% owned subsidiary located in Jerusalem, Israel. OpRegen is currently manufactured at Cell Cure and we anticipatetransitioning some or all of the manufacturing of OPC1 and VAC2 to Cell Cure as well. A portion of our OpRegen Phase 1/2a clinicaltrial has been conducted at sites in Israel. Conducting operations internationally involves a number of risks, including:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        difficulty    in staffing and managing foreign operations;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        failure    by us to obtain the appropriate regulatory approvals;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        logistics    and regulations associated with shipping drug product or patient samples, including infrastructure conditions and transportation    delays;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        financial    risks, such as longer payment cycles and exposure to foreign currency exchange rate fluctuations;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        political    and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade    and other business restrictions;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        multiple,    conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, data and    privacy laws, regulatory requirements and other governmental approvals, permits and licenses; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        regulatory    and compliance risks that may fall within the purview of the U.S. Foreign Corrupt Practices Act, UK Bribery Act, anti-boycott    laws and other anti-corruption laws.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Anyof these factors could significantly harm our international operations and, consequently, our results of operations. In addition,any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, butare not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines andpenalties, denial of export privileges, seizure of shipments, and restrictions on certain business activities. Also, the failureto comply with applicable legal and regulatory obligations could result in the disruption of our clinical trial activities.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourinternational operations could be affected by changes in laws, trade regulations, labor and employment regulations, and proceduresand actions affecting approval, production, pricing, reimbursement and marketing of tests, as well as by inter-governmental disputes.Any of these changes could adversely affect our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Oursuccess internationally will depend, in part, on our ability to develop and implement policies and strategies that are effectivein anticipating and managing these and other risks in Israel. Failure to manage these and other risks may have a material adverseeffect on our operations in Israel and on our business as a whole.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 50 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        48
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksRelated to our Intellectual Property
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourintellectual property may be insufficient to protect our products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourpatents and patent applications are directed to compositions of matter, formulations, methods of use and/or methods of manufacturing,as appropriate. In addition to patenting our own technology and that of our subsidiaries, we have licensed patents and patentapplications for certain stem cell technology, hEPC, and hES cell lines, hydrogel technology and other technology from other companies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thepatent positions of pharmaceutical and biotechnology companies, including ours, are generally uncertain and involve complex legaland factual questions. Our business could be negatively affected by any of the following:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    claims of any patents that are issued may not provide meaningful protection, may not provide a basis for commercially viable    products or may not provide us with any competitive advantages;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    patents may be challenged by third parties;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        others    may have patents that relate to our technology or business that may prevent us from marketing our product candidates unless    we are able to obtain a license to those patents;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    pending patent applications to which we have rights may not result in issued patents;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        our    patents may have terms that are inadequate to protect our competitive position on our products;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        we    may not be successful in developing additional proprietary technologies that are patentable.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, others may independently develop similar or alternative technologies, duplicate any of our technologies and, if patentsare licensed or issued to us, design around the patented technologies licensed to or developed by us. As an example, Astellas’patent portfolio with respect to the manufacture of its RPE products could adversely impact our rights to manufacture OpRegen.Moreover, we could incur substantial costs in litigation if we have to defend ourselves in patent lawsuits brought by third partiesor if we initiate such lawsuits.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete withus, which could limit opportunities for us to generate revenues by licensing our technology and selling products.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Oursuccess will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and inother countries. If we are unsuccessful at obtaining and enforcing patents, our competitors could use our technology and createproducts that compete with our products, without paying license fees or royalties to us. The preparation, filing, and prosecutionof patent applications can be costly and time consuming. Our limited financial resources may not permit us to pursue patent protectionof all of our technology and products in all key markets. Even if we are able to obtain issued patents covering our technologyor products, we may have to incur substantial legal fees and other expenses to enforce our patent rights to protect our technologyand products from infringing uses. We may not have the financial resources to finance the litigation required to preserve ourpatent and trade secret rights. Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have beenand may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights,and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third partiesto be pertinent to the manufacture, use or sale of our products. This means that patents owned or licensed by us may be lost ifthe outcome of a proceeding is unfavorable to us.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Thereis no certainty that our pending or future patent applications will result in the issuance of patents.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Oursuccess depends in part on our ability to obtain and defend patent and other intellectual property rights that are important tothe commercialization of our products and product candidates. The degree of patent protection that will be afforded to our productsand processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decidedupon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that wewill successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or thatthe protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where weconduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that wecurrently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual propertyrights held by third parties.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 51 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        49
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InEurope, there is uncertainty about the eligibility of hES cell subject matter for patent protection. The European Patent Conventionprohibits the granting of European patents for inventions that concern “uses of human embryos for industrial or commercialpurposes.” A recent decision at the Court of Justice of the European Union interpreted parthenogenetically produced hEScells as patentable subject matter. Consequently, the European Patent Office now recognizes that human pluripotent stem cells(including human ES cells) can be created without a destructive use of human embryos as of June 5, 2003, and patent applicationsrelating to hES cell subject matter with a filing and priority date after this date are no longer automatically excluded frompatentability under Article 53 (a) EPC and Rule 28(c) EPC.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Intellectualproperty we may develop using grants received from governments are subject to rights maintained by those governments.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Researchand development we perform that is funded by grants from government, and any intellectual property that we create using thosegrants, is subject to certain rights of the government entities to require that we license or grant rights to the intellectualproperty developed using government funding in certain circumstances.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Thereis no certainty that we will be able to obtain licenses to intellectual property rights owned by third parties.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereare no assurances that any of our intellectual property rights will guarantee protection or market exclusivity for our productsand product candidates. In such cases, we may need to obtain enabling licenses from third parties to protect our products andproduct candidates, try to secure market exclusivity or avoid infringing on the intellectual property rights of third parties.If we are unable to fully protect our product candidates or achieve market exclusivity for our products and product candidates,our financial success will be dependent, in part, on our ability to protect and enforce our intellectual property rights, to operatewithout infringing upon the proprietary rights of others, or, when necessary, our ability to obtain enabling licenses.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourbusiness depends on several critical technologies that are based in part on technology licensed from third parties. Those third-partylicense agreements impose obligations on us, including payment obligations and obligations to pursue development of commercialproducts under the licensed patents or technology. If a licensor believes that we have failed to meet our obligations under alicense agreement, the licensor could seek to limit or terminate our license rights, which could lead to costly and time-consuminglitigation and, potentially, a loss of the licensed rights. During the period of any such litigation, our ability to carry outthe development and commercialization of potential products, and our ability to raise any capital that we might then need, couldbe significantly and negatively affected. If our license rights were restricted or ultimately lost, we would not be able to continueto use the licensed technology in our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksRelated to our Dependence on Third Parties
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wemay become dependent on possible future collaborations to develop and commercialize many of our product candidates and to providethe regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemay enter into various kinds of collaborative research and development and product marketing agreements to develop and commercializeour products. The expected future milestone payments and cost reimbursements from collaboration agreements could provide an importantsource of financing for our research and development programs, thereby facilitating the application of our technology to the developmentand commercialization of our products, but there are risks associated with entering into collaboration arrangements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 52 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        50
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereis a risk we could become dependent upon one or more collaborative arrangements. A collaborative arrangement upon which we mightdepend might be terminated by our collaboration partner or a partner might determine not to actively pursue the development orcommercialization of our products. A collaboration partner also may not be precluded from independently pursuing competing productsand drug delivery approaches or technologies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereis a risk that a collaboration partner might fail to perform its obligations under the collaborative arrangements or may be slowin performing its obligations. In addition, a collaboration partner may experience financial difficulties at any time that couldprevent it from having available funds to contribute to the collaboration. If a collaboration partner fails to conduct its productdevelopment, commercialization, regulatory compliance, sales and marketing or distribution activities successfully and in a timelymanner, or if it terminates or materially modifies its agreements with us, the development and commercialization of one or moreproduct candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilitiesto continue such development and commercialization on our own.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wedo not have the ability to independently conduct clinical trials required to obtain regulatory approvals for our product candidates.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wewill need to rely on third parties, such as CROs, data management companies, contract clinical research associates, medical institutions,clinical investigators and contract laboratories to conduct any clinical trials we may undertake for our product candidates. Wemay also rely on third parties to assist with preclinical development of our product candidates. If we outsource clinical trials,we may not directly control the timing, conduct and expense of our clinical trials. If we enlist third parties to conduct clinicaltrials and they fail to perform their contractual duties or regulatory obligations or fail to meet expected deadlines, if theyneed to be replaced or if the quality or accuracy of the data they obtain is compromised due to failing to adhere to our clinicalprotocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended,delayed, suspended or terminated, and we may not obtain regulatory approval for or successfully commercialize our product candidates.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or otherrestrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impactpersonnel at these third parties, which could disrupt our clinical timelines, which could have a material adverse impact on ourbusiness, prospects, financial condition and results of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wehave relied on CIRM to fund past clinical trials of OPC1 and we do not know if they will provide additional funding for futurestudies of OPC1.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wereceived $14.3 million of funding from CIRM to support clinical development of OPC1. We intend to apply for additionalCIRM grants, if available; however, we cannot provide any assurance that such grants will be awarded. If we are unable to obtainanother CIRM grant, we will need to raise funds through other mechanisms to support future clinical studies of OPC1, which maytake additional time and effort. If capital is not immediately available, this may force us to amend, delay, or discontinue theclinical trial and development work for OPC1 until funding is secured.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Wemay need to rely on marketing partners or contract sales companies.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe are able to develop our product candidates and obtain necessary regulatory approvals, we may need to rely on marketing, sellingor distributing partners. If we do not partner for commercial services, we will depend on our ability to build our own marketing,selling and distribution capabilities, which would require the investment of significant financial and management resources, orwe will need to find collaborative marketing partners, sales representatives or wholesale distributors for the commercial saleof our products.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ifwe market products through arrangements with third parties, we may pay sales commissions to sales representatives or we may sellor consign products to distributors at wholesale prices. As a result, our gross profit from product sales may be lower than itwould be if we sold our products directly to end users at retail prices through our own sales force. There can be no assurancewe will be able to negotiate distribution or sales agreements with third parties on favorable terms to justify our investmentin our products or achieve sufficient revenues to support our operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 53 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        51
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RisksPertaining to Our Common Shares
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Becausewe are engaged in the development of pharmaceutical and stem cell therapy products, the price of our common shares may rise andfall rapidly.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Themarket price of our common shares, like that of the shares of many biotechnology companies, has been highly volatile. The priceof our common shares may rise rapidly in response to certain events, such as the commencement of clinical trials of an experimentalnew therapy, even though the outcome of those trials and the likelihood of ultimate FDA approval of a therapeutic product remainuncertain. Similarly, prices of our common shares may fall rapidly in response to certain events such as unfavorable results ofclinical trials or a delay or failure to obtain FDA approval. The failure of our earnings to meet analysts’ expectationscould result in a significant rapid decline in the market price of our common shares.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Currenteconomic and stock market conditions may adversely affect the price of our common shares.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thestock market has been experiencing extreme price and volume fluctuations which have affected the market price of the equity securitieswithout regard to the operating performance of the issuing companies. Broad market fluctuations, as well as general economic,political and other conditions (such as the recent coronavirus outbreak), may adversely affect the market price of our commonshares.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Becausewe do not pay cash dividends, our common shares may not be a suitable investment for anyone who needs to earn dividend income.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wedo not pay cash dividends on our common shares. For the foreseeable future, we anticipate that any earnings generated in our businesswill be used to finance the growth of our business and will not be paid out as dividends to holders of our common shares. Thismeans that our common shares may not be a suitable investment for anyone who needs to earn income from their investments.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Insiderscontinue to have substantial influence over our company, which could limit your ability to influence the outcome of key transactions,including a change of control.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourdirectors, executive officers and their affiliates, in the aggregate, owned approximately 27% of our outstanding commonshares as of December 31, 2020. As a result, these shareholders, if acting together, will be able to heavily influence or controlmatters requiring approval by our shareholders, including the election of directors and the approval of mergers, acquisitionsor other extraordinary transactions. They may also have interests that differ from yours and may vote in a way with which youdisagree, and which may be averse to your interests. This concentration of ownership may have the effect of delaying, preventingor deterring a change of control of our company, could deter certain public investors from purchasing our common shares and mightultimately affect the market price of our common shares.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ourbusiness could be negatively affected as a result of actions of activist shareholders, and such activism could affect the tradingvalue of our securities.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Shareholdersmay, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changesand assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategicdirection or seek changes in the composition of our board of directors could have an adverse effect on our operating results andfinancial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expensesand administrative and associated costs and require significant time and attention by our board of directors and management, divertingtheir attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control,our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arisingfrom a proxy contest could lead to the perception of a change in the direction of our business or instability which may resultin the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our abilityto attract and retain qualified personnel and business partners, any of which could adversely affect our business and operatingresults. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our abilityto effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, ormay become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serveas a further distraction to our board of directors and management and would require us to incur significant additional costs.In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporaryor speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects ofour business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 54 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        52
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Securitiesanalysts may not initiate coverage or continue to cover our common shares, and this may have a negative impact on the market priceof our common shares.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thetrading market for our common shares depends, in part, on the research and reports that securities analysts publish about ourbusiness and our common shares. We do not have any control over these analysts. There is no guarantee that securities analystswill cover our common shares. If securities analysts do not cover our common shares, the lack of research coverage may adverselyaffect the market price of those shares. If securities analysts do cover our common shares, they could issue reports or recommendationsthat are unfavorable to the price of our common shares, and they could downgrade a previously favorable report or recommendation,and in either case our share prices could decline as a result of the report. If one or more of these analysts does not initiatecoverage, ceases to cover our common shares or fails to publish regular reports on our business, we could lose visibility in thefinancial markets, which could cause our share prices or trading volume to decline.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Ifwe or our subsidiaries issue additional common shares or preferred shares, investors in our common shares may experience dilutionof their ownership interests.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weand our subsidiaries may issue additional common shares or other securities convertible into or exercisable for common sharesto raise additional capital or to hire or retain employees or consultants, or in connection with future acquisitions of companiesor licenses to technology or rights, or for other business purposes. The future issuance of additional securities may be dilutiveto our shareholders and may create downward pressure on the trading price of our common shares.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare currently authorized to issue an aggregate of 252,000,000 shares of capital stock consisting of 250,000,000 common sharesand 2,000,000 “blank check” preferred shares, which means we may issue, without stockholder approval, one or moreseries of preferred stock having such designation, powers, privileges, preferences, including preferences over our common sharesrespecting dividends and distributions, terms of redemption and relative participation, optional, or other rights, if any, ofthe shares of each such series of preferred stock and any qualifications, limitations or restrictions thereof, as our board ofdirectors may determine. The terms of one or more series of preferred stock could dilute the voting power or reduce the valueof our common shares. Any preferred shares may also be convertible into common shares on terms that would be dilutive to holdersof common shares. Our subsidiaries may also issue their own preferred shares with a similar impact on our ownership of the subsidiaries.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, Lineage had 153,095,883 common shares outstanding, 16,214,547 common shares reserved for issuance upon theexercise of outstanding options under our employee stock option plans, 92,700 common shares reserved for issuance upon the vestingand settlement of restricted stock units under our equity incentive plan, and 1,089,900 common shares subject to warrants.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition, in May 2020 we entered into a Controlled Equity Offering
     <sup>
      SM
     </sup>
     Sales Agreement (the “Sales Agreement”)with Cantor Fitzgerald &amp; Co., as sales agent (“Cantor Fitzgerald”), pursuant to which we may, but are not obligatedto, raise up to $25.0 million through the sale of common shares from time to time in at-the-market transactions under the SalesAgreement. As of December 31, 2020, we made $5.1 million in sales under the Sales Agreement (which excludes $0.3 millionof cash in transit related to 2020 sales that settled in 2021).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theoperation of some of our subsidiaries has been financed in part through the sale of shares of capital stock and warrants to purchasesecurities of those subsidiaries to private investors. Future sales of such securities by our subsidiaries could reduce our ownershipinterest in the applicable subsidiary, and correspondingly dilute our shareholder’s ownership interests in our consolidatedenterprise. Certain of our subsidiaries also have their own stock option plans and the exercise of stock options or the sale ofrestricted stock under those plans would also reduce our ownership interest in the applicable subsidiary, with a resulting dilutiveeffect on the ownership interest of our shareholders in our consolidated enterprise.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_004">
         </span>
         ITEM    1B.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         UNRESOLVED    STAFF COMMENTS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     None.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 55 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        53
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span id="a_005">
       </span>
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         ITEM    2.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         PROPERTIES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      General
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ingeneral, we believe that our properties are well-maintained, adequate and suitable for their current requirements and for ouroperations in the foreseeable future. See the Notes to Consolidated Financial Statements – Note 14. Commitments andContingencies included elsewhere in this Report.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LineageFacilities
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourcorporate headquarters comprise 8,841 square feet of rentable space in an office park in Carlsbad, California. We also sublease2,432 square feet of space in Alameda, California.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CellCure Facilities
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     CellCure leases 728.5 square meters (approximately 7,842 square feet) of office and laboratory space in the Bio Park on the campusof the Hadassah University Hospital in Jerusalem, Israel under a lease that expires on December 31, 2025. We have an option toextend the term for an additional 5 years.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     InJanuary 2018, Cell Cure entered into another lease for an additional 934 square meters (approximately 10,054 square feet) of officespace in the same facility in Jerusalem, Israel under a lease that expires on December 31, 2025, with two options to extend thelease for 5 years each. The term of this lease commenced on April 1, 2018 and includes a leasehold improvement construction allowanceof up to NIS 4,000,000 (approximately up to $1.1 million) from the landlord. The leasehold improvements were substantially completedby December 31, 2018 and the construction allowance was fully utilized.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_006">
         </span>
         ITEM    3.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         LEGAL    PROCEEDINGS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Fromtime to time, we are subject to legal proceedings and claims in the ordinary course of business. While management presently believesthat the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position,cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorablerulings or outcomes could occur that have individually or in aggregate, a material adverse effect on our business, financial conditionor operating results. Except as described below, we are not currently subject to any pending material litigation, other than ordinaryroutine litigation incidental to our business, as described above.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnFebruary 19, 2019, a putative shareholder class action lawsuit was filed (captioned
     <i>
      Lampe v. Asterias Biotherapeutics, Inc.et al
     </i>
     ., Case No. RG19007391) in the Superior Court of the State of California, County of Alameda challenging the AsteriasMerger. On March 1, 2019, Asterias made certain amendments and supplements to its public disclosures regarding the Asterias Merger(the “Supplemental Disclosures”). On May 3, 2019, an amended class action complaint (the “Amended Complaint”)was filed. The Amended Complaint named Lineage, Patrick Merger Sub, Inc., the Asterias board of directors, one member of Lineage’sboard of directors, and certain stockholders of both Lineage and Asterias. The action was brought by two purported stockholdersof Asterias, on behalf of a putative class of Asterias stockholders, and asserted breach of fiduciary duty and aiding and abettingclaims under Delaware law. The Amended Complaint alleged, among other things, that the process leading up to the Asterias Mergerwas conflicted and inadequate, and that the proxy statement filed by Asterias with the Commission omitted certain material information,which allegedly rendered the information disclosed materially misleading. The Amended Complaint sought, among other things, thata class be certified, the recovery of monetary damages, and attorneys’ fees and costs.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnJune 3, 2019, defendants filed demurrers to the Amended Complaint. On August 13, 2019, the parties submitted a stipulation tothe court seeking dismissal of the action with prejudice as to the named Plaintiffs and without prejudice as to the unnamed putativeclass members, and disclosing to the court the parties’ agreement to resolve, for $200,000, Plaintiffs’ claim foran award of attorneys’ fees and expenses in connection with the purported benefit conferred on Asterias stockholders bythe Supplemental Disclosures. The court granted the stipulation and dismissed the action August 14, 2019. Lineage continues tobelieve that the claims and allegations in the action lack merit, but believed that it was in Lineage’s shareholders’best interest for the action to be dismissed and to resolve the fee claim in a timely manner without additional costly litigationexpenses.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnOctober 14, 2019, another putative class action lawsuit was filed challenging the Asterias Merger. This action (captioned
     <i>
      Rossv. Lineage Cell Therapeutics, Inc., et al.
     </i>
     , C.A. No. 2019-0822) was filed in Delaware Chancery Court and names Lineage, theAsterias board of directors, one member of Lineage’s board of directors, and certain stockholders of both Lineage and Asteriasas defendants. The action was brought by a purported stockholder of Asterias, on behalf of a putative class of Asterias stockholders,and asserts breach of fiduciary duty and aiding and abetting claims under Delaware law. The complaint alleges, among other things,that the process leading up to the Asterias Merger was conflicted, that the Asterias Merger consideration was inadequate, andthat the proxy statement filed by Asterias with the Commission omitted certain material information, which allegedly renderedthe information disclosed materially misleading. The complaint seeks, among other things, that a class be certified, the recoveryof monetary damages, and attorneys’ fees and costs. On December 20, 2019, the defendants moved to dismiss the complaint.On February 10, 2020, the plaintiff filed an opposition. Defendants filed their replies on March 13, 2020. On June 23, 2020, ahearing on the motions to dismiss occurred. On September 21, 2020, the Chancery Court denied the motion to dismiss as to Lineageand certain members of the Asterias board of directors, and it granted the motion to dismiss as to all other defendants. On October30, 2020, the remaining defendants filed an answer to the complaint.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineagebelieves the allegations in the action lack merit and intends to vigorously defend the claims asserted. It is impossible at thistime to assess whether the outcome of this proceeding will have a material adverse effect on Lineage’s consolidated resultsof operations, cash flows or financial position. Therefore, in accordance with ASC 450,
     <i>
      Contingencies,
     </i>
     Lineage has notrecorded any accrual for a contingent liability associated with this legal proceeding based on its belief that a liability, whilepossible, is not probable nor estimable, and any range of potential contingent liability amounts cannot be reasonably estimatedat this time. Lineage records legal expenses as incurred.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_007">
         </span>
         ITEM    4.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         MINE    SAFETY DISCLOSURES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Notapplicable.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 56 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        54
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_008">
      </span>
      PARTII
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_009">
         </span>
         ITEM    5.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         MARKET    FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      MarketInformation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourcommon shares trade on the NYSE American and on the Tel Aviv Stock Exchange under the ticker symbol LCTX.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Holders
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof March 1, 2021, there were 384 record holders of our common shares. The number of beneficial owners is substantiallygreater than the number of record holders because a large portion of our common shares is held of record through brokerage firmsin “street name.”
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      DividendPolicy
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave not paid dividends on our common shares. We currently intend to retain any earnings for use in the operations of our business.We, therefore, do not anticipate paying cash dividends on our common shares in the foreseeable future.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RecentSales of Unregistered Securities
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Exceptas previously reported in our quarterly reports on Form 10-Q and current reports on Form 8-K filed with the Securities and ExchangeCommission, during the year ended December 31, 2020, there were no unregistered sales of equity securities by us duringthe year ended December 31, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_010">
         </span>
         ITEM    6.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         SELECTED    FINANCIAL DATA
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Weare a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended. Accordingly, we arenot required to provide the information required by this item in this Report.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 57 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        55
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_011">
         </span>
         ITEM    7.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         MANAGEMENT’S    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Thefollowing Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide informationnecessary to understand our audited consolidated financial statements for the two-year period ended December 31, 2020, and highlightcertain other information which, in the opinion of management, will enhance a reader’s understanding of our financial condition,changes in financial condition and results of operations. In particular, the discussion is intended to provide an analysis ofsignificant trends and material changes in our financial position and the operating results of our business during the year endedDecember 31, 2020 as compared to the year ended December 31, 2019. This discussion should be read in conjunction with our consolidatedfinancial statements and related notes included elsewhere in this Report. These historical financial statements may not be indicativeof our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations containsa number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertaintiesand risks described throughout this Report, particularly in “Item 1A. Risk Factors.”
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Overview
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Our focus is to develop therapiesfor degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting andcombating cancer. Specifically, we are testing therapies to treat dry age-related macular degeneration (“AMD”), spinalcord injuries, and non-small cell lung cancer. Our programs are based on our proprietary cell-based therapy platform and associateddevelopment and manufacturing capabilities. From this platform, we develop and manufacture specialized, terminally or functionally differentiated human cells from established and well-characterized pluripotent cell lines. These differentiatedcells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumaticinjury, or are administered as a means of helping the body mount an effective immune response to cancer.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave three allogeneic, or “off-the-shelf,” cell therapy programs in clinical development:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         OpRegen
        </i>
        <sup>
         ®
        </sup>
        ,    a retinal pigment epithelium cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for the treatment    of advanced dry AMD with geographic atrophy. There currently are no therapies approved by the U.S. Food and Drug Administration    (“FDA”) for dry AMD, which accounts for approximately 85-90% of all AMD cases and is the leading cause of blindness    in people over the age of 60.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         OPC1
        </i>
        ,    an oligodendrocyte progenitor cell therapy currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries.    This clinical trial has been partially funded by the California Institute for Regenerative Medicine.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         VAC2
        </i>
        ,    an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 clinical trial in non-small    cell lung cancer. This clinical trial is being funded and conducted by Cancer Research UK, the world’s largest independent    cancer research charity.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Lineagecompleted its merger (the “Asterias Merger”) with Asterias Biotherapeutics, Inc. (“Asterias”) on March8, 2019, which incorporated OPC1 and VAC2 into its cell therapy product portfolio.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inaddition to seeking to create value for shareholders by developing product candidates and other technologies through our clinicaldevelopment programs, we also seek to create value from our technologies through partnering and strategic transactions. We foundedtwo companies that later became publicly traded companies: OncoCyte Corporation (“OncoCyte”) and AgeX Therapeutics,Inc. (“AgeX”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Duringthe year ended December 31, 2020, we received approximately $12.6 million in gross proceeds in connection with our sale of sharesof OncoCyte and AgeX. In August 2020, we also received $24.6 million from Juvenescence Limited (“Juvenescence”), representingprincipal and accrued interest under a promissory note we received in connection with our sale of AgeX shares to Juvenescence inAugust 2018.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weno longer hold any common stock in AgeX. The value of our OncoCyte holdings as of March 5, 2021, was approximately $4.2million, based on the closing price of its common stock on that date. In this Report, see Part I, Item 1A, “Risk Factors—RisksRelated to Our Business Operations and Capital Requirements—The value of our investments in public companies fluctuatesbased on their respective stock prices and could be negatively affected by poor business performance.”
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 58 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        56
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thoughour principal focus is on advancing our three cell therapy programs in clinical development, we may seek to create additionalvalue through corporate transactions, as we have in the past.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CriticalAccounting Policies
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thepreparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States(“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in our consolidatedfinancial statements and related notes. Our significant accounting policies are described in Note 2 to our consolidated financialstatements included elsewhere in this Report. We have identified below our critical accounting policies and estimates that webelieve require the greatest amount of judgment. On an ongoing basis, we evaluate estimates which are subject to significant judgment,including those related to going concern assessment of our consolidated financial statements, useful lives associated with long-livedassets, including evaluation of asset impairment, allowances for uncollectible accounts and financing receivables, v
     <span style="background-color: white">
      aluingshares owned in nonconsolidated companies using the equity method of accounting,
     </span>
     loss contingencies, deferred income taxesand tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards,debt or other equity instruments. Actual results could differ materially from those estimates. On an ongoing basis, we evaluateour estimates compared to historical experience and trends which form the basis for making judgments about the carrying valueof assets and liabilities. To the extent that there are material differences between our estimates and our actual results, ourfuture financial statement presentation, financial condition, results of operations and cash flows will be affected.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Webelieve the assumptions and estimates associated with the following have the greatest potential impact on our consolidated financialstatements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      BusinessCombinations
     </i>
     – We account for business combinations, such as the Asterias Merger, in accordance with Accounting StandardsCodification (“ASC”) Topic 805,
     <i>
      Business Combinations
     </i>
     , which requires the purchase price to be measured atfair value. When the purchase consideration consists entirely of our common shares, we calculate the purchase price by determiningthe fair value, as of the acquisition date, of shares issued in connection with the closing of the acquisition. We recognize estimatedfair values of the tangible assets and intangible assets acquired, including in-process research and development (“IPR&amp;D”),and liabilities assumed as of the acquisition date, and we record as goodwill any amount of the fair value of the tangible andintangible assets acquired and liabilities assumed in excess of the purchase price.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Goodwilland IPR&amp;D
     </i>
     – Goodwill is calculated as the difference between the acquisition date fair value of the considerationtransferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested forimpairment at least annually, or more frequently if circumstances indicate potential impairment. IPR&amp;D assets are indefinite-livedintangible assets until the completion or abandonment of the associated research and development (“R&amp;D”) efforts.Once the R&amp;D efforts are completed or abandoned, the IPR&amp;D will either be amortized over the asset life as a finite-livedintangible asset or be impaired, respectively, in accordance with ASC 350,
     <i>
      Intangibles – Goodwill and Other
     </i>
     . In accordancewith ASC 350, goodwill and acquired IPR&amp;D are determined to have indefinite lives and, therefore, are not amortized. Instead,they are tested for impairment at least annually and between annual tests if we become aware of an event or a change in circumstancesthat would indicate the asset may be impaired.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Leases
     </i>
     – We account for leases in accordance with ASC 842,
     <i>
      Leases
     </i>
     . We determine if an arrangement is a lease at inception.Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in theconsolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, we account for thelease and non-lease components as a single lease component. We recognize right-of-use (“ROU”) assets and lease liabilitiesfor leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent our right to use an underlyingasset during the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operatinglease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the leaseterm. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information availableat commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Theoperating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include optionsto extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease paymentsis recognized on a straight-line basis over the lease term. Operating leases are included as right-of-use assets in property andequipment, and ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases are includedin property and equipment, and in financing lease liabilities, current and long-term, in the consolidated balance sheets. We disclosethe amortization of our ROU assets and operating lease payments as a net amount, “Amortization of ROU assets”, onthe consolidated statement of cash flows.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 59 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        57
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Goingconcern assessment
     </i>
     – In accordance with Accounting Standards Update (“ASU”) 2014-15,
     <i>
      Presentation ofFinancial Statements – Going Concern
     </i>
     , we assess going concern uncertainty in our consolidated financial statements todetermine if we have sufficient cash and cash equivalents on hand and working capital to operate for a period of at least oneyear from the date our consolidated financial statements are issued or are available to be issued, which is referred to as the“look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are knownand reasonably knowable to us, we will consider various scenarios, forecasts, projections, and estimates, and we will make certainkey assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtailthose expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we makecertain assumptions concerning our ability to curtail or delay research and development programs and expenditures to the extentwe deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forwardperiod in accordance with ASU 2014-15.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      MarketableEquity Securities
     </i>
     – We account for our shares in OncoCyte and HBL (and previously AgeX) as marketable equity securitiesin accordance with ASC 320-10-25,
     <i>
      Investments – Debt and Equity Securities
     </i>
     , as amended by Accounting Standards Update(“ASU”) 2016-01,
     <i>
      Financial Instruments–Overall: Recognition and Measurement of Financial Assets and FinancialLiabilities,
     </i>
     further discussed below
     <i>
      .
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OncoCyteand AgeX shares have readily determinable fair values quoted on the NYSE American under trading symbols “OCX” and“AGE”. The HBL shares have a readily determinable fair value quoted on the Tel Aviv Stock Exchange (“TASE”)under trading symbol “HDST” where share prices are denominated in New Israeli Shekels (NIS).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Priorto September 11, 2019, we accounted for our OncoCyte shares held at fair value, using the equity method of accounting. On September11, 2019, Lineage’s ownership percentage decreased from 24% to 16% when it sold 4.0 million shares of OncoCyte common stock.Accordingly, as the ownership percentage was reduced to less than 20%, we are no longer considered to exercise significant influenceover OncoCyte and are now accounting for our OncoCyte holdings as marketable equity securities. Prior to the Asterias Merger completedon March 8, 2019, we accounted for our Asterias shares held at fair value, using the equity method of accounting.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Royaltiesfrom product sales and license fees
     </i>
     – Lineage’s performance obligations in agreements with certain customers isto provide a license to allow customers to make, import and sell company licensed products or methods for preclinical studiesand commercial use. Customers pay a combination of a license issue fee paid up front and a sales-based royalty, if any, in somecases with yearly minimums. The transaction price is deemed to be the license issue fee stated in the contract. The license offeredby Lineage is a functional license with significant standalone functionality and provides customers with the right to use Lineage’sintellectual property. This allows Lineage to recognize revenue on the license issue fee at a point in time at the beginning ofthe contract, which is when the customer begins to have use of the license. Variable consideration related to sales-based royaltiesis recognized only when (or as) the later of one or more of the following events occur: (i) a sale or usage occurs; or (ii) theperformance obligation to which some, or all, of the sales-based or usage-based royalty that has been allocated and has been satisfiedor partially satisfied. Due to the contract termination clauses, Lineage does not expect to receive all of the minimum royaltypayments throughout the term of the agreements. Therefore, Lineage fully constrains recognition of the minimum royalty paymentsas revenues until its customers are obligated to pay, which is generally within 60 days prior to the beginning of each year theminimum royalty payments are due.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Grantrevenues
     </i>
     – In applying the provisions of Topic 606, Lineage has determined that government grants are out of the scopeof Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606,as there is not considered to be a transfer of control of good or services to the government entities funding the grant. Lineagehas, and will continue to, account for grants received to perform research and development services in accordance with ASC 730-20,
     <i>
      Research and Development Arrangements
     </i>
     , which requires an assessment, at the inception of the grant, of whether the grantis a liability or a contract to perform research and development services for others. If Lineage or a subsidiary receiving thegrant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities,then Lineage is required to estimate and recognize that liability. Alternatively, if Lineage or a subsidiary receiving the grantis not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful,then the grant agreement is accounted for as a contract to perform research and development services for others, in which case,grant revenue is recognized when the related research and development expenses are incurred.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 60 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        58
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Deferredgrant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have notyet been incurred as of the balance sheet date reported.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Long-livedintangible assets
     </i>
     – Long-lived intangible assets, consisting primarily of acquired patents, patent applications, andlicenses to use certain patents are stated at acquired cost, less accumulated amortization. Amortization expense is computed usingthe straight-line method over the estimated useful lives of the assets, generally over five to ten years.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Impairmentof long-lived assets –
     </i>
     Our long-lived assets, including long-lived intangible assets, are reviewed for impairment wheneverevents or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairmentindicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted netcash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amountby which the carrying amount exceeds the estimated fair value of the assets.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Researchand development
     </i>
     – Research and development expenses consist of costs incurred for company-sponsored, collaborative andcontracted research and development activities. These costs include direct and research-related overhead expenses including compensationand related benefits, stock-based compensation, consulting fees, research and laboratory fees, rent of research facilities, amortizationof intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology.We expense research and development costs as incurred. Research and development expenses incurred and reimbursed by grants fromthird parties approximate the grant income recognized in the consolidated statements of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Stock-basedcompensation
     </i>
     – We follow accounting standards governing share-based payments, which require the measurement and recognitionof compensation expense for all share-based compensation awards made to directors and employees, including employee stock options,based on estimated fair values. We utilize the Black-Scholes option pricing model. Our determination of fair value of share-basedpayment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regardinga number of complex and subjective variables. These variables include, but are not limited to, expected stock price volatilityover the term of the awards, and the expected term of options granted, which is derived using the simplified method, which isan average of the contractual term of the option and its vesting period, as we do not have sufficient historical exercise data.The risk-free rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes withmaturities similar to the expected term of the awards. Forfeitures are accounted for as they occur.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Althoughthe fair value of employee stock options is determined in accordance with FASB guidance, changes in the assumptions can materiallyaffect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inmanagement’s opinion, the existing valuation models may not provide an accurate measure of the fair value of employee stockoptions because the option-pricing model value may not be indicative of the fair value that would be established in a willingbuyer/willing seller market transaction.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     <i>
      Incometaxes –
     </i>
     We account for income taxes in accordance with ASC 740,
     <i>
      Income Taxes
     </i>
     , which prescribe the use of theasset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet dateusing current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assetswhen it is more likely than not that a portion or all of the deferred tax assets will not be realized. ASC 740 guidance also prescribesa recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions takenor expected to be taken in a tax return. For benefits to be recognized, a tax position must be more-likely-than-not sustainableupon examination by taxing authorities. We file a U.S. federal income tax return as well as various state and foreign income taxreturns. Our judgments regarding future taxable income may change over time due to changes in market conditions, changes in taxlaws, tax planning strategies or other factors. If our assumptions, and consequently the estimates, change in the future withrespect to our own deferred tax assets and liabilities, the valuation allowance may be increased or decreased, which may havea material impact on our consolidated financial statements.
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     Werecognize accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense, however, no amountswere accrued for the payment of interest and penalties as of December 31, 2020 and 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 61 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        59
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Principlesof consolidation –
     </i>
     Our consolidated financial statements include the accounts of our wholly owned and majority-ownedsubsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financialstatements are presented in accordance with accounting principles generally accepted in the U.S. and with the accounting and reportingrequirements of SEC Regulation S-X.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Resultsof Operations
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Comparisonof Years Ended December 31, 2020 and 2019
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Revenues
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows our revenues for the years ended December 31, 2020 and 2019 (amounts in thousands except percentages).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       $ Increase/
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       % Increase/
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       (Decrease)
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       (Decrease)
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 40%; text-align: justify">
       Grant revenues
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       1,053
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       2,037
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       (984
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 11%; text-align: right">
       (48
      </td>
      <td style="width: 1%; text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Royalties from product sales and license fees
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       773
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1,221
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (448
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (37
      </td>
      <td style="text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify; padding-bottom: 1.5pt">
       Sale of research products and services
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       -
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       257
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (257
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (100
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: justify">
       Total revenues
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1,826
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       3,515
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (1,689
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (48
      </td>
      <td style="text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify; padding-bottom: 1.5pt">
       Cost of sales
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (385
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (412
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (27
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (7
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: justify; padding-bottom: 2.5pt">
       Gross profit
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       1,441
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       3,103
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (1,662
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (54
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       %)
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Totalrevenues for the year ended December 31, 2020 were $1.8 million compared to $3.5 million for the year ended December 31, 2019.
     <span style="background-color: white">
      The decrease of $1.7 million is primarily due to a $1.0 million decrease in grant revenue,a $0.4 million decrease in royalties from product sales and license fees and a $0.3 million decrease in the sale of research productsand services
     </span>
     due to the cessation of such sales
     <span style="background-color: white">
      .
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Grantrevenues are generated primarily by our subsidiary Cell Cure Neurosciences Ltd (“Cell Cure”) from the Israel InnovationAuthority (“IIA”) for the development of OpRegen® and our bio retina program, and from a Small BusinessInnovation Research grant from the National Institutes of Health for our vision restoration program (the “NIH grant”).The decreases in our grant revenues for the year ended December 31, 2020 as compared to the year ended December 31, 2019, wereprimarily due to less grant-related activities. Grant revenues generated by Cell Cure from the IIA for the development of OpRegenand our bio retina program (commencing in 2020) amounted to $0.7 million and $1.4 million for the years ended December31, 2020 and 2019, respectively, and grant revenues generated by the NIH grant amounted to $0.4 million and $0.6 million for theyears ended December 31, 2020 and 2019, respectively.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Royaltiesfrom product sales and license fees are generated from non-exclusive license agreements with multiple third parties. A majorityof our royalties from product sales and license fees for the year ended December 31, 2020 are related to technologies that wereacquired in the Asterias Merger. The decrease of $0.4 million for the year ended December 31, 2020 compared to the year endedDecember 31, 2019 was primarily related to the impact from a $0.6 million upfront, non-refundable payment for a new license agreementwith a third party for the use of certain patents related to the culture of undifferentiated pluripotent stem cells in suspensionthat was recorded in 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       OperatingExpenses
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows our operating expenses for the years ended December 31, 2020 and 2019 (amounts in thousands, except percentages).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       $
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       %
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Decrease
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Decrease
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 40%; text-align: left">
       Research and development expenses
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       12,317
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       17,948
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       (5,631
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 11%; text-align: right">
       (31
      </td>
      <td style="width: 1%; text-align: left">
       %)
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       General and administrative expenses
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       15,571
      </td>
      <td style="text-align: left">
       <sup>
        (1)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       24,031
      </td>
      <td style="text-align: left">
       <sup>
        (2)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (8,460
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (35
      </td>
      <td style="text-align: left">
       %)
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes    $0.7 million of acquisition related costs for the Asterias Merger.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes    $5.1 million of acquisition related costs for the Asterias Merger.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 62 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        60
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Researchand development expenses
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Researchand development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and developmentactivities. These costs include direct and research-related overhead expenses including compensation and related benefits, stock-basedcompensation, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, andlicense fees paid to third parties to acquire patents or licenses to use patents and other technology. We expense research anddevelopment costs as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximatethe grant income recognized in the consolidated statements of operations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows the amount of our total research and development expenses allocated to our primary research and developmentprojects for the periods presented (amounts in thousands, except percentages).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Year                                         Ended December 31,
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          (unaudited)
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Amount
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Percent of Total
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       Program
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 40%; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        OpRegen
        <sup>
         ®
        </sup>
        and other ophthalmic applications
       </span>
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       5,569
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 11%; text-align: right">
       12,069
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 11%; text-align: right">
       45
      </td>
      <td style="width: 1%; text-align: left">
       %
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 11%; text-align: right">
       67
      </td>
      <td style="width: 1%; text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
       OPC1
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       3,958
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       4,488
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       32
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       25
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       VAC platform
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2,472
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       322
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       20
      </td>
      <td style="text-align: left">
       %
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Renevia and all other
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       318
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       1,069
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       3
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       %
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       6
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 2.5pt">
       Total research and development expenses
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       12,317
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       17,948
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       100
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       %
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       100
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       %
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Researchand development expenses for the year ended December 31, 2020 were $12.3 million as compared to $17.9 million for the yearended December 31, 2019.
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     The decrease of $5.6million is mainly attributable to the following:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        a    decrease of $6.5 million in OpRegen and other ophthalmic application expenses, attributable primarily to a decrease in manufacturing    activities in 2020 as compared to 2019,
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        a    decrease of $0.5 million in OPC1 related expenses, primarily related to return of unspent project funds of approximately    $0.8 million from a former Asterias service provider,
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        a    decrease of $0.8 million in Renevia and other related expenses as Renevia received a CE Mark in September 2019 and we are    spending less on research activities as we are actively looking for a commercialization partner in Europe, offset by
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        an    increase of $2.2 million in VAC program expenses, primarily related to the accrual of the signature fee of £1.25 million    ($1.6 million) to Cancer Research UK.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Generaland administrative expenses
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Generaland administrative expenses include employee and director compensation allocated to general and administrative expenses, consultingfees other than those paid for science-related consulting, facilities and equipment rent and maintenance related expenses, insurancecosts allocated to general and administrative expenses, costs of patent applications, prosecution and maintenance,
     <span style="background-color: white">
      stockexchange-related costs, depreciation expense, marketing costs, board fees, legal and accounting costs, and other miscellaneousexpenses which are allocated to general and administrative expense.
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Generaland administrative expenses for the year ended December 31, 2020 were $15.6 million as compared to $24.0 million for the yearended December 31, 2019.
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     The total net decreaseof $8.4 million was primarily attributable to a $5.5 million reduction in Asterias Merger related expenses, a $2.1 million reductionin compensation costs as a result of headcount reductions in 2019, a $0.9 million reduction in accounting expenses, a $0.5million reduction in rent and utilities, a $0.3 million reduction in travel expenses, a $0.3 million reduction in office and informationtechnology related expenses and a $0.2 million reduction in consulting expenses, offset by a $0.9 million increase related tothe cessation of shared services reimbursements and a $0.5 million increase in legal and patent expenses.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 63 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        61
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Otherincome and expenses, net
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows the amount of other income, net, during the year ended December 31, 2020 and 2019 (in thousands):
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       Other income, net
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="width: 64%; text-align: left">
       Interest income, net
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       1,039
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       1,685
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Gain on sale of marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       4,560
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2,421
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Unrealized loss on marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (3,782
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (2,898
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Gain on sale of equity method investment in OncoCyte
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       546
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Unrealized gain on equity method investment in OncoCyte at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       8,001
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Unrealized gain on equity method investment in Asterias at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       6,744
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Unrealized (loss) gain on warrant liability
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (174
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       611
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Other income, net
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       2,880
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       2,532
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 2.5pt">
       Total other income, net
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       4,523
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       19,642
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Interestincome and expense, net –
     </i>
     During the years ended December 31, 2020 and 2019, we earned $1.0 million and $1.5 millionof interest income, respectively, from our promissory note with Juvenescence Limited (“Juvenescence”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Gainon equity method investment in Asterias –
     </i>
     Prior to the closing of the Asterias Merger on March 8, 2019, we owned 21.7million shares of common stock of Asterias, which we accounted for at fair value using the equity method of accounting. The fairvalue of our Asterias shares was approximately $20.2 million as of March 8, 2019, the closing date of the Asterias Merger, basedon $0.93 per share, which was calculated by multiplying: (i) $1.31, the closing price of our common shares on such date; by (ii)the merger exchange ratio of 0.71. The fair value of our Asterias shares was approximately $13.5 million as of December 31, 2018,based on the closing price of Asterias common stock of $0.62 per share on such date. Accordingly, we recorded an unrealized gainof $6.7 million for the year ended December 31, 2019, representing the change in fair value of Asterias common stock from December31, 2018 to March 8, 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Gain(loss) on investment in OncoCyte
     </i>
     – Prior to September 11, 2019, we elected to account for our shares of OncoCyte commonstock at fair value using the equity method of accounting. We sold 2.25 million shares of OncoCyte common stock for net proceedsof $4.2 million in July 2019. Accordingly, our ownership in OncoCyte was reduced from 28% to 24%. We sold an additional 4.0 millionshares of OncoCyte common stock for net proceeds of $6.5 million on September 11, 2019. Our ownership in OncoCyte was furtherreduced to 16% at this time. Effective September 11, 2019, we began accounting for our shares of OncoCyte common stock as marketableequity securities.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2019, we had 8.4 million shares of OncoCyte common stock. These shares had a fair value of $19.0 million, basedon the closing price of OncoCyte common stock of $2.25 per share on December 31, 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, we owned 3.6 million shares of OncoCyte common stock. These shares had a fair value of $8.7 million, basedon the closing price of OncoCyte common stock of $2.39 per share on December 31, 2020,
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe year ended December 31, 2020, we recorded a realized gain of $3.1 million due to sales of OncoCyte shares in the period. Inthe same period, we also recorded an unrealized loss of $2.5 million related to our OncoCyte shares. The unrealized loss is comprisedof $3.7 million related to the difference between the book cost basis of OncoCyte shares sold in the period versus the applicableprior month’s ending OncoCyte stock price, which is offset by $1.2 million related to the shares remaining at December 31,2020 and the increase in OncoCyte’s stock price from $2.25 at December 31, 2019 to $2.39 at December 31, 2020. For the yearended December 31, 2019, we recorded a realized gain of $0.5 million due to sales of OncoCyte shares in the period. Wealso recorded an unrealized gain of $8.8 million due to the increase in OncoCyte’s stock price from $1.38 per share at December31, 2018 to $2.25 per share at December 31, 2019. $8.0 million of the unrealized gain was recorded as an unrealized gain on anequity method investment as it was prior to September 11, 2019; the remaining $0.8 million was recorded as an unrealized gainon marketable equity securities.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 64 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        62
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Allshare prices are determined based on the closing price of OncoCyte common stock on the NYSE American on the applicable dates,or the last day of trading of the applicable quarter, if the last day of a quarter fell on a weekend.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weexpect our other income and expenses, net, to continue to fluctuate each reporting period based on the changes in the market priceof our OncoCyte shares, which could significantly impact our net income or loss reported in our condensed consolidated statementsof operations for each period.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Marketableequity securities
     </i>
     – We account for the shares we held in Hadasit Bio-Holdings (“HBL”) and AgeX as marketableequity securities, carried at fair market value on our consolidated balance sheets.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe year ended December 31, 2020, we recorded realized gains of $0.8 million and $0.6 million due to sales of AgeX shares andHBL shares, respectively, in the period.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe year ended December 31, 2020, we recorded unrealized losses of $1.3 million related to our AgeX shares. $0.5 million of theunrealized loss was related to the difference between the book cost basis of AgeX shares sold in the period versus the applicableprior month’s ending AgeX share price and an additional $0.8 million was related to mark to mark adjustments throughoutthe year on the remaining shares of AgeX at each applicable period.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Otherincome and expenses, net –
     </i>
     Other income and expenses, net, in 2020 and 2019 consist primarily of net foreign currencytransaction gains and losses recognized by Cell Cure and ESI, and changes in the fair value of the Cell Cure liability classifiedwarrants. Foreign currency transaction gains and losses for the periods presented are principally related to the remeasurementof the U.S. dollar denominated notes payable by Cell Cure to Lineage.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      IncomeTaxes
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Themarket value of the shares of OncoCyte common stock we hold creates a deferred tax liability (the “OncoCyte DTL”)based on the closing prices of the shares, less our tax basis in the shares. The OncoCyte DTL is a source of future taxable incometo us, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of our deferred tax assetsto the extent of the OncoCyte DTL. The OncoCyte DTL is determined based on the closing prices of the OncoCyte shares as of December31, 2020. Due to the inherent unpredictability of future prices of those shares, we cannot reliably estimate or project the OncoCyteDTL on an annual basis. Therefore, the OncoCyte DTL is determined based on the actual closing prices on the last stock markettrading day of the applicable accounting period, and the related impacts to the valuation allowance and deferred tax asset changes,and are recorded in the accounting period in which they occur.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inconnection with the Asterias Merger, a deferred tax liability of $10.8 million (the “Asterias DTL”) was recorded aspart of the acquisition accounting (see Note 3). The Asterias DTL is related to fair value adjustments for the assets and liabilitiesacquired in the Asterias Merger, principally consisting of IPR&amp;D. This estimate of deferred taxes was determined based onthe excess of the estimated fair values of the acquired assets and liabilities over the tax basis of the assets and liabilitiesacquired. The statutory tax rate was applied, as appropriate, to the adjustment based on the jurisdiction in which the adjustmentis expected to occur. Because the IPR&amp;D (prior to completion or abandonment of the R&amp;D) is considered an indefinite-livedasset for accounting purposes, the fair value of the IPR&amp;D on the acquisition date creates a deferred income tax liabilityin accordance with ASC 740. The Asterias DTL is computed using the fair value of the IPR&amp;D assets on the acquisition datemultiplied by Lineage’s respective federal and state income tax rates. While the Asterias DTL would reverse on impairmentor sale or commencement of amortization of the related intangible assets, those events are not anticipated under ASC 740 for purposesof predicting reversal of a temporary difference to support the realization of deferred tax assets, except for certain deferredtax assets and credit carryforwards that are also indefinite in nature as of the Asterias Merger date, which may be consideredfor reversal under ASC 740 as further discussed below.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Avaluation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized.Lineage established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefitsfrom its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by itssubsidiaries. During the year ended December 31, 2019, a portion of the valuation allowance was released as it relates to Lineage’sindefinite lived assets that can be used against the indefinite lived liabilities. The amount of the valuation allowance releasedwas $7.4 million; as new indefinite lived deferred tax assets are generated, we will continue to book provision benefits untilthe deferred tax liability position is exhausted, barring any new developments.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 65 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        63
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Forthe year ended December 31, 2020, Lineage recorded a $1.2 million deferred tax benefit for income taxes.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weexpect that deferred income tax expense or benefit we record each reporting period, if any, will vary depending on the changein the closing stock prices of OncoCyte shares from period to period and the related changes in those deferred tax liabilitiesand our deferred tax assets and other credits, including changes in the valuation allowance, for each period.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     SeeNote 3 to our consolidated financial statements included elsewhere in this Report for a description of the Asterias Merger thatwas completed on March 8, 2019. We have concluded that an ownership change did occur after the Asterias Merger, and the acquiredoperating loss carryforwards are subject to limitation under Section 382 of the Internal Revenue Service Code; Lineage will onlybe able to utilize $52.8 million of these operating loss carryforwards.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Liquidityand Capital Resources
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     AtDecember 31, 2020, we had $41.6 million of cash, cash equivalents and marketable equity securities on hand, which includes ourinvestments in OncoCyte and HBL. We may use our marketable equity securities for liquidity, as necessary, and as market conditionsallow. The market value may not represent the amount that could be realized in a sale of investment shares due to various marketand regulatory factors, including trading volume or market depth factors and volume and manner of sale restrictions under Federalsecurities laws, prevailing market conditions and prices at the time of any sale, and subsequent sales of securities by the entities.In addition, the value of our marketable equity securities may be significantly and adversely impacted by deteriorating globaleconomic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States andworldwide resulting from the ongoing COVID-19 pandemic.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Sinceinception, we have incurred significant operating losses and have funded our operations primarily through the issuance of equitysecurities, the sale of common stock of our former subsidiaries, AgeX and OncoCyte, payments from research grants, royalties fromproduct sales and sales of research products and services. At December 31, 2020, we had an accumulated deficit of approximately$294.1 million, working capital of $36.2 million and shareholders’ equity of $95.1 million. We evaluated the projected cashflows for Lineage and our subsidiaries, and we believe that our $41.6 million in cash, cash equivalents and marketable equitysecurities at December 31, 2020, provide sufficient cash, cash equivalents, and liquidity to carry out our current planned operationsthrough at least twelve months from the issuance date of our consolidated financial statements included elsewhere in this Report.If we need near term working capital or liquidity to supplement our cash and cash equivalents for our operations, we may sellsome, or all, of our investments, as necessary.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OnMarch 8, 2019, the Asterias Merger closed and Asterias became our wholly owned subsidiary. We began consolidating Asterias’operations and results with our operations and results beginning on March 8, 2019. As we integrated Asterias’ operationsinto our own, we made extensive reductions in headcount and reduced non-clinical related spend, in each case, as compared to Asterias’operations before the merger. We implemented significant cost savings initiatives and achieved reduced operational spend in 2020compared to prior periods.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourprojected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meetfuture capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our current planned operations.Our determination as to when we will seek new financing and the amount of financing that we will need will be based on our evaluationof the progress we make in our research and development programs, any changes to the scope and focus of those programs, any changesin grant funding for certain of those programs, and projection of future costs, revenues, and rates of expenditure. Our abilityto raise additional funds may be adversely impacted by deteriorating global economic conditions and the disruptions to and volatilityin the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. We may berequired to delay, postpone, or cancel our clinical trials or limit the number of clinical trial sites, unless we are able toobtain adequate financing. We cannot assure that adequate financing will be available on favorable terms, if at all. Sales ofadditional equity securities by us or our subsidiaries and affiliates could result in the dilution of the interests of our currentshareholders.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 66 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        64
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Cashused in operating activities
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Netcash used in operating activities of $19.8 million for the year ended December 31, 2020 primarily reflects the loss from operationsof $26.4 million adjusted for the changes in assets and liabilities of $1.3 million. These items were offset primarilyby non-cash expenses of $2.2 million for stock-based compensation and $2.1 million of depreciation and amortization. The unrealizedgains on equity method investments and marketable securities, foreign currency remeasurement and deferred tax benefit are non-cashitems that had no effect on cash flows.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Netcash used in operating activities of $31.9 million for the year ended December 31, 2019 primarily reflects the loss from operationsof $38.9 million adjusted for the changes in assets and liabilities of $2.1 million. These items were offset primarily by non-cashexpenses of $3.6 million for stock-based compensation and $3.1 million of depreciation and amortization. The unrealized gainson equity method investments and marketable securities, foreign currency remeasurement and deferred tax benefit are non-cash itemsthat had no effect on cash flows.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Cashused in investing activities
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Cashprovided by investing activities of $13.0 million for the year ended December 31, 2020 was associated primarily with receiptsof $10.9 million from sales of a portion of our OncoCyte holdings, $1.3 million in sales of our AgeX holdings and $0.8 millionin sales of a portion of our HBL holdings.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Cashprovided by investing activities of $17.0 million for the year ended December 31, 2019 was associated primarily with receiptsof $10.7 million from sales of a portion of our OncoCyte holdings, $1.7 million in sales of a portion of our AgeX holdings and$1.7 million in sales of a portion of our HBL holdings as well as the receipt of $3.1 million of cash that Asterias had on theclosing date of the Asterias Merger, offset by $0.4 million in purchases of equipment and other assets.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       Cashprovided by financing activities
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Cashprovided by financing activities of $29.9 million for the year ended December 31, 2020 was associated primarily with proceedsof $24.6 million from payment of the Juvenescence promissory note, gross proceeds of $5.1 million from sales of our commonshares in at-the-market transactions under our Controlled Equity Offering
     <sup>
      SM
     </sup>
     Sales Agreement with Cantor Fitzgerald&amp; Co (which excludes $0.3 million of cash in transit related to 2020sales that settled in 2021), and proceeds of $0.5 million from a Paycheck Protection Program (“PPP”) loan under the CoronavirusAid, Relief, and Economic Security Act, all offset by $0.4 million in financing costs.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Cashprovided by financing activities of $0.6 million for the year ended December 31, 2019 was associated primarily with $0.8 millionin landlord reimbursements for tenant improvements, offset by $0.1 million in common shares received and retired for employeetaxes paid.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Off-BalanceSheet Arrangements
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asof December 31, 2020, we did not have any off-balance sheet arrangements, as defined under the rules of the Securities and ExchangeCommission.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_012">
         </span>
         ITEM    7A.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         QUANTITATIVE    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Underrules and regulations of the Securities and Exchange Commission, as a smaller reporting company, we are not required to providethe information required by this item.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 67 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        65
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_013">
         </span>
         ITEM    8.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         FINANCIAL    STATEMENTS AND SUPPLEMENTARY DATA
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
     <b>
      Indexto consolidated financial statements
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="#z_001" tabindex="18">
        Report of OUM &amp; CO. LLP, Independent Registered Public Accounting Firm – Audit Opinion
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        67
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <td style="font: 10pt Times New Roman, Times, Serif">
       Financial Statements:
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="#z_002" tabindex="18">
         Consolidated    Balance Sheets
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        69
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="#z_003" tabindex="18">
         Consolidated    Statements of Operations
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        70
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="#z_004" tabindex="18">
         Consolidated    Statements of Comprehensive Loss
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        71
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="#z_005" tabindex="18">
         Consolidated    Statements of Shareholders Equity
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        72
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="#z_006" tabindex="18">
         Consolidated    Statements of Cash Flows
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        73
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 68 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        66
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
     <b>
      <span id="z_001">
      </span>
      Reportof Independent Registered Public Accounting Firm
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Shareholdersand Board of Directors
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     LineageCell Therapeutics, Inc.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Carlsbad,California
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Opinionon the Consolidated Financial Statements
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave audited the consolidated balance sheets of Lineage Cell Therapeutics, Inc. and Subsidiaries (collectively, the “Company”)as of December 31, 2020 and 2019, and the related consolidated statements of operations, comprehensive income (loss), changesin shareholders’ equity, and cash flows for each of the two years in the period ended December 31, 2020, and the relatednotes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financialstatements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, andthe results of their operations and their cash flows for each of the two years in the period ended December 31, 2020
     <b>
      ,
     </b>
     inconformity with accounting principles generally accepted in the United States of America.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Basisfor Opinion
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theseconsolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express anopinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registeredwith the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities lawsand the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weconducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditto obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whetherdue to error or fraud.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ouraudits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whetherdue to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating theaccounting principles used and significant estimates made by management, as well as evaluating the overall presentation of theconsolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CriticalAudit Matter
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thecritical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statementsthat was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures thatare material to the consolidated financial statements; and (2) involved our especially challenging, subjective, or complex judgments.The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, takenas a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical auditmatter or on the accounts or disclosures to which it relates.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 69 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        67
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       IntangibleAssets Impairment Assessment - In-Process Research and Development
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      Descriptionof the Matter
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asdescribed in Note 7 to the consolidated financial statements, the Company’s in-process research and development indefinite-livedintangible assets had a balance of $46.5 million as of December 31, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Indefinite-livedintangible assets are tested for impairment annually and when events or changes in circumstances indicate that the asset mightbe impaired. As part of its indefinite-live intangible asset impairment assessment, management estimates the fair values of theCompany’s indefinite-lived intangible assets using an income approach that utilizes a discounted cash flow model or, whereappropriate, a market approach. The discounted cash flow model is dependent upon management’s estimates of future cash flowsand other factors such as estimates of (i) future operating performance, including future sales, long-term growth rates, operatingmargins, discount rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cashflows, and (ii) future economic conditions.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Auditingthe Company’s impairment analysis of its indefinite-lived intangible assets is complex because of the significant judgmentand estimates used by management in developing the fair value measurement of in-process research and development intangible assets.This in turn leads to significant audit effort and a high degree of auditor judgment and subjectivity in performing proceduresto evaluate management’s estimated cash flows, including significant assumptions related to future sales, long-term growthrates, operating margins, discount rates, variations in the amount and timing of cash flows and the probability of achieving theestimated cash flows, and future economic conditions in determining the fair value of each of the in-process research and developmentintangible assets.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      HowWe Addressed the Matter in Our Audit
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Addressingthe matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on theconsolidated financial statements. These procedures included, among others, obtaining an understanding of and evaluating management’sprocess for identifying potential impairment events; evaluating the appropriateness of the cash flow model used in the impairmenttesting process; testing the completeness, accuracy, and relevance of underlying data used in the model; and evaluating the reasonablenessof the significant assumptions used by management, including the future cash flow projections and discount rates. We evaluatedthe reasonableness of management’s assumptions for future cash flow projections and discount rates in consideration of (i)the current and past performance of the asset group, (ii) the consistency with external market and industry data, and (iii) whetherthese assumptions were consistent with evidence obtained in other areas of the audit.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      /s/OUM &amp; CO. LLP
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     SanFrancisco, California
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     March11, 2021
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave served as the Company’s auditor since 2014.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 70 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        68
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="z_002">
      </span>
      LINEAGECELL THERAPEUTICS, INC. AND SUBSIDIARIES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CONSOLIDATEDBALANCE SHEETS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      (INTHOUSANDS)
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" id="xdx_304_111_pn3n3_zCSMxRQRvWza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Consolidated Balance Sheets">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_491_20201231_zisZjABBXSa6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       December 31, 2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_49E_20191231_zP5tKWWlRsd5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       December 31, 2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold">
       ASSETS
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       CURRENT ASSETS
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzKX4_zZD69X3pwUTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; width: 64%; text-align: left">
       Cash and cash equivalents
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-34" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         32,585
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-35" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         9,497
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--MarketableSecuritiesCurrent_i02I_pn3n3_maACzKX4_zMEY35iahIui" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-36" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         8,977
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-37" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         21,219
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--AccountsNotesAndLoansReceivableNetCurrent_i02I_pn3n3_maACzKX4_zacDmmdlxGT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Promissory note from Juvenescence (Note 5)
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0064">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0064" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-38" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-39" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         23,616
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_ecustom--TradeAccountsAndGrantsReceivableNetCurrent_i02I_pn3n3_maACzKX4_zWPpPTkTUOni" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Trade accounts and grants receivable, net
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-40" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:TradeAccountsAndGrantsReceivableNetCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         4
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-41" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:TradeAccountsAndGrantsReceivableNetCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         317
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--DueFromAffiliateCurrent_i02I_pn3n3_maACzKX4_zIQisE5TUSbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Receivables from affiliates, net
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0070">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0070" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-42" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DueFromAffiliateCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-43" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DueFromAffiliateCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         7
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzKX4_zp0L3L21F3X6" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Prepaid expenses and other current assets
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-44" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,433
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-45" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,863
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzKX4_maAzz4Q_zrLDNFgpHn5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Total current assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-46" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         43,999
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-47" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         57,519
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       NONCURRENT ASSETS
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pn3n3_maAzz4Q_zlFOw6rwJONd" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Property and equipment, net (Notes 6 and 14)
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-48" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         5,630
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-49" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         8,175
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--DepositsAssetsNoncurrent_i02I_pn3n3_maAzz4Q_zTsPOrPs5Sc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Deposits and other long-term assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-50" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepositsAssetsNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         616
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-51" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepositsAssetsNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         864
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--Goodwill_i02I_pn3n3_maAzz4Q_ziKuMWtSSNX8" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt">
       Goodwill
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-52" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Goodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,672
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-53" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Goodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,672
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_pn3n3_maAzz4Q_zHuIvpU9dLai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Intangible assets, net
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-54" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         47,032
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-55" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         48,248
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--Assets_i01TI_pn3n3_mtAzz4Q_zbfsyZ4AtD2l" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 2.5pt">
       TOTAL ASSETS
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-56" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         107,949
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-57" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         125,478
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left">
       LIABILITIES AND SHAREHOLDERS’ EQUITY
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       CURRENT LIABILITIES
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pn3n3_maLCzVZG_zZo3g1co6i38" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Accounts payable and accrued liabilities
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-58" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         6,813
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-59" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         5,226
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_pn3n3_maLCzVZG_zp6czvth2lt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Financing lease and right-of-use liabilities, current portion (Note 14)
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-60" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         762
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-61" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,223
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_i02I_pn3n3_maLCzVZG_zSDYZTIjlo54" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Deferred revenues
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-62" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         193
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-63" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         45
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_ecustom--LiabilityClassifiedWarrantsCurrentPortion_i02I_pn3n3_maLCzVZG_z89vZFrWMwNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Liability classified warrants, current portion
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-64" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:LiabilityClassifiedWarrantsCurrentPortion" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0113">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0113" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-65" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:LiabilityClassifiedWarrantsCurrentPortion" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       -
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzVZG_maLzeqX_zj1UycKb903e" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Total current liabilities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-66" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         7,769
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-67" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         6,494
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       LONG-TERM LIABILITIES
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i02I_pn3n3_maLzeqX_zalQY4Ru7Xfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Deferred tax liability
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-68" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,076
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-69" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,315
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--DeferredRevenueNoncurrent_i02I_pn3n3_maLzeqX_zXePHVdNuif4" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Deferred revenues, net of current portion
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0124">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0124" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-70" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-71" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         200
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLzeqX_z51473GNlsPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Right-of-use lease liability, net of current portion (Note 14)
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-72" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,514
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-73" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,868
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_pn3n3_maLzeqX_zyXTqYWZsvN9" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Financing lease, net of current portion
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-74" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         26
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-75" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         77
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_ecustom--LiabilityClassifiedWarrantsAndOtherLongtermLiabilities_i02I_pn3n3_maLzeqX_zsiIXWmSpkha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Liability classified warrants and other long-term    liabilities
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-76" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:LiabilityClassifiedWarrantsAndOtherLongtermLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         437
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-77" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:LiabilityClassifiedWarrantsAndOtherLongtermLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         277
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--Liabilities_i02TI_pn3n3_mtLzeqX_maLASEzhgo_z4p03sf8ZLR5" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       TOTAL LIABILITIES
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-78" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         12,822
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-79" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         14,231
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzhgo_zSyIAWFoU2U3" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Commitments and contingencies (Note 14)
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0139">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0139" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-80" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommitmentsAndContingencies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="display: none; text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0140">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0140" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-81" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommitmentsAndContingencies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="display: none; text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_401_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       SHAREHOLDERS’ EQUITY
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_pn3n3_maSEzHvQ_z5eYVMGesMic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Preferred shares,
       <span id="xdx_906_eus-gaap--PreferredStockNoParValue_iI_pii_do_c20201231_z1kdy44Uh5J1" title="Preferred stock, no par value">
        <span id="xdx_907_eus-gaap--PreferredStockNoParValue_iI_pii_do_c20191231_zes3olj4Cvvb" title="Preferred stock, no par value">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-82" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockNoParValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-83" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockNoParValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             no
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       par value, authorized
       <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20201231_zsRL0vaINJfk" title="Preferred stock, shares authorized">
        <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_c20191231_zB5S19hdgpI2" title="Preferred stock, shares authorized">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-84" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-85" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
             2,000
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       shares;
       <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pii_dn_c20201231_zFSxWtKQfAq4" title="Preferred stock, shares issued">
        <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pii_dn_c20191231_zxGQrYgTCZn1" title="Preferred stock, shares issued">
         <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dn_c20201231_zXq2i5d00e0b" title="Preferred stock, shares outstanding">
          <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dn_c20191231_zHgzxQ8nfJg3" title="Preferred stock, shares outstanding">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-86" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             <span>
              <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-87" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
               <span>
                <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-88" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                 <span>
                  <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-89" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                   none
                  </ix:nonfraction>
                 </span>
                </ix:nonfraction>
               </span>
              </ix:nonfraction>
             </span>
            </ix:nonfraction>
           </span>
          </span>
         </span>
        </span>
       </span>
       issued and    outstanding as of December 31, 2020 and 2019, respectively
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0145">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0145" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-90" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0146">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0146" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-91" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzHvQ_z3hlY3WMOlYg" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt">
       Common shares,
       <span id="xdx_907_eus-gaap--CommonStockNoParValue_iI_pii_do_c20201231_zgglWFANLD59" title="Common stock, no par value">
        <span id="xdx_90E_eus-gaap--CommonStockNoParValue_iI_pii_do_c20191231_z85YHzWuM496" title="Common stock, no par value">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-92" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockNoParValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-93" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockNoParValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             no
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       par value, authorized
       <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20201231_znpfwZR0DJS8" title="Common stock, shares authorized">
        <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20191231_zOvHXlqvCCl6" title="Common stock, shares authorized">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-94" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-95" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
             250,000
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       shares;
       <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20201231_zHqCzcFQT9P" title="Common stock, shares issued">
        <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20201231_zhpNlp6jKFKj" title="Common stock, shares outstanding">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-96" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-97" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
             153,096
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       and
       <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20191231_z1tXsR8mI6G6" title="Common stock, shares issued">
        <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20191231_zjGQHCXc23gi" title="Common stock, shares outstanding">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-98" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-99" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
             149,804
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       shares issued and    outstanding as of December 31, 2020 and 2019, respectively
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-100" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         393,944
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-101" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         387,062
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzHvQ_zwpQG8G4BSr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Accumulated other comprehensive loss
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-102" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         3,667
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-103" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         681
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzHvQ_zFV6lnHuDPY7" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Accumulated deficit
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-104" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:RetainedEarningsAccumulatedDeficit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         294,078
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-105" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:RetainedEarningsAccumulatedDeficit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         273,422
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzHvQ_maSEIPAzxRl_zQ7wDypSTG93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Lineage Cell Therapeutics, Inc. shareholders’ equity
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-106" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         96,199
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-107" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         112,959
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--MinorityInterest_i02I_pn3n3_maSEIPAzxRl_zba8pH5mPTUj" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Noncontrolling interest (deficit)
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-108" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         1,072
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-109" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         1,712
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_mtSEIPAzxRl_maLASEzhgo_zJMDZxNAsoQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Total shareholders’ equity
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-110" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         95,127
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-111" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         111,247
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzhgo_z2QwTSCKlcn4" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 2.5pt">
       TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-112" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAndStockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         107,949
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-113" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAndStockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         125,478
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <!-- Field: Page; Sequence: 71 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        69
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span id="z_003">
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LINEAGECELL THERAPEUTICS, INC. AND SUBSIDIARIES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CONSOLIDATEDSTATEMENTS OF OPERATIONS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      (INTHOUSANDS, EXCEPT PER SHARE DATA)
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zsjABapcQgOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Consolidated Statements of Operations">
    <tbody>
     <tr style="display: none; vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_490_20200101__20201231_zht40wVbeEZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_498_20190101__20191231_zqgUJagIsHD8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold">
       REVENUES:
      </td>
      <td style="font-weight: bold">
      </td>
      <td colspan="2" style="font-weight: bold; text-align: center">
      </td>
      <td style="font-weight: bold">
      </td>
      <td style="font-weight: bold">
      </td>
      <td colspan="2" style="font-weight: bold; text-align: center">
      </td>
      <td style="font-weight: bold">
      </td>
     </tr>
     <tr id="xdx_40E_ecustom--RevenueGrants_i01_pn3n3_maRFCWCz3Mm_ztF9kNiDbSTj" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; width: 64%; text-align: left">
       Grant revenue
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-114" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RevenueGrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,053
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-115" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RevenueGrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,037
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_ecustom--RoyaltiesFromProductSalesAndLicenseFees_i01_pn3n3_maRFCWCz3Mm_zIBa1AuTWAFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Royalties from product sales and license fees
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-116" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RoyaltiesFromProductSalesAndLicenseFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         773
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-117" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RoyaltiesFromProductSalesAndLicenseFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,221
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_401_ecustom--SaleOfResearchProductsAndServices_i01_pn3n3_maRFCWCz3Mm_z3BPXu9Xzt04" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Sale of research products and services
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0210">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0210" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-118" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SaleOfResearchProductsAndServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       -
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-119" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SaleOfResearchProductsAndServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         257
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01T_pn3n3_mtRFCWCz3Mm_maGPzboe_zCCx2GRkzf6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 20pt; text-align: left">
       Total revenues
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-120" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,826
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-121" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,515
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--CostOfRevenue_iN_pn3n3_di_msGPzboe_zRzyUCACDKu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-bottom: 1.5pt">
       Cost of sales
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-122" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CostOfRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         385
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-123" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CostOfRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         412
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--GrossProfit_iT_pn3n3_mtGPzboe_maOILz7ws_z46ocjsPxbRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Gross profit
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-124" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GrossProfit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,441
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-125" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GrossProfit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,103
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       OPERATING EXPENSES:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEz8mN_zfhwfQf7amca" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Research and development
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-126" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ResearchAndDevelopmentExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         12,317
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-127" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ResearchAndDevelopmentExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         17,948
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEz8mN_z4YS3e1rC2m3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       General and administrative
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-128" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GeneralAndAdministrativeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         15,571
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-129" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GeneralAndAdministrativeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         24,031
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEz8mN_msOILz7ws_zJUbtykfYlLe" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">
       Total operating expenses
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-130" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         27,888
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-131" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         41,979
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILz7ws_maILFCOz0DT_zdhFjzVIxaQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Loss from operations
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-132" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         26,447
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-133" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         38,876
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       OTHER INCOME, NET:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--InterestIncomeOther_i01_pn3n3_maNIEzMMS_zVtZPMiu5Xoj" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Interest income, net
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-134" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestIncomeOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,039
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-135" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestIncomeOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,685
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--MarketableSecuritiesGainLossOnSale_i01_pn3n3_maNIEzMMS_zUiMtLxmgABk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Gain on sale of marketable securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-136" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MarketableSecuritiesGainLossOnSale" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         4,560
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-137" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MarketableSecuritiesGainLossOnSale" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,421
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--GainLossOnSaleOfEquityInvestments_i01_pn3n3_maNIEzMMS_zoNpm9eur5ma" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Gain on sale of equity method investment in OncoCyte
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0246">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0246" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-138" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainLossOnSaleOfEquityInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-139" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainLossOnSaleOfEquityInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         546
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_pn3n3_maNIEzMMS_z1s9Wpsahhpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized loss on marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-140" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         3,782
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-141" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         2,898
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_i01_pn3n3_maNIEzMMS_z6ssuEWxKkP6" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized gain on equity method investment in OncoCyte at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0252">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0252" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-142" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-143" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         8,001
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_ecustom--EquityMethodInvestmentRealizedGainLossOnDisposalOne_i01_pn3n3_maNIEzMMS_zymZLessrAdb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized gain on equity method investment in Asterias at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0255">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0255" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-144" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:EquityMethodInvestmentRealizedGainLossOnDisposalOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-145" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:EquityMethodInvestmentRealizedGainLossOnDisposalOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         6,744
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_ecustom--UnrealizedLossGainOnWarrantLiability_i01_pn3n3_maNIEzMMS_zamduWqERrQg" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized (loss) gain on warrant liability
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-146" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:UnrealizedLossGainOnWarrantLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         174
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-147" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UnrealizedLossGainOnWarrantLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         611
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_i01_pn3n3_maNIEzMMS_zASTE3HdiAYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Other income, net
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-148" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherNonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,880
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-149" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherNonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,532
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_mtNIEzMMS_maILFCOz0DT_z9nofM4CSUqj" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">
       Total other income, net
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-150" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         4,523
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-151" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         19,642
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOz0DT_maPLzrAn_zGvhIlD75U59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       LOSS BEFORE INCOME TAXES
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-152" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         21,924
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-153" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         19,234
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLzrAn_zNiV7BBa9Waa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">
       Income tax benefit
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-154" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         1,239
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-155" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         7,407
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--ProfitLoss_iT_pn3n3_mtPLzrAn_maNILznRr_zynFTOUC1c02" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left">
       NET LOSS
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-156" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         20,685
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-157" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         11,827
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILznRr_zVMjXUMwuPb" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Net loss attributable to noncontrolling interest
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-158" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         36
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-159" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         118
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILznRr_z3NladOpAhLc" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">
       NET LOSS ATTRIBUTABLE TO LINEAGE
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-160" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         20,649
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-161" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         11,709
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: White">
      <td>
       NET LOSS PER COMMON SHARE:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
       BASIC AND DILUTED
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-162" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
         0.14
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-163" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
         0.08
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
       WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pii" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
       BASIC AND DILUTED
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-164" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
         150,044
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-165" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
         145,533
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 72 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        70
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="z_004">
      </span>
      LINEAGECELL THERAPEUTICS, INC. AND SUBSIDIARIES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CONSOLIDATEDSTATEMENTS OF COMPREHENSIVE LOSS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      (INTHOUSANDS)
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" id="xdx_30D_113_pn3n3_zMoWXvGDuRH8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss">
    <tbody>
     <tr style="display: none; vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_49E_20200101__20201231_zl4eekDseyH6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_49D_20190101__20191231_z4ZlvFF1Sdw2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--ProfitLoss_maCINOTzwv9_z8Uzn4mtYru2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 64%; font-weight: bold; text-align: left">
       NET LOSS
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-166" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         20,685
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-167" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         11,827
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Other comprehensive loss, net of tax:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_i01_pn3n3_maCINOTzwv9_zs4UnndBa6j5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">
       Foreign currency translation adjustments, net of tax
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-168" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         2,986
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-169" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         2,107
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_iT_pn3n3_mtCINOTzwv9_maCINOTzUHz_zncAXQJEYDU9" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left">
       COMPREHENSIVE LOSS
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-170" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         23,671
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-171" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         13,934
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_iN_pn3n3_di_msCINOTzUHz_zujr1IUPuxZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Less: comprehensive loss attributable to noncontrolling    interest
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-172" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         36
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-173" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         118
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTax_iT_pn3n3_mtCINOTzUHz_zPbqnSHnIKK5" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">
       COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-174" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         23,635
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-175" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         13,816
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       )
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 73 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        71
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span id="z_005">
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LINEAGECELL THERAPEUTICS, INC. AND SUBSIDIARIES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CONSOLIDATEDSTATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      (INTHOUSANDS)
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" id="xdx_30B_114_pn3n3_zP5K2PZb5Vji" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Consolidated Statements of Changes in Shareholders' Equity">
    <tbody>
     <tr style="display: none; vertical-align: bottom">
      <td style="font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Number
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          of                                         Shares
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z61BGDE9OWe5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Amount
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Number
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          of                                         Shares
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zFcORCbrDw68" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Amount
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zfqzQaJ2BqOd" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Accumulated
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Deficit
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_z3ille2l6yf8" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Noncontrolling
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Interest/(Deficit)
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zpjcBqHTst44" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Other
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Comprehensive
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Income/(Loss)
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" id="xdx_4BA_zI7tnhmEiaR1" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Total
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Shareholders’
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Equity
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td style="text-align: center; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Preferred    Shares
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Common    Shares
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Accumulated
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="text-align: center">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td style="font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Number
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          of                                         Shares
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Amount
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Number
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          of                                         Shares
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       <span style="font-size: 9pt">
        Amount
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Accumulated
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Deficit
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Noncontrolling
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Interest/(Deficit)
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Other
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Comprehensive
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Income/(Loss)
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Total
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Shareholders’
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">
        <span style="font: 9pt Times New Roman, Times, Serif">
         <b>
          Equity
         </b>
        </span>
       </p>
      </td>
      <td style="text-align: center; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_435_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zGyfE3JtbC24" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 28%; font-weight: bold">
       <span style="font-size: 9pt">
        BALANCE AT DECEMBER 31, 2018
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zn9GNJYB6aag" style="width: 5%; font-weight: bold; text-align: right" title="Balance, shares">
       <span style="-sec-ix-hidden: xdx2ixbrl0319">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0319" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-176" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 2%">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; text-align: right">
       <span style="-sec-ix-hidden: xdx2ixbrl0312">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0312" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-177" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_981_eus-gaap--SharesOutstanding_iS_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvj4dCSUNzMf" style="width: 5%; font-weight: bold; text-align: right" title="Balance, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-178" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          127,136
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-179" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          354,270
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-180" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          261,856
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-181" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          1,594
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-182" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          1,426
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 2%; font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="width: 5%; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-183" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          92,246
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="width: 1%; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_z80oK5mGNzM1" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued in connection with the Asterias Merger
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvmvNi85zLz4" style="text-align: right" title="Shares issued in connection with the Asterias Merger, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0330">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0330" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-184" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0323">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0323" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-185" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziYE00kn2Wy2" style="text-align: right" title="Shares issued in connection with the Asterias Merger, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-186" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          24,696
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-187" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          32,352
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0325">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0325" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-188" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0326">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0326" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-189" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0327">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0327" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-190" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-191" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          32,352
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_401_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares retired in connection with the Asterias Merger
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_986_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQ83e28F8PNl" style="text-align: right" title="Shares retired in connection with the Asterias Merger, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0341">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0341" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-192" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0334">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0334" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-193" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_980_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z55kQVvVYnE4" style="text-align: right" title="Shares retired in connection with the Asterias Merger, shares">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-194" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="Shares">
          2,622
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-195" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          3,435
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0336">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0336" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-196" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0337">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0337" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-197" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0338">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0338" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-198" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-199" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          3,435
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants_i_pn3n3" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued for settlement of Lineage Warrants
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesSharesIssuedForSettlementOfLineageShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJUMa6WjARI7" style="text-align: right" title="Shares issued for settlement of Lineage Warrants, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0352">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0352" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-200" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodSharesSharesIssuedForSettlementOfLineageShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0345">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0345" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-201" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesSharesIssuedForSettlementOfLineageShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkNkLLUZ3PN1" style="text-align: right" title="Shares issued for settlement of Lineage Warrants, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-202" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodSharesSharesIssuedForSettlementOfLineageShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          252
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-203" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          302
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0347">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0347" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-204" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0348">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0348" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-205" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0349">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0349" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-206" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-207" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockIssuedDuringPeriodValueSharesIssuedForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          302
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued upon vesting of restricted stock units, net of shares    retired to pay employees’ taxes
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zcfh49vIiDRc" style="text-align: right" title="Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0363">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0363" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-208" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0356">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0356" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-209" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSnQjW056h7" style="text-align: right" title="Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-210" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          189
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-211" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          110
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0358">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0358" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-212" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0359">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0359" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-213" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0360">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0360" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-214" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-215" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          110
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Shares issued for services
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zM6Fu0E8mcWl" style="text-align: right" title="Shares issued for services, shares">
       <span style="-sec-ix-hidden: xdx2ixbrl0374">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0374" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-216" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
          -
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSJEKRPlWPjg" style="text-align: right">
       <span style="-sec-ix-hidden: xdx2ixbrl0375">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0375" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-217" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
          -
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zBYUN9qAZJii" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Stock-based compensation
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZXSCwFEn7Ie" style="text-align: right" title="Stock-based compensation, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0384">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0384" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-218" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0377">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0377" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-219" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5ONS5AnJNNk" style="text-align: right" title="Stock-based compensation, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0386">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0386" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-220" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-221" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          3,501
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0379">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0379" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-222" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0380">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0380" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-223" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0381">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0381" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-224" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-225" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          3,501
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_40E_ecustom--StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Stock-based compensation for shares issued upon vesting of Asterias    restricted stock units attributable to post combination services
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98F_ecustom--StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServicesShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pii" style="text-align: right" title="Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0395">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0395" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-226" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServicesShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0388">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0388" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-227" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_984_ecustom--StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServicesShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" style="text-align: right" title="Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-228" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServicesShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          60
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-229" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          79
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0390">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0390" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-230" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0391">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0391" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-231" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0392">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0392" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-232" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-233" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockbasedCompensationForSharesIssuedUponVestingOfRestrictedStockUnitsAttributableToPostCombinationServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          79
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pn3n3" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued through ATM
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pii" style="text-align: right" title="Shares issued through ATM, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0406">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0406" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-234" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0399">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0399" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-235" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" style="text-align: right" title="Shares issued through ATM, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-236" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          93
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-237" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          103
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0401">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0401" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-238" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0402">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0402" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-239" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0403">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0403" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-240" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-241" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          103
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_40A_ecustom--AdjustmentUponAdoptionOfLeasingStandard_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Adjustment upon adoption of leasing standard
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0410">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0410" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-242" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0411">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0411" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-243" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-244" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          143
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0413">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0413" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-245" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0414">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0414" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-246" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-247" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AdjustmentUponAdoptionOfLeasingStandard" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          143
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_406_ecustom--FinancingRelatedFees_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Financing related fees
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--DissolutionOfBiotimeAsia_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Dissolution of BioTime Asia
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--HadasitNoncashWarrantExercise_i_pn3n3" style="display: none; vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Hadasit non-cash warrant exercise
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zKjFGffddGig" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Foreign currency translation gain (loss)
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0438">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0438" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-248" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0439">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0439" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-249" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0440">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0440" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-250" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0441">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0441" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-251" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-252" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          2,107
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-253" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          2,107
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
        NET LOSS
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0445">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0445" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-254" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0446">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0446" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-255" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-256" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          11,709
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-257" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          118
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0449">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0449" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-258" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-259" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          11,827
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_437_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zuJBXDHh6JWd" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
        BALANCE AT DECEMBER 31, 2019
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_983_eus-gaap--SharesOutstanding_iE_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMZPjP4OTGOj" style="font-weight: bold; text-align: right" title="Balance, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0459">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0459" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-260" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0452">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0452" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-261" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcdndsjSy6Ni" style="font-weight: bold; text-align: right" title="Balance, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-262" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          149,804
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-263" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          387,062
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-264" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          273,422
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-265" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          1,712
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-266" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          681
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-267" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          111,247
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_438_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zIS93j9XXkj5" style="display: none; vertical-align: bottom; background-color: White">
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
        BALANCE AT DECEMBER 31, 2019
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_986_eus-gaap--SharesOutstanding_iS_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfsC9QIwi1w2" style="font-weight: bold; text-align: right" title="Balance, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0470">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0470" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-268" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0463">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0463" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-269" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj76pSbTWpn2" style="font-weight: bold; text-align: right" title="Balance, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-270" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          149,804
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-271" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          387,062
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-272" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          273,422
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-273" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          1,712
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-274" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          681
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-275" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          111,247
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkVGOVdfgEXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued through ATM
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pii" style="text-align: right" title="Shares issued through ATM, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0481">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0481" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-276" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0474">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0474" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-277" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgaZuCSXAnt9" style="text-align: right" title="Shares issued through ATM, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-278" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          3,095
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-279" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          5,404
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0476">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0476" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-280" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0477">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0477" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-281" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0478">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0478" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-282" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-283" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          5,404
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zhP7TgEuu2Pi" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued upon vesting of restricted stock units, net of shares    retired to pay employees’ taxes
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pii" style="text-align: right" title="Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0492">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0492" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-284" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0485">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0485" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-285" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" style="text-align: right" title="Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-286" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          47
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-287" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          27
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0487">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0487" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-288" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0488">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0488" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-289" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0489">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0489" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-290" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-291" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          27
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zbiPgOOE3n28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Shares issued for services
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pii" style="text-align: right" title="Shares issued for services, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0503">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0503" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-292" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0496">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0496" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-293" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" style="text-align: right" title="Shares issued for services, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-294" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          150
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-295" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          119
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0498">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0498" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-296" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0499">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0499" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-297" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0500">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0500" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-298" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-299" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          119
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zN2a94FhLYQ9" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Stock-based compensation
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXHiKn6BVKYi" style="text-align: right" title="Stock-based compensation, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0514">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0514" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-300" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0507">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0507" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-301" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFF6aWLFKGMj" style="text-align: right" title="Stock-based compensation, shares">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0516">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0516" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-302" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right" title="Stock-based compensation, shares">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-303" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          2,227
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0509">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0509" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-304" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0510">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0510" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-305" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0511">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0511" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-306" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-307" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          2,227
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_405_ecustom--FinancingRelatedFees_zuWkkGlPc20h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Financing related fees
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0518">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0518" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-308" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-309" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          209
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0520">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0520" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-310" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0521">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0521" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-311" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0522">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0522" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-312" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-313" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:FinancingRelatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          209
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--DissolutionOfBiotimeAsia_zLUzVolANXif" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Dissolution of BioTime Asia
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0525">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0525" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-314" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-315" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          676
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-316" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          7
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-317" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          676
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0529">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0529" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-318" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-319" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:DissolutionOfBiotimeAsia" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          7
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--HadasitNoncashWarrantExercise_zk3jRFr9Y9dc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Hadasit non-cash warrant exercise
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0532">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0532" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-320" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-321" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          44
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0534">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0534" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-322" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0535">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0535" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-323" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0536">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0536" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-324" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-325" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:HadasitNoncashWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          44
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zKEePcIQbSxg" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font-size: 9pt">
        Foreign currency translation gain (loss)
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0539">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0539" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-326" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0540">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0540" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-327" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0541">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0541" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-328" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0542">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0542" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-329" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-330" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          2,986
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td>
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-331" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          2,986
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--ProfitLoss_z9DinRnc2BB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
        NET LOSS
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0546">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0546" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-332" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0547">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0547" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-333" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-334" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          20,649
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-335" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          36
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0550">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0550" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-336" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        -
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-337" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          20,685
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
     </tr>
     <tr id="xdx_43A_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z54Zu277hlQe" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
        BALANCE AT DECEMBER 31, 2020
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_988_eus-gaap--SharesOutstanding_iE_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhg91US9GHdh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0559">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0559" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-338" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span style="-sec-ix-hidden: xdx2ixbrl0553">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0553" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-339" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
           -
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUdbxxY0eq38" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-340" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          153,096
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-341" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          393,944
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-342" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          294,078
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-343" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          1,072
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        (
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-344" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
          3,667
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        )
       </span>
      </td>
      <td style="font-weight: bold; padding-bottom: 2.5pt">
       <span style="font-size: 9pt">
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
        $
       </span>
      </td>
      <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
       <span style="font-size: 9pt">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-345" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          95,127
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
       <span style="font-size: 9pt">
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 74 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        72
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="z_006">
      </span>
      LINEAGECELL THERAPEUTICS, INC. AND SUBSIDIARIES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      CONSOLIDATEDSTATEMENTS OF CASH FLOWS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      (INTHOUSANDS)
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" id="xdx_30A_112_pn3n3_zJHnqitW9dca" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Consolidated Statements of Cash Flows">
    <tbody>
     <tr style="display: none; vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_496_20200101__20201231_zclJg7DrnzO1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" id="xdx_49F_20190101__20191231_zAVpJdokknE" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Year Ended December 31,
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zo1z9wswkskg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       CASH FLOWS FROM OPERATING ACTIVITIES:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maOp1_zS8bTj253C9h" style="vertical-align: bottom; background-color: White">
      <td style="width: 64%; text-align: left">
       Net loss attributable to Lineage
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-346" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         20,649
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 14%; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-347" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         11,709
        </ix:nonfraction>
       </span>
      </td>
      <td style="width: 1%; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_i01_maOp1_zLEGsaRGTIzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Net loss attributable to noncontrolling interest
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-348" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         36
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-349" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         118
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zUh0vY3X6Sp4" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Adjustments to reconcile net loss attributable to Lineage to net cash used in operating activities:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--UnrealizedGainLossOnInvestments_i02N_di_msOp1_zXADp2S26bO3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized gain on equity method investment in OncoCyte at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0574">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0574" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-350" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrealizedGainLossOnInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right" title="Unrealized Gain (Loss) on Investments">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right" title="Unrealized Gain (Loss) on Investments">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-351" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrealizedGainLossOnInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         8,001
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_400_ecustom--UnrealizedGainLossOnInvestmentsOne_i02N_di_msOp1_z4rHHZVnuPek" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized gain on equity method investment in Asterias at fair value
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0577">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0577" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-352" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UnrealizedGainLossOnInvestmentsOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right" title="Unrealized Gain (Loss) on Investments">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right" title="Unrealized Gain (Loss) on Investments">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-353" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UnrealizedGainLossOnInvestmentsOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         6,744
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--GainOnSaleOfInvestments_i02N_di_msOp1_z6KaOJTOqlD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Gain on sale of marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-354" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainOnSaleOfInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         4,560
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-355" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainOnSaleOfInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,967
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_409_ecustom--MarketableSecuritiesUnrealizedLoss_i02_maOp1_z42oSuOXnwH3" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Unrealized loss on marketable equity securities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-356" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MarketableSecuritiesUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,782
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-357" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MarketableSecuritiesUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,898
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i02_maOp1_zPIR2wmbXs53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Income tax benefit
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-358" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         1,239
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-359" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         7,407
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_i02_maOp1_zyFkQk6onTvd" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Depreciation expense, including amortization of leasehold improvements
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-360" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepreciationDepletionAndAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         823
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-361" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepreciationDepletionAndAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,002
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_maOp1_zK4yEm9UJKza" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Amortization of right-of-use assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-362" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         72
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-363" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         129
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--AmortizationOfIntangibleAssets_i02_maOp1_zBkEzEjiZkZd" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Amortization of intangible assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-364" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,216
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-365" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,998
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_maOp1_zXfFBR68eHk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Stock-based compensation
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-366" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,227
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-367" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,580
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maOp1_z9oxyJ5HSNwa" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Common stock issued for services
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-368" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         119
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0602">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0602" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-369" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40E_ecustom--ChangeInUnrealizedGainOnWarrantLiability_i02N_pn3n3_di_msOp1_zEOI19hZ1GGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Change in unrealized loss (gain) on warrant liability
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-370" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:ChangeInUnrealizedGainOnWarrantLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         174
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-371" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ChangeInUnrealizedGainOnWarrantLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         611
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_402_ecustom--WriteoffOfSecurityDeposit_i02_maOp1_zNIK6mVFBPY4" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Write-off of security deposit
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-372" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:WriteoffOfSecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         150
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0608">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0608" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-373" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:WriteoffOfSecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--AmortizationOfDeferredLicenseFees_i02_maOp1_zU5fQt2VSNr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Amortization of deferred license fee
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-374" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:AmortizationOfDeferredLicenseFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         200
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0611">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0611" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-375" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AmortizationOfDeferredLicenseFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_ecustom--ForeignCurrencyRemeasurementAndOtherGainLoss_i02N_di_msOp1_zRWU9635Cym3" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Foreign currency remeasurement and other (gain) loss
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-376" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ForeignCurrencyRemeasurementAndOtherGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,957
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-377" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ForeignCurrencyRemeasurementAndOtherGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         2,367
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--GainsLossesOnSalesOfAssets_i02N_di_msOp1_zywXuIOT8da5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       (Gain) loss on sale of assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-378" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainsLossesOnSalesOfAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         20
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-379" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:GainsLossesOnSalesOfAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         273
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--RealizedGainLossOnWarrantExercise_i02_maOp1_zP7mnqHPNNq7" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Realized loss on warrant exercise
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-380" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RealizedGainLossOnWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         44
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0620">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0620" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-381" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RealizedGainLossOnWarrantExercise" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_409_ecustom--DividendReceived_i02_maOp1_ziMl6EMGlpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Dividend received
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0622">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0622" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-382" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DividendReceived" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-383" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DividendReceived" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         182
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zxPGVTj5KhA7" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Changes in operating assets and liabilities:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msOp1_zn8EgHjGTQmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Accounts and grants receivable, net
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-384" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsReceivable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         287
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-385" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsReceivable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         467
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i03N_di_msOp1_zKgb5DDQXZX7" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Accrued interest receivable
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-386" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,008
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-387" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,512
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_402_eus-gaap--IncreaseDecreaseDueFromAffiliates_i03N_pn3n3_di_msOp1_zb7rOpeQ9GP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Receivables from affiliates, net of payables
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-388" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseDueFromAffiliates" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         7
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-389" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseDueFromAffiliates" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         2,105
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msOp1_zXCwH9xj7aR9" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Prepaid expenses and other current assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-390" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         1,575
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-391" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         260
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maOp1_zEH1Rybwzcjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Accounts payable and accrued liabilities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-392" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         308
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-393" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         2,885
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40C_ecustom--IncreaseDecreaseInDeferredRevenueCurrent_i03_maOp1_z0MFC8Zigdoi" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Deferred revenue and other liabilities
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-394" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IncreaseDecreaseInDeferredRevenueCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         132
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0644">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0644" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-395" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IncreaseDecreaseInDeferredRevenueCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       -
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCzdqh_mtOp1_zDuGcRHTisuk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Net cash used in operating activities
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-396" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         19,753
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-397" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         31,947
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z4dd4akin1K1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       CASH FLOWS FROM INVESTING ACTIVITIES:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--ProceedsFromSaleOfInvestment_i01_maCzH29_zupxjEYW6p95" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from sale of OncoCyte common shares
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-398" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,941
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-399" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,738
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--ProceedsFromSaleOfInvestmentOne_i01_maCzH29_zqwFTSe4FFD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from the sale of AgeX common shares
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-400" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestmentOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,290
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-401" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestmentOne" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,734
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--ProceedsFromSaleOfInvestmentTwo_i01_maCzH29_zYl7mmgNLjS8" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from the sale of Hadasit common shares
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-402" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestmentTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         830
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-403" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromSaleOfInvestmentTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         1,743
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_403_eus-gaap--CashAcquiredFromAcquisition_i01_maCzH29_zPt4CoPBqG8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Cash and cash equivalents acquired in the Asterias Merger
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0661">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0661" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-404" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAcquiredFromAcquisition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-405" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAcquiredFromAcquisition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         3,117
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzH29_zhmi8w92db78" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Purchase of property and equipment
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-406" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         64
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-407" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         440
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_401_eus-gaap--ProceedsFromSaleOfProductiveAssets_i01_maCzH29_zGQenf0c1I2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from sale of assets
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-408" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfProductiveAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         23
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-409" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfProductiveAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         82
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_ecustom--SecurityDepositPaidAndOther_i01N_di_msCzH29_zUmx9X9HVCx2" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Security deposit paid and other
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-410" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:SecurityDepositPaidAndOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         18
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-411" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SecurityDepositPaidAndOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         17
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzH29_maCzdqh_zGsE9GDRoJBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Net cash provided by investing activities
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-412" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         13,038
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-413" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         16,957
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zsV0sRvlLOP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       CASH FLOWS FROM FINANCING ACTIVITIES:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_i01_maCzDM2_zit7pDsN25ya" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from payment of Juvenescence promissory note
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-414" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         24,624
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0680">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0680" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-415" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_ecustom--CommonSharesReceivedAndRetiredForEmployeeTaxesPaid_i01N_di_msCzDM2_zsZUaHL5puY8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Common shares received and retired for employee taxes paid
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-416" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:CommonSharesReceivedAndRetiredForEmployeeTaxesPaid" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         27
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-417" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:CommonSharesReceivedAndRetiredForEmployeeTaxesPaid" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         110
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_407_ecustom--PaymentsForProceedsFromSaleOfSubsidiaryWarrants_i01_maCzDM2_zjYe0967Qkoa" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from sale of subsidiary warrants
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0685">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0685" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-418" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PaymentsForProceedsFromSaleOfSubsidiaryWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-419" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:PaymentsForProceedsFromSaleOfSubsidiaryWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         40
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzDM2_zdnOUbL4MyS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from sale of common shares
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-420" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         5,127
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-421" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         103
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_409_ecustom--PaymentsForOfferingCosts_i01N_di_msCzDM2_zQpuKxgl2frb" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Payments for offering costs
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-422" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PaymentsForOfferingCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         356
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0692">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0692" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-423" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PaymentsForOfferingCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_ecustom--RepaymentOfFinancingLeaseLiabilities_i01N_di_msCzDM2_zDDw2eOkFrAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Repayment of financing lease liabilities
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-424" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RepaymentOfFinancingLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         26
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-425" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RepaymentOfFinancingLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         30
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_404_ecustom--ProceedsFromPaycheckProtectionProgramLoan_i01_pn3n3_maCzDM2_z7clYQiAgnr8" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Proceeds from Paycheck Protection Program (“PPP”) Loan (Note    8)
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-426" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromPaycheckProtectionProgramLoan" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         523
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0698">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0698" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-427" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromPaycheckProtectionProgramLoan" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_ecustom--ReimbursementFromLandlordOnTenantImprovements_i01_maCzDM2_zNf9ZW8GagPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Reimbursement from landlord on tenant improvements
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0700">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0700" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-428" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReimbursementFromLandlordOnTenantImprovements" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-429" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReimbursementFromLandlordOnTenantImprovements" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         764
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40C_eus-gaap--RepaymentsOfDebt_i01N_di_msCzDM2_zYSh3yj4IKN5" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
       Repayment of principal portion of promissory notes
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0703">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0703" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-430" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RepaymentsOfDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       -
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-431" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RepaymentsOfDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         70
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzDM2_maCzdqh_zDIoactIWfY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Net cash provided by financing activities
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-432" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         29,865
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-433" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         617
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_400_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCzdqh_ztEH7PkTFFo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 1.5pt">
       Effect of exchange rate changes on cash, cash equivalents and restricted    cash
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-434" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         63
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       )
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-435" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         70
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzdqh_zkH15zBeCIwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-436" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         23,087
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       (
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-437" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
         14,303
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
       )
      </td>
     </tr>
     <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_ze6vV4g45YZk" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       At beginning of year
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-438" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,096
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2018-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-439" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         24,399
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zJ0gK3hzUR0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 2.5pt">
       At end of year
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-440" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         33,183
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       <span>
        <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-441" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         10,096
        </ix:nonfraction>
       </span>
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zCVNdOkjXRb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_zjGfnslbQGT" style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Cash paid during year for interest
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-442" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestPaidNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         20
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-443" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestPaidNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         28
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_404_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zfIga6OOFaT7" style="vertical-align: bottom; background-color: White">
      <td style="font-weight: bold; text-align: left">
       SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40F_ecustom--ReceivableFromSaleOfCommonSharesInAtMarketOffering_i01_z74c3QI4Hp1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Receivable from sale of common shares in at the market offering
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-444" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReceivableFromSaleOfCommonSharesInAtMarketOffering" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         269
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       <span style="-sec-ix-hidden: xdx2ixbrl0731">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0731" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-445" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReceivableFromSaleOfCommonSharesInAtMarketOffering" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
          -
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40A_ecustom--ReceivableFromSaleOfAgexCommonShares_i01_zfGsr8tUAlL3" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Receivable from sale of AgeX common shares
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0733">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0733" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-446" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReceivableFromSaleOfAgexCommonShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-447" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReceivableFromSaleOfAgexCommonShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         41
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_40E_eus-gaap--StockIssued1_i01_zTibmjijcFxl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Issuance of common shares for the Asterias Merger (Note 3)
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0736">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0736" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-448" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssued1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-449" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssued1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         32,353
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_408_eus-gaap--LiabilitiesAssumed1_i01_ztkmd099OAN8" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Assumption of liabilities in the Asterias Merger
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0739">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0739" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-450" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAssumed1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-451" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAssumed1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         982
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_405_ecustom--AssumptionOfWarrants_i01_zdeXWksAOFH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       Assumption of warrants in the Asterias Merger
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0742">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0742" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-452" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AssumptionOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-453" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AssumptionOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         867
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr id="xdx_402_ecustom--IssuanceOfCommonSharesForSettlementOfWarrants_i01_zqTt5QMvdph8" style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       Issuance of common shares for settlement of Lineage Warrants
      </td>
      <td>
      </td>
      <td style="text-align: left">
       <span style="-sec-ix-hidden: xdx2ixbrl0745">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0745" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-454" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IssuanceOfCommonSharesForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
         </ix:nonfraction>
        </span>
       </span>
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-455" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IssuanceOfCommonSharesForSettlementOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
         332
        </ix:nonfraction>
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Seeaccompanying notes to the consolidated financial statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 75 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        73
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      LINEAGECELL THERAPEUTICS, INC.
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-456" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5jDOoROz43h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        1.
        <span id="xdx_824_zItjv6S1NiP1">
         Organization, Basis of Presentation and Liquidity
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        General–
       </i>
       Lineage Cell Therapeutics, Inc. (“Lineage”) is a clinical-stage biotechnology company developing novelcell therapies for unmet medical needs. Lineage’s focus is to develop therapies for degenerative retinal diseases, neurologicalconditions associated with demyelination, and aiding the body in detecting and combating cancer. Specifically, Lineage is testingtherapies to treat dry age-related macular degeneration, spinal cord injuries, and non-small cell lung cancer. Lineage’sprograms are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. Fromthis platform, Lineage develops and manufactures specialized, terminally or functionally differentiated human cellsfrom its pluripotent and progenitor cell starting materials. These differentiated cells are transplanted into a patient eitherto replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administeredas a means of helping the body mount an effective immune response to cancer.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagehas
       <span id="xdx_905_ecustom--NumberOfCellTherapyPrograms_pii_dxL_uSubsidiary_c20200101__20201231_zCAT3hZp1Zfj" title="Number of cell therapy programs::XDX::3">
        <span style="-sec-ix-hidden: xdx2ixbrl0750">
         <span>
          <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0750" decimals="INF" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-457" inside-table="false" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfCellTherapyPrograms" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Subsidiary">
           three
          </ix:nonfraction>
         </span>
        </span>
       </span>
       allogeneic, or “off-the-shelf,” cell therapy programs in clinical development:
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
      <tbody>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif; width: 0.36in">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <i>
           OpRegen
          </i>
          <sup>
           ®
          </sup>
          ,    a retinal pigment epithelium cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for the treatment    of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy. There currently are no therapies    approved by the U.S. Food and Drug Administration (“FDA”) for dry AMD, which accounts for approximately 85-90%    of all AMD cases and is the leading cause of blindness in people over the age of 60.
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <i>
           OPC1
          </i>
          ,    an oligodendrocyte progenitor cell therapy currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries    (“SCI”). This clinical trial has been partially funded by the California Institute for Regenerative Medicine.
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <i>
           VAC2
          </i>
          ,    cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 clinical trial in non-small cell lung cancer.    This clinical trial is being funded and conducted by Cancer Research UK, the world’s largest independent cancer research    charity.
         </span>
        </td>
       </tr>
      </tbody>
     </table>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inaddition to seeking to create value for shareholders by developing product candidates and other technologies through our clinicaldevelopment programs, we also seek to create value from our technologies through partnering and strategic transactions. We foundedtwo companies that later became publicly traded companies: OncoCyte Corporation (“OncoCyte”) and AgeX Therapeutics,Inc. (“AgeX”).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe year ended December 31, 2020, we received approximately $
       <span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zk9tNABNcTLl" title="Proceeds from issuance or sale of equity">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-458" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          12.6
         </ix:nonfraction>
        </span>
       </span>
       million in gross proceeds in connection with our sale of sharesof OncoCyte and AgeX. In August 2020, we also received $
       <span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200801__20200831__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zUYZZGHSIon2">
        <span>
         <ix:nonfraction contextref="From2020-08-012020-08-31_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-459" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          24.6
         </ix:nonfraction>
        </span>
       </span>
       million from Juvenescence Limited (“Juvenescence”), representingprincipal and accrued interest under a promissory note we received in connection with our sale of AgeX shares to Juvenescence inAugust 2018.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Weno longer hold any common stock in AgeX. The value of our OncoCyte holdings as of March 5, 2021, was approximately $
       <span id="xdx_905_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_za5WBe5VMWVc" title="Common stock closing price">
        <span>
         <ix:nonfraction contextref="AsOf2021-03-05_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-460" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockValueOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          4.2
         </ix:nonfraction>
        </span>
       </span>
       million, based on the closing price of its common stock on that date.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thoughour principal focus is on advancing our three cell therapy programs currently in clinical development, we may seek to create additionalvalue through corporate transactions, as we have in the past, or by initiating new programs using our protocols or with new protocolsand cell lines.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        AsteriasMerger
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnNovember 7, 2018, Lineage, Asterias Biotherapeutics, Inc. (“Asterias”) and Patrick Merger Sub, Inc., a wholly ownedsubsidiary of Lineage, entered into an Agreement and Plan of Merger (the “Merger Agreement”) whereby Lineage agreedto acquire all of the outstanding common stock of Asterias in a stock-for-stock transaction (the “Asterias Merger”).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMarch 7, 2019, the shareholders of each of Lineage and Asterias approved the Merger Agreement. Prior to the Asterias Merger, Lineageowned approximately
       <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20190307__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pii" title="Ownership percentage">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-07_custom_MergerAgreementMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-461" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          38
         </ix:nonfraction>
        </span>
        %
       </span>
       of Asterias’ issued and outstanding common stock and accounted for Asterias as an equity methodinvestment.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 76 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           74
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMarch 8, 2019, the Asterias Merger closed with Asterias surviving as a wholly owned subsidiary of Lineage. The former stockholdersof Asterias (other than Lineage) received
       <span id="xdx_901_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__dei--LegalEntityAxis__custom--AsteriasMember_pii" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-462" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          0.71
         </ix:nonfraction>
        </span>
       </span>
       common shares of Lineage for every share of Asterias common stock they owned. Lineageissued
       <span id="xdx_905_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z4mOndfUmVh2" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-463" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          24,695,898
         </ix:nonfraction>
        </span>
       </span>
       common shares, including
       <span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__dei--LegalEntityAxis__custom--AsteriasMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOmYzBk0lsag" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember_us-gaap_RestrictedStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-464" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          58,085
         </ix:nonfraction>
        </span>
       </span>
       shares issued in respect of restricted stock units issued by Asterias that immediatelyvested in connection with the closing of the Asterias Merger. The aggregate dollar value of such shares, based on the closingprice of Lineage common shares on March 8, 2019, was $
       <span id="xdx_90A_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_iI_pn5n6_c20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zMIrcwI9e6H5" title="Aggregate merger consideration amount">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-465" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          32.4
         </ix:nonfraction>
        </span>
       </span>
       million. Lineage also assumed warrants to purchase shares of Asteriascommon stock.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheAsterias Merger has been accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification(“ASC”) Topic 805,
       <i>
        Business Combinations
       </i>
       , which requires, among other things, that the assets and liabilitiesassumed be recognized at their fair values as of the acquisition date.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       SeeNote 3 for a full discussion of the Asterias Merger.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Investmentin OncoCyte
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagehas significant equity holdings in OncoCyte, which Lineage founded and, in the past, was a majority-owned consolidated subsidiaryuntil February 17, 2017, when Lineage deconsolidated OncoCyte’s financial statements. OncoCyte is focused on developingand commercializing laboratory-developed tests to serve unmet medical needs across the cancer care continuum. As of December 31,2020, Lineage owned approximately
       <span id="xdx_90A_ecustom--NumberOfSharesOwned_iI_pn5n6_c20201231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--OwnershipAxis__custom--OncoCyteCorporationMember_z5xAJTxP7tDa" title="Number of shares owned">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_srt_ParentCompanyMember_us-gaap_CommonStockMember_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-466" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfSharesOwned" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          3.6
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock, or
       <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20201231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--OwnershipAxis__custom--OncoCyteCorporationMember_pii" title="Ownership percentage">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_srt_ParentCompanyMember_us-gaap_CommonStockMember_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-467" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          5.4
         </ix:nonfraction>
        </span>
        %
       </span>
       of its outstanding shares (see Note 4).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Useof estimates
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thepreparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”)requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosureof contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenuesand expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions whichare subject to significant judgment include those related to going concern assessment of consolidated financial statements, usefullives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables,loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, andassumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from thoseestimates.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Principlesof consolidation
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-468" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89D_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zpY3uxkFR2O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Lineage’sconsolidated financial statements include the accounts of its subsidiaries. The following table reflects Lineage’s ownership,directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2020.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B2_zBa2I00yzo9h" style="display: none">
          Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Subsidiary
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Field of Business
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Lineage Ownership
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Country
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 30%; text-align: left">
           Asterias BioTherapeutics, Inc.
          </td>
          <td style="width: 2%">
          </td>
          <td id="xdx_983_ecustom--FieldOfBusinessDescription_c20200101__20201231__srt--OwnershipAxis__custom--AsteriasBiotherapeuticsIncMember" style="width: 34%; text-align: left" title="Field of business description">
           <span>
            <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-469" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:FieldOfBusinessDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             Cell therapy clinical development programs in spinal cord injury and oncology
            </ix:nonnumeric>
           </span>
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_c20201231__srt--OwnershipAxis__custom--AsteriasBiotherapeuticsIncMember_zhkWG40dM104" style="width: 10%; text-align: right" title="Lineage ownership">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-470" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterestOwnershipPercentageByParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             100
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           %
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 18%; text-align: center">
           USA
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Cell Cure Neurosciences Ltd (“Cell Cure”)
          </td>
          <td>
          </td>
          <td id="xdx_98A_ecustom--FieldOfBusinessDescription_c20200101__20201231__srt--OwnershipAxis__custom--CellCureNeurosciencesLtdMember" style="text-align: left" title="Field of business description">
           <span>
            <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_CellCureNeurosciencesLtdMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-471" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:FieldOfBusinessDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             Development and manufacturing of Lineage’s cell replacement platform technology
            </ix:nonnumeric>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_c20201231__srt--OwnershipAxis__custom--CellCureNeurosciencesLtdMember_fKDEp_zRGcwdwyICZb" style="text-align: right" title="Lineage ownership">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureNeurosciencesLtdMember" continued-taxonomy="false" data-original-id="Fact000779" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-472" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterestOwnershipPercentageByParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             99
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
           <sup id="xdx_F24_zn6vJQpu7U8g">
            (1)
           </sup>
          </td>
          <td>
          </td>
          <td style="text-align: center">
           Israel
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           ES Cell International Pte. Ltd. (“ESI”)
          </td>
          <td>
          </td>
          <td id="xdx_98D_ecustom--FieldOfBusinessDescription_c20200101__20201231__srt--OwnershipAxis__custom--EsCellInternationalPteLtdMember" style="text-align: left" title="Field of business description">
           <span>
            <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_EsCellInternationalPteLtdMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-473" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:FieldOfBusinessDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             Stem cell products for research, including clinical grade cell lines produced under cGMP
            </ix:nonnumeric>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_c20201231__srt--OwnershipAxis__custom--EsCellInternationalPteLtdMember_z27hUsccOtOb" style="text-align: right" title="Lineage ownership">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_EsCellInternationalPteLtdMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-474" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterestOwnershipPercentageByParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             100
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: center">
           Singapore
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           OrthoCyte Corporation (“OrthoCyte”)
          </td>
          <td>
          </td>
          <td id="xdx_988_ecustom--FieldOfBusinessDescription_c20200101__20201231__srt--OwnershipAxis__custom--OrthocyteCorporationMember" style="text-align: left" title="Field of business description">
           <span>
            <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_OrthocyteCorporationMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-475" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:FieldOfBusinessDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             Developing bone grafting products for orthopedic diseases and injuries
            </ix:nonnumeric>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_c20201231__srt--OwnershipAxis__custom--OrthocyteCorporationMember_zzFXYY7NK2Na" style="text-align: right" title="Lineage ownership">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OrthocyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-476" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MinorityInterestOwnershipPercentageByParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             99.8
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: center">
           USA
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="margin-top: 0; margin-bottom: 0">
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
           <span id="xdx_F05_zCYsfFmIKdjk" style="font: 10pt Times New Roman, Times, Serif">
            (1)
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif">
           <span id="xdx_F1F_zF5HBL7uFy2e" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote000788" xml:lang="en-US">
             Includes    shares owned by Lineage and ESI
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AA_z9GK5R2XukMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Allmaterial intercompany accounts and transactions have been eliminated in consolidation. As of December 31, 2020, Lineage consolidatedits direct and indirect wholly owned or majority-owned subsidiaries because Lineage has the ability to control their operatingand financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate elementof shareholders’ equity on Lineage’s consolidated balance sheets.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 77 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           75
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Liquidity
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Sinceinception, Lineage has incurred significant operating losses and has funded its operations primarily through sale of common stockof AgeX and OncoCyte, both former subsidiaries, sale of common stock of Hadasit Bio-Holdings (“HBL”), receipt of researchgrants, royalties from product sales, license revenues, sales of research products and issuance of equity securities.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMay 1, 2020, Lineage entered into a Controlled Equity Offering
       <sup>
        SM
       </sup>
       Sales Agreement (the “Sales Agreement”)with Cantor Fitzgerald &amp; Co., as sales agent (“Cantor Fitzgerald”), pursuant to which Lineage may, but is notobligated to, raise up to $
       <span id="xdx_901_ecustom--ObligatedCommonShares_pn5n6_c20200428__20200501__srt--TitleOfIndividualAxis__custom--ControlledEquityOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z70AM5iu2lN8">
        <span>
         <ix:nonfraction contextref="From2020-04-282020-05-01_custom_ControlledEquityOfferingMember_custom_SalesAgreementMember_custom_CantorFitzgeraldAndCoMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-477" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ObligatedCommonShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          25.0
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million through the sale of common shares(“ATM Shares”) from time to time in at-the-market transactions under the Sales Agreement. As of December 31, 2020,Lineage raised $
       <span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20200101__20201231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z8rHvBworaQ4">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_srt_ParentCompanyMember_custom_SalesAgreementMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-478" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          5.1
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million in gross proceeds underthe Sales Agreement (which excludes $
       <span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20200101__20201231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--AwardTypeAxis__custom--TwentyTwentySalesMember_zk06QjjoUynb">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_srt_ParentCompanyMember_custom_SalesAgreementMember_custom_TwentyTwentySalesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-479" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million in cash in transit related to 2020 sales that settled in 2021) and duringthe first quarter through March 5, 2021, Lineage raised $
       <span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20210305__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhpWXhVoSenl">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-480" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.9
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million in gross proceeds underthe Sales Agreement (which includes $
       <span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20210305__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--TwentyTwentySalesMember_zFn73FfgkUX7">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember_custom_TwentyTwentySalesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-481" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million in cash in transit related to 2020 sales that settled in 2021). On March5, 2021, Lineage filed a prospectus supplement with the Securities and Exchange Commission (the “SEC”) in connectionwith the offer and sale of an additional $
       <span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20210301__20210305__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjOuSYA6ICdh">
        <span>
         <ix:nonfraction contextref="From2021-03-012021-03-05_srt_ParentCompanyMember_custom_SalesAgreementMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-482" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          25
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million of ATM Shares.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       AtDecember 31, 2020, Lineage had an accumulated deficit of approximately $
       <span id="xdx_90C_ecustom--RetainedEarningAccumulatedDeficit_c20201231_pn5n6" title="Accumulated deficit">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-483" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RetainedEarningAccumulatedDeficit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          294.1
         </ix:nonfraction>
        </span>
       </span>
       million, working capital of $
       <span id="xdx_901_ecustom--WorkingCapital_c20201231_pn5n6" title="Working capital">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-484" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:WorkingCapital" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          36.2
         </ix:nonfraction>
        </span>
       </span>
       million and shareholders’equity of $
       <span id="xdx_900_ecustom--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1_c20201231_pn5n6" title="Shareholders' equity">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-485" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          95.1
         </ix:nonfraction>
        </span>
       </span>
       million. Lineage has evaluated its projected cash flows and believes that its $
       <span id="xdx_902_eus-gaap--CashCashEquivalentsAndShortTermInvestments_c20201231_pn5n6" title="Cash and cash equivalents and marketable securities">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-486" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          41.6
         </ix:nonfraction>
        </span>
       </span>
       million of cash, cash equivalentsand marketable equity securities are sufficient to fund Lineage’s planned operations for at least the next twelve monthsfrom the issuance date of the condensed consolidated financial statements included herein. If Lineage needs near term workingcapital or liquidity to supplement its cash and cash equivalents for its operations, Lineage may sell some, or all, of its marketableequity securities, as necessary.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMarch 8, 2019, Asterias became Lineage’s wholly owned subsidiary, and Lineage began consolidating Asterias’ operationsand results with its operations and results (see Note 3). Lineage has made extensive reductions in headcount and reduced non-clinicalrelated spend, in each case, as compared to Asterias’ operations before the Asterias Merger.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineage’sprojected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meetfuture capital needs could force Lineage to modify, curtail, delay, or suspend some or all aspects of its planned operations.Lineage’s determination as to when it will seek new financing and the amount of financing that it will need will be basedon Lineage’s evaluation of the progress it makes in its research and development programs, any changes to the scope andfocus of those programs, any changes in grant funding for certain of those programs, and projection of future costs, revenues,and rates of expenditure. Lineage’s ability to raise additional funds may be adversely impacted by deteriorating globaleconomic conditions and the disruptions to and volatility in the credit and financial markets in the United States and worldwideresulting from the ongoing COVID-19 pandemic. Lineage may be required to delay, postpone, or cancel clinical trials or limit thenumber of clinical trial sites, unless it is able to obtain adequate financing. In addition, Lineage has incurred significantcosts in connection with the acquisition of Asterias and with integrating its operations. Lineage may incur additional costs tomaintain employee morale and to retain key employees. Lineage cannot assure that adequate financing will be available on favorableterms, if at all. Sales of additional equity securities by Lineage or its subsidiaries and affiliates could result in the dilutionof the interests of current shareholders.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-487" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zQZ6Cw6xjC61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        2.
        <span id="xdx_823_z9tx0qeW2g0g">
         Summary of Significant Accounting Policies
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-488" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:BusinessCombinationsPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_846_eus-gaap--BusinessCombinationsPolicy_zu93DIlEofY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86B_zHoEvPtalyD2">
            BusinessCombinations
           </span>
          </span>
         </i>
         – Lineage accounts for business combinations, such as the Asterias Merger completed in March 2019, in accordancewith ASC Topic 805, which requires the purchase price to be measured at fair value. When the purchase consideration consists entirelyof Lineage common shares, Lineage calculates the purchase price by determining the fair value, as of the acquisition date, ofshares issued in connection with the closing of the acquisition. Lineage recognizes estimated fair values of the tangible assetsand intangible assets acquired, including in-process research and development (“IPR&amp;D”), and liabilities assumedas of the acquisition date, and records as goodwill any amount of the fair value of the tangible and intangible assets acquiredand liabilities assumed in excess of the purchase price.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-489" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:MarketableSecuritiesPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_841_eus-gaap--MarketableSecuritiesPolicy_ztupeTli64tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_861_z8xJmiE2vOh8">
           MarketableEquity Securities
          </span>
         </i>
         – Lineage accounts for the shares it holds in OncoCyte and HBL (and AgeX previously) as marketableequity securities in accordance with ASC 320-10-25,
         <i>
          Investments – Debt and Equity Securities
         </i>
         , as amended by AccountingStandards Update (“ASU”) 2016-01,
         <i>
          Financial Instruments–Overall: Recognition and Measurement of FinancialAssets and Financial Liabilities,
         </i>
         further discussed below
         <i>
          .
         </i>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 78 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             76
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         TheOncoCyte and AgeX shares have readily determinable fair values quoted on the NYSE American under trading symbols “OCX”and “AGE”. The HBL shares have a readily determinable fair value quoted on the Tel Aviv Stock Exchange (“TASE”)under trading symbol “HDST” where share prices are denominated in New Israeli Shekels (NIS).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Priorto September 11, 2019, Lineage accounted for its OncoCyte shares held at fair value, using the equity method of accounting.
         <span id="xdx_90B_ecustom--OwnershipPercentageDescription_c20190909__20190911" title="Ownership percentage, description">
          <span>
           <ix:nonnumeric contextref="From2019-09-092019-09-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-490" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:OwnershipPercentageDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            OnSeptember 11, 2019, Lineage’s ownership percentage decreased from
            <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20190910__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pii" title="Ownership percentage">
             <span>
              <ix:nonfraction contextref="AsOf2019-09-10_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-491" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
               24
              </ix:nonfraction>
             </span>
             %
            </span>
            to
            <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pii" title="Ownership percentage">
             <span>
              <ix:nonfraction contextref="AsOf2019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-492" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
               16
              </ix:nonfraction>
             </span>
             %
            </span>
            when it sold
            <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20190909__20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_z0WsniJ8RbO7" title="Number of stock sold">
             <span>
              <ix:nonfraction contextref="From2019-09-092019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-493" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
               4.0
              </ix:nonfraction>
             </span>
            </span>
            million shares of OncoCytecommon stock. Accordingly, as the ownership percentage was reduced to less than
            <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember__srt--RangeAxis__srt--MaximumMember_pii" title="Ownership percentage">
             <span>
              <ix:nonfraction contextref="AsOf2019-09-11_custom_OncoCyteCorporationMember_srt_MaximumMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-494" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
               20
              </ix:nonfraction>
             </span>
             %
            </span>
            , Lineage is no longer considered to exercisesignificant influence over OncoCyte and is now accounting for its OncoCyte holdings as marketable equity securities.
           </ix:nonnumeric>
          </span>
         </span>
         Prior tothe Asterias Merger completed on March 8, 2019, Lineage accounted for its Asterias shares held at fair value, using the equitymethod of accounting.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-495" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgDMOR11elI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_867_z73w6JENIZEf">
           RevenueRecognition
          </span>
         </i>
         – Lineage recognizes revenue in accordance with Financial Accounting Standards Board (“FASB”)Accounting Standards Update (“ASU”)
         <i>
          ASU 2014-09, Revenues from Contracts with Customers (Topic 606),
         </i>
         and ina manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the considerationit is entitled to receive in exchange for such product or service. In doing so, Lineage follows a five-step approach: (i) identifythe contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price;(iv) allocate the transaction price to the performance obligations; and (v) recognize revenue when (or as) the customer obtainscontrol of the product or service. Lineage considers the terms of a contract and all relevant facts and circumstances when applyingthe revenue recognition standard. Lineage applies the revenue recognition standard, including the use of any practical expedients,consistently to contracts with similar characteristics and in similar circumstances.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Lineage’slargest source of revenue is currently related to government grants. In applying the provisions of ASU 2014-09, Lineage has determinedthat government grants are out of the scope of ASU 2014-09 because the government entities do not meet the definition of a “customer,”as defined by ASU 2014-09, as there is not considered to be a transfer of control of good or services to the government entitiesfunding the grant. Lineage has, and will continue to, account for grants received to perform research and development servicesin accordance with ASC 730-20,
         <i>
          Research and Development Arrangements
         </i>
         , which requires an assessment, at the inception ofthe grant, of whether the grant is a liability or a contract to perform research and development services for others. If Lineageor a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the researchand development activities, then Lineage is required to estimate and recognize that liability. Alternatively, if Lineage or asubsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research anddevelopment activities are successful, then the grant agreement is accounted for as a contract to perform research and developmentservices for others, in which case, grant revenue is recognized when the related research and development expenses are incurred(see Note 14).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Deferredgrant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have notyet been incurred as of the balance sheet date reported. As of December 31, 2020, deferred grant revenue was $
         <span id="xdx_900_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20201231_zMJ2kLYGqaqk" title="Contract with Customer, Liability">
          <span>
           <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-496" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ContractWithCustomerLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
            193,000
           </ix:nonfraction>
          </span>
         </span>
         .
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-497" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:EarningsPerSharePolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zzOrvH4feEWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_86A_zeqPowq5Isig">
           Basicand diluted net income (loss) per share attributable to common shareholders
          </span>
         </i>
         – Basic earnings per share is calculatedby dividing net income or loss attributable to Lineage common shareholders by the weighted average number of common shares outstanding,net of unvested restricted stock or restricted stock units, subject to repurchase by Lineage, if any, during the period. Dilutedearnings per share is calculated by dividing the net income or loss attributable to Lineage common shareholders by the weightedaverage number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstandingstock options and warrants, using the treasury-stock method, convertible preferred stock, if any, using the if-converted method,and treasury stock held by subsidiaries, if any.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Forthe years ended December 31, 2020 and 2019, respectively, Lineage reported a net loss attributable to common shareholders, andtherefore, all potentially dilutive common shares were considered antidilutive for those periods.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 79 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             77
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
       </span>
       <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
       </span>
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-498" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
         <p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWGRUyXEMFKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           Thefollowing common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periodspresented because including them would have been antidilutive (in thousands):
          </span>
         </p>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           <span id="xdx_8BF_zSkV9BT27os" style="display: none">
            Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
           </span>
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
          <tbody>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                Years                                         Ended
               </b>
              </span>
             </p>
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                December31,
               </b>
              </span>
             </p>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
           </tr>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2020
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2019
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="width: 64%; text-align: left">
             Stock options
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z7wHX2rPKJX5" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-499" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               16,215
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z7oYjixSmvj7" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-500" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               15,060
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="text-align: left">
             <span style="font: 10pt Times New Roman, Times, Serif">
              Lineage Warrants
              <sup id="xdx_F4D_zZdL3tlIAzWc">
               (1)
              </sup>
              (Note 3)
             </span>
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LineageWarrantMember_fKDEp_zrvctpSt1W15" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_LineageWarrantMember" continued-taxonomy="false" data-original-id="Fact000832" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-501" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               1,090
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LineageWarrantMember_fKDEp_zwUdxwECA9Z5" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_LineageWarrantMember" continued-taxonomy="false" data-original-id="Fact000834" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-502" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               1,090
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="text-align: left">
             Restricted stock units
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zW0JgK27CQi1" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_RestrictedStockUnitsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-503" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               93
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zIV3JTSeXhU5" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_RestrictedStockUnitsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-504" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="Shares">
               166
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
           </tr>
          </tbody>
         </table>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
          <span style="font: 10pt Times New Roman, Times, Serif">
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
          <tbody>
           <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
             <span style="font: 10pt Times New Roman, Times, Serif">
              <sup id="xdx_F00_zgAXDRxk7Pt1">
               (1)
              </sup>
             </span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
             <span id="xdx_F1C_z8IXew27uPo8" style="font: 10pt Times New Roman, Times, Serif">
              <ix:footnote id="Footnote000839" xml:lang="en-US">
               Although    the Lineage Warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations    in accordance with ASC 260,
               <i>
                Earnings Per Share
               </i>
               , and determined to be anti-dilutive for the period presented.
              </ix:footnote>
             </span>
            </td>
           </tr>
          </tbody>
         </table>
        </ix:nonnumeric>
       </span>
       <p id="xdx_8A5_zkRny2ZSIXfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-505" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zppIHs6ICvJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_862_zmIo9XONL8R8">
           RestrictedCash
          </span>
         </i>
         – In accordance with ASU 2016-18,
         <i>
          Statement of Cash Flows (Topic 230): Restricted Cash
         </i>
         , Lineage explainsthe change during the year in the total of cash, cash equivalents and restricted cash, and includes restricted cash withcash and cash equivalents when reconciling the beginning-of-year and end-of-year total amounts shown on the condensedconsolidated statements of cash flows.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Lineagehas several certificates of deposit as required under our facility leases and credit card program. Lineage is restricted fromusing this cash for working capital purposes. At December 31, 2020, Lineage maintains $
         <span id="xdx_907_eus-gaap--RestrictedCash_iI_pp0p0_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember_z9cqRbzecrsg" title="Restricted cash">
          <span>
           <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-506" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
            420,000
           </ix:nonfraction>
          </span>
         </span>
         pursuant to the Cell Cure Leases,$
         <span id="xdx_90A_eus-gaap--RestrictedCash_iI_pp0p0_c20201231__srt--ProductOrServiceAxis__us-gaap--CreditCardMember_zOJ9VMl4Xaqh" title="Restricted cash">
          <span>
           <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CreditCardMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-507" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
            100,000
           </ix:nonfraction>
          </span>
         </span>
         pursuant to its credit card program and $
         <span id="xdx_901_eus-gaap--RestrictedCash_iI_pp0p0_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlamedaLeaseMember_zkrfwgFAXFB7" title="Restricted cash">
          <span>
           <ix:nonfraction contextref="AsOf2020-12-31_custom_AlamedaLeaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-508" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
            78,000
           </ix:nonfraction>
          </span>
         </span>
         pursuant to the Alameda Lease. Amounts related to the Cell Cure Leasesand credit card program are recorded in deposits and other long-term assets and the amount related to the Alameda Lease is recordedin prepaid expenses and other current assets, as this certificate of deposit is expected to be released within the first quarterof 2021.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
       </span>
       <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
       </span>
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-509" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
         <p id="xdx_89F_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_zO6EAgjSknQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           Thefollowing table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidatedbalance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flowsfor all periods presented herein (in thousands):
          </span>
         </p>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           <span id="xdx_8B0_z0wBS1tZ5qXh" style="display: none">
            Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
           </span>
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%">
          <tbody>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                December                                         31,
               </b>
              </span>
             </p>
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                2020
               </b>
              </span>
             </p>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                December                                         31,
               </b>
              </span>
             </p>
             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
              <span style="font: 10pt Times New Roman, Times, Serif">
               <b>
                2019
               </b>
              </span>
             </p>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
           </tr>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td>
            </td>
            <td colspan="2">
            </td>
            <td>
            </td>
            <td>
            </td>
            <td colspan="2" style="text-align: center">
            </td>
            <td>
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="width: 60%; text-align: left">
             Cash and cash equivalents
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20201231_zzx4zxIK54yc" style="width: 16%; text-align: right" title="Cash and cash equivalents">
             <span>
              <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-510" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               32,585
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20191231_pn3n3" style="width: 16%; text-align: right" title="Cash and cash equivalents">
             <span>
              <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-511" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               9,497
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="text-align: left">
             Restricted cash included in deposits and other long-term assets (see Note 14)
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_986_eus-gaap--OtherRestrictedAssetsNoncurrent_c20201231_pn3n3" style="text-align: right" title="Restricted cash included in deposits and other long-term assets (see Note 15)">
             <span>
              <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-512" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherRestrictedAssetsNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               520
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98F_eus-gaap--OtherRestrictedAssetsNoncurrent_c20191231_pn3n3" style="text-align: right" title="Restricted cash included in deposits and other long-term assets (see Note 15)">
             <span>
              <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-513" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherRestrictedAssetsNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               599
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="text-align: left; padding-bottom: 1.5pt">
             Restricted cash included in prepaid expenses and other current assets    (see Note 14)
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_98F_ecustom--RestrictedCashIncludedInPrepaidExpensesAndOtherCurrentAssetsSeeNote15_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restricted cash included in prepaid expenses and other current assets (see Note 15)">
             <span>
              <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-514" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RestrictedCashIncludedInPrepaidExpensesAndOtherCurrentAssetsSeeNote15" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               78
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_987_ecustom--RestrictedCashIncludedInPrepaidExpensesAndOtherCurrentAssetsSeeNote15_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restricted cash included in prepaid expenses and other current assets (see Note 15)">
             <span style="-sec-ix-hidden: xdx2ixbrl0861">
              <span>
               <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl0861" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-515" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RestrictedCashIncludedInPrepaidExpensesAndOtherCurrentAssetsSeeNote15" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
                -
               </ix:nonfraction>
              </span>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="text-align: left; padding-bottom: 2.5pt">
             Total cash, cash equivalents, and restricted cash as shown in the condensed    consolidated statements of cash flows
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_98E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows">
             <span>
              <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-516" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               33,183
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_981_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows">
             <span>
              <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-517" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               10,096
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
           </tr>
          </tbody>
         </table>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
         </p>
        </ix:nonnumeric>
       </span>
       <p id="xdx_8A3_zsvgLgaeVMke" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-518" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LesseeLeasesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zxG0oXbJUXv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_866_zRPvdSSsjgt7">
           Leaseaccounting and impact of adoption of the new lease standard
          </span>
         </i>
         – On January 1, 2019, Lineage adopted ASU 2016-02,
         <i>
          Leases
         </i>
         (Topic 842, “ASC 842”) and its subsequent amendments affecting Lineage: (i) ASU 2018-10,
         <i>
          Codification Improvementsto Topic 842, Leases
         </i>
         ; and (ii) ASU 2018-11,
         <i>
          Leases (Topic 842): Targeted improvements,
         </i>
         using the modified retrospectivemethod.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Lineagemanagement determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, withclassification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whethera lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine “major partof remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.”
         <span id="xdx_903_eus-gaap--LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription_c20200101__20201231" title="Lease payment rate, description">
          <span>
           <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-519" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            For lease classification determination, Lineage continues to use: (i) greater than or equal to 75% to determine whether the leaseterm is a major part of the remaining economic life of the underlying asset;
           </ix:nonnumeric>
          </span>
         </span>
         and (ii) greater than or equal to 90% to determinewhether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under theavailable practical expedients, Lineage accounts for the lease and non-lease components as a single lease component. Lineage recognizesright-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensedconsolidated balance sheet.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 80 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             78
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         ROUassets represent Lineage’s right to use an underlying asset during the lease term and lease liabilities represent Lineage’sobligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencementdate based on the present value of lease payments over the lease term. As most of Lineage’s leases do not provide an implicitrate, Lineage uses its incremental borrowing rate based on the information available at commencement date in determining the presentvalue of lease payments. Lineage uses the implicit rate when readily determinable. The operating lease ROU asset also includesany lease payments made and excludes lease incentives. Lineage’s lease terms may include options to extend or terminatethe lease when it is reasonably certain that Lineage will exercise that option. Lease expense for lease payments is recognizedon a straight-line basis over the lease term.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Operatingleases are included as right-of-use assets in property and equipment (see Note 6), and ROU lease liabilities, current and long-term,in the condensed consolidated balance sheets. Financing leases are included in property and equipment, and in financing leaseliabilities, current and long-term, in Lineage’s condensed consolidated balance sheets.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Inconnection with the adoption on ASC 842 on January 1, 2019, Lineage derecognized net book value of leasehold improvements andcorresponding lease liabilities of $
         <span id="xdx_906_eus-gaap--LeaseholdImprovementsGross_iI_pn5n6_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zpnsRCZTFwCf" title="Leasehold improvements, book value">
          <span>
           <ix:nonfraction contextref="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-520" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LeaseholdImprovementsGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            1.9
           </ix:nonfraction>
          </span>
         </span>
         million and $
         <span id="xdx_90B_ecustom--CorrespondingLeaseLiabilities_iI_pn5n6_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_z3iOuO5LCx1c" title="Corresponding lease liabilities">
          <span>
           <ix:nonfraction contextref="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-521" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:CorrespondingLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            2.0
           </ix:nonfraction>
          </span>
         </span>
         million, respectively, which was the carrying value of certain operatingleases as of December 31, 2018, included in property and equipment and lease liabilities, respectively, recorded pursuant to buildto suit lease accounting under the previous ASC 840 lease standard. The derecognition of these amounts from the superseded ASC840 lease standard was offset by a cumulative effect adjustment of $
         <span id="xdx_900_ecustom--LeaseCumulativeEffectAdjustment_iI_pn5n6_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__custom--ASU840Member_zAwdS9jKnGi" title="Lease cumulative effect adjustment">
          <span>
           <ix:nonfraction contextref="AsOf2019-01-02_custom_ASU840Member" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-522" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:LeaseCumulativeEffectAdjustment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            0.1
           </ix:nonfraction>
          </span>
         </span>
         million as a reduction of Lineage’s accumulateddeficit on January 1, 2019. These build to suit leases were primarily related to Lineage’s prior leases in Alameda, Californiaand Cell Cure’s leases in Jerusalem, Israel (See Note 14). ASC 842 requires build to suit leases recognized on Lineage’sconsolidated balance sheets as of December 31, 2018 to be derecognized upon the adoption of the new lease standard and be recognizedin accordance with the new standard on January 1, 2019.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Theadoption of ASC 842 had a material impact in Lineage’s consolidated balance sheets, with the most significant impact resultingfrom the recognition of ROU assets and lease liabilities for operating leases with remaining terms greater than twelve monthson the adoption date. Lineage’s accounting for financing leases (previously referred to as “capital leases”)remained substantially unchanged (see Note 14).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-523" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:GoodwillAndInProcessResearchAndDevelopment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_840_ecustom--GoodwillAndInProcessResearchAndDevelopment_zV6roWK9qYXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span id="xdx_86E_z5VOKOaSew82">
           Goodwilland IPR&amp;D
          </span>
         </i>
         – Goodwill is calculated as the difference between the acquisition date fair value of the considerationtransferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested forimpairment at least annually, or more frequently if circumstances indicate potential impairment.  IPR&amp;D assets are indefinite-livedintangible assets until the completion or abandonment of the associated research and development (“R&amp;D”) efforts.Once the R&amp;D efforts are completed or abandoned, the IPR&amp;D will either be amortized over the asset life as a finite-livedintangible asset or be impaired, respectively, in accordance with ASC 350,
         <i>
          Intangibles – Goodwill and Other
         </i>
         . In accordancewith ASC 350, goodwill and acquired IPR&amp;D are determined to have indefinite lives and, therefore, are not amortized. Instead,they are tested for impairment at least annually and between annual tests if Lineage becomes aware of an event or a change incircumstances that would indicate the asset may be impaired.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-524" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:GoingConcernPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_84F_ecustom--GoingConcernPolicyTextBlock_zTjp6aMckg78" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_865_zpebjyma2NVe">
            Goingconcern assessment
           </span>
          </span>
         </i>
         – Lineage assesses going concern uncertainty for its consolidated financial statements to determineif Lineage has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year fromthe date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forwardperiod” as defined by FASB’s ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonablyknowable to Lineage, Lineage will consider various scenarios, forecasts, projections, and estimates, and Lineage will make certainkey assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtailthose expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, Lineagemakes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures withinthe look-forward period in accordance with ASU No. 2014-15.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 81 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             79
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-525" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zfx6XEZfNYtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_861_z93U3SMsAmw6">
            Cashand cash equivalents
           </span>
          </span>
         </i>
         – Lineage considers all highly liquid investments purchased with an original maturity of threemonths or less to be cash equivalents. As of December 31, 2020 and 2019, Lineage had $
         <span id="xdx_90F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_c20201231_zkxux4q4DjNl" title="Money market funds, cash equivalent">
          <span>
           <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-526" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MoneyMarketFundsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            28.8
           </ix:nonfraction>
          </span>
         </span>
         million and $
         <span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn5n6_c20191231_zwBClTIBVxsg" title="Money market funds, cash equivalent">
          <span>
           <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-527" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MoneyMarketFundsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            6.6
           </ix:nonfraction>
          </span>
         </span>
         million in money marketfunds, respectively, considered to be cash equivalents.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-528" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ConcentrationRiskCreditRisk" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zR7F08PstpG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_862_zn1fHHkiwjm4">
            Concentrationsof credit risk and significant sources of supply
           </span>
          </span>
         </i>
         – Financial instruments that potentially subject Lineage to significantconcentrations of credit risk consist primarily of cash and cash equivalents. Lineage limits the amount of credit exposure ofcash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financialinstitutions may occasionally exceed the limits of insurance on bank deposits; however, Lineage has not experienced any losseson such accounts.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Lineagerelies on single-source, third-party suppliers for a few key components of our product candidates. If these single-source, third-partysuppliers are unable to continue providing a key component, the initiation or progress of any clinical studies of its productcandidates may be impeded.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-529" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zpwwvyQPvhM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86D_zyXJatxZsz48">
            Propertyand equipment, net
           </span>
          </span>
         </i>
         – Property and equipment is stated at cost and is being depreciated using the straight-line methodover their estimated useful lives ranging from
         <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zBkn1z3UVfC3" title="Estimated useful life">
          <span>
           <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MinimumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-530" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            3
           </ix:nonnumeric>
          </span>
         </span>
         to
         <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zIYUVns0sVh7" title="Estimated useful life">
          <span>
           <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MaximumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-531" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            10
           </ix:nonnumeric>
          </span>
         </span>
         years. Leasehold improvements are amortized over the shorter of the usefullife or the lease term. (See Note 6).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-532" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zR4jDrFpUO32" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86D_zFVCisu0jo28">
            Long-livedintangible assets
           </span>
          </span>
         </i>
         – Long-lived intangible assets, consisting primarily of acquired patents, patent applications, andlicenses to use certain patents are stated at acquired cost, less accumulated amortization. Amortization expense is computed usingthe straight-line method over the estimated useful lives of the assets, generally over
         <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z0NffVvj0kRd" title="Intangible asset, useful life">
          <span>
           <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MinimumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-533" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            5
           </ix:nonnumeric>
          </span>
         </span>
         to
         <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zpBmqXJLykJe" title="Intangible asset, useful life">
          <span>
           <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MaximumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-534" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            10
           </ix:nonnumeric>
          </span>
         </span>
         years.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-535" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQ7Jt8oGTgbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_861_zJ5hyKSzwXkd">
            Impairmentof long-lived assets
           </span>
          </span>
         </i>
         – Long-lived assets, including long-lived intangible assets, are reviewed annually for impairmentand whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. Ifan impairment indicator is present, Lineage evaluates recoverability by a comparison of the carrying amount of the assets to futureundiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measuredby the amount by which the carrying amount exceeds the estimated fair value of the assets.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-536" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:AccountingForWarrantsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_843_ecustom--AccountingForWarrantsPolicyTextBlock_zsxo92jI8oMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_862_zE7HVhhHeUab">
            Accountingfor warrants
           </span>
          </span>
         </i>
         – Lineage determines the accounting classification of warrants that it or its subsidiaries issue, as eitherliability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10,
         <i>
          Accountingfor Certain Financial Instruments with Characteristics of both Liabilities and Equity
         </i>
         , and then in accordance with ASC 815-40,
         <i>
          Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock
         </i>
         . UnderASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settlethe warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuingvariable number of shares. If warrants do not meet liability classification under ASC 480-10, Lineage assesses the requirementsunder ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilitiesrecorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature.If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, Lineageassesses whether the warrants are indexed to its common stock or its subsidiary’s common stock, as applicable, and whetherthe warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments are made, Lineageconcludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accountedfor at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair valueafter the issuance date recorded in the consolidated statements of operations as a gain or loss. Equity classified warrants areaccounted for at fair value on the issuance date with no changes in fair value recognized subsequent to the issuance date. In2017, Cell Cure issued certain liability classified warrants (see Note 11) and in 2019, Lineage assumed certain warrantsin connection with the closing of the Asterias Merger (see Note 3).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 82 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             80
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-537" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zzY65McGIppj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_866_zz27nJae3Ps2">
            Transactionswith noncontrolling interests of subsidiaries
           </span>
          </span>
         </i>
         - Lineage accounts for a change in ownership interests in its subsidiaries thatdoes not result in a change of control of the subsidiary by Lineage under the provisions of ASC
         <span style="background-color: white">
          810-10-45-23,
          <i>
           Consolidation
          </i>
          –
          <i>
           Other Presentation Matters,
          </i>
          which prescribes the accounting for changes in ownership interestthat do not result in a change in control of the subsidiary, as defined by GAAP, before and after the transaction
         </span>
         . Underthis guidance, changes in a controlling shareholder’s ownership interest that do not result in a change of control, as definedby GAAP, in the subsidiary are accounted for as equity transactions. Thus, if the controlling shareholder retains control, nogain or loss is recognized in the statements of operations of the controlling shareholder. Similarly, the controlling shareholderwill not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiaryif there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and thenoncontrolling shareholders occurs based on the respective ownership percentages.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-538" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPHoyh8Nwy08" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86D_zMy1NAMpQdBi">
            Researchand development expenses
           </span>
          </span>
         </i>
         - Research and development expenses consist of costs incurred for company-sponsored, collaborativeand contracted research and development activities. These costs include direct and research-related overhead expenses includingcompensation and related benefits, stock-based compensation, consulting fees, research and laboratory fees, rent of research facilities,amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and othertechnology. Research and development are expensed as incurred. Research and development expenses incurred and reimbursed by grantsfrom third parties approximate the grant income recognized in the consolidated statements of operations.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-539" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_842_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMG3CLJktgY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_863_z4H1D5D8eV8e">
            Generaland administrative expenses
           </span>
          </span>
         </i>
         - General and administrative expenses consist of compensation and related benefits, includingstock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead suchas facilities and equipment rent and maintenance, insurance costs allocated to general and administrative expenses, costs of patentapplications, prosecution and maintenance, stock exchange-related costs, depreciation expense, marketing costs, and other miscellaneousexpenses which are allocated to general and administrative expense.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-540" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:ForeignCurrencyTranslationAdjustmentsAndOtherComprehensiveIncomeOrLossPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_844_ecustom--ForeignCurrencyTranslationAdjustmentsAndOtherComprehensiveIncomeOrLossPolicyTextBlock_zzAcnV2MH8v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_866_zYqPY9zsREWh">
            Foreigncurrency translation adjustments and other comprehensive income or loss
           </span>
          </span>
         </i>
         - In countries in which Lineage operates where thefunctional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effectat the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted averageexchange rate for the period. Resulting foreign currency translation adjustments are recorded as other comprehensive income orloss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated othercomprehensive income or loss on the consolidated balance sheets. Foreign currency translation adjustments are primarily attributableto Cell Cure and ESI, Lineage’s consolidated foreign subsidiaries. For the years ended December 31, 2020 and 2019, comprehensiveloss includes foreign currency translation adjustments, net of tax, of $
         <span id="xdx_906_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxAdjustments_pn5n6_c20200101__20201231_z4HucJE1XBwd" title="Foreign currency translation adjustment, net of tax">
          <span>
           <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-541" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxAdjustments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            3.0
           </ix:nonfraction>
          </span>
         </span>
         million and $
         <span id="xdx_903_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxAdjustments_pn5n6_c20190101__20191231_zISKjOfbVt6a" title="Foreign currency translation adjustment, net of tax">
          <span>
           <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-542" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTaxAdjustments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
            2.1
           </ix:nonfraction>
          </span>
         </span>
         million, respectively.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-543" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_843_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zZ7F9rae5mg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86E_zIf2sHslHAuk">
            Foreigncurrency transaction gains and losses
           </span>
          </span>
         </i>
         - For transactions denominated in other than the functional currency of Lineage or itssubsidiaries, Lineage recognizes transaction gains and losses in the consolidated statements of operations and classifies thegain or loss based on the nature of the item that generated it. The majority of Lineage’s foreign currency transaction gainsand losses are generated by Cell Cure’s intercompany debt due to Lineage, which are U.S. dollar-denominated, while CellCure’s functional currency is the Israeli New Shekel (“ILS”). At each balance sheet date, Lineage remeasuresthe intercompany debt using the current exchange rate at that date pursuant to ASC 830,
         <i>
          Foreign Currency Matters.
         </i>
         Theseforeign currency remeasurement gains and losses are included in other income and expenses, net.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-544" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:IncomeTaxPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zNVbq3Qnylek" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86F_zXyyOGkWlQqk">
            Incometaxes
           </span>
          </span>
         </i>
         - Lineage accounts for income taxes in accordance with ASC 740,
         <i>
          Income Taxes
         </i>
         , which prescribe the use of theasset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet dateusing current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assetswhen it is more likely than not that a portion or all of the deferred tax assets will not be realized. ASC 740 guidance also prescribesa recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions takenor expected to be taken in a tax return. For benefits to be recognized, a tax position must be more-likely-than-not sustainableupon examination by taxing authorities. Lineage files a U.S. federal income tax return as well as various state and foreign incometax returns. Lineage’s judgments regarding future taxable income may change over time due to changes in market conditions,changes in tax laws, tax planning strategies or other factors. If Lineage assumptions, and consequently the estimates, changein the future with respect to Lineage’s own deferred tax assets and liabilities, the valuation allowance may be increasedor decreased, which may have a material impact on Lineage’s consolidated financial statements. Lineage recognizes accruedinterest and penalties related to unrecognized tax benefits, if any, as income tax expense; however, no amounts were accruedfor the payment of interest and penalties as of December 31, 2020 and 2019.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 83 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             81
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-545" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ztjdUok6hy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86E_zNyzS2OyLe9l">
            Stock-basedcompensation
           </span>
          </span>
          -
         </i>
         Lineage follows accounting standards governing share-based payments in accordance with ASC 718,
         <i>
          Compensation– Stock Compensation
         </i>
         , which require the measurement and recognition of compensation expense for all share-based paymentawards made to directors and employees, including employee stock options, based on estimated fair values. Lineage utilizes theBlack-Scholes option pricing model for valuing share-based payment awards. Lineage’s determination of fair value of share-basedpayment awards on the date of grant using that option-pricing model is affected by Lineage’s stock price as well as by assumptionsregarding a number of complex and subjective variables. These variables include, but are not limited to, expected stock pricevolatility over the term of the awards, and the expected term of options granted, which is derived using the simplified method,which is an average of the contractual term of the option and its vesting period, as we do not have sufficient historical exercisedata. The risk-free rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury noteswith maturities similar to the expected term of the awards. Forfeitures are accounted for as they occur.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Althoughthe fair value of employee stock options is determined in accordance with FASB guidance, changes in the assumptions can materiallyaffect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-546" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:RoyaltiesFromProductSalesAndLicenseFeesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_84E_ecustom--RoyaltiesFromProductSalesAndLicenseFeesPolicyTextBlock_zZFd3Kvv7Tb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_86F_zQqnNS3YbZrk">
            Royaltiesfrom product sales and license fees
           </span>
          </span>
         </i>
         - Lineage’s performance obligations in agreements with certain customers is to providea license to allow customers to make, import and sell company licensed products or methods for preclinical studies and commercialuse. Customers pay a combination of a license issue fee paid up front and a sales-based royalty, if any, in some cases with yearlyminimums. The transaction price is deemed to be the license issue fee stated in the contract. The license offered by Lineage isa functional license with significant standalone functionality and provides customers with the right to use Lineage’s intellectualproperty. This allows Lineage to recognize revenue on the license issue fee at a point in time at the beginning of the contract,which is when the customer begins to have use of the license. Variable consideration related to sales-based royalties is recognizedonly when (or as) the later of one or more of the following events occur: (a) a sale or usage occurs, or (b) the performance obligationto which some, or all, of the sales-based or usage-based royalty that has been allocated and has been satisfied or partially satisfied.Due to the contract termination clauses, Lineage does not expect to receive all of the minimum royalty payments throughout theterm of the agreements. Therefore, Lineage fully constrains recognition of the minimum royalty payments as revenues until itscustomers are obligated to pay, which is generally within 60 days prior to the beginning of each year the minimum royalty paymentsare due.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-547" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:GrantRevenuesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_843_ecustom--GrantRevenuesPolicyTextBlock_z8s9CvnEb6Ac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_869_zoGIlh9t0TVk">
            Grantrevenues
           </span>
          </span>
          -
         </i>
         In applying the provisions of Topic 606, Lineage has determined that government grants are out of the scope ofTopic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, asthere is not considered to be a transfer of control of good or services to the government entities funding the grant. Lineagehas, and will continue to, account for grants received to perform research and development services in accordance with ASC 730-20,
         <i>
          Research and Development Arrangements
         </i>
         , which requires an assessment, at the inception of the grant, of whether the grantis a liability or a contract to perform research and development services for others. If Lineage or a subsidiary receiving thegrant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities,then Lineage is required to estimate and recognize that liability. Alternatively, if Lineage or a subsidiary receiving the grantis not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful,then the grant agreement is accounted for as a contract to perform research and development services for others, in which case,grant revenue is recognized when the related research and development expenses are incurred.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Deferredgrant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have notyet been incurred as of the balance sheet date reported.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-548" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:RevenueRecognitionBySourceAndGeographyPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_84E_ecustom--RevenueRecognitionBySourceAndGeographyPolicyTextBlock_zr9BYYFppEyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_862_zwZfyWLa2RVl">
            RevenueRecognition by Source and Geography
           </span>
          </span>
         </i>
         - Revenues are recognized when control of the promised goods or services is transferredto customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount thatreflects the consideration Lineage or a subsidiary, depending on which company has the customer or the grant, expects to be entitledto in exchange for those goods or services.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 84 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             82
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
       </span>
       <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
       </span>
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-549" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
         <p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zs0cqpKNJyIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           Thefollowing table presents Lineage’s consolidated revenues disaggregated by source (in thousands).
          </span>
         </p>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
          <span style="font: 10pt Times New Roman, Times, Serif">
           <span id="xdx_8B2_zOaYvNBVaPe7" style="display: none">
            Schedule of Disaggregated Revenues
           </span>
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
          <tbody>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             Year Ended December 31,
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2020
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2019
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="font-weight: bold">
             REVENUES:
            </td>
            <td style="font-weight: bold">
            </td>
            <td colspan="2" style="font-weight: bold; text-align: center">
            </td>
            <td style="font-weight: bold">
            </td>
            <td style="font-weight: bold">
            </td>
            <td colspan="2" style="font-weight: bold; text-align: center">
            </td>
            <td style="font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="width: 60%; text-align: left">
             Grant revenue
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" style="width: 16%; text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_GrantMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-550" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,053
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" style="width: 16%; text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_GrantMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-551" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               2,037
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="text-align: left">
             Royalties from product sales and license fees
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--RoyaltiesFromProductSalesAndLicenseFeesMember_pn3n3" style="text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-552" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               773
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
            <td>
            </td>
            <td style="text-align: left">
            </td>
            <td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--RoyaltiesFromProductSalesAndLicenseFeesMember_pn3n3" style="text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-553" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,221
              </ix:nonfraction>
             </span>
            </td>
            <td style="text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="text-align: left; padding-bottom: 1.5pt">
             Sale of research products and services
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--SaleOfResearchProductsAndServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">
             <span style="-sec-ix-hidden: xdx2ixbrl0939">
              <span>
               <ix:nonfraction contextref="From2020-01-012020-12-31_custom_SaleOfResearchProductsAndServicesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl0939" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-554" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
                -
               </ix:nonfraction>
              </span>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--SaleOfResearchProductsAndServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_SaleOfResearchProductsAndServicesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-555" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               257
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
             Total revenues
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-556" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,826
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-557" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               3,515
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
           </tr>
          </tbody>
         </table>
        </ix:nonnumeric>
       </span>
       <p id="xdx_8AE_zJNFohHfdcKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
       </span>
       <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
       </span>
       <span>
        <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-558" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:ScheduleOfDisaggregateByGeographicalRevenueTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
         <p id="xdx_891_ecustom--ScheduleOfDisaggregateByGeographicalRevenueTableTextBlock_z22HbyR7Vmhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
          <span style="font: 10pt Times New Roman, Times, Serif">
           Thefollowing table presents consolidated revenues, disaggregated by geography, based on the billing addresses of customers, or inthe case of grant revenues, based on where the governmental entities that fund the grant are located (in thousands).
          </span>
         </p>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
          <span>
           <span id="xdx_8BE_zrsRDdktmxe9" style="display: none">
            Schedule of Revenues Disaggregatedby Geography
           </span>
          </span>
          <span style="font: 10pt Times New Roman, Times, Serif">
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
          <tbody>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             Year Ended December 31,
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom">
            <td>
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2020
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
            <td style="font-weight: bold; padding-bottom: 1.5pt">
            </td>
            <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
             2019
            </td>
            <td style="padding-bottom: 1.5pt; font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="font-weight: bold">
             REVENUES:
            </td>
            <td style="font-weight: bold">
            </td>
            <td colspan="2" style="font-weight: bold; text-align: center">
            </td>
            <td style="font-weight: bold">
            </td>
            <td style="font-weight: bold">
            </td>
            <td colspan="2" style="font-weight: bold; text-align: center">
            </td>
            <td style="font-weight: bold">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="width: 60%; text-align: left">
             United States
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zQWQdeBByEJb" style="width: 16%; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_country_US" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-559" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,160
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
            <td style="width: 2%">
            </td>
            <td style="width: 1%; text-align: left">
             $
            </td>
            <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20190101__20191231__srt--StatementGeographicalAxis__country--US_zciFo6W9o3yl" style="width: 16%; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_country_US" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-560" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               2,092
              </ix:nonfraction>
             </span>
            </td>
            <td style="width: 1%; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
            <td style="padding-bottom: 1.5pt">
             <span style="font: 10pt Times New Roman, Times, Serif">
              Foreign
              <sup id="xdx_F4E_zlumUfzeDgmc">
               (1)
              </sup>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_zo74Jw4k7LL7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact000953" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-561" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               666
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 1.5pt">
            </td>
            <td style="border-bottom: Black 1.5pt solid; text-align: left">
            </td>
            <td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20190101__20191231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_zKxXjxprGiwd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact000955" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-562" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,423
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 1.5pt; text-align: left">
            </td>
           </tr>
           <tr style="vertical-align: bottom; background-color: White">
            <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
             Total revenues
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20200101__20201231_zLn5huL5bDKc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-563" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               1,826
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
            <td style="padding-bottom: 2.5pt">
            </td>
            <td style="border-bottom: Black 2.5pt double; text-align: left">
             $
            </td>
            <td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20190101__20191231_zdiWIU9pPsTl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenues">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-564" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
               3,515
              </ix:nonfraction>
             </span>
            </td>
            <td style="padding-bottom: 2.5pt; text-align: left">
            </td>
           </tr>
          </tbody>
         </table>
         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
          <span style="font: 10pt Times New Roman, Times, Serif">
          </span>
         </p>
         <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
          <tbody>
           <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
             <span id="xdx_F09_zWZ58fYuGiUf" style="font: 10pt Times New Roman, Times, Serif">
              (1)
             </span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
             <span id="xdx_F13_zqlCDyubDPCg" style="font: 10pt Times New Roman, Times, Serif">
              <ix:footnote id="Footnote000960" xml:lang="en-US">
               Foreign    revenues are primarily generated from grants in Israel.
              </ix:footnote>
             </span>
            </td>
           </tr>
          </tbody>
         </table>
        </ix:nonnumeric>
       </span>
       <p id="xdx_8AF_zA8IcRwGtUPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-565" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zpd7YjpvTY5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          <span>
           <span id="xdx_868_z6COUZEUa1e5">
            RecentlyAdopted Accounting Pronouncements
           </span>
          </span>
         </i>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         InAugust 2018, the FASB issued ASU 2018-13,
         <i>
          Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the DisclosureRequirements for Fair Value Measurement
         </i>
         , which modifies certain disclosure requirements for reporting fair value measurements.ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Lineageadopted this standard on January 1, 2020 and it did not have a significant impact on our consolidated financial statements.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
         </i>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <i>
          RecentlyIssued Accounting Pronouncements Not Yet Adopted
         </i>
         - The following accounting standards, which are not yet effective, are presentlybeing evaluated by Lineage to determine the impact that they might have on its consolidated financial statements.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         InDecember 2019, the FASB issued ASU 2019-12,
         <i>
          Simplifying the Accounting for Income Taxes
         </i>
         . The ASU enhances and simplifiesvarious aspects of the income tax accounting guidance in ASC 740 and removes certain exceptions for recognizing deferred taxesfor investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidanceto reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members ofa consolidated group. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within thosefiscal years with early adoption permitted. Lineage adopted this standard as of January 1, 2021 and it is not expected to havea material impact on the consolidated financial statements.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         InJune 2016, the FASB issued ASU 2016-13,
         <i>
          Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losseson Financial Instruments
         </i>
         . ASU 2016-13 is intended to provide financial statement users with more decision-useful informationabout the expected credit losses on financial instruments and other commitments and requires consideration of a broader rangeof reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for Lineage beginning January1, 2023. Lineage has not yet completed its assessment of the impact of the new standard on its consolidated financial statements.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
      </ix:nonnumeric>
     </span>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-566" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:BusinessCombinationDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zT5kCzkxTNmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        3.
        <span id="xdx_825_zQKtmyucC0k">
         Asterias Merger
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMarch 8, 2019, the Asterias Merger closed with Asterias surviving as a wholly owned subsidiary of Lineage. The former stockholdersof Asterias (other than Lineage) received
       <span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__dei--LegalEntityAxis__custom--AsteriasMember_zRvPUNwmajKi" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-567" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          0.71
         </ix:nonfraction>
        </span>
       </span>
       common shares of Lineage (the “Merger Consideration”) for every shareof Asterias common stock they owned (the “Merger Exchange Ratio”). Lineage issued
       <span id="xdx_90C_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zeOjyBEePzl6" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-568" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          24,695,898
         </ix:nonfraction>
        </span>
       </span>
       common shares, including
       <span id="xdx_909_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__dei--LegalEntityAxis__custom--AsteriasMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr5P3PPbh728" title="Stock-for-stock transaction">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_MergerConsiderationMember_custom_AsteriasMember_us-gaap_RestrictedStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-569" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          58,085
         </ix:nonfraction>
        </span>
       </span>
       shares issued in respect of restricted stock units issued by Asterias that immediately vested in connection with the closingof the Asterias Merger. The fair value of such shares, based on the closing price of Lineage common shares on March 8, 2019, was$
       <span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn5n6_c20190308__us-gaap--BusinessAcquisitionAxis__custom--MergerConsiderationMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zK1R0n78rDj1" title="Closing price of common stock">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-08_custom_MergerConsiderationMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-570" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          32.4
         </ix:nonfraction>
        </span>
       </span>
       million.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 85 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           83
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the closing of the Asterias Merger, Lineage assumed outstanding warrants to purchase shares of Asterias commonstock, as further discussed below and in Note 11, and assumed sponsorship of the Asterias 2013 Equity Incentive Plan (seeNote 12). All stock options to purchase shares of Asterias common stock outstanding immediately prior to the closing ofthe Asterias Merger were canceled at the closing for no consideration.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2019, the assets and liabilities of Asterias have been included in the consolidated balance sheet of Lineage.The results of operations of Asterias from March 8, 2019 through December 31, 2019 have been included in the consolidated statementof operations of Lineage for the year ended December 31, 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Calculationof the purchase price
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-571" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_899_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zcxsAllCELx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thecalculation of the purchase price for the Asterias Merger and the Merger Consideration transferred on March 8, 2019 was as follows(in thousands, except for share and per share amounts):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B6_zZsfpEPoSZNc" style="display: none">
          Schedule of Merger Consideration Transferred
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Lineage
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (38%
              <br/>
              ownership
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              interest)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Shareholders
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              other                                         than
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Lineage
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (approximate
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              62%                                         ownership
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              interest)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Total
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 46%">
           Outstanding Asterias common stock as of March 8, 2019
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--SharesOutstanding_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" style="width: 14%; text-align: right" title="Outstanding Asterias common stock">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-572" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             21,747,569
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--SharesOutstanding_iI_pii_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_fKDEp_zz63LO8sbDql" style="width: 14%; text-align: right" title="Outstanding Asterias common stock">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember" continued-taxonomy="false" data-original-id="Fact000978" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-573" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             34,783,333
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           <sup id="xdx_F22_zOsSMhz06ad6">
            (1)
           </sup>
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--SharesOutstanding_iI_pii_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_fKDEp_zybhzuyfhlf3" style="width: 14%; text-align: right" title="Outstanding Asterias common stock">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="Fact000980" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-574" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             56,530,902
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           <sup id="xdx_F23_z5pmDajfX5Cg">
            (1)
           </sup>
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Exchange ratio
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_ecustom--BusinessAcquisitionExchangeRatio_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange ratio">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-575" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessAcquisitionExchangeRatio" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             0.710
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_983_ecustom--BusinessAcquisitionExchangeRatio_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange ratio">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-576" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessAcquisitionExchangeRatio" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             0.710
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_984_ecustom--BusinessAcquisitionExchangeRatio_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange ratio">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-577" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessAcquisitionExchangeRatio" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             0.710
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Lineage common shares issuable
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_fKDIp_zzHGsQP8M772" style="text-align: right" title="Lineage common shares issuable">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" data-original-id="Fact000988" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-578" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             15,440,774
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           <sup id="xdx_F25_zIaIL7ZakTk6">
            (2)
           </sup>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_fKDMp_zFribaAtEaz5" style="text-align: right" title="Lineage common shares issuable">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember" continued-taxonomy="false" data-original-id="Fact000990" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-579" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             24,695,898
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           <sup id="xdx_F28_zCtFr8hrZHG2">
            (3)
           </sup>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_pii" style="text-align: right" title="Lineage common shares issuable">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-580" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             40,136,672
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-bottom: 1.5pt">
           Per share price of Lineage common shares as of March 8, 2019
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--SharesIssuedPricePerShare_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Per share price of Lineage common shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-581" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesIssuedPricePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.31
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
           $
          </td>
          <td id="xdx_984_eus-gaap--SharesIssuedPricePerShare_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Per share price of Lineage common shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-582" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesIssuedPricePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.31
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
           $
          </td>
          <td id="xdx_98A_eus-gaap--SharesIssuedPricePerShare_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Per share price of Lineage common shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-583" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesIssuedPricePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.31
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 2.5pt">
           Purchase price (in $000s)
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_989_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_fKDIp_z2ZXoYrdp7pg" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchase price">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" data-original-id="Fact001000" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-584" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationConsiderationTransferred1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             20,227
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
           <sup id="xdx_F20_z221jOlPazxd">
            (2)
           </sup>
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--BusinessCombinationConsiderationTransferred1_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--MajorityShareholderMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchase price">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_MajorityShareholderMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-585" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationConsiderationTransferred1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             32,353
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_989_eus-gaap--BusinessCombinationConsiderationTransferred1_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchase price">
           <span>
            <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-586" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationConsiderationTransferred1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             52,580
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.9pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <sup id="xdx_F02_z02rxpHAxeL9">
             (1)
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F1A_zt5uD4J2CJmf" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001005" xml:lang="en-US">
             Includes
             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1lcmdlciBDb25zaWRlcmF0aW9uIFRyYW5zZmVycmVkIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pii_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zk34KSjbJ6u4" title="Number of restricted stock vested">
              <span>
               <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_us-gaap_RestrictedStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-587" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                81,810
               </ix:nonfraction>
              </span>
             </span>
             shares of Asterias restricted stock unit awards that immediately vested on March 8, 2019 and converted into the right    to receive common shares of Lineage based on the Merger Exchange Ratio, resulting in
             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1lcmdlciBDb25zaWRlcmF0aW9uIFRyYW5zZmVycmVkIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190306__20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" title="Number of shares issued">
              <span>
               <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-588" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                58,085
               </ix:nonfraction>
              </span>
             </span>
             common shares of Lineage issued    on March 8, 2019 as part of the Merger Consideration. These restricted stock units were principally attributable to pre-combination    services and included as part of the purchase price in accordance with ASC 805. See Note 12 for Asterias restricted stock    units that vested on the closing of the Asterias Merger attributable to post-combination services that were recorded outside    of the purchase price as an immediate charge to stock-based compensation expense.
            </ix:footnote>
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
          <td style="font: 10pt Times New Roman, Times, Serif">
           <span style="font: 10pt Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
          <td style="font: 10pt Times New Roman, Times, Serif">
           <span id="xdx_F0E_zPX7TK68Liad" style="font: 10pt Times New Roman, Times, Serif">
            <sup>
             (2)
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F15_zAgUokEG51R3" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001010" xml:lang="en-US">
             Estimated    fair value for Lineage’s previously held 38% ownership interest in Asterias common stock is part of the total purchase    price of Asterias for purposes of the purchase price allocation under ASC 805 and for Lineage’s adjustment of its
             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1lcmdlciBDb25zaWRlcmF0aW9uIFRyYW5zZmVycmVkIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20190308__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" title="Ownership interest">
              <span>
               <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasBiotherapeuticsIncMember_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-589" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
                38
               </ix:nonfraction>
              </span>
              %
             </span>
             interest to fair value at the effective date of the Asterias Merger and immediately preceding the consolidation of Asterias’    results with Lineage. No actual common shares of Lineage were issued to Lineage in connection with the Asterias Merger.
            </ix:footnote>
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
          <td style="font: 10pt Times New Roman, Times, Serif">
           <span style="font: 10pt Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
          <td style="font: 10pt Times New Roman, Times, Serif">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <sup id="xdx_F02_z4G5h2liRiUe">
             (3)
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F17_zwJWXO0fEt96" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001013" xml:lang="en-US">
             Net    of a
             <i>
              de minimis
             </i>
             number of fractional shares which were paid in cash.
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A2_zUyIkzEQLlxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Purchaseprice allocation
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageallocated the acquisition consideration to tangible and identifiable intangible assets acquired and liabilities assumed basedon their estimated fair values as of the acquisition date. The fair value of the acquired tangible and identifiable intangibleassets were determined based on inputs that are unobservable and significant to the overall fair value measurement. It is alsobased on estimates and assumptions made by management at the time of the acquisition. As such, this was classified as Level 3fair value hierarchy measurements and disclosures.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 86 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           84
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-590" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_898_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_z2e43sAg7S33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Theallocation of the purchase price in the table below is based on our estimates of the fair values of tangible and intangible assetsacquired, including IPR&amp;D, and liabilities assumed as of the acquisition date, with the excess recorded as goodwill (in thousands).As of December 31, 2019, Lineage had finalized its purchase price allocation.
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B1_zvskbkX54XN6" style="display: none">
          Schedule of Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
        <tbody>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; text-align: left">
           Assets acquired:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="width: 80%; text-align: left">
           Cash and cash equivalents
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="width: 16%; text-align: right" title="Cash and cash equivalents">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-591" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,117
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Prepaid expenses and other assets, current and noncurrent
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssetsCurrentAndNoncurrent_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="text-align: right" title="Prepaid expenses and other assets, current and noncurrent">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-592" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssetsCurrentAndNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             660
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Machinery and equipment
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="text-align: right" title="Machinery and equipment">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-593" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             308
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Long-lived intangible assets - royalty contracts
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLonglivedIntangibleAssetsRoyaltyContracts_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="text-align: right" title="Long-lived intangible assets - royalty contracts">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-594" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLonglivedIntangibleAssetsRoyaltyContracts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             650
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Acquired in-process research and development (“IPR&amp;D”)
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title='Acquired in-process research and development ("IPR&amp;D")'>
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-595" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             46,540
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Total assets acquired
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets acquired">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-596" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             51,275
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
        <tbody>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; text-align: left">
           Liabilities assumed:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="width: 80%; text-align: left">
           Accrued liabilities and accounts payable
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="width: 16%; text-align: right" title="Accrued liabilities and accounts payable">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-597" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             982
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Liability classified warrants
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilityClassifiedWarrants_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="text-align: right" title="Liability classified warrants">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-598" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilityClassifiedWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             867
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Deferred license revenue
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="text-align: right" title="Deferred license revenue">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-599" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             200
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Long-term deferred income tax liability
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term deferred income tax liability">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-600" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             10,753
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
           Total liabilities assumed
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total liabilities assumed">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-601" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             12,802
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Net assets acquired, excluding goodwill (a)
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net assets acquired, excluding goodwill (a)">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-602" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             38,473
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Fair value of Lineage common shares held by Asterias (b)
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of Lineage common shares held by Asterias (b)">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-603" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,435
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
           Total purchase price (c)
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total purchase price (c)">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-604" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationConsiderationTransferred1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             52,580
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Estimated goodwill (c-a-b)
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--Goodwill_c20191231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated goodwill (c-a-b)">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-605" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Goodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             10,672
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A3_zxDjEVVKNy54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-606" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:ScheduleOfValuationOfIdentifiableIntangibleAssetsAndTheirEstimatedUsefulLivesTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89B_ecustom--ScheduleOfValuationOfIdentifiableIntangibleAssetsAndTheirEstimatedUsefulLivesTableTextBlock_zmvDmuBOyU97" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thevaluation of identifiable intangible assets and their estimated useful lives are as follows (in thousands, except for useful life):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span id="xdx_8B2_zdWw3TGcjKf4" style="display: none">
         Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives
        </span>
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Preliminary Estimated Asset    Fair Value
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Useful                                         Life
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Years)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold">
          </td>
          <td colspan="6" style="font-weight: bold; text-align: center">
           (in thousands, except for useful life)
          </td>
          <td style="font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           In process research and development (“IPR&amp;D”)
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Preliminary Estimated Asset Fair Value">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_us-gaap_InProcessResearchAndDevelopmentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-607" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             46,540
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 16%; text-align: right">
           <span style="font: 10pt Times New Roman, Times, Serif">
            n/a
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Royalty contracts
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RoyaltyContractsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Preliminary Estimated Asset Fair Value">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_RoyaltyContractsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-608" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             650
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: right" title="Useful Life (Years)">
           <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RoyaltyContractsMember_zdFod048k9yg" title="Useful Life (Years)">
            <span>
             <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_RoyaltyContractsMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-609" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              5
             </ix:nonnumeric>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Preliminary Estimated Asset Fair Value">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139169281" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-610" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             47,190
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A8_zrBE0s1diyt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thefollowing is a discussion of the valuation methods used to determine the fair value of Asterias’ significant assets andliabilities in connection with the Asterias Merger:
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        IPR&amp;Dand Deferred Income Tax Liability
       </i>
       - The fair value of identifiable acquired IPR&amp;D intangible assets consisting of $
       <span id="xdx_90E_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn5n6_c20190306__20190308__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zJoGlvlYkLpf" title="Identifiable intangible asset acquired">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_us-gaap_InProcessResearchAndDevelopmentMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-611" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          31.7
         </ix:nonfraction>
        </span>
       </span>
       million pertaining to the OPC1 program that is currently in a Phase 1/2a clinical trial for SCI, which has been partially fundedby the California Institute for Regenerative Medicine and $
       <span id="xdx_905_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190306__20190308__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_pn5n6" title="Identifiable intangible asset acquired">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_CaliforniaInstituteForRegenerativeMedicineMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-612" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          14.8
         </ix:nonfraction>
        </span>
       </span>
       million pertaining to the VAC2 program, which is an allogeneic,or “off-the-shelf,” cancer immunotherapy derived from pluripotent stem cells for which a clinical trial in non-smallcell lung cancer is being funded and sponsored by Cancer Research UK. The identification of these intangible assets are basedon consideration of historical experience and a market participant’s view further discussed below; collectively, OPC1 andVAC2 are referred to as the “AST-Clinical Programs”. These intangible assets are valued primarily through the useof a probability weighted discounted cash flow method under the income approach further discussed below. Lineage considered Asterias’VAC1 program, which is an autologous, or patient-specific, cancer immunotherapy derived from the patient’s own cells, tohave de minimis value due to significant risks, substantial costs and limited opportunities.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 87 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           85
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagedetermined that the estimated aggregate fair value of the AST-Clinical programs was $
       <span id="xdx_90E_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190306__20190308__us-gaap--TypeOfArrangementAxis__custom--AStClinincalProgramMember_pn5n6" title="Identifiable intangible asset acquired">
        <span>
         <ix:nonfraction contextref="From2019-03-062019-03-08_custom_AStClinincalProgramMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-613" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          46.5
         </ix:nonfraction>
        </span>
       </span>
       million as of the acquisition date usinga probability weighted discounted cash flow method for each respective program. This approach estimates the probability of theAST-Clinical Programs achieving successful completion of remaining clinical trials and related approvals into the valuation technique.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Tocalculate fair value of the AST-Clinical programs under the discounted cash flow method, Lineage used probability-weighted, projectedcash flows discounted at a rate considered appropriate given the significant inherent risks associated with cell therapy developmentby clinical-stage companies. Cash flows were calculated based on estimated projections of revenues and expenses related to eachrespective program. Cash flows were assumed to extend through a seven-year market exclusivity period for the OPC1 program fromthe date of market launch. Revenues from commercialization of the AST-Clinical Programs were based on estimated market potentialfor the indication of each program. The resultant cash flows were then discounted to present value using a weighted-average costof capital for companies with profiles substantially similar to that of Lineage, which Lineage believes represents the rate thatmarket participants would use to value the assets. Lineage compensated for the phase of development of the program by applyinga probability factor to its estimation of the expected future cash flows. The projected cash flows were based on significant assumptions,including the indications in which Lineage will pursue development of the AST-Clinical programs, the time and resources neededto complete the development and regulatory approval, estimates of revenue and operating profit related to the program consideringits stage of development, the life of the potential commercialized product, market penetration and competition, and risks associatedwith achieving commercialization, including delay or failure to obtain regulatory approvals to conduct clinical studies, failureof clinical studies, delay or failure to obtain required market clearances, and intellectual property litigation.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheseIPR&amp;D assets are indefinite-lived intangible assets until the completion or abandonment of the associated research and development(“R&amp;D”) efforts. Once the R&amp;D efforts are completed or abandoned, the IPR&amp;D will either be amortized overthe asset life as a finite-lived intangible asset or be impaired, respectively, in accordance with ASC 350,
       <i>
        Intangibles - Goodwilland Other
       </i>
       . In accordance with ASC 350, goodwill and acquired IPR&amp;D are determined to have indefinite lives and, therefore,are not amortized. Instead, they are tested for impairment at least annually and between annual tests if Lineage becomes awareof an event or a change in circumstances that would indicate the asset may be impaired.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Becausethe IPR&amp;D (prior to completion or abandonment of the R&amp;D) is considered an indefinite-lived asset for accounting purposes,the fair value of the IPR&amp;D on the acquisition date creates a deferred income tax liability (“DTL”) in accordancewith ASC 740,
       <i>
        Income Taxes
       </i>
       (see Note 13). This DTL is computed using the fair value of the IPR&amp;D assets on theacquisition date multiplied by Lineage’s federal and state income tax rates. While this DTL would reverse on impairmentor sale or commencement of amortization of the related intangible assets, those events are not anticipated under ASC 740 for purposesof predicting reversal of a temporary difference to support the realization of deferred tax assets, except for certain deferredtax assets and credit carryforwards that are also indefinite in nature as of the closing of the Asterias Merger, which may beconsidered for reversal under ASC 740 as further discussed in Note 13.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Royaltycontracts
       </i>
       – Asterias has certain royalty revenues for “research only use” culture media for preclinicalresearch applications under certain, specific patent families under contracts which preclude the customers to sell for commercialuse or for clinical trials. These royalty cash flows are generated under certain specific patent families which Asterias previouslyacquired from Geron Corporation (“Geron”). Asterias pays Geron a royalty for all royalty revenues received from thesecontracts. Because these patents are a subset of the clinical programs discussed above, are expected to continue to generate revenuesfor Asterias and are not to be used in the OPC1 or the VAC2 programs, these patents are considered to be separate long-lived intangibleassets under ASC 805. These intangible assets are also valued primarily through the use of the discounted cash flow method underthe income approach, and will be amortized over their useful life, estimated to be
       <span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--RoyaltyContractsMember_zGndBDIFh1d4" title="Intangible assets, estimated useful life">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_RoyaltyContractsMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-614" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          5
         </ix:nonnumeric>
        </span>
       </span>
       years. The discounted cash flow method estimatedthe amount of net royalty income that can be expected under the contracts in future years. The amounts were based on observedhistorical trends in the growth of these revenue streams, and were estimated to terminate in approximately five years, when thekey patents under these contracts will begin to expire. The resulting cash flows were discounted to the valuation date based ona rate of return that recognizes a lower level of risk associated with these assets as compared to the AST-Clinical programs discussedabove.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 88 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           86
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Deferredlicense revenue –
       </i>
       In September 2018, Asterias and Novo Nordisk A/S (“Novo Nordisk”) entered into an optionfor Novo Nordisk or its designated U.S. affiliate to license, on a non-exclusive basis, certain intellectual property relatedto culturing pluripotent stem cells, such as hES cells, in suspension. Under the terms of the option, Asterias received a one-timeupfront payment of $
       <span id="xdx_90C_ecustom--UpfrontPaymentReceived_c20180901__20180930__dei--LegalEntityAxis__custom--AsteriasMember_pn5n6" title="Upfront payment received">
        <span>
         <ix:nonfraction contextref="From2018-09-012018-09-30_custom_AsteriasMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-615" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UpfrontPaymentReceived" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.0
         </ix:nonfraction>
        </span>
       </span>
       million, in exchange for a 24-month period option to negotiate a non-exclusive license during which timeAsterias has agreed to not grant any exclusive licenses inconsistent with the Novo Nordisk option. This option is considered aperformance obligation as it provides Novo Nordisk with a material right that it would not receive without entering into the contract.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forbusiness combination purposes under ASC 805, the fair value of this performance obligation to Lineage, from a market participantperspective, is the estimated costs Lineage may incur, plus a normal profit margin for the level of effort required to performunder the contract after the acquisition date, assuming Novo Nordisk exercised its option, including, but not limited to, negotiationcosts, legal fees, arbitration, if any, and other related costs. Management has estimated those costs, plus a normal profit margin,to be approximately $
       <span id="xdx_90C_eus-gaap--BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionNetEffectOnIncome_pp0p0_c20180901__20180930__dei--LegalEntityAxis__custom--AsteriasMember_zmNjRzqa6OTj" title="Estimated purchase price">
        <span>
         <ix:nonfraction contextref="From2018-09-012018-09-30_custom_AsteriasMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-616" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionNetEffectOnIncome" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          200,000
         </ix:nonfraction>
        </span>
       </span>
       in the purchase price allocation. This amount was originally recorded as deferred revenue and subsequentlyrecognized as revenue in September 2020 when Novo Nordisk did not exercise the option.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Liabilityclassified warrants –
       </i>
       On May 13, 2016, in connection with a common stock offering, Asterias issued warrants to purchase
       <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20160513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrants issued to purchase of common stock">
        <span>
         <ix:nonfraction contextref="AsOf2016-05-13_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-617" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,959,559
         </ix:nonfraction>
        </span>
       </span>
       shares of Asterias common stock (the “Asterias Warrants”) with an exercise price of $
       <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20160513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Exercise price">
        <span>
         <ix:nonfraction contextref="AsOf2016-05-13_us-gaap_CommonStockMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-618" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          4.37
         </ix:nonfraction>
        </span>
       </span>
       per share thatexpire in
       <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20160513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb3PBdf0ujHg" title="Warrant term::XDX::P5Y">
        <span style="-sec-ix-hidden: xdx2ixbrl1073">
         <span>
          <ix:nonnumeric contextref="AsOf2016-05-13_us-gaap_CommonStockMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1073" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-619" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:WarrantsAndRightsOutstandingTerm" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           five
          </ix:nonnumeric>
         </span>
        </span>
       </span>
       years from the issuance date, or
       <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20160513__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaiZQENn6ao8" title="Warrant expiration date">
        <span>
         <ix:nonnumeric contextref="AsOf2016-05-13_us-gaap_CommonStockMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-620" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          May 13, 2021
         </ix:nonnumeric>
        </span>
       </span>
       . As of the closing of the Asterias Merger, there were
       <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20160513__us-gaap--StatementEquityComponentsAxis__custom--AsteriasWarrantsMember_pii" title="Number of warrants issued to purchase of common stock">
        <span>
         <ix:nonfraction contextref="AsOf2016-05-13_custom_AsteriasWarrantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-621" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,813,159
         </ix:nonfraction>
        </span>
       </span>
       AsteriasWarrants outstanding. The Asterias Warrants contain certain provisions in the event of a Fundamental Transaction, as defined inthe warrant agreement governing the Asterias Warrants (“Warrant Agreement”), that Asterias or any successor entitywill be required to purchase, at a holder’s option, exercisable at any time concurrently with or within thirty days afterthe consummation of the fundamental transaction, the Asterias Warrants for cash in an amount equal to the calculated value ofthe unexercised portion of such holder’s warrants, determined in accordance with the Black-Scholes option pricing modelwith significant inputs as specified in the Warrant Agreement. The Asterias Merger was a Fundamental Transaction for purposesof the Asterias Warrants.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thefair value of the Asterias Warrants was determined by using Black-Scholes option pricing models which take into considerationthe probability of the Fundamental Transaction, which for purposes of the above valuation was assumed to be at
       <span id="xdx_90D_ecustom--FairValueOfWarrantsPercentage_c20201231_pii" title="Fair value of warrants percentage">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-622" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FairValueOfWarrantsPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          100
         </ix:nonfraction>
        </span>
        %
       </span>
       and net cashsettlement occurring, using the contractual remaining term of the warrants. In applying these models, these inputs included keyassumptions including the per share closing price of Lineage common shares on March 8, 2019, volatility computed in accordancewith the provisions of the Warrant Agreement and, to a large extent, assumptions based on discussions with a majority of the holdersof the Asterias Warrants since the closing of the Asterias Merger to settle the Asterias Warrants in cash or in common sharesof Lineage. Based on such discussions, Lineage believes the fair value of the Asterias Warrants as of the closing of the AsteriasMerger is not subject to change significantly, however, to the extent any Asterias Warrants that were not settled in cash or inLineage common shares discussed below, were automatically converted to Lineage warrants 30 days after the closing of the AsteriasMerger. In April 2019, Asterias Warrants representing approximately $
       <span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20190401__20190430_zeCVQ0D7BHed" title="Fair Value Adjustment of Warrants">
        <span>
         <ix:nonfraction contextref="From2019-04-012019-04-30" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-623" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FairValueAdjustmentOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          372,000
         </ix:nonfraction>
        </span>
       </span>
       in fair value were settled: $
       <span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20190401__20190430__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zzDeO65QvxAf" title="Fair Value Adjustment of Warrants">
        <span>
         <ix:nonfraction contextref="From2019-04-012019-04-30_srt_ParentCompanyMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-624" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FairValueAdjustmentOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          332,000
         </ix:nonfraction>
        </span>
       </span>
       in fair valuewas settled in exchange for
       <span id="xdx_90A_ecustom--ExchangeOfShares_c20190430__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pii" title="Exchange of shares">
        <span>
         <ix:nonfraction contextref="AsOf2019-04-30_srt_ParentCompanyMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-625" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ExchangeOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          251,835
         </ix:nonfraction>
        </span>
       </span>
       common shares of Lineage, and $
       <span id="xdx_907_ecustom--ExchangeForCash_iI_pp0p0_c20190430__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zHolLpZOZ9jd" title="Exchange for cash">
        <span>
         <ix:nonfraction contextref="AsOf2019-04-30_srt_ParentCompanyMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-626" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ExchangeForCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          40,000
         </ix:nonfraction>
        </span>
       </span>
       in fair value was settled in exchange for cash. TheAsterias Warrants settled in exchange for common shares of Lineage were held by Broadwood Partners, L.P., an Asterias and Lineageshareholder. The Asterias Warrants settled in exchange for cash were held by other parties. The remaining Asterias Warrants (representingapproximately $
       <span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20190330__20190331__us-gaap--StatementEquityComponentsAxis__custom--LineageWarrantsMember_zd0RJBpVW76" title="Fair Value Adjustment of Warrants">
        <span title="Fair Value Adjustment of Warrants">
         <span>
          <ix:nonfraction contextref="From2019-03-302019-03-31_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-627" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FairValueAdjustmentOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
           495,000
          </ix:nonfraction>
         </span>
        </span>
       </span>
       in fair value as of March 31, 2019) were converted into warrants to purchase common shares of Lineage usingthe Merger Exchange Ratio (the “Lineage Warrants”).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, the total number of common shares of Lineage subject to warrants that were assumed by Lineage in connectionwith the Asterias Merger was
       <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--StatementEquityComponentsAxis__custom--LineageWarrantsMember_pii" title="Number of warrants issued to purchase of common stock">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-628" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          1,089,900
         </ix:nonfraction>
        </span>
       </span>
       , with similar terms and conditions retained under the Lineage Warrants as per the originalWarrant Agreements. The Lineage Warrants have an exercise price of $
       <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--StatementEquityComponentsAxis__custom--LineageWarrantsMember_pii" title="Exercise price">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-629" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          6.15
         </ix:nonfraction>
        </span>
       </span>
       per warrant share and expire on
       <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201231__us-gaap--StatementEquityComponentsAxis__custom--LineageWarrantsMember_zXwtUZWEiTRh" title="Warrant expiration date">
        <span>
         <ix:nonnumeric contextref="AsOf2020-12-31_custom_LineageWarrantsMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-630" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          May 13, 2021
         </ix:nonnumeric>
        </span>
       </span>
       . Lineageis accounting for the outstanding Lineage Warrants as a liability at fair value, with subsequent changes to the fair value ofthe Lineage Warrants at each reporting period thereafter included in the consolidated statement of operations (see Note 11).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 89 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           87
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Fairvalue of Lineage common shares held by Asterias
       </i>
       – As of March 8, 2019, Asterias held
       <span id="xdx_90E_ecustom--CommonStockHeldInInvestment_c20190308_pii" title="Common stock held in investment">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-08" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-631" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:CommonStockHeldInInvestment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,621,811
         </ix:nonfraction>
        </span>
       </span>
       common shares of Lineageas marketable securities on its standalone financial statements. The fair value of those shares acquired by Lineage from Asteriasis determined based on the $
       <span id="xdx_90C_eus-gaap--SharePrice_c20190308_pii" title="Share price, per share">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-08" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-632" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          1.31
         </ix:nonfraction>
        </span>
       </span>
       per share closing price of Lineage common shares on March 8, 2019. Although treasury shares arenot considered an asset and were retired upon Lineage’s acquisition of Asterias, the fair value of those shares is a partof the purchase price allocation shown in the tables above. These Lineage shares were retired at the completion of the AsteriasMerger.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Goodwill–
       </i>
       Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferredand the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairmentat least annually, or more frequently if circumstances indicate potential impairment.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Dependingon the structure of a particular acquisition, goodwill and identifiable intangible assets may not be deductible for tax purposes.Goodwill recorded in the Asterias Merger is not expected to be deductible for tax purposes (see Note 13).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe years ended December 31, 2020 and 2019, Lineage incurred $
       <span id="xdx_908_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn5n6" title="Acquisition related costs">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-633" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.7
         </ix:nonfraction>
        </span>
       </span>
       million and $
       <span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn5n6" title="Acquisition related costs">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-634" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          5.1
         </ix:nonfraction>
        </span>
       </span>
       million, respectively, in acquisition relatedcosts which were recorded in general and administrative expenses in the accompanying consolidated statements of operations.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Priorto the Asterias Merger being consummated in March 2019, Lineage elected to account for its
       <span id="xdx_903_ecustom--FairValueOfEquityMethodInvestmentShares_iI_pin6_c20190331_zPsdT8saAwi3" title="Fair value of equity method investment, shares">
        <span>
         <ix:nonfraction contextref="AsOf2019-03-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-635" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FairValueOfEquityMethodInvestmentShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          21.7
         </ix:nonfraction>
        </span>
       </span>
       million shares of Asterias commonstock at fair value using the equity method of accounting.
       <span id="xdx_900_ecustom--FairValueCalculationDescription_c20190306__20190308" title="Fair value calculation, description">
        <span>
         <ix:nonnumeric contextref="From2019-03-062019-03-08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-636" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:FairValueCalculationDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          The fair value of the Asterias shares was approximately $20.2 millionas of March 8, 2019, the closing date of the Asterias Merger, based on $0.93 per share, which was calculated by multiplying (a)$1.31, the closing price of Lineage common shares on such date by (b) the Merger Exchange Ratio.
         </ix:nonnumeric>
        </span>
       </span>
       The fair value of the Asteriasshares was approximately $
       <span id="xdx_909_eus-gaap--EquityMethodInvestmentAggregateCost_c20181231_pn5n6" title="Fair value of equity method investment, value">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-637" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentAggregateCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          13.5
         </ix:nonfraction>
        </span>
       </span>
       million as of December 31, 2018, based on the closing price of Asterias common stock of $
       <span id="xdx_90B_eus-gaap--SharePrice_c20181231_pii" title="Share price, per share">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-638" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          0.62
         </ix:nonfraction>
        </span>
       </span>
       pershare on such date. Accordingly, Lineage recorded an unrealized gain of $
       <span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AsteriasBiotherapeuticsMember_pn5n6" title="Unrealized loss">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_AsteriasBiotherapeuticsMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-639" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrealizedGainLossOnInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          6.7
         </ix:nonfraction>
        </span>
       </span>
       million for the year ended December 31, 2019, representingthe change in fair value of Asterias common stock from December 31, 2018 to March 8, 2019. All share prices were determined basedon the closing price of Lineage or Asterias common stock on the NYSE American on the applicable dates.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        AsteriasMerger Related Litigation –
       </i>
       See Note 14 Commitments and Contingencies for discussion regarding litigation relatedto the Asterias Merger.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-640" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:AccountingForCommonStockOfOncoCyteAtFairValueTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80D_ecustom--AccountingForCommonStockOfOncoCyteAtFairValueTextBlock_zpKw4RAp6PSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        4.
        <span id="xdx_824_zMs7O9j0zPE2">
         Accounting for Common Stock of OncoCyte, at Fair Value
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Priorto September 11, 2019, Lineage elected to account for its shares of OncoCyte common stock at fair value using the equity methodof accounting. Lineage sold
       <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20190701__20190731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_z1LYovWHK6He" title="Number of stock sold">
        <span>
         <ix:nonfraction contextref="From2019-07-012019-07-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-641" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2.25
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock for net proceeds of $
       <span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20190701__20190731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zf2YGOWgNCni" title="Number of stock sold, value">
        <span>
         <ix:nonfraction contextref="From2019-07-012019-07-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-642" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          4.2
         </ix:nonfraction>
        </span>
       </span>
       million in July 2019. Accordingly,Lineage’s ownership in OncoCyte was reduced from
       <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20190731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zCtknqxuds9c" title="Ownership percentage">
        <span>
         <ix:nonfraction contextref="AsOf2019-07-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-643" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          28
         </ix:nonfraction>
        </span>
        %
       </span>
       to
       <span title="Reduction in ownership percentage">
        24%
       </span>
       . Lineage sold an additional
       <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20190909__20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zNefjQmYvN7g" title="Number of stock sold">
        <span>
         <ix:nonfraction contextref="From2019-09-092019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-644" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          4.0
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte commonstock for net proceeds of $
       <span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20190909__20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zG2ApCst1Aqj" title="Number of stock sold, value">
        <span>
         <ix:nonfraction contextref="From2019-09-092019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-645" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          6.5
         </ix:nonfraction>
        </span>
       </span>
       million on September 11, 2019. Lineage’s ownership in OncoCyte was further reduced to
       <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zX2kvdCZK5db" title="Ownership percentage">
        <span>
         <ix:nonfraction contextref="AsOf2019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-646" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          16
         </ix:nonfraction>
        </span>
        %
       </span>
       at this time. Effective September 11, 2019, Lineage began accounting for its shares of OncoCyte common stock as marketable equitysecurities. The calculation of fair value is the same under the equity method and as a marketable equity security.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2019, we had
       <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_pin6_c20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_z7r2O7Fh0ZK5" title="Number of shares owned">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-647" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InvestmentOwnedBalanceShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          8.4
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock. These shares had a fair value of $
       <span id="xdx_90C_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn5n6_c20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zBTyg7zp3Lag" title="Fair value on investment">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-648" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.0
         </ix:nonfraction>
        </span>
       </span>
       million, basedon the closing price of OncoCyte common stock of $
       <span id="xdx_902_eus-gaap--SharePrice_c20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pii" title="Closing price of common stock per share">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-649" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          2.25
         </ix:nonfraction>
        </span>
       </span>
       per share on December 31, 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe year ended December 31, 2020, Lineage sold approximately
       <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zPPRsdrt7GLk" title="Number of stock sold">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-650" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          4.8
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock for net proceeds of $
       <span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zknIFUvth1h9" title="Number of stock sold, value">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-651" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          10.9
         </ix:nonfraction>
        </span>
       </span>
       million.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, we owned
       <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pin6_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zEZ6Wi0UANu7" title="Number of shares owned">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-652" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InvestmentOwnedBalanceShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          3.6
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock. These shares had a fair value of $
       <span id="xdx_90D_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn5n6_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zzEeDNHKmKWi" title="Fair value on investment">
        <span id="xdx_909_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn5n6_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zT2JMiwTDDqb" title="Fair value on investment">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-653" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-654" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
             8.7
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       million, basedon the closing price of OncoCyte common stock of $
       <span id="xdx_904_eus-gaap--SharePrice_iI_pii_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zOsOZB3LkBP9" title="Closing price of common stock per share">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-655" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          2.39
         </ix:nonfraction>
        </span>
       </span>
       per share on December 31, 2020.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe year ended December 31, 2020, we recorded a realized gain of $
       <span id="xdx_904_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pn5n6" title="Equity Method Investment, Realized Gain (Loss) on Disposal">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-656" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.1
         </ix:nonfraction>
        </span>
       </span>
       million due to sales of OncoCyte shares in the period. Inthe same period, we also recorded an unrealized loss of $
       <span id="xdx_909_eus-gaap--UnrealizedGainLossOnInvestments_pn5n6_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_ztuF2Kuq87Vi" title="Unrealized Gain (Loss) on Investments">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-657" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrealizedGainLossOnInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          2.5
         </ix:nonfraction>
        </span>
       </span>
       million related to its OncoCyte shares. The unrealized loss is comprisedof $
       <span id="xdx_904_ecustom--UnrealizedLossOnEquityMethodInvestmentsRelatedToBookCostBasis_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pn5n6" title="Unrealized loss on equity method investment related to book cost basis">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-658" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UnrealizedLossOnEquityMethodInvestmentsRelatedToBookCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.7
         </ix:nonfraction>
        </span>
       </span>
       million related to the difference between the book cost basis of OncoCyte shares sold in the period versus the applicableprior month’s ending OncoCyte stock price, which is offset by $
       <span id="xdx_90F_ecustom--NumberOfSharesRemainingForSales_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pn5n6" title="Number of shares remaining for sales">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-659" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfSharesRemainingForSales" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.2
         </ix:nonfraction>
        </span>
       </span>
       million related to the shares remaining at December 31,2020 and the increase in OncoCyte’s stock price from $2.25 at December 31, 2019 to $
       <span id="xdx_90C_eus-gaap--SharePrice_iI_pii_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_zth6l8mxbhK" title="Closing price of common stock per share">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-660" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          2.39
         </ix:nonfraction>
        </span>
       </span>
       at December 31, 2020.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 90 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           88
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe year ended December 31, 2019, we recorded a realized gain of $
       <span id="xdx_905_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pn5n6" title="Equity Method Investment, Realized Gain (Loss) on Disposal">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-661" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.5
         </ix:nonfraction>
        </span>
       </span>
       million due to sales of OncoCyte shares in the period. Wealso recorded an unrealized gain of $
       <span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pn5n6" title="Unrealized Gain (Loss) on Investments">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-662" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrealizedGainLossOnInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          8.8
         </ix:nonfraction>
        </span>
       </span>
       million due to the increase in OncoCyte’s stock price from $
       <span id="xdx_901_eus-gaap--SharePrice_c20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_pii" title="Closing price of common stock per share">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-663" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          1.38
         </ix:nonfraction>
        </span>
       </span>
       per share at December31, 2018 to $2.25 per share at December 31, 2019. $
       <span id="xdx_90F_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn5n6_c20190908__20190910__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_z1lGGQaqasmj" title="Unrealized loss on marketable equity securities">
        <span>
         <ix:nonfraction contextref="From2019-09-082019-09-10_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-664" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          8.0
         </ix:nonfraction>
        </span>
       </span>
       million of the unrealized gain was recorded as an unrealized gain on anequity method investment as it was prior to September 11, 2019; the remaining $
       <span id="xdx_90C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn5n6_c20190908__20190911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationMember_z88JsbJ10dyk" title="Unrealized gain loss on equity method investment">
        <span>
         <ix:nonfraction contextref="From2019-09-082019-09-11_custom_OncoCyteCorporationMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-665" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.8
         </ix:nonfraction>
        </span>
       </span>
       million was recorded as an unrealized gainon marketable equity securities.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Allshare prices are determined based on the closing price of OncoCyte common stock on the NYSE American on the applicable dates,or the last day of trading of the applicable quarter, if the last day of a quarter fell on a weekend.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-666" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:SaleOfSignificantOwnershipInterestTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80A_ecustom--SaleOfSignificantOwnershipInterestTextBlock_zf4KMba50Oab" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        5.
        <span id="xdx_82E_zA7qA5StjZVd">
         Sale of Significant Ownership Interest in AgeX to Juvenescence Limited
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnAugust 30, 2018, Lineage entered into a Stock Purchase Agreement with Juvenescence Limited and AgeX, pursuant to which Lineagesold
       <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z8lOygdzxuq3" title="Number of share sold">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-667" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          14.4
         </ix:nonfraction>
        </span>
       </span>
       million shares of common stock of AgeX to Juvenescence for $
       <span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_c20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_pii" title="Sale of stock price per share">
        <span>
         <ix:nonfraction contextref="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-668" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockPricePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          3.00
         </ix:nonfraction>
        </span>
       </span>
       per share, or an aggregate purchase price of $
       <span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_pn5n6" title="Purchase price of shares">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-669" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          43.2
         </ix:nonfraction>
        </span>
       </span>
       million (the “Purchase Price”). Juvenescence paid $
       <span id="xdx_903_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__srt--StatementScenarioAxis__custom--ClosingOfTransactionMember_zzTBO14hVD65" title="Purchase price amount paid">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_ClosingOfTransactionMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-670" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForRepurchaseOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          10.8
         </ix:nonfraction>
        </span>
       </span>
       million of the Purchase Price at closing, issued an unsecuredconvertible promissory note dated August 30, 2018 in favor of Lineage for $
       <span id="xdx_909_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pn5n6" title="Purchase price amount paid">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-671" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForRepurchaseOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          21.6
         </ix:nonfraction>
        </span>
       </span>
       million (the “Promissory Note”), andpaid $
       <span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20181031__20181102__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_pn5n6" title="Purchase price amount paid">
        <span>
         <ix:nonfraction contextref="From2018-10-312018-11-02_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-672" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForRepurchaseOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          10.8
         </ix:nonfraction>
        </span>
       </span>
       million on November 2, 2018. The Stock Purchase Agreement contains customary representations, warranties and indemnitiesfrom Lineage relating to the business of AgeX, including an indemnity cap of $
       <span id="xdx_900_ecustom--IndemnityCap_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_pn5n6" title="Indemnity cap">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-673" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IndemnityCap" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          4.3
         </ix:nonfraction>
        </span>
       </span>
       million, which is subject to certain exceptions.In connection with the sale, Lineage also entered into a Shared Facilities Agreement with AgeX (see Note 10).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       ThePromissory Note bore interest at
       <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_c20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zukAV8T5q4k5" title="Debt instrument interest rate">
        <span>
         <ix:nonfraction contextref="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_PromissoryNoteMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-674" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          7
         </ix:nonfraction>
        </span>
        %
       </span>
       per annum, with principal and accrued interest payable at maturity on August 30, 2020. ThePromissory Note was paid in full for a total of $
       <span id="xdx_907_eus-gaap--RepaymentsOfNotesPayable_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pn5n6" title="Repayment of debt instrument">
        <span>
         <ix:nonfraction contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_PromissoryNoteMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-675" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RepaymentsOfNotesPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          24.6
         </ix:nonfraction>
        </span>
       </span>
       million on
       <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20180828__20180830__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zBRPbAhlEkW5" title="Debt instrument maturity date">
        <span>
         <ix:nonnumeric contextref="From2018-08-282018-08-30_custom_StockPurchaseAgreementMember_custom_PromissoryNoteMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-676" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DebtInstrumentMaturityDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          August 28, 2020
         </ix:nonnumeric>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe years ended December 31, 2020, and 2019, Lineage recognized $
       <span id="xdx_90F_ecustom--InterestIncomeDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pn5n6" title="Interest income debt">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-677" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:InterestIncomeDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1,008,000
         </ix:nonfraction>
        </span>
       </span>
       and $
       <span id="xdx_90C_ecustom--InterestIncomeDebt_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pn5n6" title="Interest income debt">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockPurchaseAgreementMember_custom_JuvenescenceLimitedMember_custom_PromissoryNoteMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-678" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:InterestIncomeDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1,512,000
         </ix:nonfraction>
        </span>
       </span>
       , respectively, in interest income onthe Promissory Note.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheShared Facilities Agreement was terminated on July 31, 2019 with respect to the use of Lineage’s office and laboratory facilitiesand September 30, 2019 with respect to all other remaining shared services.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-679" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zkLVwq9nthp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        6.
        <span id="xdx_82A_zsQ12BlQKXdl">
         Property and Equipment, Net
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-680" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu99SGyITu5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         AtDecember 31, 2020 and 2019, property and equipment, net were comprised of the following (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif; display: none">
         <span id="xdx_8B2_zufgwkWaIOkf">
          Schedule of Property and Equipment, Net
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 64%; text-align: left">
           Equipment, furniture and fixtures
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentFurnitureAndFixturesMember_pn3n3" style="width: 14%; text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_EquipmentFurnitureAndFixturesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-681" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,628
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentFurnitureAndFixturesMember_pn3n3" style="width: 14%; text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_EquipmentFurnitureAndFixturesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-682" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,148
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Leasehold improvements
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-683" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,472
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-684" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,862
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Right-of-use assets
            <sup id="xdx_F44_zMy3xTtNO9Jj">
             (1)
            </sup>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--RightOfUseAssetsMember_fKDEp_zlkMtSdx9nW2" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_RightOfUseAssetsMember" continued-taxonomy="false" data-original-id="Fact001205" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-685" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,845
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--RightOfUseAssetsMember_fKDEp_ziddD8crbBJ7" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_RightOfUseAssetsMember" continued-taxonomy="false" data-original-id="Fact001207" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-686" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             5,756
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Accumulated depreciation and amortization
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_z8K4HFlTo6o" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-687" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,315
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zOpxCueSgtob" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-688" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,591
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 2.5pt">
           Property and equipment, net
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-689" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             5,630
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-690" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,175
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
           <span id="xdx_F0A_zAMlYVYHKuJ9" style="font: 10pt Times New Roman, Times, Serif">
            (1)
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F19_zu1zTM4B64C1" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001216" xml:lang="en-US">
             Lineage    adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities see    Notes 2 and 14.
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AF_zxyxShGSwsIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      Property and equipmentat December 31, 2020 and 2019 includes $
      <span>
       <span id="xdx_90D_ecustom--FinancingLeasesRelatedToPropertyAndEquipment_iI_pn3n3_c20201231_zCeWMgGt02kl">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-691" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingLeasesRelatedToPropertyAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          79
         </ix:nonfraction>
        </span>
       </span>
       ,000
      </span>
      and $
      <span>
       <span id="xdx_90A_ecustom--FinancingLeasesRelatedToPropertyAndEquipment_iI_pn3n3_c20191231_zaiKj5BcYvke">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-692" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinancingLeasesRelatedToPropertyAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          96
         </ix:nonfraction>
        </span>
       </span>
       ,000
      </span>
      financed by capital leases, respectively. In September 2020,Lineage terminated its leases in Alameda and entered into a new lease for a reduced amount of square footage. This resulted ina net reduction to right-of-use assets of approximately $
      <span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20200930__us-gaap--LeaseContractualTermAxis__custom--LineageTerminatedLeaseMember_zr7LFlIXgmD1" title="Right-of-use assets">
       <span>
        <ix:nonfraction contextref="AsOf2020-09-30_custom_LineageTerminatedLeaseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-693" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         1.4
        </ix:nonfraction>
       </span>
      </span>
      million. In December 2020, Cell Cure extended ones of itsleases (“the Original Cell Cure Lease”) for an additional five years, which resulted in a net increase to right-of-useassets of $
      <span id="xdx_901_ecustom--IncreaseInRightOfUseAssets_pn5n6_c20201201__20201231__us-gaap--LeaseContractualTermAxis__custom--OriginalCellCureLeaseMember_zPDOH1QLgJE1" title="Increase in right of use assets">
       <span>
        <ix:nonfraction contextref="From2020-12-012020-12-31_custom_OriginalCellCureLeaseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-694" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IncreaseInRightOfUseAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         0.6
        </ix:nonfraction>
       </span>
      </span>
      million. See additional information in Note 14.
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Depreciationand amortization expense amounted to $
       <span id="xdx_903_eus-gaap--DepreciationAndAmortization_pn5n6_c20200101__20201231_zxKctC0nkJ61" title="Depreciation, Depletion and Amortization">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-695" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepreciationAndAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.9
         </ix:nonfraction>
        </span>
       </span>
       million and $
       <span id="xdx_904_eus-gaap--DepreciationAndAmortization_pn5n6_c20190101__20191231_zpoWYQUUE8N9">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-696" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepreciationAndAmortization" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.1
         </ix:nonfraction>
        </span>
       </span>
       million for the years ended December 31, 2020 and 2019, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 91 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           89
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe year ended December 31, 2020, Lineage sold equipment with a net book value of $
       <span>
        <span id="xdx_90A_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn3n3_c20200101__20201231_zzTKydamh2Mk">
         <span>
          <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-697" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           32
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       and recognized a loss of $
       <span>
        <span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn3n3_c20200101__20201231_zNjqDaW15NBh">
         <span>
          <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-698" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           9
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       . Lineagealso wrote off assets with net book values of $
       <span>
        <span id="xdx_907_ecustom--PropertyAndEquipmentWrittenOffValue_iI_pn3n3_c20201231_zVy7su93mNB6">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-699" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PropertyAndEquipmentWrittenOffValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           156
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       , with $
       <span>
        <span id="xdx_902_ecustom--PropertyAndEquipmentWrittenOffValue_iI_pn3n3_c20201231__us-gaap--LeaseContractualTermAxis__custom--LineageTerminatedLeaseMember_zczSwHZGmekj">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31_custom_LineageTerminatedLeaseMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-700" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PropertyAndEquipmentWrittenOffValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           104
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       of this amount related to the termination of itsleases in Alameda. Additionally, Lineage sold non-capitalized assets for a net gain of $
       <span>
        <span id="xdx_90E_ecustom--GainOnSaleOfNoncapitalizedAssets_pn3n3_c20200101__20201231_zZ3AS31Br7W1">
         <span>
          <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-701" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:GainOnSaleOfNoncapitalizedAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           72
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe year ended December 31, 2019, Lineage sold equipment with a net book value of $
       <span>
        <span id="xdx_90A_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn3n3_c20190101__20191231_z3hCfYz7gdlc">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-702" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           209
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       and recognized a loss of $
       <span>
        <span id="xdx_902_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn3n3_c20190101__20191231_zcuZEfxTY3L8">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-703" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           109
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       .Primarily in connection with the close out of the Asterias facility, Lineage also sold non-capitalized assets for a net gain of$
       <span>
        <span id="xdx_906_ecustom--GainOnSaleOfNoncapitalizedAssets_pn3n3_c20190101__20191231_zYLsjDbIEqye">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-704" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:GainOnSaleOfNoncapitalizedAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
           337
          </ix:nonfraction>
         </span>
        </span>
        ,000
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      Gains related to thesale of assets are included in research and development expenses on the statement of operations. Write offs of assets are includedin other income, net on the statement of operations.
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-705" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_809_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zgBMosh6YYU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        7.
        <span id="xdx_82E_z7vxcgy3jku7">
         Goodwill and Intangible Assets, Net
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-706" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z6LssjbnsIWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         AtDecember 31, 2020 and 2019, goodwill and intangible assets, net consisted of the following: (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif; display: none">
         <span id="xdx_8B3_zbzS0AkmQEP3">
          Schedule of Goodwill and Intangible Assets, Net
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; padding-bottom: 2.5pt">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Goodwill
            <sup id="xdx_F49_zhOnuyFe8mei">
             (1)
            </sup>
           </span>
          </td>
          <td style="width: 2%; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_981_eus-gaap--Goodwill_iI_pn3n3_c20201231_fKDEp_zmDmL2CzEG56" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Goodwill">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" data-original-id="Fact001239" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-707" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Goodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             10,672
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="width: 2%; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--Goodwill_iI_pn3n3_c20191231_fKDEp_z8hVq35Ijbkc" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Goodwill">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="Fact001241" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-708" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Goodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             10,672
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Intangible assets:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Acquired IPR&amp;D    – OPC1 (from the Asterias Merger)
            <sup id="xdx_F43_zOg3GzoCNaC2">
             (2)
            </sup>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20201231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--InProcessResearchAndDevelopmentOPCOneMember_fKDIp_zuJFaUkZFjT7" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_InProcessResearchAndDevelopmentOPCOneMember" continued-taxonomy="false" data-original-id="Fact001243" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-709" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             31,700
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20191231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--InProcessResearchAndDevelopmentOPCOneMember_fKDIp_zHqvr3Wvv3Pg" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_InProcessResearchAndDevelopmentOPCOneMember" continued-taxonomy="false" data-original-id="Fact001245" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-710" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             31,700
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Acquired IPR&amp;D    – VAC2 (from the Asterias Merger)
            <sup id="xdx_F43_zPg0BsSKcIN3">
             (2)
            </sup>
           </span>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20201231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--InProcessResearchAndDevelopmentVACTwoMember_fKDIp_zJAYAYn0nn45" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_InProcessResearchAndDevelopmentVACTwoMember" continued-taxonomy="false" data-original-id="Fact001247" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-711" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             14,840
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20191231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--InProcessResearchAndDevelopmentVACTwoMember_fKDIp_ze4BR5tSluwk" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_InProcessResearchAndDevelopmentVACTwoMember" continued-taxonomy="false" data-original-id="Fact001249" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-712" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             14,840
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Intangible assets subject to amortization:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Acquired patents
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20201231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--PatentMember_zC9enSD5e3b2" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_PatentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-713" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             18,953
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20191231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--PatentMember_zLiBP2Er9Uh9" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_PatentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-714" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             18,953
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Acquired    royalty contracts
            <sup id="xdx_F4C_zQdoTLOLRVf8">
             (2)
            </sup>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20201231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--RoyaltyContractsMember_fKDIp_zjKwzuVPIbwb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_RoyaltyContractsMember" continued-taxonomy="false" data-original-id="Fact001255" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-715" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             650
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20191231__custom--GoodwillAndIntangibleAssetsByMajorClassAxis__custom--RoyaltyContractsMember_fKDIp_zmeiT8uj21ce" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_RoyaltyContractsMember" continued-taxonomy="false" data-original-id="Fact001257" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-716" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             650
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Total intangible assets
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_c20201231_pn3n3" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-717" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             66,143
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_c20191231_pn3n3" style="text-align: right" title="Total intangible assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-718" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             66,143
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Accumulated amortization
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_989_ecustom--AccumulatedAmortizationOfIntangibleAssets_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-719" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:AccumulatedAmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             19,111
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_981_ecustom--AccumulatedAmortizationOfIntangibleAssets_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-720" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:AccumulatedAmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             17,895
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 2.5pt">
           Intangible assets, net
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-721" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             47,032
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-722" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             48,248
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td id="xdx_F00_z0TVajmc7luc" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <sup>
             (1)
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F1E_zvdvVRNHShOe" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001270" xml:lang="en-US">
             Goodwill    represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired    and liabilities assumed in the Asterias Merger (see Note 3).
            </ix:footnote>
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <sup>
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
           </span>
          </td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <sup id="xdx_F01_zmcwr3C0tPJ7">
             (2)
            </sup>
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F16_zdZ4uFk1Ajyf" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote001271" xml:lang="en-US">
             See    Note 3 for information on the Asterias Merger which was consummated on March 8, 2019.
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A9_zPpa8jJapfOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageamortizes its intangible assets over an estimated period of
       <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zoUPd5XXU5ud" title="Amortization period of intangible assets">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MinimumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-723" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          5
         </ix:nonnumeric>
        </span>
       </span>
       to
       <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z8GUnjUubZLk" title="Amortization period of intangible assets">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MaximumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-724" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          10
         </ix:nonnumeric>
        </span>
       </span>
       years on a straight-line basis. Lineage recognized $
       <span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zn800JeJjt1b" title="Amortization of intangible assets">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-725" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.2
         </ix:nonfraction>
        </span>
       </span>
       millionand $
       <span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zeFVeOm0uxUk" title="Amortization of intangible assets">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-726" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          2.0
         </ix:nonfraction>
        </span>
       </span>
       million in amortization expense of intangible assets during the years ended December 31, 2020 and 2019, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-727" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zeVZkCe9VbDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Amortizationof intangible assets for periods subsequent to December 31, 2020 is as follows (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B5_zfCjSXjC2p29" style="display: none">
          Schedule of Intangible Assets Future Amortization Expense
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" id="xdx_493_20201231_zt8bcV4LC4Ag" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Amortization Expense
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzDVg_z8XjPNXI4Jhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: center">
           2021
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td style="width: 36%; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-728" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             210
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzDVg_zjx4Y2cIMHx2" style="vertical-align: bottom; background-color: White">
          <td style="text-align: center">
           2022
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-729" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             130
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzDVg_zReP3pkN9cvf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: center">
           2023
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-730" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             130
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzDVg_zKuUUvlddrSe" style="vertical-align: bottom; background-color: White">
          <td style="text-align: center; padding-bottom: 1.5pt">
           2024
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-731" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             22
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzDVg_zSqpc3NYNGGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: center; padding-bottom: 2.5pt">
           Total
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-732" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FiniteLivedIntangibleAssetsNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             492
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A9_zJG2VQU3XgHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 92 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           90
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
       </b>
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-733" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z60KYAlCD6J6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        8.
        <span id="xdx_82C_zTrk2E8z4hkc">
         Accounts Payable and Accrued Liabilities
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-734" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z0DepkCFtwe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         AtDecember 31, 2020 and 2019, accounts payable and accrued liabilities consist of the following (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8BF_zTePCol60pS4" style="display: none">
          Schedule of Accounts Payable and Accrued Liabilities
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
        <tbody>
         <tr style="display: none; vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" id="xdx_490_20201231_zcuYkFmm6Wr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" id="xdx_49B_20191231_zSunmdm2fiyb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzSRn_zZwMtMr7DWi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           Accounts payable
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td style="width: 16%; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-735" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,611
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td style="width: 16%; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-736" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,427
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr id="xdx_403_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maAPAALzSRn_znaQTmbVut3j" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Accrued compensation
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-737" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,959
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-738" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,549
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzSRn_zcbWuiJGFLH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Accrued liabilities
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-739" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,711
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-740" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,246
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_401_eus-gaap--LoansPayableCurrent_iI_pn3n3_maAPAALzSRn_zBrFVceWovYh" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           PPP loan payable
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-741" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LoansPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             523
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           <span style="-sec-ix-hidden: xdx2ixbrl1307">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl1307" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-742" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LoansPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: right">
           -
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzSRn_z03KoPehesfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Other current liabilities
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-743" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             9
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-744" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzSRn_zyybesRQ9wm4" style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 2.5pt">
           Total
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-745" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             6,813
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-746" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             5,226
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A3_ztbCwSab1cH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Accruedliabilities includes $
       <span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--CancerResearchMember_zbDu0VlXF3a6" title="Accrued expenses">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CancerResearchMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-747" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.0
         </ix:nonfraction>
        </span>
       </span>
       million related to the signature fee owed to Cancer Research UK, as described in Note 14.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        PPPLoan Payable
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InApril 2020, Lineage received a loan for $
       <span id="xdx_905_eus-gaap--ProceedsFromLoans_pp0p0_c20200401__20200430__dei--LegalEntityAxis__custom--AxosBankMember__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_zd9Rys3zjt28" title="Proceeds from Loans">
        <span>
         <ix:nonfraction contextref="From2020-04-012020-04-30_custom_AxosBankMember_custom_PaycheckProtectionProgramMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-748" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromLoans" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          523,305
         </ix:nonfraction>
        </span>
       </span>
       from Axos Bank under the PPP contained within the new Coronavirus Aid, Reliefand Economic Security (“CARES”) Act. The PPP loan has a term of two years, is unsecured, and is guaranteed by theU.S. Small Business Administration (“SBA”). The loan carries a fixed interest rate of one percent per annum, withthe first six months of interest deferred. Under the CARES Act and Paycheck Protection Program Flexibility Act, Lineage will beeligible to apply for forgiveness of all loan proceeds used to pay payroll costs, rent, utilities and other qualifying expensesduring the 24-week period following receipt of the loan, provided that Lineage maintains its employment and compensation withincertain parameters during such period. Not more than
       <span id="xdx_904_ecustom--PercentageOfNonPayrollCosts_iI_pii_dp_c20200430__dei--LegalEntityAxis__custom--AxosBankMember__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_zSIpHnvKk7T8" title="Percentage of non payroll costs">
        <span>
         <ix:nonfraction contextref="AsOf2020-04-30_custom_AxosBankMember_custom_PaycheckProtectionProgramMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-749" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PercentageOfNonPayrollCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          40
         </ix:nonfraction>
        </span>
        %
       </span>
       of the forgiven amount may be for non-payroll costs. If the conditionsoutlined in the PPP loan program are adhered to by Lineage, all or part of such loan could be forgiven. Lineage believes thatall or a substantial portion of the PPP loan is eligible for forgiveness within one year and classifies the loan as a short-termliability. On December 27, 2020, the Consolidated Appropriations Act, 2021 (CAA) was signed into law, retroactively allowing adeduction of the expenses that gave rise to the PPP loan forgiveness, that was previously denied under the CARES Act. Californiahas partially adopted the federal tax treatment. On February 17, 2021, California issued an Immediate Action Agreement, allowingcompanies to deduct up to $
       <span id="xdx_907_eus-gaap--LoansPayable_iI_pp0p0_c20210217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AxosBankMember__us-gaap--PlanNameAxis__custom--PaycheckProtectionProgramMember_zbz0cNCATUy6" title="Loans payable">
        <span>
         <ix:nonfraction contextref="AsOf2021-02-17_us-gaap_SubsequentEventMember_custom_AxosBankMember_custom_PaycheckProtectionProgramMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-750" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LoansPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          150,000
         </ix:nonfraction>
        </span>
       </span>
       in expenses covered by the PPP loan. However, Lineage cannot provide any assurance whetherthe PPP loan will ultimately be forgiven by the SBA. Any forgiven amounts will not be included in Lineage’s taxable incomefor federal or California purposes. Lineage applied for full forgiveness of the PPP loan on September 30, 2020.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        2019Separation Payments
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the Asterias Merger, several Asterias employees were terminated as of the Asterias Merger date. Three of theseemployees had employment agreements with Asterias which entitled them to change in control and separation payments in the aggregateof $
       <span id="xdx_909_eus-gaap--SeveranceCosts1_pn5n6_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_z5gp0Gv8t3f" title="Separation payments">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember_custom_ThreeEmployeesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-751" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SeveranceCosts1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          2.0
         </ix:nonfraction>
        </span>
       </span>
       million, which such conditions were met on the Asterias Merger date. Accordingly, $
       <span id="xdx_90E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn5n6_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwKHGloBG73d" title="Accrued compensation">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember_us-gaap_GeneralAndAdministrativeExpenseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-752" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          2.0
         </ix:nonfraction>
        </span>
       </span>
       million was accrued and recordedin general and administrative expenses on the merger date and paid in April 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.2pt; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Additionally,Lineage entered into a plan of termination with substantially all other previous employees of Asterias with potential separationpayments in the aggregate of $
       <span id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zCjcoGIx68G1" title="Separation payments">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember139172843" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-753" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SeveranceCosts1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.5
         </ix:nonfraction>
        </span>
       </span>
       million.
       <span id="xdx_900_ecustom--DescriptionOfTerminationPlan_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember" title="Description of termination plan">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_AsteriasBiotherapeuticsIncMember139172843" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-754" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:DescriptionOfTerminationPlan" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          Termination dates for these individuals ranged from May 31, 2019 to June 28, 2019
         </ix:nonnumeric>
        </span>
       </span>
       .These employees were required to provide services related to the transition and be an employee of the combined company as of theirdate of termination in order to receive separation benefits. Since the employees were required to render future services afterthe merger date, Lineage recorded the aggregate liability ratably over their respective service periods from the Asterias Mergerdate through the above termination dates, in accordance with ASC 420,
       <i>
        Exit or Disposal Cost Obligations
       </i>
       . All payments werecompleted by July 31, 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the relocation of Lineage’s corporate headquarters to Carlsbad, California, Lineage entered into a planof termination with certain Lineage employees with potential separation payments in the aggregate of $
       <span id="xdx_90D_eus-gaap--SeveranceCosts1_pn5n6_c20200101__20201231_zmptyXvJLTN8" title="Separation payments">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-755" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SeveranceCosts1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.7
         </ix:nonfraction>
        </span>
       </span>
       million.
       <span id="xdx_906_ecustom--DescriptionOfTerminationPlan_c20200101__20201231" title="Description of termination plan">
        <span>
         <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-756" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:DescriptionOfTerminationPlan" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          Terminationdates for these individuals range from August 9, 2019 to September 30, 2019.
         </ix:nonnumeric>
        </span>
       </span>
       These employees had to provide services related tothe transition of services and activities in connection with the relocation and be an employee of Lineage as of their date oftermination in order to receive separation benefits. Lineage recorded the aggregate liability ratably over their respective serviceperiods from June 2019 through the above termination dates, in accordance with ASC 420. As of December 31, 2019, all separationpayments had been made.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 93 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           91
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
       </b>
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-757" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FairValueDisclosuresTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zcD8d02SgERk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        9.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82E_z0GjnWpOcxs5">
         Fair Value Measurements
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Fairvalue is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transactionbetween market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchyprioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50),
       <i>
        Fair Value Measurements and Disclosures
       </i>
       :
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
      <tbody>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          Level    1 – Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          Level    2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar    assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated    by observable market data for substantially the full term of the assets or liabilities.
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
       </tr>
       <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif">
         <span style="font: 10pt Times New Roman, Times, Serif">
          ●
         </span>
        </td>
        <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
         <span style="font: 10pt Times New Roman, Times, Serif">
          Level    3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the    assumptions market participants would make and significant to the fair value.
         </span>
        </td>
       </tr>
      </tbody>
     </table>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-758" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zubjVU322Hqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Wemeasure cash, cash equivalents, marketable securities and our liability classified warrants at fair value on a recurring basis.The fair values of such assets were as follows for December 31, 2020 and 2019 (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span id="xdx_8B7_zNAON03v5pg8" style="display: none">
         Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis
        </span>
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Fair Value Measurements Using
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Balance at December 31, 2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quoted                                         Prices in Active Markets for Identical Assets
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         1)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Significant                                         Other Observable Inputs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         2)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Significant                                         Unobservable Inputs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         3)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Assets:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="width: 40%; text-align: left">
           Cash and cash equivalents
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98C_eus-gaap--Assets_c20201231__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_CashAndCashEquivalentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-759" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             32,585
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-760" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             32,585
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1343">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1343" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-761" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
             </ix:nonfraction>
            </span>
           </span>
           -
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1345">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1345" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-762" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Marketable securities
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--Assets_c20201231__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_MarketableSecuritiesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-763" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,977
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-764" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,977
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1351">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1351" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-765" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--Assets_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1353">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1353" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-766" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Liabilities:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Lineage Warrants
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--Liabilities_c20201231__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_LineageWarrantsMember139173453" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-767" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1357">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_LineageWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1357" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-768" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1359">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_LineageWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1359" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-769" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-770" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Cell Cure Warrants
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--Liabilities_c20201231__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-771" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             437
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1365">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_custom_CellCureWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1365" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-772" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1367">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_custom_CellCureWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1367" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-773" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--Liabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-774" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             437
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Fair Value Measurements Using
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Balance at December 31, 2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quoted                                         Prices in Active Markets for Identical Assets
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         1)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Significant                                         Other Observable Inputs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         2)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Significant                                         Unobservable Inputs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              (Level                                         3)
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Assets:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="width: 40%; text-align: left">
           Cash and cash equivalents
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--Assets_c20191231__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_CashAndCashEquivalentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-775" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             9,497
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-776" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             9,497
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98E_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1375">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1375" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-777" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
             </ix:nonfraction>
            </span>
           </span>
           -
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98D_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--CashAndCashEquivalentMember_pn3n3" style="width: 11%; text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1377">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_CashAndCashEquivalentMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1377" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-778" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Marketable securities
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--Assets_c20191231__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_MarketableSecuritiesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-779" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             21,219
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-780" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             21,219
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1383">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1383" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-781" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--Assets_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--MarketableSecuritiesMember_pn3n3" style="text-align: right" title="Assets">
           <span style="-sec-ix-hidden: xdx2ixbrl1385">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableSecuritiesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1385" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-782" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Liabilities:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Lineage Warrants
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--Liabilities_c20191231__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-783" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             20
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1389">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_LineageWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1389" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-784" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1391">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_LineageWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1391" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-785" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--LineageWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_LineageWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-786" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             20
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Cell Cure Warrants
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--Liabilities_c20191231__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-787" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             257
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1397">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_custom_CellCureWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1397" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-788" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span style="-sec-ix-hidden: xdx2ixbrl1399">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_custom_CellCureWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1399" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-789" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--Liabilities_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BalanceSheetLocationAxis__custom--CellCureWarrantsMember_pn3n3" style="text-align: right" title="Liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-790" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             257
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A1_zmIOj54eHGUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 94 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           92
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Wehave not transferred any instruments between the three levels of the fair value hierarchy.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Indetermining fair value, Lineage utilizes valuation techniques that maximize the use of observable inputs and minimize the useof unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Marketablesecurities include our positions in OncoCyte and HBL. These securities have readily determinable fair values quoted on the NYSEAmerican or TASE stock exchanges. These securities are measured at fair value and reported as current assets on the consolidatedbalance sheets based on the closing trading price of the security as of the date being presented.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thefair value of Lineage’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosuresabout fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balancesheets. The carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expensesand other current liabilities approximate fair values because of the short-term nature of these items.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
       </b>
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-791" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znlC1EyCgwqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        10.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82E_zyySZ9Dn1k0a">
         Related Party Transactions
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        SharedFacilities and Service Agreements with Affiliates
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Underthe terms of the Shared Facilities Agreements, Lineage allowed OncoCyte and AgeX to use Lineage’s premises and equipmentlocated at Lineage’s headquarters in Alameda, California for the purpose of conducting business. Lineage also provided accounting,billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte andAgeX. The Shared Facilities Agreements also allowed Lineage to provide the services of attorneys, accountants, and other professionalswho may provide professional services to Lineage. Lineage also provided OncoCyte and AgeX with the services of laboratory andresearch personnel, including Lineage employees and contractors, for the performance of research and development work for OncoCyteand AgeX at the premises. Shared services with AgeX were terminated on July 31, 2019 with respect to the use of Lineage’soffice and laboratory facilities and September 30, 2019 with respect to all other remaining shared services. Shared services withOncoCyte were terminated on September 30, 2019, and December 31, 2019 with respect to all other remaining shared services.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagecharged OncoCyte and AgeX a “Use Fee” for services provided and for use of Lineage facilities, equipment, and supplies.For each billing period, Lineage prorated and allocated to OncoCyte and AgeX costs incurred, including costs for services of Lineageemployees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. Theallocation of costs depended on key cost drivers, including actual documented use, square footage of facilities used, time spent,costs incurred by Lineage for OncoCyte and AgeX, or upon proportionate usage by Lineage, OncoCyte and AgeX, as reasonably estimatedby Lineage. Lineage, at its discretion, had the right to charge OncoCyte and AgeX a
       <span id="xdx_909_ecustom--PercentageOfMarkupFeeAllocatedButNotCharged_pii_dp_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zYAYKKdt0Th1" title="Markup rate on allocated costs">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-792" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:PercentageOfMarkupFeeAllocatedButNotCharged" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          5
         </ix:nonfraction>
        </span>
        %
       </span>
       markup on such allocated costs. The allocatedcost of Lineage employees and contractors who provided services was based upon the number of hours or estimated percentage ofefforts of such personnel devoted to the performance of services.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheUse Fee was determined and invoiced to OncoCyte and AgeX on a regular basis, generally monthly or quarterly. Each invoice waspayable in full within
       <span id="xdx_904_ecustom--TermOfPayment_dtD_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zBe1dn3sGc03" title="Term of payment">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:durday" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-793" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:TermOfPayment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          30
         </ix:nonnumeric>
        </span>
       </span>
       days after receipt. Any invoice, or portion thereof, not paid in full when due bore interest at therate of
       <span id="xdx_90B_ecustom--InterestOnUnpaidOverdueInvoice_pii_dp_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zpaXt7jDh6I6" title="Interest rate charged on unpaid and overdue invoices">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-794" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:InterestOnUnpaidOverdueInvoice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          15
         </ix:nonfraction>
        </span>
        %
       </span>
       per annum until paid, unless the failure to make a payment was due to any inaction or delay in making a payment byLineage. Lineage did not charge OncoCyte or AgeX any interest.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inaddition to the Use Fee, OncoCyte and AgeX reimbursed Lineage for any out of pocket costs incurred by Lineage for the purchaseof office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte or AgeX.Lineage was not obligated to purchase or acquire any office supplies or other goods and materials or any services for OncoCyteor AgeX, and if any such supplies, goods, materials or services were obtained, Lineage could arrange for the suppliers to invoiceOncoCyte or AgeX directly.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 95 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           93
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheUse Fees charged to OncoCyte and AgeX shown above were not reflected in revenues, but instead Lineage’s general and administrativeexpenses and research and development expenses are shown net of those charges in the consolidated statements of operations.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe year ended December 31, 2019, Lineage charged Use Fees of $
       <span id="xdx_90A_ecustom--UsageFee_pn3n3_c20191001__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zLuTeuicBMRi" title="Usage fee">
        <span>
         <ix:nonfraction contextref="From2019-10-012019-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-795" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:UsageFee" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          2,176
         </ix:nonfraction>
        </span>
       </span>
       ,000 to OncoCyte and AgeX; $
       <span id="xdx_90E_ecustom--OffsetAgainstGeneralAndAdministrativeExpenses_pn3n3_c20191001__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zBHX6P9kn3f1" title="Offset against general and administrative expenses">
        <span>
         <ix:nonfraction contextref="From2019-10-012019-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-796" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OffsetAgainstGeneralAndAdministrativeExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          890
         </ix:nonfraction>
        </span>
       </span>
       ,000 was offset against generaland administrative expenses and $
       <span id="xdx_902_ecustom--OffsetAgainstResearchAndDevelopmentExpenses_pn3n3_c20191001__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncoCyteCorporationAndAgeXTherapeuticsIncMember_zymqpro1TyA2" title="Offset against research and development expenses">
        <span>
         <ix:nonfraction contextref="From2019-10-012019-12-31_custom_OncoCyteCorporationAndAgeXTherapeuticsIncMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-797" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OffsetAgainstResearchAndDevelopmentExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          1,286
         </ix:nonfraction>
        </span>
       </span>
       ,000 was offset against research and development expenses.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Otherrelated party transactions
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagecurrently pays $
       <span id="xdx_90E_eus-gaap--PaymentsForRent_c20200101__20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember_pp0p0" title="Rent per month">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-798" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          5,050
         </ix:nonfraction>
        </span>
       </span>
       per month for the use of approximately
       <span id="xdx_909_eus-gaap--AreaOfRealEstateProperty_iI_pii_uAreaSquareMeter_c20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember_zQhH39JCRSza" title="Area of office space square feet">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-799" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AreaOfRealEstateProperty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="AreaSquareMeter">
          900
         </ix:nonfraction>
        </span>
       </span>
       square feet of office space in New York City, which is made availableto Lineage on a month-by-month basis by one of its directors at an amount that approximates his cost (see Note 14). Thesepayments are expected to cease in
       <span id="xdx_90D_ecustom--LeaseExpirationDate2_c20200101__20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember" title="Lease expires date">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-800" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LeaseExpirationDate2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          March 2021
         </ix:nonnumeric>
        </span>
       </span>
       when the office space lease expires.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InApril 2019, Lineage issued
       <span>
        <span id="xdx_904_ecustom--SharesIssuedForSettlementOfWarrantsInConnectionWithMerger_c20190401__20190430__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_pii" title="Shares issued for settlement of warrants in connection with merger">
         <span>
          <ix:nonfraction contextref="From2019-04-012019-04-30_custom_BroadwoodPartnersLPMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-801" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SharesIssuedForSettlementOfWarrantsInConnectionWithMerger" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
           251,835
          </ix:nonfraction>
         </span>
        </span>
       </span>
       common shares of Lineage to Broadwood Partners, L.P., an Asterias and Lineage shareholder,in exchange for the settlement of Asterias Warrants in connection with the Asterias Merger (see Note 3).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the putative shareholder class action lawsuits filed in February 2019 and October 2019 challenging the AsteriasMerger (see Note 14), Lineage has agreed to pay for the legal defense of Neal Bradsher, director, and Broadwood Partners,L.P., a shareholder of Lineage, and Broadwood Capital, Inc., which manages Broadwood Partners, L.P., all of which were named inthe lawsuits. Through December 31, 2020, Lineage has incurred a total of $
       <span id="xdx_903_eus-gaap--LegalFees_pn3n3_c20200101__20201231__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember__srt--TitleOfIndividualAxis__custom--NealBradsherMember_zzLNRVNrJLT1" title="Legal expenses">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_BroadwoodPartnersLPMember_custom_NealBradsherMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-802" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LegalFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          359
         </ix:nonfraction>
        </span>
       </span>
       ,000 in legal expenses on behalf of the director,shareholder and the manager of the shareholder.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Aspart of financing transactions in which there were multiple other purchasers, Broadwood Partners, L.P. purchased
       <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pii_c20190701__20190731__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zS6OTk1p03d3" title="Number of shares issued">
        <span>
         <ix:nonfraction contextref="From2019-07-012019-07-31_custom_BroadwoodPartnersLPMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-803" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          1,000,000
         </ix:nonfraction>
        </span>
       </span>
       shares,
       <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pii_c20190901__20190930__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_z7amK73zZ8La" title="Number of shares issued">
        <span>
         <ix:nonfraction contextref="From2019-09-012019-09-30_custom_BroadwoodPartnersLPMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-804" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,000,000
         </ix:nonfraction>
        </span>
       </span>
       shares and
       <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pii_c20200101__20200131__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zJpfvZaidhIk" title="Number of shares issued">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-01-31_custom_BroadwoodPartnersLPMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-805" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          623,090
         </ix:nonfraction>
        </span>
       </span>
       shares of OncoCyte common stock from Lineage in July 2019, September 2019 and January 2020, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-806" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHtM62Htvqic" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        11.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82F_zilm2Q10XDZ">
         Shareholders’ Equity
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        PreferredShares
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageis authorized to issue
       <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pii_c20191231_zs6613JODBKe">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-807" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,000,000
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       shares of preferred stock. The preferred shares maybe issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized tofix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, andrestrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding)the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of December 31, 2020,
       <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20201231_z9vpFwFFvB85" title="Preferred shares, shares issued">
        <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20201231_zEqIozIHnTD" title="Preferred shares, shares outstanding">
         <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20191231_zaysEpktuPc" title="Preferred shares, shares issued">
          <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20191231_zFOG5Yos1tT9" title="Preferred shares, shares outstanding">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-808" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             <span>
              <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-809" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
               <span>
                <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-810" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                 <span>
                  <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-811" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
                   no
                  </ix:nonfraction>
                 </span>
                </ix:nonfraction>
               </span>
              </ix:nonfraction>
             </span>
            </ix:nonfraction>
           </span>
          </span>
         </span>
        </span>
       </span>
       shares of preferred stock were issued or outstanding.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        CommonShares
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       AtDecember 31, 2020, Lineage was authorized to issue
       <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_zUiocbwsZEN5" title="Common stock, shares authorized">
        <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_z9qkEg307cTf" title="Common stock, shares authorized">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-812" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-813" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             250,000,000
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       common shares, no par value. As of December 31, 2020 and 2019,Lineage had
       <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20201231_pii" title="Common stock, issued">
        <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_c20201231_pii" title="Common stock, outstanding">
         <span>
          <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-814" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-815" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             153,095,883
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       and
       <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pii_c20191231_zs2cmEv6TPr4" title="Common stock, issued">
        <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20191231_pii" title="Common stock, outstanding">
         <span>
          <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-816" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-817" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             149,804,284
            </ix:nonfraction>
           </span>
          </ix:nonfraction>
         </span>
        </span>
       </span>
       issued and outstanding common shares, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Duringthe years ended December 31, 2020 and 2019, Lineage issued
       <span id="xdx_90C_ecustom--NumberOfCommonStockSharesWithheldAndRetiredForTaxesPaidForVestedDuringPeriod_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeeMember_zTnE8fDh9Em6" title="Number of common stock shares withheld and retired for taxes paid for vested during the period">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_EmployeeMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-818" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfCommonStockSharesWithheldAndRetiredForTaxesPaidForVestedDuringPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          47,000
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       and
       <span title="Number of common stock shares withheld and retired for taxes paid for vested during the period">
        <span id="xdx_90C_ecustom--NumberOfCommonStockSharesWithheldAndRetiredForTaxesPaidForVestedDuringPeriod_pii_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeeMember_zKjkp7w4TUck">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_custom_EmployeeMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-819" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfCommonStockSharesWithheldAndRetiredForTaxesPaidForVestedDuringPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
           189,000
          </ix:nonfraction>
         </span>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       common shares, net of shares withheldand retired for employee taxes paid, respectively, for vested restricted stock units (see Note 12).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 96 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           94
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        At-the-Market(“ATM”) Offering
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMay 1, 2020, Lineage entered into the Sales Agreement, pursuant to which Lineage may offer and sell, from time to time, throughCantor Fitzgerald, common shares of Lineage (“ATM Shares”) having an aggregate offering price of up to $
       <span id="xdx_902_ecustom--AggregateOfferingPrice_iI_pn3n3_c20200501__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSeventeenSalesAgreementMember__srt--RangeAxis__srt--MaximumMember_zwjmHaVH3bi8">
        <span>
         <ix:nonfraction contextref="AsOf2020-05-01_custom_CantorFitzgeraldAndCoMember_custom_TwoThousandSeventeenSalesAgreementMember_srt_MaximumMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-820" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AggregateOfferingPrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
          25,000
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       ,000.Lineage is not obligated to sell any ATM Shares. Subject to the terms and conditions of the Sales Agreement, Cantor Fitzgeraldwill use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federallaw, rules and regulations, and the rules of the NYSE American, to sell the ATM Shares from time to time based upon Lineage’sinstructions, including any price, time or size limits specified by Lineage. Under the Sales Agreement, Cantor Fitzgerald maysell the ATM Shares by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) under theSecurities Act of 1933, as amended, or by any other method permitted by law, including in privately negotiated transactions. CantorFitzgerald’s obligations to sell the ATM Shares are subject to satisfaction of certain conditions, including the continuedeffectiveness of Lineage’s Registration Statement on Form S-3 (File No. 333-237975), which was filed with the Commissionon May 1, 2020 and was declared effective on May 8, 2020. The Sales Agreement replaced the previous sales agreement with Cantorthat had been entered into in April 2017. As of December 31, 2020, Lineage sold
       <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200101__20201231_zzLvaF3hqulb">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-821" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          3,094,322
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       ATM Shares for gross and net proceedsof $
       <span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200101__20201231_zJpJq8A1XkJ6">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-822" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          5.1
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million and $
       <span id="xdx_90F_ecustom--ProceedsFromIssuancesOfCommonStock_pn5n6_c20200101__20201231_z6xa0vjGaoBc">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-823" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuancesOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          5.0
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million, respectively (in eachcase, which excludes $
       <span id="xdx_90A_ecustom--ProceedsFromIssuancesOfCommonStock_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SettledInTwentyTwentyOneMember_zrHRoEa4YqP2">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_SettledInTwentyTwentyOneMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-824" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuancesOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million of cash in transit related to 2020 sales that settled in 2021). In the first quarter of2021 through March 5, 2021, Lineage sold an additional
       <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--ATMSharesMember_zAspHUEACxNl" title="Additional number of shares sold">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-825" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          7,941,122
         </ix:nonfraction>
        </span>
       </span>
       ATM Shares for gross and net proceeds of $
       <span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--ATMSharesMember_z900SdhzaIQa">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-826" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.9
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million and $
       <span id="xdx_907_ecustom--ProceedsFromIssuancesOfCommonStock_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--ATMSharesMember_z1cdXtUv80xj">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-827" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuancesOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.3
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million, respectively (in eachcase, which includes $
       <span id="xdx_90E_ecustom--ProceedsFromIssuancesOfCommonStock_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--ATMSharesMember__us-gaap--TypeOfArrangementAxis__custom--SettledInTwentyTwentyOneMember_zwtGaE7MjGwi">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMSharesMember_custom_SettledInTwentyTwentyOneMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-828" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuancesOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million of cash in transit related to 2020 sales that settled in 2021). On March 5, 2021,Lineage filed a prospectus supplement with the SEC in connection with the offer and sale of an additional $
       <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pin6_c20210301__20210305_zco9G4YWzyo9">
        <span>
         <ix:nonfraction contextref="From2021-03-012021-03-05" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-829" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          25
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million of ATM Shares under the SalesAgreement.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageagreed to pay Cantor Fitzgerald a commission of
       <span id="xdx_908_ecustom--SalesCommissionPercentageOfGrossProceeds_pii_dp_uPercentage_c20200101__20201231__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSeventeenSalesAgreementMember_zGCjAcNDaFz7" title="Percentage of commission payable">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_CantorFitzgeraldAndCoMember_custom_TwoThousandSeventeenSalesAgreementMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-830" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SalesCommissionPercentageOfGrossProceeds" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          3.0
         </ix:nonfraction>
        </span>
       </span>
       % of the aggregate gross proceeds from each sale of shares, reimburse legalfees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreementmay be terminated by Cantor Fitzgerald or Lineage at any time upon notice to the other party, or by Cantor Fitzgerald at any timein certain circumstances, including the occurrence of a material and adverse change in Lineage’s business or financial conditionthat makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Warrants
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Lineage(previously Asterias) Warrants – Liability Classified
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InMarch 2019, in connection with the closing of the Asterias Merger, Lineage assumed outstanding Asterias Warrants. As of December31, 2020, the total number of common shares of Lineage subject to warrants that were assumed by Lineage in connection with theAsterias Merger was
       <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zC4ddBWyWEg5" title="Warrants issued to purchase ordinary shares">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139174593" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-831" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          1,089,900
         </ix:nonfraction>
        </span>
       </span>
       , which were converted to Lineage Warrants
       <span id="xdx_903_ecustom--ClassOfWarrantOrRightExercisedPeriod_dtD_c20200101__20200930__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zUMDDUwekd42" title="Warrants exercisable term">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-09-30_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:durday" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-832" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:ClassOfWarrantOrRightExercisedPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          30
         </ix:nonnumeric>
        </span>
       </span>
       days after the closing of the Asterias Merger, withsimilar terms and conditions retained under the Lineage Warrants as per the original Warrant Agreements. The Lineage Warrantshave an exercise price of $
       <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_z3ZQJqicVCl3" title="Warrants exercise price per share">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139174593" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-833" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          6.15
         </ix:nonfraction>
        </span>
       </span>
       per warrant share and expire on
       <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201231__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zV52vOWU5ice" title="Warrant expiration date">
        <span>
         <ix:nonnumeric contextref="AsOf2020-12-31_custom_AsteriasBiotherapeuticsIncMember139174593" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-834" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          May 13, 2021
         </ix:nonnumeric>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        CellCure Warrants – Liability Classified
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       CellCure has two sets of issued warrants (the “Cell Cure Warrants”). Warrants to purchase
       <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20170731__srt--OwnershipAxis__custom--HadasitBioHoldingsLtdMember_pii" title="Warrants issued to purchase ordinary shares">
        <span>
         <ix:nonfraction contextref="AsOf2017-07-31_custom_HadasitBioHoldingsLtdMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-835" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          24,566
         </ix:nonfraction>
        </span>
       </span>
       Cell Cure ordinary sharesat an exercise price of $
       <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170731__srt--OwnershipAxis__custom--HadasitBioHoldingsLtdMember_pii" title="Warrants exercise price per share">
        <span>
         <ix:nonfraction contextref="AsOf2017-07-31_custom_HadasitBioHoldingsLtdMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-836" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          40.5359
         </ix:nonfraction>
        </span>
       </span>
       were issued to HBL in July 2017. These warrants expire in
       <span id="xdx_900_ecustom--WarrantsAndRightsOutstandingMaturityDate1_dxL_c20170701__20170731__srt--OwnershipAxis__custom--HadasitBioHoldingsLtdMember_zJSzLZiKgiEg" title="Warrant expiration date::XDX::2022-07-31">
        <span style="-sec-ix-hidden: xdx2ixbrl1484">
         <span>
          <ix:nonnumeric contextref="From2017-07-012017-07-31_custom_HadasitBioHoldingsLtdMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1484" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-837" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:WarrantsAndRightsOutstandingMaturityDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           July 2022
          </ix:nonnumeric>
         </span>
        </span>
       </span>
       . Warrants to purchase
       <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20200930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pii" title="Warrants issued to purchase ordinary shares">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-30_custom_CellCureWarrantsMember_custom_ConsultantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-838" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          13,738
         </ix:nonfraction>
        </span>
       </span>
       Cell Cure ordinary shares at exercise prices ranging from $
       <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember__srt--RangeAxis__srt--MinimumMember_zRFhmJyxc1qf" title="Warrants exercise price per share">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_srt_MinimumMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-839" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          32.02
         </ix:nonfraction>
        </span>
       </span>
       to $
       <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember__srt--RangeAxis__srt--MaximumMember_z16zHwbHwgV" title="Warrants exercise price per share">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_srt_MaximumMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-840" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          40.02
         </ix:nonfraction>
        </span>
       </span>
       per share were issued to consultants.
       <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_c20201019__20201020_zwgyBrJjfyPb" title="Number of warrants exercised">
        <span>
         <ix:nonfraction contextref="From2020-10-192020-10-20" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-841" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          11,738
         </ix:nonfraction>
        </span>
       </span>
       of thesewarrants were cashless exercised in October 2020. The expense related to the cashless exercise was approximately $
       <span id="xdx_905_eus-gaap--OtherOperatingIncomeExpenseNet_c20200101__20201231_zu5bQuYxSvv9" title="Other income/(expense)">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-842" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherOperatingIncomeExpenseNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD">
          44,000
         </ix:nonfraction>
        </span>
       </span>
       and it was recorded as other income/(expense), net on the statements of operations. The remaining
       <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__custom--RemainingWarrantsMember_z593VqS9N5ra">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureWarrantsMember_custom_ConsultantsMember_custom_RemainingWarrantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-843" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2,000
         </ix:nonfraction>
        </span>
       </span>
       warrants have an exerciseprice of $
       <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__srt--OwnershipAxis__custom--HadasitBioHoldingsLtdMember__us-gaap--StatementEquityComponentsAxis__custom--RemainingWarrantsMember_zNnK4GEQSEg8">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_HadasitBioHoldingsLtdMember_custom_RemainingWarrantsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-844" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          40.00
         </ix:nonfraction>
        </span>
       </span>
       and expire in
       <span id="xdx_904_ecustom--WarrantsAndRightsOutstandingMaturityDate1_ddxL_c20200101__20201231__srt--OwnershipAxis__custom--HadasitBioHoldingsLtdMember__us-gaap--StatementEquityComponentsAxis__custom--RemainingWarrantsMember_zQ9C7ocJ9Wfl" title="::XDX::2024-01-31">
        <span style="-sec-ix-hidden: xdx2ixbrl1497">
         <span>
          <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_HadasitBioHoldingsLtdMember_custom_RemainingWarrantsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1497" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-845" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:WarrantsAndRightsOutstandingMaturityDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           January 2024
          </ix:nonnumeric>
         </span>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       ASC815 requires freestanding financial instruments, such as warrants, with exercise prices denominated in currencies other than thefunctional currency of the issuer to be accounted for as liabilities at fair value, with all subsequent changes in fair valueafter the issuance date to be recorded as gains or losses in the consolidated statements of operations. Because the exercise priceof the Cell Cure Warrants is U.S. dollar-denominated and settlement is not expected to occur in the next twelve months, Cell Cureclassified the Cell Cure Warrants as a long-term liability in accordance with ASC 815.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thefair value of the Cell Cure Warrants at the time of issuance was determined by using the Black-Scholes option pricing model usingthe respective contractual term of the warrants. In applying this model, the fair value is determined by applying Level 3 inputs,as defined by ASC 820; these inputs are based on certain key assumptions including the fair value of the Cell Cure ordinary shares,adjusted for lack of marketability, as appropriate, and the expected stock price volatility over the term of the Cell Cure Warrants.The fair value of the Cell Cure ordinary shares is determined by Cell Cure’s Board of Directors, which may engage a valuationspecialist to assist it in estimating the fair value, or may use recent transactions in Cell Cure shares, if any, as a reasonableapproximation of fair value, or may apply other reasonable methods to determining the fair value, including a discount for lackof marketability. In connection with the cashless exercise in October 2020, Cell Cure had an independent third-party update thefair value of the Cell Cure shares. Lineage determines the stock price volatility using historical prices of comparable publiccompany common stock for a period equal to the remaining term of the Cell Cure Warrants. The Cell Cure Warrants are revalued eachreporting period using the same methodology described above, with changes in fair value included as gains or losses in other incomeand expenses, net, in the consolidated statements of operations.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 97 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           95
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe years ended December 31, 2020 and 2019, Lineage recorded a noncash loss of $
       <span>
        <span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember_zQNtujSIw0C3" title="Noncash expense/gain">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-846" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
           0.2
          </ix:nonfraction>
         </span>
        </span>
       </span>
       million and a noncash gain of $
       <span>
        <span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureWarrantsMember_zlldX1FyDREl" title="Noncash expense/gain">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_custom_CellCureWarrantsMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-847" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
           0.1
          </ix:nonfraction>
         </span>
        </span>
       </span>
       million,respectively, for the increase/decrease in the fair value of the Cell Cure Warrants included in other income and expenses, netfor each period. The increase in the fair value of the Cell Cure Warrants was mainly attributable to an increase in the fair valueof the Cell Cure shares due to additional progress made on the OpRegen program in 2020. As of December 31, 2020 and 2019, theCell Cure Warrants, valued at $
       <span>
        <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNoYXJlaG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__custom--OtherLongTermLiabilitiesMember_z9DlnXiHnky6" title="Noncash expense/gain">
         <span>
          <ix:nonfraction contextref="From2020-01-012020-12-31_custom_OtherLongTermLiabilitiesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-848" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
           0.4
          </ix:nonfraction>
         </span>
        </span>
       </span>
       million and $
       <span>
        <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNoYXJlaG9sZGVyc5IgRXF1aXR5IChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__custom--OtherLongTermLiabilitiesMember_zLEXIcV0kKyh" title="Noncash expense/gain">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31_custom_OtherLongTermLiabilitiesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-849" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
           0.3
          </ix:nonfraction>
         </span>
        </span>
       </span>
       million, respectively, were included in long-term liabilities on the consolidatedbalance sheets.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-850" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z42EJbCaWdwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        12.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82A_zcpgNnAcGfvc">
         Stock-Based Awards
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        EquityIncentive Plan Awards
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       EffectiveNovember 8, 2019, Lineage adopted an amendment changing the name of the BioTime, Inc. 2012 Equity Incentive 2012 Plan to the LineageCell Therapeutics, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the grant of stockoptions, restricted stock, restricted stock units (“RSUs”) and stock appreciation rights. As of December 31, 2020,a maximum of
       <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_pii" title="Number of shares available for grant">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_srt_MaximumMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-851" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          24,000,000
         </ix:nonfraction>
        </span>
       </span>
       common shares were available for grant under the 2012 Plan. Recipients of stock options are eligible topurchase common shares at an exercise price equal to the fair market value of such shares on the date of grant. The maximum termof options granted under the 2012 Plan is
       <span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zFQvfGHvtHig" title="Options granted term">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_srt_MaximumMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-852" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          10
         </ix:nonnumeric>
        </span>
       </span>
       years. Stock options generally vest over a four-year period based on continuous service;however, the 2012 Plan allows for other vesting periods. Upon the expiration of the restrictions applicable to an RSU, Lineagewill either issue to the recipient, without charge, one common share per RSU or cash in an amount equal to the fair market valueof one common share. RSUs granted from the 2012 Plan reduce the shares available for grant by two shares for each RSU granted.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-853" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember_zV39pY42tWg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Asummary of Lineage’s 2012 Plan activity and other stock option awards granted outside of the 2012 Plan related informationis as follows (in thousands, except per share amounts):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p id="xdx_8B9_z02giJfCtsY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif; display: none">
         Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Shares
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Available
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              for                                         Grant
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Number
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              of                                         Options
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Outstanding
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Number
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              of                                         RSUs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Outstanding
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Weighted
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Average
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Exercise                                         Price
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 40%; font-weight: bold">
           December 31, 2018
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z9sdWIKf81Pe" style="width: 11%; font-weight: bold; text-align: right" title="Shares Available for Grant, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2018-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-854" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             1,885
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zA30uNkSkeWf" style="width: 11%; font-weight: bold; text-align: right" title="Number of Options Outstanding, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2018-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-855" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             13,867
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iS_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zGkeyyvhUUO6" style="width: 11%; font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2018-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-856" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             402
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z1IiLLWYL5Ej" style="width: 11%; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2018-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-857" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.44
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Adjustment due to the AgeX Distribution
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_ecustom--SharesAvailableForGrantAdjustmentDueToRelatedPartyDistribution_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zPHHfZJjOZy7" style="text-align: right" title="Shares Available for Grant, Adjustment due to the AgeX Distribution">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-858" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SharesAvailableForGrantAdjustmentDueToRelatedPartyDistribution" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             117
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_ecustom--NumberOfOptionsOutstandingAdjustmentDueToRelatedPartyDistribution_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zzR2JKCfa1u7" style="text-align: right" title="Number of Options Outstanding, Adjustment due to the AgeX Distribution">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-859" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:NumberOfOptionsOutstandingAdjustmentDueToRelatedPartyDistribution" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="Shares">
             2
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_ecustom--NumberOfRsusOutstandingAdjustmentToRestrictedStockUnitsDueToRelatedPartyDistribution_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zF1ns2ziWEw9" style="text-align: right" title="Number of RSUs Outstanding, Adjustment due to the AgeX Distribution">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-860" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingAdjustmentToRestrictedStockUnitsDueToRelatedPartyDistribution" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             3
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_ecustom--WeightedAverageExercisePriceOfOptionsAdjustmentDueToRelatedPartyDistribution_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zW4VsqqiM6X5" style="text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Adjustment due to the AgeX Distribution">
           <span style="-sec-ix-hidden: xdx2ixbrl1529">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1529" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-861" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:WeightedAverageExercisePriceOfOptionsAdjustmentDueToRelatedPartyDistribution" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Increase to the 2012 Plan
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAdditionalShares_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zshWfrQ1Goab" style="text-align: right" title="Shares Available for Grant, Increase to the 2012 Plan">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-862" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SharebasedCompensationArrangementBySharebasedPaymentAwardAdditionalShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             8,000
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalShares_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zyEGA17MYhSh" style="text-align: right" title="Number of Options Outstanding, Increase to the 2012 Plan">
           <span style="-sec-ix-hidden: xdx2ixbrl1533">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1533" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-863" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_ecustom--NumberOfRsusOutstandingAdditionalShares_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zLQMn6u3cMu7" style="text-align: right" title="Number of RSUs Outstanding, Increase to the 2012 Plan">
           <span style="-sec-ix-hidden: xdx2ixbrl1535">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1535" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-864" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingAdditionalShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdditionalSharesWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zI0L4ZePEWFc" style="text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Increase to the 2012 Plan">
           <span style="-sec-ix-hidden: xdx2ixbrl1537">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1537" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-865" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdditionalSharesWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Options granted
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_pii_di_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zMiEf8ZaygBi" style="text-align: right" title="Shares Available for Grant, Options granted">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-866" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             3,581
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zZAWjDzAUlT8" style="text-align: right" title="Number of Options Outstanding, Options granted">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-867" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             3,581
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsGranted_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zPBykTvMvgL6" style="text-align: right" title="Number of RSUs Outstanding, Options granted">
           <span style="-sec-ix-hidden: xdx2ixbrl1543">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1543" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-868" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsGranted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zxqvFlATJ1f1" style="text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options granted">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-869" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.06
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Options forfeited
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z3ZzyveGMVKg" style="text-align: right" title="Shares Available for Grant, Options forfeited">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-870" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             2,736
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zpmgEMJJaq4a" style="text-align: right" title="Number of Options Outstanding, Options forfeited">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-871" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             2,736
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zXFaR7ef7jB7" style="text-align: right" title="Number of RSUs Outstanding, Options forfeited">
           <span style="-sec-ix-hidden: xdx2ixbrl1551">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1551" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-872" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z2zeRtPcqMW8" style="text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options forfeited">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-873" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.13
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Restricted stock units vested
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAvailableGrantsInPeriod_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zHA9q11Q1RN1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Available for Grant, Restricted stock units vested">
           <span style="-sec-ix-hidden: xdx2ixbrl1555">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1555" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-874" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAvailableGrantsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zRCjJhWecFYh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Restricted stock units vested">
           <span style="-sec-ix-hidden: xdx2ixbrl1557">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1557" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-875" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z34TDgHA0Tea" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs Outstanding, Restricted stock units vested">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-876" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             239
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zNFWPbR3wVT1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Restricted stock units vested">
           <span style="-sec-ix-hidden: xdx2ixbrl1561">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1561" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-877" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold">
           December 31, 2019
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zhkl0uedyDF5" style="font-weight: bold; text-align: right" title="Shares Available for Grant, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-878" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             9,157
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zjs5gHA3dzla" style="font-weight: bold; text-align: right" title="Number of Options Outstanding, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-879" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             14,710
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iE_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zpVQwaucHh4b" style="font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-880" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             166
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zG7aznihmM5" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, end balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-881" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.17
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold">
           December 31, 2019
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zWLqX3KXZyHh" style="font-weight: bold; text-align: right" title="Shares Available for Grant, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-882" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             9,157
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zkiMRWsNzBwl" style="font-weight: bold; text-align: right" title="Number of Options Outstanding, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-883" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             14,710
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z4KBupAKVO86" style="font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-884" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             166
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zTNz3bgvSgV9" style="font-weight: bold; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-885" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.17
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Options granted
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_pii_di_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zt7p4pFeeb0e" style="text-align: right" title="Shares Available for Grant, Options granted">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-886" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             5,256
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zvZclM7rZJr1" style="text-align: right" title="Number of Options Outstanding, Options granted">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-887" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             5,256
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsGranted_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zEAR4VpPJn71" style="text-align: right" title="Number of RSUs Outstanding, Options granted">
           <span style="-sec-ix-hidden: xdx2ixbrl1582">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1582" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-888" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsGranted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z2YjFjSKreS" style="text-align: right">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-889" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             0.71
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Options forfeited
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z9hovQsQb7li" style="text-align: right" title="Shares Available for Grant, Options forfeited">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-890" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             4,101
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_z0Kz8UxPovKe" style="text-align: right" title="Number of Options Outstanding, Options forfeited">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-891" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             4,101
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zTnyJBn0qjJj" style="text-align: right" title="Number of RSUs Outstanding, Options forfeited">
           <span style="-sec-ix-hidden: xdx2ixbrl1589">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1589" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-892" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zdW5sC8Rn6Mj" style="text-align: right">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-893" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.61
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Restricted units vested
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAvailableGrantsInPeriod_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zXg5sxGJPjgl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Available for Grant, Restricted stock units vested">
           <span style="-sec-ix-hidden: xdx2ixbrl1592">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1592" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-894" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAvailableGrantsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zGyHCHzS0r62" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Restricted stock units vested">
           <span style="-sec-ix-hidden: xdx2ixbrl1594">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1594" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-895" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingRestrictedStockUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zwqi1eC0BSEe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs Outstanding, Restricted stock units vested">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-896" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             73
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zRKkSfD1iZvh" style="border-bottom: Black 1.5pt solid; text-align: right">
           <span style="-sec-ix-hidden: xdx2ixbrl1597">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" data-original-id="xdx2ixbrl1597" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-897" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceRSU" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; padding-bottom: 2.5pt">
           December 31, 2020
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zQRsC8Q7Y5li" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Shares Available for Grant, Ending Balance">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-898" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             8,002
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zRNdnqriA6s5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Options Outstanding, Ending Balance">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-899" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             15,865
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zDTnXJ68Zjh7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-900" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             93
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zLkKuv8xPGIa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-901" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.57
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold; padding-bottom: 2.5pt">
           Options exercisable at December 31, 2020
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zeZE1LQbNmNa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Options Outstanding, Options exercisable">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-902" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             8,341
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlanOf2012Member_zzXBU5nA31rk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options exercisable">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_StockOptionPlanOf2012Member" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-903" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             2.16
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A3_zFMlHxNfqZJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, options outstanding and options exercisable under the 2012 Plan have a weighted-average remaining contractualterm of
       <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zJNNolZ0TI6h" title="Options outstanding,weighted-average remaining contractual term">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-904" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          6.3
         </ix:nonnumeric>
        </span>
       </span>
       years and
       <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zf0Rwd0kV90d" title="Options exercisable,weighted-average remaining contractual term">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-905" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          4.1
         </ix:nonnumeric>
        </span>
       </span>
       years, respectively, and intrinsic value of $
       <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_z6ln5K0NVsqj" title="Options outstanding,intrinsic value">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-906" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          7.4
         </ix:nonfraction>
        </span>
       </span>
       million and $
       <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn5n6_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zjDXomNue1I7" title="Options exercisable,intrinsic value">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-907" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.9
         </ix:nonfraction>
        </span>
       </span>
       million, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the vested RSUs during the year ended December 31, 2020, Lineage paid $
       <span id="xdx_908_eus-gaap--RestrictedStockValueSharesIssuedNetOfTaxWithholdings_pip0_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zZKlqiL1pNSj" title="Employee withholding taxes in exchange vesting restricted stock units">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-908" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          27,000
         </ix:nonfraction>
        </span>
       </span>
       in minimum employee withholdingtaxes in exchange for
       <span id="xdx_90F_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zz5l3tjCvMXb" title="Employee withholding taxes in exchange vesting restricted stock units, shares">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-909" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          26,000
         </ix:nonfraction>
        </span>
       </span>
       vested Lineage common shares issuable to the employees and immediately retired those shares. Forthe year ended December 31, 2020, Lineage recorded a noncash stock-based compensation expense of $
       <span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbLSApGNzgX8" title="Noncash stock-based compensation expense">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-910" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AllocatedShareBasedCompensationExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.1
         </ix:nonfraction>
        </span>
       </span>
       million, in connection withthe vested RSUs, included in consolidated stock-based compensation expense.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 98 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           96
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inconnection with the vested RSUs during the year ended December 31, 2019, Lineage paid $
       <span id="xdx_908_eus-gaap--RestrictedStockValueSharesIssuedNetOfTaxWithholdings_pn5n6_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zPnuKsg2RKq9" title="Employee withholding taxes in exchange vesting restricted stock units">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-911" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.1
         </ix:nonfraction>
        </span>
       </span>
       million in minimum employee withholdingtaxes in exchange for
       <span id="xdx_90F_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_ztx3h5WOMAol" title="Employee withholding taxes in exchange vesting restricted stock units, shares">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember_custom_EmployeesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-912" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          109,000
         </ix:nonfraction>
        </span>
       </span>
       vested Lineage common shares issuable to the employees and immediately retired those shares. Forthe year ended December 31, 2019, Lineage recorded a noncash stock-based compensation expense of $
       <span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za7bN1YmTZJi" title="Noncash stock-based compensation expense">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-913" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AllocatedShareBasedCompensationExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million, in connection withthe vested RSUs, included in consolidated stock-based compensation expense.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Atthe effective time of the Asterias Merger, Lineage assumed sponsorship of the Asterias 2013 Equity Incentive Plan (the “AsteriasEquity Plan”), with references to Asterias and Asterias common stock therein to be deemed references to Lineage and Lineagecommon shares. There were
       <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zenb6aQGGVb8" title="Number of shares available for grant">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-914" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          7,309,184
         </ix:nonfraction>
        </span>
       </span>
       shares available under the Asterias Equity Plan immediately before the closing of the AsteriasMerger, which became
       <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pii_c20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zwQ4KOyenqr1" title="Number of shares available for grant">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-915" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          5,189,520
         </ix:nonfraction>
        </span>
       </span>
       shares immediately following the Asterias Merger. The shares available under the Asterias EquityPlan will be for awards granted to those former Asterias employees who continued as Lineage employees upon consummation of theAsterias Merger.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-916" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zd8zshrEwws" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         A summary of activity under the Asterias Equity Plan from the closing date of the Asterias Merger through December31, 2020 is as follows (in thousands, except per share amounts):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p id="xdx_8B6_zlWdsXjFuYa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; display: none; text-align: justify; text-indent: 0.5in">
        Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Shares
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Available
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              for                                         Grant
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Number
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              of                                         Options
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Outstanding
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Number
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              of                                         RSUs
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Outstanding
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Weighted
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Average
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Exercise                                         Price
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 40%; font-weight: bold">
           March 8, 2019
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zQSqMp3A6TO1" style="width: 11%; font-weight: bold; text-align: right" title="Shares Available for Grant, Beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-917" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             5,190
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zyfzMGhQJ0Mf" style="width: 11%; font-weight: bold; text-align: right" title="Number of Options Outstanding, Beginning balance">
           <span style="-sec-ix-hidden: xdx2ixbrl1638">
            <span>
             <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1638" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-918" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iS_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zlaTGME3Gtpf" style="width: 11%; font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Beginning balance">
           <span style="-sec-ix-hidden: xdx2ixbrl1640">
            <span>
             <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1640" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-919" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
          <td style="width: 2%; font-weight: bold">
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zLJOz96rw8vi" style="width: 11%; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, beginning balance">
           <span style="-sec-ix-hidden: xdx2ixbrl1642">
            <span>
             <ix:nonfraction contextref="AsOf2019-03-08_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1642" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-920" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="width: 1%; font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Options granted
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zuqeMztKkRv4" style="text-align: right" title="Shares Available for Grant, Options granted">
           (
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-921" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="Shares">
             490
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zBY3qu4O4ccl" style="text-align: right" title="Number of Options Outstanding, Options granted">
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-922" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             490
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsGranted_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_z4D07GdoqMyk" style="text-align: right" title="Number of RSUs Outstanding, Options granted">
           <span style="-sec-ix-hidden: xdx2ixbrl1648">
            <span>
             <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1648" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-923" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsGranted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zmRx2ZXOyfRd" style="text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options granted">
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-924" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.59
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Options forfeited
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zHNLDfOvDelb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Available for Grant, Options forfeited">
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-925" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             140
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_z2QyA4f5GFWj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Options forfeited">
           (
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-926" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             140
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zXXsiBILZWFg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs Outstanding, Options forfeited">
           <span style="-sec-ix-hidden: xdx2ixbrl1656">
            <span>
             <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1656" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-927" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zWEIwP47jlzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options forfeited">
           <span>
            <ix:nonfraction contextref="From2019-03-092019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-928" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.63
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold">
           December 31, 2019
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zAFyl7UeBwfi" style="font-weight: bold; text-align: right" title="Shares Available for Grant, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-929" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             4,840
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zsDAGyrE47Gf" style="font-weight: bold; text-align: right" title="Number of Options Outstanding, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-930" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             350
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iE_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zL5CVFRjMFG5" style="font-weight: bold; text-align: right" title="Number of RSUs Outstanding, Ending balance">
           <span style="-sec-ix-hidden: xdx2ixbrl1664">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1664" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-931" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190309__20191231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zwJNPVkArkK3" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, end balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-932" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.57
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="display: none; vertical-align: bottom; background-color: White">
          <td style="font-weight: bold">
           December 31, 2019
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_z1sC6nkwJeF3" style="font-weight: bold; text-align: right" title="Shares Available for Grant, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-933" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             4,840
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zmpxUmdSOjWe" style="font-weight: bold; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-934" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             350
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zvqaSZ1hNyoh" style="font-weight: bold; text-align: right">
           <span style="-sec-ix-hidden: xdx2ixbrl1670">
            <span>
             <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1670" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-935" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zlAWTa9ahgFj" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, beginning balance">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-936" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.57
            </ix:nonfraction>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
            Options granted
           </span>
          </td>
          <td style="font-weight: bold">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_znprkNuErBda" style="font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1673">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1673" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-937" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zgEoDOpZpFjl" style="font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1674">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1674" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-938" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_980_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsGranted_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zYHZt5cEeNpa" style="font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1675">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1675" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-939" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsGranted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_z3A2WHxafilc" style="font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options granted">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1677">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1677" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-940" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           <span style="font-family: Times New Roman, Times, Serif">
            Options forfeited
           </span>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zCTeNL2m2Wzl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1678">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1678" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-941" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zIUb3MLJjJf2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1679">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1679" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-942" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_982_ecustom--NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zoPut0WatrW7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1680">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1680" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-943" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NumberOfRsusOutstandingRestrictedStockUnitsForfeitedOrCancelled" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zhYkzkSdUqVh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options forfeited">
           <span style="font-family: Times New Roman, Times, Serif">
            <span style="-sec-ix-hidden: xdx2ixbrl1682">
             <span>
              <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1682" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-944" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">
           <span style="font-family: Times New Roman, Times, Serif">
           </span>
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; padding-bottom: 2.5pt">
           December 31, 2020
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zDAwNoDvQPMc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Shares Available for Grant, Ending balance">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-945" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             4,840
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zoX6vIUy93kl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-946" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             350
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zGXXV6IGzyJ" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">
           <span style="-sec-ix-hidden: xdx2ixbrl1686">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1686" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-947" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zqNJoKcwgktd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, end balance">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-948" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.57
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold; padding-bottom: 2.5pt">
           Options exercisable at December 31, 2020
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zV8ENthM3hD6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Options Outstanding, Options exercisable">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-949" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
             153
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="font-weight: bold; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">
           $
          </td>
          <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember__us-gaap--BusinessAcquisitionAxis__custom--AsteriasBiotherapeuticsIncMember_zH0xvmoOOR78" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Weighted Average Exercise Price of Options Outstanding, Options exercisable">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember_custom_AsteriasBiotherapeuticsIncMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-950" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             1.57
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A4_zMjbFQ8M4DJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, options outstanding and options exercisable under the Asterias Equity Plan both have a weighted-averageremaining contractual term of
       <span title="Options outstanding,weighted-average remaining contractual term">
        <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zBCKclYfJeSc">
         <span>
          <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-951" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           8.2
          </ix:nonnumeric>
         </span>
        </span>
       </span>
       years and intrinsic value of $
       <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_pn3p0" title="Options outstanding,intrinsic value">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-952" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          67,000
         </ix:nonfraction>
        </span>
       </span>
       and $
       <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zDKlWlyEDoE4" title="Options exercisable,intrinsic value">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-953" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          29,000
         </ix:nonfraction>
        </span>
       </span>
       , respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Stock-basedcompensation expense
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-954" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHy1dmzpu8ri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thefair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-averageassumptions noted in the following table:
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p id="xdx_8B2_zPMnvSPEzqV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; display: none; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           Expected life (in years)
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zxKyiADhZ0Y9" style="width: 16%; text-align: right" title="Expected life (in years)">
           <span>
            <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-955" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             6.2
            </ix:nonnumeric>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zpEQsLBVFjUk" style="width: 16%; text-align: right" title="Expected life (in years)">
           <span>
            <ix:nonnumeric contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-956" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
             6.0
            </ix:nonnumeric>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Risk-free interest rates
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zBuYrvBkhnEe" style="text-align: right" title="Risk-free interest rates">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-957" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             0.8
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zmrrmJu1Ent4" style="text-align: right" title="Risk-free interest rates">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-958" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             2.2
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Volatility
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_znPPXl9v2Ta" style="text-align: right" title="Volatility">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-959" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             67.7
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zPwjxDIiTBJh" style="text-align: right" title="Volatility">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-960" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             63.1
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Dividend yield
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Dividend yield">
           <span>
            <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPercentage_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zuyGERGLvYQi">
             <span style="-sec-ix-hidden: xdx2ixbrl1712">
              <span>
               <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1712" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-961" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage" xs:nil="true">
                -
               </ix:nonfraction>
              </span>
             </span>
            </span>
            %
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Dividend yield">
           <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelvePlanMember_zTaMCSqdOlG">
            <span style="-sec-ix-hidden: xdx2ixbrl1713">
             <span>
              <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelvePlanMember" continued-taxonomy="false" data-original-id="xdx2ixbrl1713" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-962" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage" xs:nil="true">
               -
              </ix:nonfraction>
             </span>
            </span>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A0_zrkpHztiYXk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Theweighted-average estimated fair value of stock options granted under the 2012 Plan and other stock option awards granted outsideof the 2012 Plan, during the years ended December 31, 2020 and 2019 was $
       <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember_zB7qjHkOEAv5" title="Weighted average fair value of stock option awards granted">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-963" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          0.43
         </ix:nonfraction>
        </span>
       </span>
       and $
       <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwelveEquityIncentivePlanMember_zaiug2spUT8e" title="Weighted average fair value of stock option awards granted">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31_custom_TwoThousandAndTwelveEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-964" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
          0.68
         </ix:nonfraction>
        </span>
       </span>
       per share, respectively.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-965" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zCKmjTqOCAz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Operatingexpenses include stock-based compensation expense as follows (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p id="xdx_8B6_zBLOTpWn6kgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; display: none">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Schedule of Stock Based Compensation Expense
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           Research and development
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFP6xu0IUp56" style="width: 16%; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-966" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             464
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxkszwALAlZf" style="width: 16%; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-967" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             516
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           General and administrative
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEDiCcPjJVIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-968" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,763
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zdnrEcwa1Ky4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-969" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,064
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 2.5pt">
           Total stock-based compensation expense
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231_zyJra0GiAcDf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-970" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,227
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231_zWQfWoKgpike" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-971" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,580
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A9_zZmVigOkmntg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 99 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           97
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Theexpense related to
       <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zW5YKDPJtbL9" title="Number of restricted stock units">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-972" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          84,940
         </ix:nonfraction>
        </span>
       </span>
       shares of Asterias restricted stock unit awards that immediately vested on the closing of the AsteriasMerger and converted into the right to receive common shares of Lineage based on the Merger Exchange Ratio, resulting in
       <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--AsteriasTwoThousandThirteenEquityIncentivePlanMember_zNvvItauVILj" title="Common shares issued">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_AsteriasTwoThousandThirteenEquityIncentivePlanMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-973" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          60,304
         </ix:nonfraction>
        </span>
       </span>
       common shares of Lineage issued on March 8, 2019, was included in stock-based compensation expense for the year ended December31, 2019. The expense was not included as part of the purchase price of the Asterias Merger because these awards were principallyattributable to post-combination services.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, total unrecognized compensation costs related to unvested stock options under Lineage’s 2012 Planwas $
       <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20201231__us-gaap--PlanNameAxis__custom--LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember_zY2EzqFjck7j" title="Unrecognized compensation costs related to unvested stock options">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-974" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.9
         </ix:nonfraction>
        </span>
       </span>
       million, which is expected to be recognized as expense over a weighted average period of approximately
       <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember_zs23UKsxmMC6" title="Expected recognized expense over weighted average period">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_LineagesTwoThousandAndTwoPlanAndTwoThousandAndTwelveEquityIncentivePlanMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-975" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          2.6
         </ix:nonnumeric>
        </span>
       </span>
       years.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-976" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:IncomeTaxDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_z95bq8iEvnm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        13.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_829_zBiQfDrqnOjb">
         Income Taxes
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe year ended December 31, 2020, Lineage recorded a $
       <span id="xdx_909_ecustom--DeferredIncomeTaxExpensBenefit_pn5n6_c20200101__20201231_zJmJzqKdPzf8" title="Deferred income Tax expens benefit">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-977" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DeferredIncomeTaxExpensBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.2
         </ix:nonfraction>
        </span>
       </span>
       million deferred tax benefit for income taxes.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Forthe year ended December 31, 2019, Lineage recorded a $
       <span id="xdx_90C_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20191231_zu6qnpXcDtAg" title="Income tax, valuation allowance">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-978" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TaxCreditCarryforwardValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          7.4
         </ix:nonfraction>
        </span>
       </span>
       million valuation allowance release and corresponding benefit for incometaxes. This was comprised of a federal and state deferred income tax benefit of $
       <span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pn5n6_c20201231_zq5qYKKHTs89" title="Foreign net operating loss carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-979" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.6
         </ix:nonfraction>
        </span>
       </span>
       million and $
       <span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20201231_zZBJRfGxDgCf" title="State net operating loss carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-980" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.8
         </ix:nonfraction>
        </span>
       </span>
       million, respectively, forthe year ended December 31, 2019 due to the indefinite lived assets generated in the period and the release of the valuation allowance.The Company also recorded a current foreign income tax expense of $
       <span title="Foreign income tax expense">
        <span id="xdx_900_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_c20190101__20191231_zofSyRiR9w77" title="Foreign income tax expense">
         <span>
          <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-981" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD">
           31,000
          </ix:nonfraction>
         </span>
        </span>
       </span>
       for the year ended December 31, 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-982" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zFqt4yi2J5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thedomestic and foreign breakout of loss before net income tax benefit was as follows:
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">
        <span id="xdx_8BB_zv0QyH6Uvxvj" style="display: none">
         Schedule of Income before Income Tax, Domestic and Foreign
        </span>
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%">
           Domestic
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_pn3n3" style="width: 16%; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_DomesticCountryMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-983" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             17,500
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           )
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_za2U3rkLKlfk" style="width: 16%; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_DomesticCountryMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-984" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             7,303
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 1.5pt">
           Foreign
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_ForeignCountryMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-985" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             4,424
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_ForeignCountryMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-986" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             11,931
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Loss before net income tax benefit
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_984_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-987" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             21,924
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loss before net income tax benefit">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-988" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             19,234
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
           )
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AC_zG7mIMfwjgs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-989" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsKbfOPPiPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Incometaxes differed from the amounts computed by applying the indicated current U.S. federal income tax rate to pretax losses fromoperations as a result of the following:
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
       </p>
       <p id="xdx_8B0_zBPfDY0UJakb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; display: none; text-align: justify; text-indent: 27.35pt">
        Schedule of Income Tax Rate Reconciliation
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           Computed tax benefit at federal statutory rate
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231_zHUp5vdo66Jl" style="width: 16%; text-align: right" title="Computed tax benefit at federal statutory rate">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-990" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             21
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231_z2GuBPGHyDbb" style="width: 16%; text-align: right" title="Computed tax benefit at federal statutory rate">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-991" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             21
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Research and development and other credits
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pii_dp_uPercentage_c20200101__20201231_zIymaO8MkxUl" style="text-align: right" title="Research and development and other credits">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-992" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             1
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pii_dp_uPercentage_c20190101__20191231_zwsC3noj3aKl" style="text-align: right" title="Research and development and other credits">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-993" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             3
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Removal of DTL for equity investment in Asterias due to merger
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Removal of DTL for equity investment in Asterias due to merger">
           -%
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_ecustom--RemovalOfDtlForEquityInvestmentInDueToMerger_pii_dp_uPercentage_c20190101__20191231_zzYNsXN1XAd8" style="text-align: right" title="Removal of DTL for equity investment in Asterias due to merger">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-994" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RemovalOfDtlForEquityInvestmentInDueToMerger" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             22
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Permanent differences
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Permanent differences">
           -%
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pii_dp_uPercentage_c20190101__20191231_z9ZIerYefXQ6" style="text-align: right" title="Permanent differences">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-995" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:EffectiveIncomeTaxRateReconciliationPermanentDifferences" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="Percentage">
             1
            </ix:nonfraction>
           </span>
           )%
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Change in valuation allowance
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercentage_c20200101__20201231_zBfy66yUNG9f" style="text-align: right" title="Change in valuation allowance">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-996" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="Percentage">
             17
            </ix:nonfraction>
           </span>
           )%
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercentage_c20190101__20191231_zhNSD5YPQK1j" style="text-align: right" title="Change in valuation allowance">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-997" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="Percentage">
             106
            </ix:nonfraction>
           </span>
           )%
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Establish DTL for deferred assets from Asterias Merger
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Establish DTL for deferred assets from Asterias Merger">
           -%
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_ecustom--EstablishDtlForDeferredAssets_pii_dp_uPercentage_c20190101__20191231_zIaAmLPSXoi5" style="text-align: right" title="Establish DTL for deferred assets from Asterias Merger">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-998" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:EstablishDtlForDeferredAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             42
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Deconsolidation of AgeX and subsidiaries net deferred tax assets
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right" title="Deconsolidation of AgeX and subsidiaries net deferred tax assets">
           -%
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_ecustom--DeconsolidationOfRelatedPartyAndSubsidiariesNetDeferredTaxAssets_pii_dp_uPercentage_c20190101__20191231_zE1eFNiGu1Hd" style="text-align: right" title="Deconsolidation of AgeX and subsidiaries net deferred tax assets">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-999" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DeconsolidationOfRelatedPartyAndSubsidiariesNetDeferredTaxAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             3
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           State tax benefit, net of effect on federal income taxes
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231_z2FO8hlYGC1k" style="text-align: right" title="State tax benefit, net of effect on federal income taxes">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1000" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             3
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20190101__20191231_zCnpzMpbT6Ec" style="text-align: right" title="State tax benefit, net of effect on federal income taxes">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1001" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             54
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Foreign rate differential and other
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pii_dp_uPercentage_c20200101__20201231_z8bAGtw6bcB3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Foreign rate differential and other">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1002" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="Percentage">
             2
            </ix:nonfraction>
           </span>
           )%
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pii_dp_uPercentage_c20190101__20191231_zbdJaw7TUGV4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Foreign rate differential and other">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1003" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             1
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 2.5pt">
           Income tax benefit
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercentage_c20200101__20201231_zo7RMQX2F94c" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1004" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             6
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercentage_c20190101__20191231_zoKvplFaRXS" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1005" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             39
            </ix:nonfraction>
           </span>
           %
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AB_zWXQc7PnR964" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 100 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           98
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1006" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zoxBhp3LHMP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Theprimary components of the deferred tax assets and liabilities at December 31, 2020 and 2019 were as follows (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p id="xdx_8BD_zzIAkelLljC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; display: none; text-align: justify; text-indent: 27.35pt">
        Schedule of Components of Deferred Tax Assets and Liabilities
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="display: none; vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" id="xdx_491_20201231_zN8zhTHkssc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" id="xdx_490_20191231_zq0yAz6ui9Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid">
           Deferred tax assets/(liabilities):
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zOPeAbIAmFW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           Net operating loss carryforwards
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td style="width: 16%; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1007" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             63,941
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td style="width: 16%; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1008" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             62,060
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_ztXyrwfU4uee" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Research and development and other credits
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1009" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,878
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1010" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,619
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iI_pn3n3_zIzemhYeVGpg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Patents and licenses
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1011" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,178
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1012" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,220
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zGfXFWAoHHBa" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Stock options
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1013" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,131
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1014" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,708
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zryVXkq1H6De" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Operating lease liability
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1015" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             242
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1016" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             832
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iNI_pn3n3_di_z6q4GdHJngJ4" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Operating lease ROU assets
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1017" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             215
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1018" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             775
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
         <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zstAMqSLZA23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Equity method investments and marketable securities at fair value
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1019" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             15,685
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1020" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             19,367
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
         <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_zvM84Dgrr1s2" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Other, net
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1021" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,523
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1022" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             984
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_zVXgLPfDohf3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
           Total
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1023" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             61,993
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1024" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             56,281
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z2BEbMdfFhx2" style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Valuation allowance
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1025" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             64,069
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1026" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             59,596
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iNI_pn3n3_di_zu795MkiaG9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left; padding-bottom: 2.5pt">
           Net deferred tax liabilities
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1027" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,076
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: right">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1028" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,315
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
           )
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AA_zPOF7uzGmXHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Avaluation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized.Lineage established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefitsfrom its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by itssubsidiaries. During the year ended December 31, 2019, a portion of the valuation allowance was released as it relates to Lineage’sindefinite lived assets that can be used against the indefinite lived liabilities. The amount of the valuation allowance releasedwas $
       <span id="xdx_90C_ecustom--DeferredTaxAssetValuationAllowance_iI_pn5n6_c20191231_zIoj0p0GmhPb">
        <span>
         <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1029" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DeferredTaxAssetValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          7.4
         </ix:nonfraction>
        </span>
       </span>
       million;as new indefinite lived deferred tax assets are generated, we will continue to book provision benefits until the deferred taxliability position is exhausted, barring any new developments.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, Lineage has gross net operating loss carryforwards of approximately $
       <span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20201231_z2Mo6n0TRGO2" title="Net operating loss carryforwards for federal tax purposes">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1030" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          169.9
         </ix:nonfraction>
        </span>
       </span>
       million for federal purposes.As of December 31, 2020, Lineage’s foreign subsidiaries have net operating loss carryforwards of approximately $
       <span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zxZwBZgPqZK3" title="Operating loss carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_ForeignCountryMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1031" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          88.3
         </ix:nonfraction>
        </span>
       </span>
       millionwhich carryforward indefinitely.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, Lineage has net operating losses of $
       <span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsnfxb5dQG44" title="Operating loss carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_StateAndLocalJurisdictionMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1032" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          118.6
         </ix:nonfraction>
        </span>
       </span>
       million for state tax purposes.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asof December 31, 2020, Lineage has research tax credit carryforwards for federal and state tax purposes of $
       <span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zle5p4PXq6Uj" title="Tax credit carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_DomesticCountryMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1033" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TaxCreditCarryforwardAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.2
         </ix:nonfraction>
        </span>
       </span>
       million and $
       <span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zxnVHqb3NMDb" title="Tax credit carryforwards">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_us-gaap_StateAndLocalJurisdictionMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1034" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TaxCreditCarryforwardAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          5.7
         </ix:nonfraction>
        </span>
       </span>
       million, respectively. These tax credits reflect the amounts for Lineage, Asterias and OrthoCyte as of December 31, 2020. Withthe announcement of the California agreement with the Senate, allowing a deduction of up to $
       <span id="xdx_90D_ecustom--DeductionsFromIncomeTax_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CaliforniaAgreementMember_zu1bOgAqwDS3" title="Income tax deductions">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_CaliforniaAgreementMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1035" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DeductionsFromIncomeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          150,000
         </ix:nonfraction>
        </span>
       </span>
       for expenses paid with thePPP loan proceeds, any amount disallowed for California, that relates to R&amp;D wages, may be limited. For federal purposes,
       <span id="xdx_900_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z6NckxkcyuV1" title="Tax credit carryforward, limitation on use">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_DomesticCountryMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1036" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the credits generated each year have a carryforward period of 20 years
         </ix:nonnumeric>
        </span>
       </span>
       . The federal tax credits expire in varying amounts
       <span id="xdx_90B_ecustom--NetOperatingLossesExpirationDate_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zhUqlZAnZoTd" title="Net operating losses expiration date">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_DomesticCountryMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1037" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:NetOperatingLossesExpirationDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          between2020 and 2040
         </ix:nonnumeric>
        </span>
       </span>
       , while the state tax credits have no expiration period.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnAugust 5, 2020, Lineage began the liquidation of its foreign subsidiary BioTime Asia. At the time of the liquidation, BioTimeAsia had an intercompany payable due to Lineage. For book purposes, the corresponding balances eliminate in consolidation. Forfederal purposes, the activities of their foreign subsidiaries are not included in the consolidated tax return. Accordingly, thepayable was written off for tax purposes by Lineage, creating a $
       <span id="xdx_904_ecustom--IncreaseInOperatingLossCarryforwards_pn5n6_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zloQNR16L3g4" title="Increase in NOL carryover">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_ForeignCountryMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1038" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:IncreaseInOperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.6
         </ix:nonfraction>
        </span>
       </span>
       million bad debt deduction increasing its NOL carryover.For California, the activities of its foreign subsidiaries, including BioTime Asia, are included in the combined tax return. Assuch, the corresponding intercompany balances are eliminated.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        OtherTransactions and Related Impact on Income Taxes
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Themarket value of the respective shares Lineage holds in OncoCyte, AgeX and Asterias (through the merger date of March 8, 2019)creates a deferred tax liability to Lineage based on the closing price of the security, less the tax basis of the security Lineagehas in such shares. The deferred tax liability generated by shares that Lineage holds as of December 31, 2020 and 2019, is a sourceof future taxable income to Lineage, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realizationof its deferred tax assets to the extent of those deferred tax liabilities. This deferred tax liability is determined based onthe closing price of those securities as of December 31, 2020 and 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 101 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           99
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        OtherIncome Tax Matters
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InternalRevenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can beoffset by NOL carryforwards after a change in control (generally greater than
       <span id="xdx_90E_ecustom--NetOperatingLossCarryforwardsChangeInOwnershipControl_iI_pii_dp_uPercentage_c20201231_zpigRRMxmBFh" title="Net operating loss carryforwards change in ownership control">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1039" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:NetOperatingLossCarryforwardsChangeInOwnershipControl" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          50
         </ix:nonfraction>
        </span>
       </span>
       % change in ownership within a three-year period)of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOLcarryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilizationof the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable incomein future periods.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagefiles a U.S. federal income tax return as well as various state and foreign income tax returns. In general, Lineage is no longersubject to tax examination by major taxing authorities for years before 2016. Although the statute is closed for purposes of assessingadditional income and tax in these years, the taxing authorities may still make adjustments to the NOL and credit carryforwardsused in open years. Therefore, the statute should be considered open as it relates to the NOL and credit carryforwards used inopen years.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagemay be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of incometaxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among varioustax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. Lineage’s management does not expectthat the total amount of unrecognized tax benefits will materially change over the next twelve months.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineage’spractice is to recognize interest and penalties related to income tax matters in tax expense. As of December 31, 2020 and 2019,Lineage has no accrued interest and penalties.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1040" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6ox2Yglh0n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        14.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_823_zovM3FyTAmrg">
         Commitments and Contingencies
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        CarlsbadLease
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InMay 2019, Lineage entered into a lease for approximately
       <span id="xdx_900_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20190531__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zOikzOoNVgY9" title="Rentable area">
        <span>
         <ix:nonfraction contextref="AsOf2019-05-31_custom_CarlsbadLeaseMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1041" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          8,841
         </ix:nonfraction>
        </span>
       </span>
       square feet of rentable space in an office park in Carlsbad, California(the “Carlsbad Lease”). The term of the Carlsbad Lease commenced on
       <span id="xdx_909_ecustom--LeaseCommencedDate_dd_c20190501__20190531__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zIg1f1KFbHY6" title="Lease commencement date">
        <span>
         <ix:nonnumeric contextref="From2019-05-012019-05-31_custom_CarlsbadLeaseMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1042" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LeaseCommencedDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          August 1, 2019
         </ix:nonnumeric>
        </span>
       </span>
       and expires on
       <span id="xdx_90C_eus-gaap--LeaseExpirationDate1_dd_c20190501__20190531__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zT2X8TDCk9hb" title="Lease expiration date">
        <span>
         <ix:nonnumeric contextref="From2019-05-012019-05-31_custom_CarlsbadLeaseMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1043" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeaseExpirationDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          October 31, 2022
         </ix:nonnumeric>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      Base rent under theCarlsbad Lease as of August 1, 2020 is $
      <span id="xdx_901_ecustom--BaseRent_iI_pp0p0_c20200801__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zQ1ARlcc3yMg" title="Base rent">
       <span>
        <ix:nonfraction contextref="AsOf2020-08-01_custom_CarlsbadLeaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1044" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
         18,386
        </ix:nonfraction>
       </span>
      </span>
      per month and will increase by
      <span id="xdx_90D_ecustom--BaseRentIncreaseRate_iI_pii_dp_uPercentage_c20200801__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zqDyy3i39Ice" title="Base rent increase rate">
       <span>
        <ix:nonfraction contextref="AsOf2020-08-01_custom_CarlsbadLeaseMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1045" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentIncreaseRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
         3
        </ix:nonfraction>
       </span>
      </span>
      % annually on every August1 thereafter during the lease term. Base rent for the first twenty-four months of the lease is based upon a deemed rentable areaof
      <span id="xdx_907_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20200801__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember__us-gaap--AwardDateAxis__custom--FirstTwentyFourMonthsMember_zz8Ghevd22la" title="Rentable area">
       <span>
        <ix:nonfraction contextref="AsOf2020-08-01_custom_CarlsbadLeaseMember_custom_FirstTwentyFourMonthsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1046" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
         7,000
        </ix:nonfraction>
       </span>
      </span>
      square feet. Base rent is abated for months two through five of the lease.
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inaddition to base rent, Lineage will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities(to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of thoseexpenses incurred by the landlord. As security for the performance of its obligations under the Carlsbad Lease, Lineage providedthe landlord with a security deposit of $
       <span id="xdx_901_eus-gaap--SecurityDeposit_iI_pp0p0_c20200801__us-gaap--LeaseContractualTermAxis__custom--CarlsbadLeaseMember_zIlzvAhmaP41" title="Security deposit">
        <span>
         <ix:nonfraction contextref="AsOf2020-08-01_custom_CarlsbadLeaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1047" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          17,850
         </ix:nonfraction>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        AlamedaLeases and Alameda Sublease
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InDecember 2015, Lineage entered into leases of office and laboratory space located in
       <span id="xdx_90C_ecustom--NumberOfBuildingForLeaseDescription_c20151201__20151231__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_zAQhEegVqJxc">
        <span>
         <ix:nonnumeric contextref="From2015-12-012015-12-31_custom_AlamedaLeasesMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1048" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:NumberOfBuildingForLeaseDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          twobuildings
         </ix:nonnumeric>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       in Alameda, California (the “AlamedaLeases”) comprised of
       <span id="xdx_907_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20151231__us-gaap--LeaseContractualTermAxis__custom--ThousandTenAtlanticPremisesMember_zJrDYHn2tso7">
        <span>
         <ix:nonfraction contextref="AsOf2015-12-31_custom_ThousandTenAtlanticPremisesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1049" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          22,303
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       square feet (the “1010 AtlanticPremises”) and
       <span id="xdx_906_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20151231__us-gaap--LeaseContractualTermAxis__custom--ThousandTwentyAtlanticPremisesMember_zBPnAt7pXK56">
        <span>
         <ix:nonfraction contextref="AsOf2015-12-31_custom_ThousandTwentyAtlanticPremisesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1050" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          8,492
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       square feet (the “1020 AtlanticPremises”). Base rent under the Alameda Leases beginning on February 1, 2020 was $
       <span id="xdx_90F_ecustom--BaseRent_c20200201__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_pp0p0">
        <span>
         <ix:nonfraction contextref="AsOf2020-02-01_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1051" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          72,636
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       per month with annual increases of approximately
       <span id="xdx_900_ecustom--BaseRentIncreaseRate_iI_pii_dp_uPercentage_c20200201__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_zBgPSrko1wKe">
        <span>
         <ix:nonfraction contextref="AsOf2020-02-01_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1052" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentIncreaseRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          3
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       %.
       <span style="background-color: white">
        In addition to base rent, Lineage paid a pro rata portion of increases in certain expenses,including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operatingexpenses, over the amounts of those expenses incurred by the landlord.
       </span>
       As security for its obligations, Lineage providedthe landlord with a security deposit of approximately $
       <span id="xdx_906_eus-gaap--SecurityDeposit_c20200201__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_pp0p0">
        <span>
         <ix:nonfraction contextref="AsOf2020-02-01_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1053" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          424,000
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       ,which was reduced to $
       <span id="xdx_90B_ecustom--SecurityDepositReductionInValueAfterFirstTwentyFourMonthsOfLeaseTerm_iI_pp0p0_c20190124__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_zeRkF0gcJ8N2">
        <span>
         <ix:nonfraction contextref="AsOf2019-01-24_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1054" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SecurityDepositReductionInValueAfterFirstTwentyFourMonthsOfLeaseTerm" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          78,000
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       on January 24, 2019 in accordance withthe terms of the lease. The security deposit amount is considered restricted cash and is included in prepaid expenses and othercurrent assets as of December 31, 2020 (See Note 2).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 102 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           100
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InApril 2020, Lineage entered into a sublease with Industrial Microbes, Inc. (“Industrial Microbes”) for the use of
       <span id="xdx_904_eus-gaap--LandSubjectToGroundLeases_iI_pii_uSquareFeet_c20200430__dei--LegalEntityAxis__custom--IndustrialMicrobesIncMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AlamedaSubleaseMember_zvWTIwUXX7gj" title="Lease area">
        <span>
         <ix:nonfraction contextref="AsOf2020-04-30_custom_IndustrialMicrobesIncMember_custom_AlamedaSubleaseMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1055" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LandSubjectToGroundLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          10,000
         </ix:nonfraction>
        </span>
       </span>
       square feet in the 1010 Atlantic Premises (the “Industrial Microbes Sublease”). Base rent under the IndustrialMicrobes Sublease
       <span style="background-color: white">
        was $
        <span id="xdx_905_ecustom--BaseRent_c20200430__dei--LegalEntityAxis__custom--IndustrialMicrobesIncMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AlamedaSubleaseMember_pp0p0" title="Base rent">
         <span>
          <ix:nonfraction contextref="AsOf2020-04-30_custom_IndustrialMicrobesIncMember_custom_AlamedaSubleaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1056" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
           28,000
          </ix:nonfraction>
         </span>
        </span>
        per month with annual increases of approximately
        <span id="xdx_906_ecustom--BaseRentIncreaseRate_iI_pii_dp_uPercentage_c20200430__dei--LegalEntityAxis__custom--IndustrialMicrobesIncMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AlamedaSubleaseMember_z7aTNvaRGBA4" title="Base rent increase rate">
         <span>
          <ix:nonfraction contextref="AsOf2020-04-30_custom_IndustrialMicrobesIncMember_custom_AlamedaSubleaseMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1057" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentIncreaseRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
           3
          </ix:nonfraction>
         </span>
        </span>
        %. Baserent for the first month was abated. In addition to base rent and utilities, Industrial Microbes paid a pro-rata portion of increasesin operating expenses, after an abatement period of one year.
       </span>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnSeptember 11, 2020, Lineage entered into a Lease Termination Agreement with the landlord terminating the Alameda Leases effectiveas of August 31, 2020 for the 1020 Atlantic Premises and September 30, 2020 for the 1010 Atlantic Premises.
       <span style="background-color: white">
        Inconsideration for the termination of the leases, Lineage paid a termination fee of $
        <span id="xdx_90C_ecustom--TerminationFees_pp0p0_c20200910__20200911__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_zHRhYUgYQU08" title="Termination fees">
         <span>
          <ix:nonfraction contextref="From2020-09-102020-09-11_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1058" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:TerminationFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
           130,000
          </ix:nonfraction>
         </span>
        </span>
        and other amounts due under the termsof the Alameda Leases through the applicable effective termination dates, except that no rent was due with respect to the 1020Atlantic Premises after July 31, 2020.
       </span>
       Lineage’s security deposit is expected to be returned to Lineage by March31, 2021.
       <span style="background-color: white">
        Lineage paid a separate termination fee of $
        <span id="xdx_907_ecustom--TerminationFees_c20200910__20200911__us-gaap--LeaseContractualTermAxis__custom--IndustrialMicrobesSubleaseMember_pp0p0" title="Termination fees">
         <span>
          <ix:nonfraction contextref="From2020-09-102020-09-11_custom_IndustrialMicrobesSubleaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1059" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:TerminationFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
           30,000
          </ix:nonfraction>
         </span>
        </span>
        to Industrial Microbes in connectionwith the termination of the Industrial Microbes Sublease and returned
       </span>
       the $
       <span id="xdx_907_eus-gaap--SecurityDeposit_c20200911__us-gaap--LeaseContractualTermAxis__custom--IndustrialMicrobesSubleaseMember_pp0p0" title="Security deposit">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-11_custom_IndustrialMicrobesSubleaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1060" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          56,000
         </ix:nonfraction>
        </span>
       </span>
       security deposit paid by Industrial Microbes.For the period of sublease from mid-April 2020 through September 2020, Lineage received $
       <span id="xdx_907_eus-gaap--RentalIncomeNonoperating_c20200401__20200930__us-gaap--LeaseContractualTermAxis__custom--IndustrialMicrobesSubleaseMember_zPbqNQb5yjPl" title="Rental income received">
        <span>
         <ix:nonfraction contextref="From2020-04-012020-09-30_custom_IndustrialMicrobesSubleaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1061" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RentalIncomeNonoperating" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD">
          119,000
         </ix:nonfraction>
        </span>
       </span>
       in rental income from IndustrialMicrobes.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
       Lineagewill continue to occupy approximately
       <span id="xdx_90C_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20200911__us-gaap--LeaseContractualTermAxis__custom--ThousandTenAtlanticPremisesMember_z78tvaX4O332" title="Rentable area">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-11_custom_ThousandTenAtlanticPremisesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1062" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          2,432
         </ix:nonfraction>
        </span>
       </span>
       square feet of the 1010 Atlantic Premises under a new sublease agreement (the “AlamedaSublease”).
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       The term of the Alameda Subleaseis from
       <span id="xdx_902_ecustom--LeaseCommencedDate_dd_c20200910__20200911__us-gaap--LeaseContractualTermAxis__custom--ThousandTenAtlanticPremisesMember_zyJeMlSNaA3c" title="Lease commencement date">
        <span>
         <ix:nonnumeric contextref="From2020-09-102020-09-11_custom_ThousandTenAtlanticPremisesMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1063" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LeaseCommencedDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          October 1, 2020
         </ix:nonnumeric>
        </span>
       </span>
       through
       <span id="xdx_909_eus-gaap--LeaseExpirationDate1_dd_c20200910__20200911__us-gaap--LeaseContractualTermAxis__custom--ThousandTenAtlanticPremisesMember_znkjkTEjRfo8" title="Lease expiration date">
        <span>
         <ix:nonnumeric contextref="From2020-09-102020-09-11_custom_ThousandTenAtlanticPremisesMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1064" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeaseExpirationDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          January 31, 2023
         </ix:nonnumeric>
        </span>
       </span>
       . Base rent under the Alameda Sublease is $
       <span id="xdx_906_ecustom--BaseRent_c20200911__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_pp0p0" title="Base rent">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-11_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1065" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          14,592
         </ix:nonfraction>
        </span>
       </span>
       per month with annual increasesof
       <span id="xdx_905_ecustom--BaseRentIncreaseRate_iI_pii_dp_uPercentage_c20200911__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_zS0KTgvWv2Hc" title="Base rent increase rate">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-11_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1066" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentIncreaseRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          3
         </ix:nonfraction>
        </span>
       </span>
       % each October 1 thereafter during the lease term. Base rent for the first month was abated. Lineage paid a security depositof $
       <span id="xdx_90D_eus-gaap--SecurityDeposit_c20200911__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_pp0p0" title="Security deposit">
        <span>
         <ix:nonfraction contextref="AsOf2020-09-11_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1067" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          16,000
         </ix:nonfraction>
        </span>
       </span>
       under the Alameda Sublease; this amount is considered restricted cash and is included in deposits and other long-termassets as of December 31, 2020 (see Note 2).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Basedon the smaller footprint, and after taking into consideration the fees disclosed above, Lineage has reduced its contractual obligationsby approximately $
       <span id="xdx_90B_ecustom--ReductionOfContractualObligations_c20200910__20200911__us-gaap--LeaseContractualTermAxis__custom--AlamedaLeasesMember_pp0p0" title="Reduction of contractual obligations">
        <span>
         <ix:nonfraction contextref="From2020-09-102020-09-11_custom_AlamedaLeasesMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1068" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ReductionOfContractualObligations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          780,000
         </ix:nonfraction>
        </span>
       </span>
       over the remaining life of the original leases through January 31, 2023.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        NewYork Leased Office Space
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagecurrently pays $
       <span id="xdx_904_ecustom--BaseRent_c20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember_pp0p0" title="Base rent">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1069" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          5,050
         </ix:nonfraction>
        </span>
       </span>
       per month for the use of approximately
       <span id="xdx_904_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember_zenSUXFHBMek" title="Rentable area">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1070" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          900
         </ix:nonfraction>
        </span>
       </span>
       square feet of office space in New York City, which is made availableto Lineage for use in conducting meetings and other business affairs, on a month-by-month basis, by one of its directors at anamount that approximates his cost. This lease was not in the scope of ASC 842 because it is a month to month lease (see Note 2).
       <span id="xdx_90B_ecustom--LeaseExpirationDescription_c20200101__20201231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceInNewYorkCityMember_z4mYbA2RYSs9" title="Lease expiration description">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_OfficeSpaceInNewYorkCityMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1071" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LeaseExpirationDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          These payments are expected to cease in March 2021 when the office space lease expires
         </ix:nonnumeric>
        </span>
       </span>
       .
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        CellCure Leases
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       CellCure leases
       <span id="xdx_904_eus-gaap--LandSubjectToGroundLeases_iI_pii_uAreaSquareMeter_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zWPf4ZykcfKh" title="Lease area">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1072" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LandSubjectToGroundLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="AreaSquareMeter">
          728.5
         </ix:nonfraction>
        </span>
       </span>
       square meters (approximately
       <span id="xdx_90C_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zX5zcBzqIkkh" title="Rentable area">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1073" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          7,842
         </ix:nonfraction>
        </span>
       </span>
       square feet) of office and laboratory space in Jerusalem, Israel under alease that expires
       <span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zbeVN4z4k9Fe" title="Lease expiration date">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1074" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeaseExpirationDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          December 31, 2025
         </ix:nonnumeric>
        </span>
       </span>
       , with an option to extend the lease for
       <span id="xdx_902_ecustom--LesseeOperatingLeaseRenewalTermDescription_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember" title="Lease, renewal term">
        <span>
         <ix:nonnumeric contextref="From2020-01-012020-12-31_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1075" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LesseeOperatingLeaseRenewalTermDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          5 years
         </ix:nonnumeric>
        </span>
       </span>
       (the “Original Cell Cure Lease”).Base monthly rent is NIS
       <span id="xdx_907_ecustom--BaseRent_iI_pp0p0_c20201231__us-gaap--AwardTypeAxis__custom--NISCurrencyExchangeMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zZ6DsWI9aVYc" title="Base rent">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_NISCurrencyExchangeMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1076" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          39,776
         </ix:nonfraction>
        </span>
       </span>
       (approximately US $
       <span id="xdx_908_ecustom--BaseRent_c20201231__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandEighteenExchangeRateMember_pp0p0" title="Base rent">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember_custom_DecemberTwoThousandEighteenExchangeRateMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1077" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          12,200
         </ix:nonfraction>
        </span>
       </span>
       per month using the December 7, 2020 exchange rate). In addition tobase rent, Cell Cure pays a pro rata share of real property taxes and certain costs related to the operation and maintenance ofthe building in which the leased premises are located.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnJanuary 28, 2018, Cell Cure entered into another lease agreement for an additional
       <span id="xdx_909_eus-gaap--LandSubjectToGroundLeases_iI_pii_uAreaSquareMeter_c20180128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember_z3xdWE0JOCO4" title="Lease area">
        <span>
         <ix:nonfraction contextref="AsOf2018-01-28_custom_CellCureMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1078" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LandSubjectToGroundLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="AreaSquareMeter">
          934
         </ix:nonfraction>
        </span>
       </span>
       square meters (approximately
       <span id="xdx_908_eus-gaap--NetRentableArea_iI_pii_uSquareFeet_c20180128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember_zsjWu0zFatg1" title="Rentable area">
        <span>
         <ix:nonfraction contextref="AsOf2018-01-28_custom_CellCureMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1079" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetRentableArea" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="SquareFeet">
          10,054
         </ix:nonfraction>
        </span>
       </span>
       squarefeet) of office space in the same facility in Jerusalem, Israel under a lease that expires on
       <span id="xdx_90A_eus-gaap--LeaseExpirationDate1_dd_c20180127__20180128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zEW7efJa36ff" title="Lease expiration date">
        <span>
         <ix:nonnumeric contextref="From2018-01-272018-01-28_custom_CellCureMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1080" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeaseExpirationDate1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          December 31, 2025
         </ix:nonnumeric>
        </span>
       </span>
       , with two optionsto extend the lease for
       <span id="xdx_90B_ecustom--LesseeOperatingLeaseRenewalTermDescription_c20180127__20180128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember_z5Tk39LTwj2c" title="Lease, renewal term">
        <span>
         <ix:nonnumeric contextref="From2018-01-272018-01-28_custom_CellCureMember" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1081" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:LesseeOperatingLeaseRenewalTermDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          5 years
         </ix:nonnumeric>
        </span>
       </span>
       each (the “January 2018 Lease”). The January 2018 Lease commenced on April 1, 2018and included a leasehold improvement construction allowance of up to NIS
       <span id="xdx_90D_eus-gaap--PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest_pp0p0_uNIS_c20180330__20180402__us-gaap--AwardTypeAxis__custom--NISCurrencyExchangeMember__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zRnfGBQayAf6" title="Construction allowances of leasehold improvements">
        <span>
         <ix:nonfraction contextref="From2018-03-302018-04-02_custom_NISCurrencyExchangeMember_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1082" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="NIS">
          4,000,000
         </ix:nonfraction>
        </span>
       </span>
       (approximately up to $
       <span id="xdx_90F_eus-gaap--PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest_pn5n6_c20180330__20180402__us-gaap--LeaseContractualTermAxis__custom--OfficeAndLaboratorySpaceJerusalemIsraelMember_zZPAQ60cGDuk" title="Construction allowances of leasehold improvements">
        <span>
         <ix:nonfraction contextref="From2018-03-302018-04-02_custom_OfficeAndLaboratorySpaceJerusalemIsraelMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1083" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.1
         </ix:nonfraction>
        </span>
       </span>
       million using theDecember 31, 2018 exchange rate) from the landlord. The leasehold improvements were completed in December 2018 and the entireallowance was used. Beginning on January 1, 2019, combined base rent and construction allowance payments for the January 2018Lease are NIS
       <span id="xdx_90E_ecustom--BaseRentAndConstructionAllowancePerMonth_pp0p0_uNIS_c20190127__20190128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember__us-gaap--AwardTypeAxis__custom--NISCurrencyExchangeMember_z8XREeFFGJY7" title="Base rent and construction allowance per month">
        <span>
         <ix:nonfraction contextref="From2019-01-272019-01-28_custom_CellCureMember_custom_NISCurrencyExchangeMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1084" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentAndConstructionAllowancePerMonth" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="NIS">
          93,827
         </ix:nonfraction>
        </span>
       </span>
       per month (approximately $
       <span id="xdx_904_ecustom--BaseRentAndConstructionAllowancePerMonth_c20190127__20190128__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CellCureMember_pp0p0" title="Base rent and construction allowance per month">
        <span>
         <ix:nonfraction contextref="From2019-01-272019-01-28_custom_CellCureMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1085" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:BaseRentAndConstructionAllowancePerMonth" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          26,000
         </ix:nonfraction>
        </span>
       </span>
       per month).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 103 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           101
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      Prior to the adoptionof ASC 842 on January 1, 2019, Cell Cure was considered the owner of the tenant improvements under construction under ASC 840-40-55as Cell Cure, among other things, had the primary obligation to pay for construction costs and Cell Cure retains exclusive useof the leased facilities for its office, research and cGMP manufacturing facility requirements after construction was completed(“build to suit” lease). In accordance with the ASC 840 guidance, amounts expended by Cell Cure for construction wasreported as construction in progress, and the proceeds received from the landlord, if any, are reported as a lease liability. Asof December 31, 2018, approximately $
      <span id="xdx_90C_eus-gaap--PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest_pn5n6_c20180101__20181231__us-gaap--LeaseContractualTermAxis__custom--JanuaryTwoThousandAndEighteenLeaseMember_zd8KLIm9EQOb" title="Construction allowances of leasehold improvements">
       <span>
        <ix:nonfraction contextref="From2018-01-012018-12-31_custom_JanuaryTwoThousandAndEighteenLeaseMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1086" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PublicUtilitiesAllowanceForFundsUsedDuringConstructionCapitalizedInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         1.1
        </ix:nonfraction>
       </span>
      </span>
      million under the January 2018 Lease was incurred and recorded as leasehold improvementconstruction in progress, with a corresponding amount included in long term lease liability representing the full amount utilizedfrom the landlord’s leasehold improvement construction allowance. By March 2019, the landlord paid the complete leaseholdimprovement construction allowance and the property was placed in service.
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       SeeNote 2 for discussion of the impact of adoption of ASC 842 on January 1, 2019, and below for the ROU assets and liabilities recordedin connection with the adoption of ASC 842 as of, and during the year ended December 31, 2019 for the Original Cell Cure Leaseand January 2018 Lease (the “Cell Cure Leases”).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InDecember 2018, Cell Cure made a deposit required under the January 2018 Lease, which amount of $
       <span id="xdx_900_eus-gaap--DepositAssets_c20181231__us-gaap--LeaseContractualTermAxis__custom--JanuaryTwoThousandAndEighteenLeaseMember_pp0p0" title="Deposit">
        <span>
         <ix:nonfraction contextref="AsOf2018-12-31_custom_JanuaryTwoThousandAndEighteenLeaseMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1087" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepositAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          420,000
         </ix:nonfraction>
        </span>
       </span>
       is included indeposits and other long-term assets on the consolidated balance sheet as of December 31, 2020, to be held as restricted cash duringthe term of the January 2018 Lease.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Adoptionof ASC 842
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Thebelow tables provide the amounts recorded in connection with the adoption of ASC 842 as of, and for the years ended December 31,2020 and 2019, for Lineage’s operating and financing leases, as applicable.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1088" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_895_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zuvgTqU95fgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Supplementalcash flow information related to leases was as follows (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8BB_zJM25qs8Ucrf" style="display: none">
          Schedule of Supplemental Cash Flow Information Related to Leases
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="padding-bottom: 1.5pt; text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">
           Year    Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; text-align: left">
           Cash paid for amounts included in the measurement of lease liabilities:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; width: 60%; text-align: left">
           Operating cash flows from operating leases
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--OperatingLeasePayments_c20200101__20201231_pn3n3" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1089" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasePayments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,356
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--OperatingLeasePayments_c20190101__20191231_pn3n3" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1090" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasePayments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,364
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Operating cash flows from financing leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_ecustom--OperatingCashFlowsFromFinancingLeases_c20200101__20201231_pn3n3" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from financing leases">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1091" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OperatingCashFlowsFromFinancingLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             20
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_ecustom--OperatingCashFlowsFromFinancingLeases_c20190101__20191231_pn3n3" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from financing leases">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1092" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:OperatingCashFlowsFromFinancingLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             28
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left">
           Financing cash flows from financing leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--FinanceLeasePrincipalPayments_c20200101__20201231_pn3n3" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from financing leases">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1093" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeasePrincipalPayments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             26
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--FinanceLeasePrincipalPayments_c20190101__20191231_pn3n3" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from financing leases">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1094" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeasePrincipalPayments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             30
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold; text-align: left">
           Right-of-use assets obtained in exchange for lease obligations:
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Operating leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20200101__20201231_pn3n3" style="text-align: right" title="Right of use assets obtained in exchange for lease obligations: Operating leases">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1095" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,047
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_pn3n3" style="text-align: right" title="Right of use assets obtained in exchange for lease obligations: Operating leases">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1096" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             738
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left">
           Financing leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20200101__20201231_pn3n3" style="text-align: right" title="Right of use assets obtained in exchange for lease obligations: Financing leases">
           <span style="-sec-ix-hidden: xdx2ixbrl1964">
            <span>
             <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl1964" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1097" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20190101__20191231_pn3n3" style="text-align: right" title="Right of use assets obtained in exchange for lease obligations: Financing leases">
           <span style="-sec-ix-hidden: xdx2ixbrl1966">
            <span>
             <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" data-original-id="xdx2ixbrl1966" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1098" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A4_z7oOdfH4c8m7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1099" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeaseCostTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z8lbl8M6toU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Supplementalbalance sheet information related to leases was as follows (in thousands, except lease term and discount rate):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8BB_zvNDFlx42Iya" style="display: none">
          Schedule of Supplemental Balance Sheet Information Related to Leases
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="padding-bottom: 1.5pt; text-align: center">
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="text-align: center">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold; text-align: left">
           Operating leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt">
           Right-of-use assets, net
          </td>
          <td style="width: 2%; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_989_eus-gaap--OperatingLeaseRightOfUseAsset_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Right-of-use assets, net">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1100" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,916
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="width: 2%; padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_c20191231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Right-of-use assets, net">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1101" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,666
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left">
           Right-of-use lease liabilities, current
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="Right-of-use lease liabilities, current">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1102" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             746
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_c20191231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="Right-of-use lease liabilities, current">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1103" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,190
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
           Right-of-use lease liabilities, noncurrent
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Right-of-use lease liabilities, noncurrent">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1104" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,514
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20191231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Right-of-use lease liabilities, noncurrent">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1105" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,868
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">
           Total operating lease liabilities
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_980_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_z4v19nV7Gjg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1106" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,260
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20191231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_zlrV07YH65B5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1107" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             5,058
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold; text-align: left">
           Financing leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Property and equipment, gross
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_984_ecustom--FinanceLeasePropertyAndEquipmentGross_c20201231_pn3n3" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1108" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasePropertyAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             79
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98C_ecustom--FinanceLeasePropertyAndEquipmentGross_c20191231_pn3n3" style="text-align: right" title="Property and equipment, gross">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1109" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasePropertyAndEquipmentGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             96
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
           Accumulated depreciation
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_ecustom--FinanceLeaseAccumulatedDepreciation_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1110" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeaseAccumulatedDepreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             65
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98E_ecustom--FinanceLeaseAccumulatedDepreciation_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">
           (
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1111" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeaseAccumulatedDepreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             48
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">
           Property and equipment, net
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98D_ecustom--FinanceLeasePropertyAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1112" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasePropertyAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             14
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_984_ecustom--FinanceLeasePropertyAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1113" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasePropertyAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             48
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Current liabilities
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_982_ecustom--FinanceLeasesLiabilityCurrent_c20201231_pn3n3" style="text-align: right" title="Current liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1114" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasesLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             16
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98A_ecustom--FinanceLeasesLiabilityCurrent_c20191231_pn3n3" style="text-align: right" title="Current liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1115" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:FinanceLeasesLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             33
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">
           Long-term liabilities
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityNoncurrent_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1116" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             26
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityNoncurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1117" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             77
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">
           Total finance lease liabilities
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--FinanceLeaseLiability_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total finance lease liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1118" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             42
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--FinanceLeaseLiability_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total finance lease liabilities">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1119" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             110
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold">
           Weighted average remaining lease term
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left">
           Operating leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zf7gC31CeC9j" title="Operating Lease, Weighted Average Remaining Lease Term">
             <span>
              <ix:nonnumeric contextref="AsOf2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1120" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               4.2
              </ix:nonnumeric>
             </span>
            </span>
            years
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_z1kK79lqLu4k" title="Operating Lease, Weighted Average Remaining Lease Term">
             <span>
              <ix:nonnumeric contextref="AsOf2019-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1121" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               4.1
              </ix:nonnumeric>
             </span>
            </span>
            years
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Finance leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zJJiEtND0VUc" title="Finance Lease, Weighted Average Remaining Lease Term">
             <span>
              <ix:nonnumeric contextref="AsOf2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1122" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               2.4
              </ix:nonnumeric>
             </span>
            </span>
            years
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
           <span style="font: 10pt Times New Roman, Times, Serif">
            <span id="xdx_905_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zvJwDt8wzYr8" title="Finance Lease, Weighted Average Remaining Lease Term">
             <span>
              <ix:nonnumeric contextref="AsOf2019-12-31" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1123" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               3.4
              </ix:nonnumeric>
             </span>
            </span>
            years
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="font-weight: bold">
           Weighted average discount rate
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left">
           Operating leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuALspuuNxg7" style="text-align: right" title="Weighted average discount rate Operating leases">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1124" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             8.0
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20191231_z0HGD6TvGvyg" style="text-align: right" title="Weighted average discount rate Operating leases">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1125" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             9.1
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: left">
           Finance leases
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zG3Ld5lYa4g" style="text-align: right" title="Weighted average discount rate Finance leases">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1126" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             10.0
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20191231_zK2iV6qfBPm6" style="text-align: right" title="Weighted average discount rate Finance leases">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1127" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             10.0
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AD_zCuKV3vVlGFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 104 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           102
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1128" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z4ln3ndaJRp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Futureminimum lease commitments are as follows (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B4_zFskzBaxkOL1" style="display: none">
          Schedule of Future Minimum Lease Commitments
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">
           Operating    Leases
          </td>
          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">
           Finance    Leases
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold">
           Year Ending December 31,
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; width: 52%; text-align: justify">
           2021
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="width: 20%; text-align: right" title="2021">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1129" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             957
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="width: 20%; text-align: right" title="2021">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1130" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             19
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: justify">
           2022
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="2022">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1131" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             912
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="text-align: right" title="2022">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1132" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             19
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: justify">
           2023
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="2023">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1133" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             480
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="text-align: right" title="2023">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1134" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: justify">
           2024
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="2024">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1135" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             454
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="text-align: right" title="2024">
           <span style="-sec-ix-hidden: xdx2ixbrl2042">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" data-original-id="xdx2ixbrl2042" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1136" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-left: 10pt; text-align: justify">
           2025
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="2025">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1137" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             442
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="text-align: right" title="2025">
           <span style="-sec-ix-hidden: xdx2ixbrl2046">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" data-original-id="xdx2ixbrl2046" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1138" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-bottom: 1.5pt; padding-left: 10pt">
           Thereafter
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1139" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             628
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter">
           <span style="-sec-ix-hidden: xdx2ixbrl2050">
            <span>
             <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" data-original-id="xdx2ixbrl2050" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1140" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 20pt; text-align: left">
           Total lease payments
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="text-align: right" title="Total lease payments">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1141" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,873
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="text-align: right" title="Total lease payments">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1142" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             46
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 1.5pt; text-align: left">
           Less imputed interest
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_zNXL9IpE2iMh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less imputed interest">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1143" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             613
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_z71wqmqf3Hy6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less imputed interest">
           (
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1144" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-bottom: 2.5pt; padding-left: 20pt">
           Total
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_982_eus-gaap--OperatingLeaseLiability_c20201231__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilityMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_OperatingLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1145" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,260
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--FinanceLeaseLiability_c20201231__us-gaap--BalanceSheetLocationAxis__custom--FinanceLeaseLiabilityMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_FinanceLeaseLiabilityMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1146" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:FinanceLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             42
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">
       </p>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AC_zzPB5HhQqZbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Researchand Option Agreement
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
      OnJanuary 5, 2019, Lineage and Orbit Biomedical Limited (“Orbit”) entered into a Research and Option Agreement, whichwas assigned by Orbit to Gyroscope Therapeutics, Limited (“Gyroscope”) and amended on May 7, 2019, January 30, 2020,May 1, 2020 and September 4, 2020 (the “Gyroscope Agreement”). As amended, the Gyroscope Agreement provides Lineageaccess to Gyroscope’s vitrectomy-free subretinal injection device (the “Orbit Device”) as a means of deliveringOpRegen in Lineage’s ongoing Phase 1/2a clinical trial through the earlier of: (i) December 1, 2020; or (ii) or treatmentof three additional patients with the Orbit Device between September 4, 2020 and December 1, 2020 (the “Access Period”).Following the Access Period, Lineage also has an exclusive right to negotiate a definitive agreement to distribute and sell theOrbit Device for the subretinal delivery of RPE cells for the treatment of dry AMD, which was extended through May 2021 (the “OptionPeriod”). Pursuant to the terms of the Gyroscope Agreement, Lineage paid access fees totaling $
      <span id="xdx_90E_ecustom--AccessFeesPayable_pn5n6_c20190101__20190105__us-gaap--TypeOfArrangementAxis__custom--ResearchandOptionAgreementMember__dei--LegalEntityAxis__custom--OrbitBiomedicalLimitedMember_zLIyTOv73BEl">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-01-05_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1147" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AccessFeesPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         2.5
        </ix:nonfraction>
       </span>
      </span>
      million: (i) $
      <span id="xdx_90D_ecustom--AccessFees_pn4n6_c20190101__20190131__us-gaap--TypeOfArrangementAxis__custom--ResearchandOptionAgreementMember__dei--LegalEntityAxis__custom--OrbitBiomedicalLimitedMember_zPFFf7VUHZX9">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-01-31_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember" continued-taxonomy="false" decimals="-4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1148" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AccessFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         1.25
        </ix:nonfraction>
       </span>
      </span>
      million in January 2019 upon execution of the Gyroscope Agreement; and (ii) $
      <span id="xdx_900_ecustom--AccessFees_pn4n6_c20190802__20190831__us-gaap--TypeOfArrangementAxis__custom--ResearchandOptionAgreementMember__dei--LegalEntityAxis__custom--OrbitBiomedicalLimitedMember_zEwaJSm5sua6">
       <span>
        <ix:nonfraction contextref="From2019-08-022019-08-31_custom_ResearchandOptionAgreementMember_custom_OrbitBiomedicalLimitedMember" continued-taxonomy="false" decimals="-4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1149" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AccessFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         1.25
        </ix:nonfraction>
       </span>
      </span>
      million in August 2019 upon completion of certain collaborative research activities using the Gyroscope technology forthe OpRegen Phase 1/2a clinical trial. These access fees of $
      <span id="xdx_90C_ecustom--AccessFeesPayable_pn5n6_c20190101__20191231_z6Sn7ZkvOyN2">
       <span>
        <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1150" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AccessFeesPayable" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         2.5
        </ix:nonfraction>
       </span>
      </span>
      million were amortized on a straight-line basis throughout 2019 and included in research and development expenses. Lineagealso agreed to reimburse Gyroscope for costs of consumables, training services, travel costs and other out of pocket expensesincurred by Gyroscope for performing services under the Gyroscope Agreement. In January 2020, Lineage agreed to pay an additional$
      <span id="xdx_901_ecustom--AgreedSignatureFeeAmount_pn5n6_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__dei--LegalEntityAxis__custom--GyroscopeTherapeuticsLimitedMember_zRmH6rmYQtUf">
       <span>
        <ix:nonfraction contextref="From2020-01-012020-01-31_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1151" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         0.5
        </ix:nonfraction>
       </span>
      </span>
      million to extend the Access Period to July 5, 2020, $
      <span id="xdx_908_ecustom--ExtensionFees_pn5n6_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__dei--LegalEntityAxis__custom--GyroscopeTherapeuticsLimitedMember__us-gaap--AwardTypeAxis__custom--UponSigningMember_zPAXUKxdUnca">
       <span>
        <ix:nonfraction contextref="From2020-02-012020-02-29_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember_custom_UponSigningMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1152" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ExtensionFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         0.2
        </ix:nonfraction>
       </span>
      </span>
      million of which was paid in February 2020 and $
      <span id="xdx_90A_ecustom--ExtensionFees_pn5n6_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__dei--LegalEntityAxis__custom--GyroscopeTherapeuticsLimitedMember_zvcb0kA0D0n2">
       <span>
        <ix:nonfraction contextref="From2020-11-012020-11-30_custom_SecondAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1153" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ExtensionFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         0.3
        </ix:nonfraction>
       </span>
      </span>
      million of which was paid in November 2020. The Access Period was subsequently extended at no cost as described above.In February 2021, Lineage paid $
      <span id="xdx_901_ecustom--AgreedSignatureFeeAmount_pn5n6_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentMember__dei--LegalEntityAxis__custom--GyroscopeTherapeuticsLimitedMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPeh8iCjdVq2">
       <span>
        <ix:nonfraction contextref="From2021-02-012021-02-28_custom_ThirdAmendmentMember_custom_GyroscopeTherapeuticsLimitedMember_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1154" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
         0.5
        </ix:nonfraction>
       </span>
      </span>
      million to extend the Option Period.
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Litigation– General
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageis subject to various claims and contingencies in the ordinary course of its business, including those related to litigation,business transactions, employee-related matters, and others. When Lineage is aware of a claim or potential claim, it assessesthe likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonablyestimated, Lineage will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonablyestimated, Lineage discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved couldbe material. Lineage is not aware of any claims likely to have a material adverse effect on its financial condition or resultsof operations.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 105 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           103
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnFebruary 19, 2019, a putative shareholder class action lawsuit was filed (captioned
       <i>
        Lampe v. Asterias Biotherapeutics, Inc.et al
       </i>
       ., Case No. RG19007391) in the Superior Court of the State of California, County of Alameda challenging the AsteriasMerger. On March 1, 2019, Asterias made certain amendments and supplements to its public disclosures regarding the Asterias Merger(the “Supplemental Disclosures”). On May 3, 2019, an amended class action complaint (the “Amended Complaint”)was filed. The Amended Complaint named Lineage, Patrick Merger Sub, Inc., the Asterias board of directors, one member of Lineage’sboard of directors, and certain stockholders of both Lineage and Asterias. The action was brought by two purported stockholdersof Asterias, on behalf of a putative class of Asterias stockholders, and asserted breach of fiduciary duty and aiding and abettingclaims under Delaware law. The Amended Complaint alleged, among other things, that the process leading up to the Asterias Mergerwas conflicted and inadequate, and that the proxy statement filed by Asterias with the Commission omitted certain material information,which allegedly rendered the information disclosed materially misleading. The Amended Complaint sought, among other things, thata class be certified, the recovery of monetary damages, and attorneys’ fees and costs.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnJune 3, 2019, defendants filed demurrers to the Amended Complaint. On August 13, 2019, the parties submitted a stipulation tothe court seeking dismissal of the action with prejudice as to the named Plaintiffs and without prejudice as to the unnamed putativeclass members, and disclosing to the court the parties’ agreement to resolve, for $
       <span id="xdx_90C_eus-gaap--LossContingencyDamagesAwardedValue_c20190812__20190813_pp0p0" title="Loss Contingency, Damages Awarded, Value">
        <span>
         <ix:nonfraction contextref="From2019-08-122019-08-13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1155" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LossContingencyDamagesAwardedValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          200,000
         </ix:nonfraction>
        </span>
       </span>
       , Plaintiffs’ claim foran award of attorneys’ fees and expenses in connection with the purported benefit conferred on Asterias stockholders bythe Supplemental Disclosures. The court granted the stipulation and dismissed the action August 14, 2019. Lineage continues tobelieve that the claims and allegations in the action lack merit, but believed that it was in Lineage’s shareholders’best interest for the action to be dismissed and to resolve the fee claim in a timely manner without additional costly litigationexpenses.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnOctober 14, 2019, another putative class action lawsuit was filed challenging the Asterias Merger. This action (captioned
       <i>
        Rossv. Lineage Cell Therapeutics, Inc., et al.
       </i>
       , C.A. No. 2019-0822) was filed in Delaware Chancery Court and names Lineage, theAsterias board of directors, one member of Lineage’s board of directors, and certain stockholders of both Lineage and Asteriasas defendants. The action was brought by a purported stockholder of Asterias, on behalf of a putative class of Asterias stockholders,and asserts breach of fiduciary duty and aiding and abetting claims under Delaware law. The complaint alleges, among other things,that the process leading up to the Asterias Merger was conflicted, that the Asterias Merger consideration was inadequate, andthat the proxy statement filed by Asterias with the Commission omitted certain material information, which allegedly renderedthe information disclosed materially misleading. The complaint seeks, among other things, that a class be certified, the recoveryof monetary damages, and attorneys’ fees and costs. On December 20, 2019, the defendants moved to dismiss the complaint.On February 10, 2020, the plaintiff filed an opposition. Defendants filed their replies on March 13, 2020. On June 23, 2020, ahearing on the motions to dismiss occurred. On September 21, 2020, the Chancery Court denied the motion to dismiss as to Lineageand certain members of the Asterias board of directors, and it granted the motion to dismiss as to all other defendants. On October30, 2020, the remaining defendants filed an answer to the complaint.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagebelieves the allegations in the action lack merit and intends to vigorously defend the claims asserted. It is impossible at thistime to assess whether the outcome of this proceeding will have a material adverse effect on Lineage’s consolidated resultsof operations, cash flows or financial position. Therefore, in accordance with ASC 450,
       <i>
        Contingencies,
       </i>
       Lineage has notrecorded any accrual for a contingent liability associated with this legal proceeding based on its belief that a liability, whilepossible, is not probable nor estimable, and any range of potential contingent liability amounts cannot be reasonably estimatedat this time. Lineage records legal expenses as incurred.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        EmploymentContracts
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagehas entered into employment agreements with certain executive officers. Under the provisions of the agreements, Lineage may berequired to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntaryterminations.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 106 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           104
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Indemnification
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inthe normal course of business, Lineage may provide indemnifications of varying scope under Lineage’s agreements with othercompanies or consultants, typically Lineage’s clinical research organizations, investigators, clinical sites, suppliersand others. Pursuant to these agreements, Lineage will generally agree to indemnify, hold harmless, and reimburse the indemnifiedparties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connectionwith the use or testing of Lineage’s products and services. Indemnification provisions could also cover third party infringementclaims with respect to patent rights, copyrights, or other intellectual property pertaining to Lineage products and services.The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particularresearch, development, services, or license agreement to which they relate. The potential future payments Lineage could be requiredto make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, Lineagehas not been subject to any claims or demands for indemnification. Lineage also maintains various liability insurance policiesthat limit Lineage’s financial exposure. As a result, Lineage believes the fair value of these indemnification agreementsis minimal. Accordingly, Lineage has not recorded any liabilities for these agreements as of December 31, 2020 and 2019.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        SecondAmendment to Clinical Trial and Option Agreement and License Agreement with Cancer Research UK
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnMay 6, 2020, Lineage and its wholly owned subsidiary Asterias entered into a Second Amendment to Clinical Trial and Option Agreement(the “CTOA Amendment”) with Cancer Research UK (“CRUK”) and Cancer Research Technology Limited (“CRT”),which amends the Clinical Trial and Option Agreement entered into between Asterias, CRUK and CRT dated September 8, 2014, as amendedSeptember 8, 2014. Pursuant to the CTOA Amendment, Lineage assumed all obligations of Asterias and exercised early its optionto acquire data generated in the Phase 1 clinical trial of VAC2 in non-small cell lung cancer being conducted by CRUK. CRUK willcontinue conducting the VAC2 study.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageand CRT effectuated the option by simultaneously entering into a license agreement (the “License Agreement”) pursuantto which Lineage agreed to pay the previously agreed signature fee of £
       <span id="xdx_90C_ecustom--AgreedSignatureFeeAmount_pp0p0_uGBP_c20200504__20200506__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_z6lLeTfCZysf" title="Agreed signature fee amount">
        <span>
         <ix:nonfraction contextref="From2020-05-042020-05-06_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1156" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          1,250,000
         </ix:nonfraction>
        </span>
       </span>
       (approximately $
       <span id="xdx_909_ecustom--AgreedSignatureFeeAmount_pn5n6_uUSD_c20200504__20200506__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zLoC9b1mdY56">
        <span>
         <ix:nonfraction contextref="From2020-05-042020-05-06_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1157" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          1.6
         </ix:nonfraction>
        </span>
       </span>
       million). In considerationof Lineage’s agreement to exercise the option prior to completion of the study, the parties agreed to defer the signaturefee as follows: £
       <span id="xdx_901_ecustom--AgreedSignatureFeeAmount_pp0p0_uGBP_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zhYgYAn3iih" title="Agreed signature fee amount">
        <span>
         <ix:nonfraction contextref="From2020-09-012020-09-30_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1158" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          500,000
         </ix:nonfraction>
        </span>
       </span>
       in September 2020, £
       <span id="xdx_903_ecustom--AgreedSignatureFeeAmount_pp0p0_uGBP_c20210101__20210131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zD6S3x5OLa2g" title="Agreed signature fee amount">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-01-31_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1159" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          500,000
         </ix:nonfraction>
        </span>
       </span>
       in January 2021 and £
       <span id="xdx_90F_ecustom--AgreedSignatureFeeAmount_pp0p0_uGBP_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zVKyl2lScX8h" title="Agreed signature fee amount">
        <span>
         <ix:nonfraction contextref="From2021-04-012021-04-30_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1160" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          250,000
         </ix:nonfraction>
        </span>
       </span>
       in April 2021. For the primarylicensed product for the first indication, the License Agreement provides for milestone fees of up to £
       <span id="xdx_90C_ecustom--ClinicalRegulatoryMilestone_pp0p0_uGBP_c20200504__20200506__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zESinvR2inCg" title="Clinical regulatory milestone">
        <span>
         <ix:nonfraction contextref="From2020-05-042020-05-06_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1161" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ClinicalRegulatoryMilestone" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          8,000,000
         </ix:nonfraction>
        </span>
       </span>
       based uponinitiation of a Phase 3 clinical trial and the filing for regulatory approval and up to £
       <span id="xdx_90E_ecustom--SalesRelatedMilestones_pp0p0_uGBP_c20200504__20200506__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--GBPPoundSterlingMember_zeu7lgilmNcc" title="Sales related milestones">
        <span>
         <ix:nonfraction contextref="From2020-05-042020-05-06_custom_LicenseAgreementMember_custom_GBPPoundSterlingMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1162" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SalesRelatedMilestones" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="GBP">
          22,500,000
         </ix:nonfraction>
        </span>
       </span>
       in sales-based milestonespayments. Additional milestone fees and sales-based milestone payments would be payable for other products or indications, andmid-single-digit royalty payments are payable on sales of commercial products.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Eitherparty may terminate the License Agreement for the uncured material breach of the other party. CRT may terminate the License Agreementin the case of Lineage’s insolvency or if Lineage ceases all development and commercialization of all products under theLicense Agreement.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        SecondAmended and Restated License Agreement
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       OnJune 15, 2017, Cell Cure entered into a Second Amended and Restated License Agreement (the “License Agreement”) withHadasit Medical Research Services and Development Ltd. (“Hadasit”), the commercial arm and a wholly owned subsidiaryof Hadassah Medical Organization. Pursuant to the License Agreement, Hadasit granted Cell Cure an exclusive, worldwide, royaltybearing license (with the right to grant sublicenses) in its intellectual property portfolio of materials and technology relatedto human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the “Licensed IP”), to use, commercializeand exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of (i) human stem cellderived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders,and (ii) human stem cell derived retinal pigment epithelial cells, solely for use in cell therapy for the diagnosis, amelioration,prevention and treatment of eye disorders.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Asconsideration for the Licensed IP, Cell Cure will pay a small one-time lump sum payment, a royalty in the mid-single digits ofnet sales from sales of Licensed IP by any invoicing entity, and a royalty of
       <span id="xdx_90A_ecustom--RoyaltyPercentage_pii_dp_uPercentage_c20200101__20201231_z0v64SfdCL0k" title="Royalty percentage">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1163" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:RoyaltyPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          21.5
         </ix:nonfraction>
        </span>
       </span>
       % of sublicensing receipts. In addition, CellCure will pay Hadasit an annual minimal non-refundable royalty, which will become due and payable the first January 1 followingthe completion of services to Cell Cure by a research laboratory.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 107 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           105
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       CellCure will pay Hadasit non-refundable milestone payments upon the recruitment of the first patient for the first Phase 2b clinicaltrial, upon the enrollment of the first patient in the first Phase 3 clinical trials, upon delivery of the report for the firstPhase 3 clinical trials, upon the receipt of an NDA or marketing approval in the European Union, whichever is the first to occur,and upon the first commercial sale in the United States or European Union, whichever is the first to occur. Such milestones, inthe aggregate, may be up to $
       <span id="xdx_900_ecustom--MilestoneAggregateAmount_pn5n6_c20200101__20201231_zA9CSpJp7g3k" title="Milestone aggregate amount">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1164" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MilestoneAggregateAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          3.5
         </ix:nonfraction>
        </span>
       </span>
       million. As of December 31, 2020, Cell Cure had not accrued any milestone payments under theLicense Agreement.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       TheLicense Agreement terminates upon the expiration of Cell Cure’s obligation to pay royalties for all licensed products, unlessearlier terminated. In addition to customary termination rights of both parties, Hadasit may terminate the License Agreement ifCell Cure fails to continue the clinical development of the Licensed IP or fails to take actions to commercialize or sell theLicensed IP over any consecutive 12 month period. The License Agreement also contains mutual confidentiality obligations of CellCure and Hadasit, and indemnification obligations of Cell Cure.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Royaltyobligations and license fees
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineageand its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and otherparties for the rights to use those licenses and other intellectual property in conducting research and development activities.These licensing agreements provide for the payment of royalties by Lineage or the applicable party to the agreement on futureproduct sales, if any. In addition, in order to maintain these licenses and other rights during the product development, Lineageor the applicable party to the contract must comply with various conditions including the payment of patent related costs andannual minimum maintenance fees. Annual minimum maintenance fees are expected to be approximately $
       <span id="xdx_904_ecustom--MaintenanceFees_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Minimum annual maintenance fees">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_srt_MinimumMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1165" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MaintenanceFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          30,000
         </ix:nonfraction>
        </span>
       </span>
       to $
       <span id="xdx_90D_ecustom--MaintenanceFees_c20200101__20201231__us-gaap--AwardDateAxis__custom--FutureYearsMember_pp0p0" title="Minimum annual maintenance fees">
        <span>
         <ix:nonfraction contextref="From2020-01-012020-12-31_custom_FutureYearsMember" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1166" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:MaintenanceFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          60,000
         </ix:nonfraction>
        </span>
       </span>
       per year.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Grants
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Underthe terms of the grant agreement between Cell Cure and Israel Innovation Authority (“IIA”) (formerly the Office ofthe Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of OpRegen
       <sup>
        ®
       </sup>
       , Cell Curewill be required to pay royalties on future product sales, if any, up to the amounts received from the IIA, plus interest indexedto LIBOR. Cell Cure’s research and product development activities under the grant are subject to substantial risks and uncertaintiesand performed on a best efforts basis. As a result, Cell Cure is not required to make any payments under the grant agreement unlessit successfully commercializes OpRegen
       <sup>
        ®
       </sup>
       . Accordingly, pursuant to ASC 730-20, the Cell Cure grant is considereda contract to perform research and development services for others and grant revenue is recognized as the related research anddevelopment expenses are incurred (see Note 2).
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Israelilaw pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transferof intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined bythe IIA.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1167" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DefinedContributionPlanTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_800_eus-gaap--DefinedContributionPlanTextBlock_z32vOz7V6LP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        15.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_823_ztdRJJ5lDbaf">
         Employee Benefit Plan
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Wehave a defined contribution 401(k) plan for all employees. Under the terms of the plan, employees may make voluntary contributionsas a percentage or defined amount of compensation. We provide a safe harbor contribution of up to
       <span id="xdx_90B_ecustom--DefinedContributionPlanMaximumContributionsPercent_pii_dp_uPercentage_c20200101__20201231_zmXynNYcnBC3" title="Safe harbour contribution, maximum contribution percentage">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1168" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:DefinedContributionPlanMaximumContributionsPercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
          5.0
         </ix:nonfraction>
        </span>
       </span>
       % of the employee’scompensation, not to exceed eligible limits, and subject to employee participation. For the years ended December 31, 2020 and2019, we incurred approximately $
       <span id="xdx_906_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_c20200101__20201231_pp0p0" title="Expenses related to safe harbor contribution">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1169" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          149,000
         </ix:nonfraction>
        </span>
       </span>
       and $
       <span id="xdx_901_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_c20190101__20191231_pp0p0" title="Expenses related to safe harbor contribution">
        <span>
         <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1170" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="USD">
          287,000
         </ix:nonfraction>
        </span>
       </span>
       , respectively, in expenses related to the safe harbor contribution.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1171" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SegmentReportingDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zZTKc6yCtKyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        16.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82F_znkDrRcGX6U7">
         Segment Information
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineage’sexecutive management team, as a group, represents the entity’s chief operating decision makers. Lineage’s executivemanagement team views Lineage’s operations as
       <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_pii_dc_uSubsidiary_c20200101__20201231_zlCJGEHREmJi" title="Number of operating segments">
        <span>
         <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt-sec:numwordsen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1172" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NumberOfOperatingSegments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Subsidiary">
          one
         </ix:nonfraction>
        </span>
       </span>
       segment that includes the research and development of therapeutic productsfor retinal diseases, neurological diseases and disorders and oncology. As a result, the financial information disclosed materiallyrepresents all of the financial information related to Lineage’s sole operating segment.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <ix:exclude>
      <!-- Field: Page; Sequence: 108 -->
      <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
        <tbody>
         <tr style="vertical-align: top; text-align: left">
          <td style="text-align: center; width: 100%">
           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
           106
           <!-- Field: /Sequence -->
          </td>
         </tr>
        </tbody>
       </table>
      </div>
      <div style="break-before: page; margin-top: 6pt">
       <p style="margin: 0pt">
       </p>
      </div>
      <!-- Field: /Page -->
     </ix:exclude>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
       </b>
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1173" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:EnterpriseWideDisclosuresTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80A_ecustom--EnterpriseWideDisclosuresTextBlock_zo7CG41Y8aF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        17.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_82C_zlZ2zaBsn2Ne">
         Enterprise-Wide Disclosures
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        GeographicArea Information
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1174" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zp2GFsA72p38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thefollowing table presents consolidated revenues, including license fees, royalties, grant income, and other revenues, disaggregatedby geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entitiesthat fund the grant are located (in thousands).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B1_zMG0QBR0p6t6" style="display: none">
          Schedule of Geographic Area Information
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
           Geographic Area
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           United States
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__country--US_z5385MX5jcm2" style="width: 16%; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_country_US" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1175" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,160
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--StatementGeographicalAxis__country--US_ztMiA0F0lU5e" style="width: 16%; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_country_US" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1176" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,092
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 1.5pt">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Foreign
            <sup>
             (1)
            </sup>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td id="xdx_F2A_zdokG80C3ZQc" style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_zbzHAe4FSVg3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact002115" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1177" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             666
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_zVYXlBLOCer9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact002117" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1178" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,423
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Total revenues
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zdygfkw4zY5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1179" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,826
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231_zwXI8FpAjzb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1180" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,515
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
           <span id="xdx_F08_zo0oLObSu0Rg" style="font: 10pt Times New Roman, Times, Serif">
            (1)
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F16_zyT5toJ1j496" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote002122" xml:lang="en-US">
             Foreign    revenues are primarily generated from grants in Israel.
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thecomposition of Lineage’s long-lived assets, consisting of plant and equipment, net, between those in the United States andin foreign countries, as of December 31, 2020 and 2019, is set forth below (in thousands):
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%">
           Domestic
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--NoncurrentAssets_c20201231__srt--StatementGeographicalAxis__custom--DomesticMember_pn3n3" style="width: 16%; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_DomesticMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1181" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,035
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98F_eus-gaap--NoncurrentAssets_c20191231__srt--StatementGeographicalAxis__custom--DomesticMember_pn3n3" style="width: 16%; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_DomesticMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1182" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,654
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="padding-bottom: 1.5pt">
           <span style="font: 10pt Times New Roman, Times, Serif">
            Foreign
            <sup>
             (1)
            </sup>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td id="xdx_F29_zwEEladNmFn8" style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--NoncurrentAssets_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_znYnPjpWu1S7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact002128" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1183" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,595
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--NoncurrentAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__custom--ForeignMember_fKDEp_zxALrRJfGYvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31_custom_ForeignMember" continued-taxonomy="false" data-original-id="Fact002130" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1184" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             4,521
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-bottom: 2.5pt">
           Total
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--NoncurrentAssets_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1185" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             5,630
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_982_eus-gaap--NoncurrentAssets_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-lived assets">
           <span>
            <ix:nonfraction contextref="AsOf2019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1186" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NoncurrentAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,175
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tbody>
         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
           <span id="xdx_F08_zPBdiaeRrw65" style="font: 10pt Times New Roman, Times, Serif">
            (1)
           </span>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
           <span id="xdx_F1A_zGN8yKfqb9Ja" style="font: 10pt Times New Roman, Times, Serif">
            <ix:footnote id="Footnote002135" xml:lang="en-US">
             Assets    in foreign countries principally include laboratory equipment and leasehold improvements in Israel.
            </ix:footnote>
           </span>
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8AC_zOgKSLMITnJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        MajorSources of Revenues
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1187" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="LCTX:ScheduleOfRevenuesDisaggregatedBySourceTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89F_ecustom--ScheduleOfRevenuesDisaggregatedBySourceTableTextBlock_zGVDKj52EzBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thefollowing table presents Lineage’s consolidated revenues disaggregated by source (in thousands).
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B4_zg0YfWdrcWnk" style="display: none">
          Scheduleof Revenues Disaggregated by Source
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="font-weight: bold">
           REVENUES:
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; text-align: right">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
          <td style="font-weight: bold; text-align: right">
          </td>
          <td style="font-weight: bold; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="width: 60%; text-align: left">
           Grant revenue
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" style="width: 16%; text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_GrantMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1188" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,053
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" style="width: 16%; text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_us-gaap_GrantMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1189" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,037
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Royalties from product sales and license fees
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--RoyaltiesFromProductSalesAndLicenseFeesMember_pn3n3" style="text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1190" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             773
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--RoyaltiesFromProductSalesAndLicenseFeesMember_pn3n3" style="text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1191" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,221
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left; padding-bottom: 1.5pt">
           Sale of research products and services
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--SaleOfResearchProductsAndServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">
           <span style="-sec-ix-hidden: xdx2ixbrl2147">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_SaleOfResearchProductsAndServicesMember" continued-taxonomy="false" data-original-id="xdx2ixbrl2147" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1192" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USD" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="border-bottom: Black 1.5pt solid; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--SaleOfResearchProductsAndServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_SaleOfResearchProductsAndServicesMember" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1193" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             257
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">
           Total revenues
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1194" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,826
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 2.5pt">
          </td>
          <td style="border-bottom: Black 2.5pt double; text-align: left">
           $
          </td>
          <td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1195" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             3,515
            </ix:nonfraction>
           </span>
          </td>
          <td style="padding-bottom: 2.5pt; text-align: left">
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A7_zWPKPmI5cpD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Prepaidexpenses and other current assets at December 31, 2020 includes $
       <span id="xdx_900_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn5n6_c20201231__srt--ProductOrServiceAxis__custom--RoyaltiesFromProductSalesAndLicenseFeesMember_zzXpWaENzBa">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_RoyaltiesFromProductSalesAndLicenseFeesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1196" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.2
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million of receivables related to royaltiesfrom product sales and license fees, and $
       <span id="xdx_90F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn5n6_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMSharesMember_zqRHkl58nYl9">
        <span>
         <ix:nonfraction contextref="AsOf2020-12-31_custom_ATMSharesMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1197" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
       million of receivables related to cash in transit for sales of ATM Shares in2020 that settled in 2021.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1198" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_898_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zuCIN6pQyIC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Thefollowing table shows Lineage’s major sources of revenues, as a percentage of total revenues, that were recognized duringthe years ended December 31, 2020 and 2019:
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8B1_zQ0PojTHZAb1" style="display: none">
          Schedule of Sources of Revenues
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
        <tbody>
         <tr style="vertical-align: bottom">
          <td>
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           Year Ended December 31,
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
           Sources of Revenues
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2020
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
          <td style="font-weight: bold; padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
           2019
          </td>
          <td style="padding-bottom: 1.5pt; font-weight: bold">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 60%; text-align: left">
           NIH grant income
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20200101__20201231__srt--MajorCustomersAxis__custom--NIHGrantIncomeMember_zKACAEHk1e9k" style="width: 16%; text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_NIHGrantIncomeMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1199" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             21.2
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           %
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20190101__20191231__srt--MajorCustomersAxis__custom--NIHGrantIncomeMember_zr2uxS3ZAbV7" style="width: 16%; text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_NIHGrantIncomeMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1200" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             17.5
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
           %
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           IIA grant income (Cell Cure Neurosciences, Ltd, Israel)
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20200101__20201231__srt--MajorCustomersAxis__custom--IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember_zzDvQ0dM57O" style="text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1201" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             36.5
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20190101__20191231__srt--MajorCustomersAxis__custom--IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember_zn3GaJ34fEq9" style="text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_IIAGrantIncomeCellCureNeurosciencesLimitedIsraelMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1202" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             40.5
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Royalties, licenses, subscriptions, advertising and other
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20200101__20201231__srt--MajorCustomersAxis__custom--RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember_znAzUwx7VND5" style="text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-12-31_custom_RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1203" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             42.3
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20190101__20191231__srt--MajorCustomersAxis__custom--RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember_zAWuQh8YBPfb" style="text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_RoyaltiesLicensesSubscriptionsAdvertisingAndOtherMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1204" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             34.7
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Sale of research products
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20200101__20201231__srt--MajorCustomersAxis__custom--SaleofResearchProductsMember_zpcHtF7AC2p3" style="text-align: right" title="Percentage of total revenues">
           <span style="-sec-ix-hidden: xdx2ixbrl2171">
            <span>
             <ix:nonfraction contextref="From2020-01-012020-12-31_custom_SaleofResearchProductsMember" continued-taxonomy="false" data-original-id="xdx2ixbrl2171" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1205" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Percentage" xs:nil="true">
              -
             </ix:nonfraction>
            </span>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercentage_c20190101__20191231__srt--MajorCustomersAxis__custom--SaleofResearchProductsMember_zshULefHtNxh" style="text-align: right" title="Percentage of total revenues">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-12-31_custom_SaleofResearchProductsMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1206" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="Percentage">
             7.3
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           %
          </td>
         </tr>
        </tbody>
       </table>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
        </span>
       </p>
       <ix:exclude>
        <!-- Field: Page; Sequence: 109 -->
        <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
         <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
          <tbody>
           <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center; width: 100%">
             <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
             107
             <!-- Field: /Sequence -->
            </td>
           </tr>
          </tbody>
         </table>
        </div>
        <div style="break-before: page; margin-top: 6pt">
         <p style="margin: 0pt">
         </p>
        </div>
        <!-- Field: /Page -->
       </ix:exclude>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
         </b>
        </span>
       </p>
      </ix:nonnumeric>
     </span>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1207" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:QuarterlyFinancialInformationTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80F_eus-gaap--QuarterlyFinancialInformationTextBlock_zw7eMI3At0lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        18.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span>
         <span id="xdx_824_ztfMjMKWdAci">
          Selected Quarterly Financial Information
         </span>
         (UNAUDITED,in thousands, except per share data)
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Lineagehas derived this data from the unaudited consolidated interim financial statements that, in Lineage’ s opinion, have beenprepared on substantially the same basis as the audited consolidated financial statements contained herein and include all normalrecurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unauditedconsolidated quarterly results should be read in conjunction with the consolidated financial statements and notes thereto includedherein. The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that maybe expected for any future period.
      </span>
     </p>
     <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
     </span>
     <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
     </span>
     <span>
      <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1208" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
       <p id="xdx_89E_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zj3hggl5lM4i" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <span id="xdx_8BB_zYaubs8U2n53" style="display: none">
          Schedule of Selected Quarterly Financial Information
         </span>
        </span>
       </p>
       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
        <tbody>
         <tr style="vertical-align: bottom">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
           Year Ended December 31, 2020
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              First
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quarter
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Second
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quarter
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Third
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quarter
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Fourth
             </b>
            </span>
           </p>
           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
            <span style="font: 10pt Times New Roman, Times, Serif">
             <b>
              Quarter
             </b>
            </span>
           </p>
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="width: 40%; text-align: left">
           Revenues, net
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200331_pn3n3" style="width: 11%; text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1209" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             514
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200401__20200630_pn3n3" style="width: 11%; text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2020-04-012020-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1210" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             386
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200701__20200930_pn3n3" style="width: 11%; text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2020-07-012020-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1211" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             571
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td style="width: 2%">
          </td>
          <td style="width: 1%; text-align: left">
          </td>
          <td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20201001__20201231_pn3n3" style="width: 11%; text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2020-10-012020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1212" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             355
            </ix:nonfraction>
           </span>
          </td>
          <td style="width: 1%; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Operating expenses
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--OperatingExpenses_c20200101__20200331_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2020-01-012020-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1213" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             7,858
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--OperatingExpenses_c20200401__20200630_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2020-04-012020-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1214" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             6,713
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98A_eus-gaap--OperatingExpenses_c20200701__20200930_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2020-07-012020-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1215" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             7,194
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_981_eus-gaap--OperatingExpenses_c20201001__20201231_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2020-10-012020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1216" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             6,123
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Loss from operations
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20200331_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1217" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             7,438
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--OperatingIncomeLoss_c20200401__20200630_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2020-04-012020-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1218" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             6,402
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20200701__20200930_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2020-07-012020-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1219" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             6,725
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20201001__20201231_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2020-10-012020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1220" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             5,882
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Net income (loss) attributable to Lineage
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--NetIncomeLoss_c20200101__20200331_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1221" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             8,399
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--NetIncomeLoss_c20200401__20200630_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2020-04-012020-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1222" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             6,522
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200701__20200930_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2020-07-012020-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1223" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             7,760
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--NetIncomeLoss_c20201001__20201231_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           <span>
            <ix:nonfraction contextref="From2020-10-012020-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1224" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             2,032
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Basic net income (loss) per share
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--EarningsPerShareBasic_c20200101__20200331_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2020-01-012020-03-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1225" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.06
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_980_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2020-04-012020-06-30" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1226" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.04
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_986_eus-gaap--EarningsPerShareBasic_c20200701__20200930_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2020-07-012020-09-30" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1227" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.05
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_98B_eus-gaap--EarningsPerShareBasic_c20201001__20201231_pii" style="text-align: right" title="Basic net income (loss) per share">
           <span>
            <ix:nonfraction contextref="From2020-10-012020-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1228" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             0.01
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
           Year Ended December 31, 2019
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: right">
          </td>
          <td style="padding-bottom: 1.5pt; text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Revenues, net
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20190331_pn3n3" style="text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1229" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             928
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190401__20190630_pn3n3" style="text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2019-04-012019-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1230" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             779
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190701__20190930_pn3n3" style="text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2019-07-012019-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1231" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             567
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20191001__20191231_pn3n3" style="text-align: right" title="Revenues, net">
           <span>
            <ix:nonfraction contextref="From2019-10-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1232" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             1,241
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Operating expenses
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--OperatingExpenses_c20190101__20190331_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1233" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             13,621
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98D_eus-gaap--OperatingExpenses_c20190401__20190630_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2019-04-012019-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1234" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             11,493
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98B_eus-gaap--OperatingExpenses_c20190701__20190930_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2019-07-012019-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1235" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             8,875
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_980_eus-gaap--OperatingExpenses_c20191001__20191231_pn3n3" style="text-align: right" title="Operating expenses">
           <span>
            <ix:nonfraction contextref="From2019-10-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1236" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             7,990
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td style="text-align: left">
           Loss from operations
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20190331_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2019-01-012019-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1237" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             12,761
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20190401__20190630_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2019-04-012019-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1238" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             10,821
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20190701__20190930_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2019-07-012019-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1239" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             8,422
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20191001__20191231_pn3n3" style="text-align: right" title="Loss from operations">
           (
           <span>
            <ix:nonfraction contextref="From2019-10-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1240" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             6,872
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Net income (loss) attributable to Lineage
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--NetIncomeLoss_c20190101__20190331_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-03-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1241" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" tabindex="18" unitref="USD">
             39,310
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190401__20190630_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2019-04-012019-06-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1242" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             30,032
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_989_eus-gaap--NetIncomeLoss_c20190701__20190930_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2019-07-012019-09-30" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1243" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             16,505
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td id="xdx_984_eus-gaap--NetIncomeLoss_c20191001__20191231_pn3n3" style="text-align: right" title="Net income (loss) attributable to Lineage">
           (
           <span>
            <ix:nonfraction contextref="From2019-10-012019-12-31" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1244" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="3" selected-taxonomy="false" sign="-" tabindex="18" unitref="USD">
             4,482
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
          <td>
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
          </td>
          <td style="text-align: right">
          </td>
          <td style="text-align: left">
          </td>
         </tr>
         <tr style="vertical-align: bottom; background-color: White">
          <td style="text-align: left">
           Basic net income (loss) per share
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20190101__20190331_pii" style="text-align: right" title="Basic net income (loss) per share">
           <span>
            <ix:nonfraction contextref="From2019-01-012019-03-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1245" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="USDPShares">
             0.30
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_983_eus-gaap--EarningsPerShareBasic_c20190401__20190630_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2019-04-012019-06-30" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1246" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.20
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_985_eus-gaap--EarningsPerShareBasic_c20190701__20190930_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2019-07-012019-09-30" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1247" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.11
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
          <td>
          </td>
          <td style="text-align: left">
           $
          </td>
          <td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20191001__20191231_pii" style="text-align: right" title="Basic net income (loss) per share">
           (
           <span>
            <ix:nonfraction contextref="From2019-10-012019-12-31" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1248" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" sign="-" tabindex="18" unitref="USDPShares">
             0.03
            </ix:nonfraction>
           </span>
          </td>
          <td style="text-align: left">
           )
          </td>
         </tr>
        </tbody>
       </table>
      </ix:nonnumeric>
     </span>
     <p id="xdx_8A3_zBiMib5ysf19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Quarterlyand year-to-date computations of net income (loss) per share amounts are calculated using the respective period weighted averageshares outstanding. Therefore, the sum of the per share amounts for the quarters may not agree with the per share amounts forthe year.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
   </span>
   <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
   </span>
   <span>
    <ix:nonnumeric contextref="From2020-01-01to2020-12-31" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1249" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SubsequentEventsTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
     <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zzErzXIhulUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        19.
       </b>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       <b>
        <span id="xdx_829_zNfYLtL8Zng8">
         Subsequent Events
        </span>
       </b>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Saleof OncoCyte Shares
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InJanuary and February 2021, Lineage sold
       <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn5n6_c20210101__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWdNa3r6S1Oe" title="Number of shares sold">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-02-28_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1250" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="Shares">
          2.5
         </ix:nonfraction>
        </span>
       </span>
       million shares of OncoCyte common stock for gross proceeds of $
       <span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpF7BdeKhsR2" title="Proceeds from sale of common stock">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-02-28_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1251" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          10.1
         </ix:nonfraction>
        </span>
       </span>
       million. Afterthese sales, Lineage owns
       <span id="xdx_905_ecustom--SharesOwnedAfterSalesShares_c20210304__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares owned after sales, shares">
        <span>
         <ix:nonfraction contextref="From2021-03-042021-03-05_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1252" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SharesOwnedAfterSalesShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          1,122,401
         </ix:nonfraction>
        </span>
       </span>
       shares of OncoCyte common stock, which has a value of $
       <span id="xdx_90B_ecustom--SharesOwnedAfterSales_pn5n6_c20210304__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8j6WNW2F1p4" title="Shares owned after sales">
        <span>
         <ix:nonfraction contextref="From2021-03-042021-03-05_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1253" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:SharesOwnedAfterSales" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          4.2
         </ix:nonfraction>
        </span>
       </span>
       million as of March 5, 2021.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Salesof Lineage Shares Under the ATM
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       Inthe first quarter of 2021 through March 5, 2021, Lineage sold
       <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMShareMember_zfJc9s85dIH4">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMShareMember" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1254" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="Shares">
          7,941,122
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       commonshares of Lineage ATM Shares for gross and net proceeds of $
       <span id="xdx_902_ecustom--ProceedsFromIssuanceOrSaleOfEquityGross_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMShareMember_zWfjB54yWSQe">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMShareMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1255" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuanceOrSaleOfEquityGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.9
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       millionand $
       <span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMShareMember_zfJvzHkHgbUf">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMShareMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1256" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          19.3
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       million,respectively (in each case, which includes $
       <span id="xdx_90E_ecustom--ProceedsFromIssuanceOrSalesOfEquity_pn5n6_c20210101__20210305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMShareMember_zYCoBz2WH464">
        <span>
         <ix:nonfraction contextref="From2021-01-012021-03-05_us-gaap_SubsequentEventMember_custom_ATMShareMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1257" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:ProceedsFromIssuanceOrSalesOfEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.3
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       millionof proceeds in transit related to 2020 sales that settled in 2021).
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       See Note 11 for additional information. On March 5, 2021, Lineage filed a prospectus supplement with the SEC inconnection with the offer and sale of an additional $
       <span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210301__20210305__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMShareMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmca6WbBVW3c">
        <span>
         <ix:nonfraction contextref="From2021-03-012021-03-05_custom_ATMShareMember_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1258" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          25
         </ix:nonfraction>
        </span>
       </span>
      </span>
      <span style="font: 10pt Times New Roman, Times, Serif">
       millionof ATM Shares.
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
      <span style="font: 10pt Times New Roman, Times, Serif">
       <i>
        Researchand Option Agreement
       </i>
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
      </span>
     </p>
     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
      <span style="font: 10pt Times New Roman, Times, Serif">
       InFebruary 2021, Lineage extended the Option Period with Gyroscope for $
       <span id="xdx_902_ecustom--AgreedSignatureFeeAmount_pn5n6_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--ResearchandOptionAgreementMember__dei--LegalEntityAxis__custom--GyroscopeTherapeuticsLimitedMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zw2NfPeEefd3" title="Agreed signature fee amount">
        <span>
         <ix:nonfraction contextref="From2021-02-012021-02-28_custom_ResearchandOptionAgreementMember_custom_GyroscopeTherapeuticsLimitedMember_us-gaap_SubsequentEventMember" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1259" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="LCTX:AgreedSignatureFeeAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="USD">
          0.5
         </ix:nonfraction>
        </span>
       </span>
       million for an additional three months. See Note 14for additional information.
      </span>
     </p>
    </ix:nonnumeric>
   </span>
   <p id="xdx_81D_znvKx74l5TC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 110 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        108
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_014">
         </span>
         ITEM    9.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         CHANGES    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Notapplicable.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_015">
         </span>
         ITEM    9A.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         CONTROLS    AND PROCEDURES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Evaluationof Disclosure Controls and Procedures
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Itis management’s responsibility to establish and maintain adequate internal control over all financial reporting pursuantto Rule 13a-15 under the Securities Exchange Act of 1934 (“Exchange Act”). Our management, including our principalexecutive officer and our principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controlsand procedures as of the end of our fourth quarter. Following this review and evaluation
     <i>
      ,
     </i>
     management collectively determinedthat our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reportsthat we file or submit under the Exchange Act: (i) is recorded, processed, summarized and reported within the time periods specifiedin Securities and Exchange Commission rules and forms; and (ii) is accumulated and communicated to management, including our chiefexecutive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Changesin Internal Control over Financial Reporting
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Therewere no changes in our internal control over financial reporting that occurred during the period covered by this Report that havematerially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Management’sReport on Internal Control over Financial Reporting
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting. Internal controlover financial reporting, as defined in Exchange Act Rule 13a-15(f), is a process designed by, or under the supervision of, ourprincipal executive officer, our principal operations officer, and our principal financial officer, and effected by our Boardof Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reportingand the preparation of financial statements for external purposes in accordance with generally accepted accounting principlesand includes those policies and procedures that:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Pertain    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of    our assets;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Provide    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance    with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with    authorizations of our management and directors; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Provide    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets    that could have a material effect on the financial statements.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Becauseof its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections ofany evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changesin conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems,no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide onlyreasonable assurance with respect to financial statement preparation and presentation. The scope of management’s assessmentof the effectiveness of internal control over financial reporting includes our consolidated subsidiaries.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Ourmanagement assessed the effectiveness of our internal control over financial reporting as of December 31, 2020, based oncriteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizationsof the Treadway Commission. Based on this assessment, management believes that, as of that date, our internal control over financialreporting was effective.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_016">
         </span>
         ITEM    9B.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         OTHER    INFORMATION
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Notapplicable
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 111 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        109
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_017">
      </span>
      PARTIII
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <tbody>
     <tr style="vertical-align: top">
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_018">
         </span>
         ITEM     10.
        </b>
       </span>
      </td>
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         DIRECTORS,    EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Boardof Directors
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Setforth below are the names, ages, board committee assignments, tenure, and certain biographical information of each of the membersof our Board of Directors (our “Board”) as of March 11, 2021.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 27%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Name
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Age
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Committees
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Director    Since
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Alfred    D. Kingsley
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        77
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Financial    Strategy*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        July    2009
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Deborah    Andrews
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        63
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Audit*,    Compensation, Nominating &amp; Corporate Governance
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        April    2014
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Don    M. Bailey
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        75
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Nominating    &amp; Corporate Governance*, Financial Strategy
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    2019
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Neal    C. Bradsher, CFA
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        55
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Nominating    &amp; Corporate Governance, Financial Strategy
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        July    2009
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Brian    M. Culley
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        49
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        None
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        September    2018
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Michael    H. Mulroy
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        54
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Compensation*,    Audit, Nominating &amp; Corporate Governance, Financial Strategy
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        October    2014
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Angus    C. Russell
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        65
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Audit,    Compensation
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        December    2014
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     *Committee chairperson
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       AlfredD. Kingsley
      </i>
     </b>
     <i>
      .
     </i>
     Mr. Kingsley has been Chairman of the Board since July 2009. Mr. Kingsley has been general partnerof Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993.Greenbelt served as our financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation(OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer.From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnologycompany focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also servedas a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until our acquisition of Asterias in March 2019. Mr. Kingsleywas Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degreein economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York UniversityLaw School. Mr. Kingsley’s long career in corporate finance and mergers and acquisitions includes substantial experiencein helping companies to improve their management and corporate governance, and to restructure their operations. Mr. Kingsley developedan intimate knowledge of our business in his role as our financial advisor before he joined our Board. Mr. Kingsley has been instrumentalin structuring our equity and debt financings, and in the transition of our business focus into the field of stem cell technology,and the business acquisitions that have helped us expand the scope of our business.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       DeborahAndrews
      </i>
     </b>
     . Ms. Andrews served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development,manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from September 2017 untilJune 30, 2020 after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical’sVice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President,International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm.Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino. Ms. Andrews brings to our Boardsignificant experience in finance, financial reporting, accounting, and auditing, and in management as a senior financial andaccounting executive of a public medical device company during a period of significant growth.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 112 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        110
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       DonM. Bailey
      </i>
     </b>
     <i>
      .
     </i>
     <span style="background-color: white">
      Mr. Bailey previously served as a director and Chairman of AsteriasBiotherapeutics, Inc. (AST) from February 2016 until our acquisition of Asterias in March 2019. Mr. Bailey served as Presidentand Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment ofpatients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodtplc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was theChairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director andChairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX).From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent directorand chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquarteredin Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR SurgicalCompany (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietarytechnologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governancecommittee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformedinto a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operationsresearch from the University of Southern California and an M.B.A. from Pepperdine University. Mr. Bailey has also served as aboard member on several non-profit and academic enterprises. Mr. Bailey is a founding board member of the University of CaliforniaIrvine’s (UCI) Applied Innovation Institute. Mr. Bailey brings to our Board significant knowledge of the pharmaceuticalsindustry and extensive experience as an executive and board member of publicly traded pharmaceutical companies
     </span>
     .
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       NealC. Bradsher, CFA
      </i>
     </b>
     <i>
      .
     </i>
     Mr. Bradsher has been President of Broadwood Capital, Inc., a private investment firm, since2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was adirector of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. Mr.Bradsher brings to our Board a wealth of experience in finance, management and corporate governance attained through his investmentsin other companies, including companies in the pharmaceutical, biotechnology, medical device, medical diagnostics, health careservices and health care information systems sectors. He has worked with several health care companies to improve their managementand governance. Entities that Mr. Bradsher controls have invested in most of Lineage’s financing transactions over the lastseveral years. Mr. Bradsher is the president of the general partner of Broadwood Partners, L.P., currently our largest shareholder.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       BrianM. Culley
      </i>
     </b>
     <i>
      .
     </i>
     <span style="background-color: white">
      Mr. Culley joined Lineage as Chief Executive Officer in September2018 and was appointed as Interim Chief Financial Officer in January 2021. Prior to joining Lineage, Mr. Culley served from August2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served asChief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011,until Mast’s merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast’s Chief BusinessOfficer and Senior Vice President, from 2006 to 2007 as Mast’s Senior Vice President, Business Development, and from 2004to 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Developmentand Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department ofTechnology Transfer &amp; Intellectual Property Services and from 1996 to 1999 he conducted drug development research for NeurocrineBiosciences, Inc. (NBIX). Mr. Culley has also served on the Board of Orphagen Pharmaceuticals, Inc. since May 2017. Mr. Culleyhas more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology fromBoston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A.from The Johnson School of Business at Cornell University. Mr. Culley brings to our Board significant knowledge of the biotechnologyindustry and extensive experience as an executive and board member of publicly traded pharmaceutical companies
     </span>
     .
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       MichaelH. Mulroy
      </i>
     </b>
     . Mr. Mulroy served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics,Inc. (AST) from June 2017 until our acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leadingmanufacturer of motor test equipment and hysteresis brakes and clutches, on a part time basis, where he also serves on its boardof directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT PartnersInc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its salein 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of QuestcorPharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary.From 2003 to 2011, Mr. Mulroy was employed by the law firm of Stradling Yocca Carlson &amp; Rauth, where he served as a partnerfrom 2004. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch. He is also a member of the Boardof Trustees of the Pegasus School, an independent primary school in Orange County, California. From January 2017 to July 2019,Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on thedevelopment and commercialization of novel therapeutics targeting human aging. Mr. Mulroy earned his J.D. degree from the Universityof California, Los Angeles and his B.A. degree in economics from the University of Chicago. Mr. Mulroy brings to our Board hisexperience as the Chief Executive Officer of a publicly traded biotechnology company and member of a senior management team ofa larger biopharmaceutical company that experienced a period of rapid growth. Mr. Mulroy also brings to our Board his experiencein corporate finance and investor relations.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 113 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        111
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       AngusC. Russell
      </i>
     </b>
     <i>
      .
     </i>
     Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company,from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served asits Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served atICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr.Russell also serves as Chairman of the Board of Directors of Mallinckrodt plc (MNK) and Revance Therapeutics, Inc. (RVNC) andas a director of Therapeutics MD, Inc. (TXMD). Mr. Russell previously served as a director of Shire plc, Questcor Pharmaceuticals,Inc. (QCOR) until it was acquired by Mallinckrodt plc (MNK) in 2014, and InterMune, Inc. (ITMN) prior to its acquisition by RocheHoldings, Inc. (RHHBY) in 2014. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K.Mr. Russell brings to our Board numerous years of experience as a Chief Executive Officer of an international publicly tradedspecialty biopharmaceutical company and his substantial experience as an officer and director in the specialty pharmaceuticalindustry.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      ExecutiveOfficers
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Setforth below are the names, ages, offices held, tenure and certain biographical information of each of our executive officers asof March 11, 2021.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 27%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Name
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Age
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Office(s)
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 16%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Officer    Since
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Brian    M. Culley
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        49
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chief    Executive Officer, Interim Chief Financial Officer, and Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        September    2018
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chase    C. Leavitt
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        39
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        General    Counsel and Corporate Secretary
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        May    2019
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Gary    S. Hogge, D.V.M., Ph.D.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        53
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Senior    Vice President of Clinical &amp; Medical Affairs
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    2019
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Mr.Culley’s biographical information is included above with those of the other members of our Board.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       ChaseC. Leavitt.
      </i>
     </b>
     <span style="background-color: white">
      Mr. Leavitt joined Lineage as General Counsel and Corporate Secretaryin May 2019. Prior to joining Lineage, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC,a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc. (ODT), a publicly traded biotechnologycompany, from June 2018 to May 2019. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc.(SWCH), a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017.From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham &amp; Watkins LLP, where his practice focused on public companyrepresentation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt receiveda B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice lawby the State Bar of California.
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       GaryHogge, D.V.M., Ph.D
      </i>
     </b>
     . Dr. Hogge joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018.Dr. Hogge has more than 20 years of experience developing and supporting the commercialization of a number of products over abroad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeuticareas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at QuestcorPharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs atElan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri® (natalizumab) in Crohn’sdisease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director followingthe approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene® (histaminedihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained hisB.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visitingscientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia
     <span style="background-color: white">
      .
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 114 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        112
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      FamilyRelationships; Arrangements; Legal Proceedings
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereare no family relationships among any of our directors and executive officers. There are no arrangements or understandings withanother person under which our directors and officers was or is to be selected as a director or executive officer. Additionally,none of our directors or executive officers is involved in any legal proceeding that requires disclosure under Item 401(f) ofRegulation S-K.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Codeof Ethics
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.2pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to our principal executive officers,our principal financial officer and accounting officer, our other executive officers, and our directors. The purpose of the Codeof Ethics is to promote: (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interestbetween personal and professional relationships; (ii) full, fair, accurate, timely, and understandable disclosure in reports anddocuments that we file with or submit to the Securities and Exchange Commission (the “SEC”) and in our other publiccommunications; (iii) compliance with applicable governmental rules and regulations; (iv) prompt internal reporting of violationsof the Code of Ethics to an appropriate person or persons identified in the Code of Ethics; and (v) accountability for adherenceto the Code of Ethics. A copy of our Code of Ethics has been posted on our internet website at www.lineagecell.com. We intendto disclose any future amendments to certain provisions of our Code of Ethics, and any waivers of those provisions granted toour principal executive officer, principal financial officer, principal accounting officer or controller or persons performingsimilar functions, by posting the information on our website within four business days following the date of the amendment orwaiver.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      AuditCommittee and Audit Committee Financial Expert
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurAudit Committee is established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the“Exchange Act”). Our Board has determined that each member of our Audit Committee: (i) is able to read and understandfundamental financial statements, including our balance sheet, income statement and cash flow statement; and (ii) qualifies asan “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K; and (iii) meets the independencerequirements contemplated by Rule 10-3A under the Exchange Act. Ms. Andrews’ expertise is based on her experience as ChiefFinancial Officer and other financial roles of STAAR Surgical Company and as a senior accountant at a major accounting firm. Mr.Russell’s expertise is based on his experience as the Chief Executive Officer and Chief Financial Officer of Shire plc,a biopharmaceutical company. Mr. Mulroy’s expertise is based on his experience as Chief Executive Officer of Asterias Biotherapeutics,Inc.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Changesin Stockholder Nomination Procedures
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Therehave been no material changes to the procedures by which stockholders may recommend nominees to our Board since such procedureswere last described in our proxy statement filed with the SEC on August 7, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
    <tbody>
     <tr style="vertical-align: top">
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_019">
         </span>
         ITEM    11.
        </b>
       </span>
      </td>
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         EXECUTIVE    COMPENSATION
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weare a “smaller reporting company” under Item 10 of Regulation S-K promulgated under the Exchange Act and the followingcompensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. Although the rulesallow us to provide less detail about our executive compensation program, our Compensation Committee is committed to providingthe information necessary to help our shareholders understand its executive compensation-related decisions. Accordingly, thissection includes supplemental narratives that describe our executive compensation practices.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 115 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        113
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurCompensation Committee oversees our compensation and employee benefit plans and practices, including executive compensation arrangementsand incentive plans and awards of stock options and other equity-based awards under the Lineage Cell Therapeutics, Inc. 2012 EquityIncentive Plan (the “2012 Plan”). Our Compensation Committee recommends to our Board the terms and amount of executivecompensation and grants of equity-based awards to executives, key employees, consultants, and independent contractors. The ChiefExecutive Officer may make recommendations to our Compensation Committee concerning executive compensation and performance, butour Compensation Committee makes its own determination or recommendation to our Board with respect to the amount and componentsof compensation, including salary, bonus, and equity awards to executive officers, generally considering factors such as companyperformance, individual performance, and compensation paid by peer group companies.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     During2020, our Compensation Committee engaged Marsh &amp; McLennan (“Marsh”) to provide compensation consulting servicesand advice to our Compensation Committee, which included market survey information and competitive market trends in employee,executive, and director compensation programs. Marsh also made recommendations to our Compensation Committee with respect to paymix components such as salary, bonus, and equity awards, and the target market pay percentiles in which executive compensationshould fall so Lineage can be competitive in executive hiring and retention.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inreviewing each executive’s overall compensation, our Compensation Committee considers an aggregate view of base salary andbonus opportunities, equity incentive grants, and the dollar value of benefits and perquisites. These factors have been balancedagainst our financial position and capital resources. In making 2020 compensation decisions, our Compensation Committee reviewedmarket data for each named executive officer’s position, compiled from Marsh, from the following peer group companies for2020:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Abeona    Therapeutics, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Concert    Pharmaceuticals, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Inovio    Pharmaceuticals, Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Aeglea    Biotherapeutics, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Curis,    Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Mersana    Therapeutics, Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Aravive,    Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Fate    Therapeutics, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Neon    Therapeutics, Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Athersys,    Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Genocea    Biosciences, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        NewLink    Genetics Corporation
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Bellicum    Pharmaceuticals, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Geron    Corporation
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Proteostasis    Therapeutics, Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Calithera    Biosciences, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Harpoon    Therapeutics, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Syndax    Pharmaceuticals, Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Celldex    Therapeutics, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Idera    Pharmaceuticals, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Synlogic,    Inc.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chimerix,    Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Infinity    Pharmaceuticals, Inc.
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     The2020 peer group was recommended by Marsh and consisted of companies operating in the biopharmaceutical industry, generally withfewer than 150 employees, less than $50 million in revenue, less than $400 million in market capitalization and a lead developmentprogram in Phase 1 or 2. A limited number of companies fell outside of these parameters but were included due to their havingsimilar areas of focus.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     For2021, our Compensation Committee engaged Anderson Pay Advisors, LLC to provide compensation consulting services and advice toour Compensation Committee. In making 2021 compensation decisions, our Compensation Committee reviewed market data for each namedexecutive officer’s position, compiled from Anderson, from an updated peer group of companies. The following companies wereadded to the 2021 peer group: Apellis Pharmaceuticals, Inc., Applied Genetic Technologies Corp., Atreca, Inc., G1Therapeutics,Inc., GlycoMimetics, Inc., Spero Therapeutics, Inc., UNITY Biotechnology, Inc., and Ziopharm Oncology, Inc. The following companieswere removed from the 2021 peer group: Inovio Pharmaceuticals, Inc., Mersana Therapeutics, Inc., Neon Therapeutics, Inc., NewLinkGenetics Corporation, Syndax Pharmaceuticals, Inc.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      SummaryCompensation Table
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thetable below shows the compensation earned by the following, who we refer to as our named executive officers, during the fiscalyears indicated: (i) our principal executive officer during the year ended December 31, 2020; and (ii) our two most highly compensatedexecutive officers other than the principal executive officer who were serving as executive officers as of December 31, 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 116 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        114
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       <p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Name                                         and Principal Position
          <sup>
           (1)
          </sup>
         </b>
        </span>
       </p>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Fiscal Year
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Salary
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          ($)
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Bonus
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          ($)
          <sup>
           (2)
          </sup>
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Option                                         Awards
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          ($)
          <sup>
           (3)
          </sup>
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          All                                         Other Compensation
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          ($)
          <sup>
           (4)
          </sup>
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Total
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          ($)
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 40%; text-align: left">
       Brian M. Culley
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 6%; text-align: right">
       2020
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 6%; text-align: right">
       551,900
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 6%; text-align: right">
       262,200
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 6%; text-align: right">
       521,563
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 6%; text-align: right">
       14,250
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 6%; text-align: right">
       1,349,913
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-style: italic; text-align: left">
       Chief Executive Officer and Interim Chief Financial Officer
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2019
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       535,800
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       214,300
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       22,642
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       772,742
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Brandi L. Roberts
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2020
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       393,200
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       260,802
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       14,250
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       668,252
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="font-style: italic; text-align: left">
       Former Chief Financial Officer
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2019
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       376,137
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       169,900
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       397,948
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       3,978
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       947,963
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Chase C. Leavitt
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2020
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       346,300
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       131,600
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       260,802
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       14,250
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       752,952
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-style: italic; text-align: left">
       General Counsel and Corporate Secretary
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       2019
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       210,146
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       102,100
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       277,310
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       9,542
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       599,098
      </td>
      <td style="text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Mr.    Culley was appointed as our Chief Executive Officer on September 17, 2018, Ms. Roberts was appointed as our Chief Financial    Officer on January 7, 2019, and Mr. Leavitt was appointed as our General Counsel and Corporate Secretary on May 20, 2019.    Ms. Roberts resigned from the company, and Mr. Culley was appointed as Interim Chief Financial Officer, effective January    20, 2021. The amounts reported in the table for each named executive officer represent the portion of earned compensation    during the period of time such officer was in service with us.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    2020 amounts represent discretionary annual bonuses as described below under “Elements of Compensation.”
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    amounts in this column represent the grant date fair value of stock options granted to the applicable individual during the    applicable year. The grant date fair value and incremental fair value of the stock options were determined in accordance with    ASC Topic 718, Compensation – Stock Compensation (ASC Topic 718). See Note 12, Stock-Based Awards to our consolidated    financial statements included in this Report for details as to the assumptions used to determine grant date fair value of    the awards.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    2020 amounts in this column represent 401(k) plan company-matching contributions.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Narrativeto Summary Compensation Table
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       EmploymentAgreements and Termination of Employment &amp; Change in Control Arrangements
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Beloware descriptions of the material terms of the employment arrangements entered into with our current named executive officers.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      BrianM. Culley, Chief Executive Officer and Interim Chief Financial Officer
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InSeptember 2018, we entered into an employment agreement with Mr. Culley (the “
     <b>
      <i>
       Culley Agreement
      </i>
     </b>
     ”). TheCulley Agreement initially provided Mr. Culley with a base salary of $530,000 annually. Mr. Culley’s salary was $551,900in 2020 and has been increased to $580,000 for 2021. Mr. Culley is also eligible to receive an annual performance bonus of upto 50% of his base salary based upon the attainment of certain corporate and individual objectives as determined by our Boardor Compensation Committee. The Culley Agreement provided Mr. Culley with reimbursement for certain travel costs to our formerheadquarters in Alameda, California and a monthly stipend not to exceed $3,900 for housing costs near our former headquarters,each of which ceased in August 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheCulley Agreement provides that if Mr. Culley’s employment is terminated without cause or he resigns for good reason, hemay be eligible for certain severance payments, including the payment of an amount equal to 12 months of his base salary, hisfull annual bonus amount and the payment of 6 months of health insurance premiums pursuant to our group health insurance plansas provided pursuant to COBRA. If Mr. Culley’s employment is terminated without cause or he resigns for good reason within12 months following a change of control, then he is entitled to the acceleration of all outstanding equity awards.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 117 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        115
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      ChaseC. Leavitt, General Counsel and Corporate Secretary
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InMay 2019, we entered into an employment agreement with Mr. Leavitt (the “
     <b>
      <i>
       Leavitt Agreement
      </i>
     </b>
     ”). The LeavittAgreement initially provided Mr. Leavitt with a base salary of $340,000 annually and a one-time sign-on bonus of $35,000. Mr.Leavitt’s salary was $346,300 for 2020 and has been increased to $356,700 for 2021. Mr. Leavitt is also eligible to receivean annual performance bonus of up to 40% of his base salary based upon the attainment of certain corporate and individual objectivesas determined by our Board or Compensation Committee.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheLeavitt Agreement provides that if Mr. Leavitt’s employment is terminated without cause or he resigns for good reason, hemay be eligible for certain severance payments, including the payment of an amount equal to three months of his base salary (ifterminated on or before May 20, 2020) or nine months base salary (if terminated after May 20, 2020), his prorated annual bonusamount and the payment of 6 months of health insurance premiums pursuant to our group health insurance plans as provided pursuantto COBRA. If Mr. Leavitt’s employment is terminated without cause or he resigns for good reason within 12 months followinga change of control, then he is entitled to the acceleration of 50% of all outstanding equity awards (if terminated on or beforeMay 20, 2020) or all outstanding equity awards (if terminated after May 20, 2020).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      BrandiL. Roberts, Former Chief Financial Officer
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InJanuary 2019, we entered into an employment agreement with Ms. Roberts (the “Roberts Agreement”). The Roberts Agreementinitially provided Ms. Roberts with a base salary of $381,924 annually, which was raised by 3% to $393,200 for 2020. Ms. Robertswas also eligible to receive an annual performance bonus of up to 40% of her base salary based upon the attainment of certaincorporate and individual objectives as determined by our Board or Compensation Committee.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     TheRoberts Agreement provides that if Ms. Roberts’ employment is terminated without cause or she resigns for good reason, shemay be eligible for certain severance payments, including the payment of an amount equal to three months of her base salary (ifterminated on or before January 7, 2020) or nine months base salary (if terminated after January 7, 2020), her prorated annualbonus amount, and the payment of 6 months of health insurance premiums pursuant to our group health insurance plans as providedpursuant to COBRA. If Ms. Robert’s employment is terminated without cause or she resigns for good reason within 12 monthsfollowing a change of control, then she is entitled to the acceleration of 50% of all outstanding equity awards (if terminatedon or before January 7, 2020) or all outstanding equity awards (if terminated after January 7, 2020).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inconnection with her resignation on January 20, 2021, we entered into a Separation and Consulting Agreement with Ms. Roberts (the“Roberts Consulting Agreement”) pursuant to which Ms. Roberts agreed to assist us with finance and accounting mattersand such other matters as we and Ms. Roberts may agree to from time to time. Ms. Roberts will be compensated at the rate of $250per hour for her services under the Roberts Consulting Agreement, which fees shall not exceed $50,000 without our approval. Asadditional compensation for her services under the Roberts Consulting Agreement, the equity awards held by Ms. Roberts as of January20, 2021 will continue to vest during the term of the Roberts Consulting Agreement.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Elementsof Compensation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      BaseSalary
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurCompensation Committee or Board reviews the base salaries of our executive officers, including our named executive officers, fromtime to time and makes adjustments as it determines to be reasonable and necessary to reflect the scope of an executive officer’sperformance, contributions, responsibilities, experience, prior salary level, position (in the case of a promotion), and marketconditions.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      AnnualPerformance Bonuses
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Eachof our named executive officers are eligible to receive an annual performance bonus based on a specific target bonus amount, expressedas a percentage of base salary, and our overall achievement of specific corporate goals and objectives set by our Board and CompensationCommittee each year. After the end of the year, our Board and Compensation Committee conducts an annual performance review processthat evaluates achievement of overall corporate goals and achievement of specific goals and objectives by each individual executive.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 118 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        116
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Anyfinal bonus payments to our named executive officers are recommended by our Compensation Committee and approved by our Board (excludingMr. Culley), which retains full discretion to adjust individual target bonus awards. The actual bonuses, if any, awarded eachyear may vary from target, depending on individual performance and the achievement of corporate objectives and may also vary basedon other factors at the discretion of our Compensation Committee.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     For2020, the corporate performance objective categories and respective weightings toward overall corporate bonus achievement wereas follows:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        advancement    of product candidates (50% weighting);
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Investor    engagement activities and total shareholder return (“TSR”) (30% weighting);
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        business    development and licensing activities (10% weighting); and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        capital    raising activities and efficient capital deployment (10% weighting).
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InFebruary 2021, our Board and Compensation Committee assessed each of the corporate performance objectives and determined thatthe company had an overall corporate achievement level of 95% for 2020. Specifically, our Board and Compensation committee consideredin its assessment that the company:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        completed    enrollment in its Phase 1/2a clinical study of OpRegen with encouraging preliminary signs of tolerability and efficacy;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        made    manufacturing improvements to its OPC1 program;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        negotiated    and executed the early exercise of its option with Cancer Research UK to bring the VAC immune-oncology program in house;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        outperformed    its peers and the broad indices in total shareholder return during the year ended December 31, 2020, with the strong shareholder    return being sustained in early 2021; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (5)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        efficiently    raised capital and achieved significant budget reductions.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurBoard and Compensation Committee determined that it was appropriate to pay each of Mr. Culley and Mr. Leavitt performance bonusesfor 2020 equivalent to their target amounts multiplied by the 95% corporate achievement level. Accordingly, our Board and CompensationCommittee approved cash bonuses for Mr. Culley and Mr. Leavitt in the amount of $262,200 and $131,600, respectively, which willbe payable in March 2021. Ms. Roberts did not receive a performance cash bonus for 2020 because she ceased serving as an executiveofficer.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <i>
      OtherBenefits
     </i>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wemaintain a 401(k) defined contribution employee retirement plan for all of our employees. Employee contributions are voluntaryand are determined on an individual basis, limited to the maximum amounts allowable under U.S. federal tax regulations. We providea safe harbor contribution of up to 5.0% of the employee’s compensation, not to exceed eligible limits, and subject to employeeparticipation.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wedo not have any annuity, pension or deferred compensation plan or other arrangements for our executive officers or any employees.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 119 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        117
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      OutstandingEquity Awards at Fiscal Year-End
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table sets forth information concerning equity awards held by our named executive officers that were outstanding asof December 31, 2020:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="text-align: justify">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="vertical-align: bottom; text-align: center">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Option Awards
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Stock Awards
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Name
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
       Grant Date
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0pt; margin-bottom: 0pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Number                                         of securities underlying unexercised options exercisable
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          (#)
         </span>
        </p>
       </div>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0pt; margin-bottom: 0pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Number                                         of securities
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           underlying
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           unexercised
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           options                                         unexercisable
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           (#)
           <sup>
            (1)
           </sup>
          </b>
         </span>
        </p>
       </div>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0pt; margin-bottom: 0pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Option
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           exercise                                         price
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           ($)
          </b>
         </span>
        </p>
       </div>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Option expiration date
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0pt; margin-bottom: 0pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Number                                         of shares or units of stock that have not vested
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           (#)
          </b>
         </span>
        </p>
       </div>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0pt; margin-bottom: 0pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Market                                         value of shares of units of stock that have not vested
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           ($)
           <sup>
            (2)
           </sup>
          </b>
         </span>
        </p>
       </div>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 20%; text-align: justify">
       Brian M. Culley
      </td>
      <td style="width: 2%">
      </td>
      <td style="vertical-align: bottom; width: 8%; text-align: center">
       9/17/2018
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 7%; text-align: right">
       1,042,875
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 9%; text-align: right">
       811,125
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 8%; text-align: right">
       1.87
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 8%; text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        9/16/2028
       </span>
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 7%; text-align: right">
       —
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 7%; text-align: right">
       —
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       9/17/2018
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       92,700
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       163,152
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       3/17/2020
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1,233,300
      </td>
      <td style="text-align: left">
       <sup>
        (3)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       0.6919
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3/17/2030
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: justify">
       Brandi L. Roberts
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       1/7/2019
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       239,586
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       260,414
      </td>
      <td style="text-align: left">
       <sup>
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1.08
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        1/6/2029
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       6/30/2019
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       71,875
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       78,125
      </td>
      <td style="text-align: left">
       <sup>
        (4)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1.10
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        6/29/2029
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       3/17/2020
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       616,700
      </td>
      <td style="text-align: left">
       <sup>
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       0.6919
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3/17/2030
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify">
       Chase C. Leavitt
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       5/20/2019
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       118,750
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       181,250
      </td>
      <td style="text-align: left">
       <sup>
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1.13
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        5/19/2029
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       7/31/2019
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       49,479
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       75,521
      </td>
      <td style="text-align: left">
       <sup>
        (5)
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1.10
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        7/31/2029
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: justify">
      </td>
      <td>
      </td>
      <td style="vertical-align: bottom; text-align: center">
       3/17/2020
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       616,700
      </td>
      <td style="text-align: left">
       <sup>
       </sup>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       0.6919
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3/17/2030
       </span>
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       —
      </td>
      <td style="text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Except    as otherwise provided, 25% of the options vest on the first anniversary of the grant date, and the balance vest in equal    monthly installments over the three years thereafter, subject to the executive’s continued services.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    dollar amounts shown in this column are calculated by multiplying the number of shares shown in the adjacent column by the    closing market price of our common shares as reported on NYSE American on December 31, 2020 ($1.76), the last trading day    of our fiscal year.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        This    grant was approved by the independent members of our Board in reliance on the employment inducement exemption to shareholder    approval provided under the NYSE American Company Guide.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        25%    of the options vested on January 7, 2020, and the balance vest in equal monthly installments over the three years thereafter,    subject to Ms. Roberts’ continued services.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (5)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        25%    of the options vested on May 20, 2020, and the balance vest in equal monthly installments over the three years thereafter,    subject to Mr. Leavitt’s continued services.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Considerationof Shareholder Advisory Vote on Executive Compensation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theresults of the advisory vote of our shareholders on the compensation of our named executive officers (commonly called the “say-on-pay”vote) at our 2020 Annual Meeting of Shareholders showed that more than 94% of our shareholders that voted approved the compensationof our named executive officers during 2019. Our Compensation Committee carefully evaluated and considered the results of thisadvisory vote. Aligned with the voting feedback of more than two-thirds of the shares voted, our Compensation Committee concludedthat our shareholders generally supported our executive pay program and we did not make significant changes to our program for2020. Our
     <span style="background-color: white">
      Compensation Committee expects to continue to consider the outcome of our “sayon pay” votes and our stockholders’ views when making future compensation decisions for our named executive officers.
     </span>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     <b>
      DirectorCompensation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Wecompensate our non-employee directors for their service on our Board and on its committees with the compensation provided below.In addition, all of our non-employee directors are entitled to reimbursements for their out-of-pocket expenses incurred in attendingour Board and committee meetings.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Thefollowing table shows the annual cash fees paid to the Chairman of our Board, our directors other than the Chairman, and to thedirectors who served on the standing committees of our Board during 2020.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td>
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Fees Paid
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 78%; text-align: left">
       Chairman of the Board
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 18%; text-align: right">
       75,000
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Director other than Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       40,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Audit Committee Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       20,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Audit Committee Member other than Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       10,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Compensation Committee Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       15,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Compensation Committee Member other than Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       7,500
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Nominating and Corporate Governance Committee Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       12,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Nominating and Corporate Governance Committee Member other than Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       6,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Financial Strategy Committee Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       160,000
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Financial Strategy Committee Member other than Chair
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       -
      </td>
      <td style="text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 120 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        118
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Inconnection with the increase of the size of our Nominating and Corporate Governance Committee from three to four members on August4, 2020, annual cash fees for the Chair and members other than the Chair were reduced from $15,000 and $7,500, respectively tokeep overall fees for such Committee consistent. The annual cash fees are paid in four equal quarterly installments, based onthe director’s continued service through the last day of the applicable quarter, other than the annual cash fees paid tothe Financial Strategy Committee Chair, which are paid monthly in arrears.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Inaddition to cash fees, our Chairman receives an annual stock option grant to purchase 70,000 common shares and all other non-employeedirectors receive an annual stock option grant to purchase 40,000 common shares. All grants are made under the 2012 Plan. Theoptions vest and become exercisable one year after the grant date.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      2020Director Compensation
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table summarizes certain information concerning the compensation paid during our fiscal year ended December 31, 2020to each person who served as a director during that time and who was not our employee on the date the compensation was earned.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Name
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Fees                                         Earned
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          or                                         Paid in
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Cash
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Option
         </b>
        </span>
       </p>
       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">
         <b>
          Award
          <sup>
           (1)
          </sup>
         </b>
        </span>
       </p>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Total
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 49%; text-align: left">
       Deborah Andrews
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 13%; text-align: right">
       69,946
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 13%; text-align: right">
       19,932
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 13%; text-align: right">
       89,878
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Don M. Bailey
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       59,855
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       19,932
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       79,787
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Neal C. Bradsher
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       50,185
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       19,932
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       70,117
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Stephen C. Farrell
        <sup>
         (2)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       38,906
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       19,932
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       58,838
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Alfred D. Kingsley
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       235,000
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       34,881
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       269,881
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left">
       Michael H. Mulroy
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       58,071
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       19,932
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       78,003
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left">
       Angus C. Russell
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       52,058
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       19,932
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
       $
      </td>
      <td style="text-align: right">
       71,990
      </td>
      <td style="text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        The    dollar amounts in this column represent the aggregate fair market value of such awards determined based on the price of our    common shares on the grant date in accordance with ASC Topic 718,
        <i>
         Compensation-Stock Compensation (ASC Topic 718)
        </i>
        .    See Note 12 Stock-Based Awards to our consolidated financial statements included in our Form 10-K for details as to    the assumptions used to determine the fair value of the awards. As of December 31, 2020, the aggregate number of option    awards outstanding for Ms. Andrews and Messrs. Bailey, Bradsher, Farrell, Kingsley, Mulroy, and Russell was 178,880, 140,000,    178,880, 0, 350,120, 178,880 and 178,880, respectively.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Mr.    Farrell did not stand for re-election and was no longer a director as of September 22, 2020.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
    <tbody>
     <tr style="vertical-align: top">
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in">
       <span id="a_020">
       </span>
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         ITEM    12.
        </b>
       </span>
      </td>
      <td style="text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         SECURITY OWNERSHIP    OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT, AND RELATED STOCKHOLDER MATTERS
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thetables below sets forth certain information, as of March 5, 2021, regarding the beneficial ownership of our common shares for:(i) each person known by us to be the beneficial owner of more than 5% of our common stock; (ii) each of our directors; (iii)each of our named executive officers; and (iv) all of our current directors and executive officers as a group.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 121 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        119
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave determined beneficial ownership in accordance with applicable SEC rules, and the information reflected in the table belowis not necessarily indicative of beneficial ownership for any other purpose. Under applicable SEC rules, beneficial ownershipincludes any shares of common stock as to which a person has sole or shared voting power or investment power and any shares ofcommon stock which the person has the right to acquire within 60 days after the date set forth in the paragraph above throughthe exercise of any option, warrant or right or through the conversion of any convertible security. Unless otherwise indicatedin the footnotes to the table below and subject to community property laws where applicable, we believe, based on the informationfurnished to us and on SEC filings, that each of the persons named in table below has sole voting and investment power with respectto the shares indicated as beneficially owned.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Theinformation set forth in the tables below is based on 161,637,890 common shares issued and outstanding on March 5, 2021.In computing the number of common shares beneficially owned by a person and the percentage ownership of that person, we deemedto be outstanding all common shares subject to options, warrants, rights or other convertible securities held by that person thatare currently exercisable or will be exercisable within 60 days after such date. We did not deem these shares outstanding, however,for the purpose of computing the percentage ownership of any other person. Except as otherwise noted, the address for each personlisted in the table below is c/o Lineage Cell Therapeutics, Inc., 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold">
       Name and Address of Beneficial Owner
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Number of Shares Beneficially    Owned
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Percentage of Shares Beneficially    Owned
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       Greater than 5% Holders
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; width: 60%; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Broadwood    Partners, L.P.
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 16%; text-align: right">
       34,207,167
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 16%; text-align: right">
       21.1
      </td>
      <td style="width: 1%; text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="font-weight: bold; text-align: left">
       Named Executive Officers and Directors
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Neal    C. Bradsher
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       34,207,167
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       21.1
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Alfred    D. Kingsley
        <sup>
         (2)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       7,107,262
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       4.4
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Brian    M. Culley
        <sup>
         (3)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1,732,445
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       1.1
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Brandi    L. Roberts
        <sup>
         (4)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       537,651
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chase    C. Leavitt
        <sup>
         (5)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       375,667
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Michael    H. Mulroy
        <sup>
         (6)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       365,715
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Angus    C. Russell
        <sup>
         (7)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       206,380
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Don    M. Bailey
        <sup>
         (8)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       193,970
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="padding-left: 10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Deborah Andrews
        <sup>
         (9)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       148,880
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        *
       </span>
      </td>
      <td style="text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-left: 10pt; text-align: left">
       <span style="font: 10pt Times New Roman, Times, Serif">
        All    executive officers and directors as a group (10 persons)
        <sup>
         (10)
        </sup>
       </span>
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       45,280,465
      </td>
      <td style="text-align: left">
      </td>
      <td>
      </td>
      <td style="text-align: left">
      </td>
      <td style="text-align: right">
       <span style="font: 10pt Times New Roman, Times, Serif">
        27.4
       </span>
      </td>
      <td style="text-align: left">
       %
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     *Less than 1%
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 34,005,379 shares owned by Broadwood Partners, L.P.; (ii) 62,908 shares owned by Neal C. Bradsher; and (iii) 138,880 shares    that may be acquired by Mr. Bradsher upon the exercise of options that are presently exercisable or may become exercisable    within 60 days of March 5, 2021. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., and Mr. Bradsher    is the President of Broadwood Capital, Inc. Mr. Bradsher and Broadwood Capital, Inc. may be deemed to beneficially own the    shares that Broadwood Partners, L.P. owns. Mr. Bradsher disclaims beneficial ownership of the shares held by Broadwood    Partners, L.P. except to the extent of his pecuniary interest therein. The Address of the foregoing entities and Mr. Bradsher    is c/o Broadwood Capital, Inc., 142 West 57
        <sup>
         th
        </sup>
        Street, 11
        <sup>
         th
        </sup>
        Floor, New York, New York 10019.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 1,043,346 shares owned by Greenbelt Corporation; (ii) 375,351 shares owned by Greenway Partners, L.P.; (iii) 5,408,445    shares owned solely by Alfred D. Kingsley; and (iv) 280,120 shares that may be acquired by Mr. Kingsley upon the exercise    of options that are presently exercisable or may become exercisable within 60 days of March 5, 2021. Mr. Kingsley controls    Greenbelt Corp. and Greenway Partners, L.P. and may be deemed to beneficially own the shares that Greenbelt Corp. and Greenway    Partners, L.P. own.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (3)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 185,602 shares held directly by Mr. Culley; (ii) 1,531,393 shares that may be acquired upon the exercise of options that    are presently exercisable or that may become exercisable within 60 days of March 5, 2021; and (iii) 15,450 shares underlying    RSU awards that are scheduled to vest on March 31, 2021. Does not include 77,250 shares underlying RSU awards that are subject    to vesting more than 60 days after March 5, 2021.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (4)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 5,000 shares held directly by Ms. Roberts; and (ii) 532,651 shares that may be acquired upon the exercise of options that    are presently exercisable or that may become exercisable within 60 days of March 5, 2021.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 122 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        120
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (5)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 5,000 shares held directly by Mr. Leavitt; and (ii) 370,667 shares that may be acquired upon the exercise of options that    are presently exercisable or that may become exercisable within 60 days of March 5, 2021.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (6)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 226,835 shares held directly by Mr. Mulroy; and (ii) 138,880 shares that may be acquired upon the exercise of options    that are presently exercisable or that may become exercisable within 60 days of March 5, 2021.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (7)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 67,500 shares held directly by Mr. Russell; and (ii) 138,880 shares that may be acquired upon the exercise of options    that are presently exercisable or that may become exercisable within 60 days of March 5, 2021.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (8)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 62,647 shares held directly by Mr. Bailey; (ii) 100,000 shares that may be acquired upon the exercise of options that    are presently exercisable or that may become exercisable within 60 days of March 5, 2021; and (iii) 31,323 shares that may    be acquired upon the exercise of warrants that are presently exercisable.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (9)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 10,000 shares held directly by Ms. Andrews; and (ii) 138,880 shares that may be acquired upon the exercise of options    that are presently exercisable or that may become exercisable within 60 days of March 5, 2021.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (10)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Includes:    (i) 41,486,458 shares held directly by such executive officers and directors; (ii) 3,747,234 shares that may be acquired    upon the exercise of options that are presently exercisable or that may become exercisable within 60 days of March 5, 2021; (iii) 31,323 shares that may be acquired upon the exercise of warrants that are presently exercisable; and (iv) 15,450    shares underlying RSU awards that are subject to vest on March 31, 2021. Does not include 77,250 shares underlying RSU    awards that are subject to vesting more than 60 days after March 5, 2021.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      EquityCompensation Plan Information
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows certain information concerning the options outstanding and available for issuance under all of our compensationplans and agreements as of December 31, 2020 (in thousands, except weighted average exercise prices):
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Plan Category
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Number of Shares to be Issued    Upon Exercise of Outstanding Options and Vesting of Restricted Stock Units, and Rights
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Weighted Average Exercise    Price of the Outstanding Options, and Rights
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Number of Shares Remaining    Available for Future Issuance under Equity Compensation Plans
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 49%; text-align: left">
       Equity Compensation Plans Approved by Shareholders
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 13%; text-align: right">
       14,011
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 13%; text-align: right">
       1.53
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 13%; text-align: right">
       8,002
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
        Equity    Compensation Plans Not Approved by Shareholders
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       1,854
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
       $
      </td>
      <td style="padding-bottom: 1.5pt; text-align: right">
       1.87
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       —
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="padding-bottom: 2.5pt">
       Total
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       15,865
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
       $
      </td>
      <td style="padding-bottom: 2.5pt; text-align: right">
       1.57
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       8,002
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Reflects    an option grant approved by the independent members of our Board in reliance on the employment inducement exemption to shareholder    approval provided under the NYSE American Company Guide.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows certain information concerning the options outstanding and available for issuance under all of our compensationplans and agreements for our consolidated subsidiary companies as of December 31, 2020 (in thousands, except weighted averageexercise prices):
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Plan Category
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Number of Shares to be Issued    Upon Exercise of Outstanding Options and Vesting of Restricted Stock Units, and Rights
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Weighted Average Exercise    Price of the Outstanding Options, and Rights
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       Number of Shares Remaining    Available for Future Issuance under Equity Compensation Plans
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 49%; text-align: left; padding-bottom: 2.5pt">
       <span style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
        Asterias    Equity Compensation Plans Approved by Shareholders
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td style="width: 2%; padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">
       350
      </td>
      <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="width: 2%; padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">
       1.57
      </td>
      <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="width: 2%; padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">
      </td>
      <td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">
       4,840
      </td>
      <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Lineage    is the sole shareholder. In connection with its acquisition of Asterias, Lineage assumed sponsorship of the Asterias 2013    Equity Incentive Plan, with references to Asterias and Asterias common stock therein to be deemed references to Lineage and    Lineage common shares, respectively.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 123 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        121
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
    <tbody>
     <tr style="vertical-align: top">
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_021">
         </span>
         ITEM    13.
        </b>
       </span>
      </td>
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         CERTAIN    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      RelatedPerson Transactions
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     SinceJuly 1, 2009, Alfred D. Kingsley has made available to us the use of approximately 900 square feet of office space in New YorkCity. We pay the office building owner $5,050 per month for the use of the space. These monthly payments are expected to ceasein March 2021 when the office space lease expires.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     InApril 2019, Lineage issued 251,835 common shares of Lineage to Broadwood Partners, L.P., a shareholder of Lineage and AsteriasBiotherapeutics, Inc. (“Asterias”), in exchange for the settlement of warrants to purchase shares of Asterias commonstock in connection with our acquisition of Asterias (the “Asterias Merger”).
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Inconnection with the putative shareholder class action lawsuits filed in February 2019 and October 2019 challenging the AsteriasMerger, Lineage has agreed to pay for the legal defense of Neal Bradsher, director, and Broadwood Partners, L.P., a shareholderof Lineage, and Broadwood Capital, Inc., which manages Broadwood Partners, L.P., all of which were named in the lawsuits. Duringthe year ending December 31, 2020, Lineage has incurred a total of $359,000 in legal expenses on behalf of the director, shareholderand the manager of the shareholder.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Aspart of a financing transactions in which there were multiple other purchasers, Broadwood Partners, L.P.
     <br/>
     purchased 1,000,000, 2,000,000, and 623,090 shares of common stock of OncoCyte Corporation (“OncoCyte”) from Lineagein July 2019, September 2019, and January 2020, respectively.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     During2019, we invoiced OncoCyte $1.2 million for certain “Use Fees” and other charges under the terms of a Shared Facilitiesand Services Agreement (the “
     <b>
      <i>
       Shared Facilities Agreement
      </i>
     </b>
     ”) between Lineage and OncoCyte. Under the SharedFacilities Agreement, Lineage allowed OncoCyte to use Lineage’s premises and equipment located at Alameda, California forthe sole purpose of conducting business. Lineage also provided accounting, billing, bookkeeping, payroll, treasury, payment ofaccounts payable, and other similar administrative services to OncoCyte. The Shared Facilities Agreements also allowed Lineageto provide the services of attorneys, accountants, and other professionals who may provide professional services to Lineage. Lineagealso provided OncoCyte with the services of laboratory and research personnel, including Lineage employees and contractors, forthe performance of research and development work for OncoCyte at the premises. Shared services with OncoCyte were terminated withrespect to the use of Lineage’s office and laboratory facilities on September 30, 2019, and December 31, 2019 with respectto all other remaining shared services.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Weentered into a similar Shared Facilities Agreement with AgeX in 2018. During 2019, we invoiced AgeX $0.9 million for certain “UseFee” and other charges and expenses for that period. Shared services with AgeX were terminated on July 31, 2019 with respectto the use of Lineage’s office and laboratory facilities and September 30, 2019 with respect to all other remaining sharedservices.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     Atthe time of our acquisition of Asterias, two of our directors, Alfred D. Kingsley, and Michael H. Mulroy, and an officer of Broadwood,were directors of Asterias. Immediately following the acquisition, Don M. Bailey joined our Board, and Edward D. Wirth, III, M.D.,Ph.D. joined as our Chief Medical Officer. Mr. Bailey was a director of Asterias, and Dr. Wirth was an executive officer of Asterias.All of our directors and executive officers (including Mr. Bailey and Dr. Wirth) and 5% Shareholders as reported in this report,in the aggregate beneficially owned approximately 12% of the outstanding shares of Asterias common stock as of December 31, 2018,and approximately 12% of the outstanding shares of Asterias common stock immediately prior to the acquisition on March 8, 2019.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 124 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        122
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Mr.Kingsley is a director of OncoCyte. Broadwood Partners, L.P., a shareholder of Lineage (“Broadwood”) beneficiallyowns more than 20% of the outstanding common stock of OncoCyte, and all of our directors and executive officers and 5% Shareholdersas reported in this report, including Neal C. Bradsher who may be deemed to beneficially own the shares owned by Broadwood, inthe aggregate beneficially own more than 20% of the outstanding shares of OncoCyte common stock. The fact that certain of ourexecutive officers and directors own shares of OncoCyte common stock should not be considered to mean that they constitute orare acting in concert as a “group” with respect to those shares or that they otherwise share power or authority tovote or dispose of the shares that each of them own. All decisions of Lineage regarding transactions in shares of OncoCyte aremade by an independent committee of our Board in which Messrs. Kingsley and Bradsher do not participate.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <i>
       RelatedPerson Transaction Policy
      </i>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Wehave adopted a Related Person Transaction Policy that applies to transactions exceeding $120,000 in which any of our officers,directors, 5% Shareholders, or any member of their immediate family, has a direct or indirect material interest, determined inaccordance with the policy (a “Related Person Transaction”). A Related Person Transaction must be reported to ourChief Financial Officer and General Counsel or outside legal counsel and will be subject to review and approval by our Audit Committeeprior to effectiveness or consummation, to the extent practical. In addition, any Related Person Transaction that is ongoing innature will be reviewed by our Audit Committee annually to ensure that the transaction has been conducted in accordance with anyprevious approval and that all required disclosures regarding the transaction are made.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Asappropriate for the circumstances, our Audit Committee will review and consider:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    interest of the officer, director, beneficial owner of more than 5% of our common shares, or any member of their immediate    family (“Related Person”) in the Related Person Transaction;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    approximate dollar value of the amount involved in the Related Person Transaction;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    approximate dollar value of the amount of the Related Person’s interest in the transaction without regard to the amount    of any profit or loss;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        whether    the transaction was undertaken in the ordinary course of our business;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        whether    the transaction with the Related Person is proposed to be, or was, entered into on terms no less favorable to us than terms    that could have been reached with an unrelated third party;
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        the    purpose of, and the potential benefits to the transaction to us; and
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ●
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        any    other information regarding the Related Person Transaction or the Related Person in the context of the proposed transaction    that would be material to investors in light of the circumstances of the particular transaction.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurAudit Committee will review all relevant information available to it about a Related Person Transaction. Our Audit Committee mayapprove or ratify the Related Person Transaction only if our Audit Committee determines that, under all of the circumstances,the transaction is in, or is not in conflict with, our best interests. Our Audit Committee may, in its sole discretion, imposesuch conditions as it deems appropriate on us or the Related Person in connection with approval of the Related Person Transaction.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Acopy of our Related Person Transaction Policy can be found on our website at www.lineagecell.com.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
    <tbody>
     <tr style="vertical-align: top">
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.75in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_022">
         </span>
         ITEM    14.
        </b>
       </span>
      </td>
      <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         PRINCIPAL    ACCOUNTING FEES AND SERVICES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing table shows the fees billed or expected to be billed by OUM &amp; Co. LLP (“OUM”), our principalaccountant, for the audit of our annual consolidated financial statements for our last two fiscal years and for other servicesrendered by OUM during our last two fiscal years.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <tbody>
     <tr style="vertical-align: bottom">
      <td style="text-align: center">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2020
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
      <td style="font-weight: bold; padding-bottom: 1.5pt">
      </td>
      <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
       2019
      </td>
      <td style="padding-bottom: 1.5pt; font-weight: bold">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="width: 60%">
       <span style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
        Audit    Fees
        <sup>
         (1)
        </sup>
       </span>
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 16%; text-align: right">
       319,000
      </td>
      <td style="width: 1%; text-align: left">
      </td>
      <td style="width: 2%">
      </td>
      <td style="width: 1%; text-align: left">
       $
      </td>
      <td style="width: 16%; text-align: right">
       503,000
      </td>
      <td style="width: 1%; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: White">
      <td style="text-align: left; padding-bottom: 1.5pt">
       <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
        Audit    Related Fees
        <sup>
         (2)
        </sup>
       </span>
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       50,000
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 1.5pt">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: left">
      </td>
      <td style="border-bottom: Black 1.5pt solid; text-align: right">
       37,000
      </td>
      <td style="padding-bottom: 1.5pt; text-align: left">
      </td>
     </tr>
     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
      <td style="text-align: left; padding-bottom: 2.5pt">
       Total Fees
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       369,000
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
      <td style="padding-bottom: 2.5pt">
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: left">
       $
      </td>
      <td style="border-bottom: Black 2.5pt double; text-align: right">
       540,000
      </td>
      <td style="padding-bottom: 2.5pt; text-align: left">
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (1)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Audit    Fees consist of fees billed or expected to be billed for professional services rendered for the audit of the consolidated    annual financial statements of Lineage and its several subsidiaries included in our Annual Report on Form 10-K, the reviews    of the interim consolidated financial statements included in our Quarterly Reports on Form 10-Q, and services that are normally    provided by our independent registered public accountants in connection with statutory and regulatory filings or engagements.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (2)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Audit-Related    Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit    or review of Lineage’s consolidated financial statements and are not reported under “Audit Fees.” This category    includes fees related to non-routine SEC filings.
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 125 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        123
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      Pre-Approvalof Audit and Permissible Non-Audit Services
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurAudit Committee requires pre-approval of all audit and non-audit services. Other than
     <i>
      de minimis
     </i>
     services incidental toaudit services, non-audit services shall generally be limited to tax services such as advice and planning and financial due diligenceservices. All fees for such non-audit services must be approved by the Audit Committee, except to the extent otherwise permittedby applicable SEC regulations. Our Audit Committee may delegate to one or more designated members of our Audit Committee the authorityto grant pre-approvals, provided such approvals are presented to our Audit Committee at a subsequent meeting.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      DirectorIndependence
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     OurBoard has determined that Deborah Andrews, Don M. Bailey, Neal C. Bradsher, Michael H. Mulroy, and Angus C. Russell qualify as“independent” in accordance with Section 803(A) of the NYSE American Company Guide. The members of our Audit Committeemeet the additional independence standards under Section 803(B)(2) of the NYSE American Company Guide and Section 10A-3 underthe Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the members of our Compensation Committeemeet the additional independence standards under Section 805(c)(1) of the NYSE American Company Guide.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     BrianM. Culley does not qualify as “independent” under Section 803(A) of the NYSE American Company Guide because he isour Chief Executive Officer and Interim Chief Financial Officer. Alfred D. Kingsley does not qualify as “independent”under Section 803(A) of the NYSE American Company Guide because he was an employee of a subsidiary of ours during the past threeyears. Specifically, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc., which was our consolidated subsidiaryuntil August 30, 2018.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_023">
      </span>
      PARTIV
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         <span id="a_024">
         </span>
         ITEM    15.
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         EXHIBITS,    FINANCIAL STATEMENT SCHEDULES
        </b>
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (a)(1)Financial Statements.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thefollowing financial statements of Lineage are filed in this Report:
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ConsolidatedBalance Sheets
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ConsolidatedStatements of Operations
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ConsolidatedStatements of Comprehensive Loss
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ConsolidatedStatements of Changes in Shareholders’ Equity
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ConsolidatedStatements of Cash Flows
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Notesto Consolidated Financial Statements
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (a)(2)Financial Statement Schedules
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Thereare no financial statement schedules provided because the information called for is either not required or is shown either inthe financial statements or the notes thereto.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 126 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        124
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
     (a)(3)Exhibits.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td colspan="7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Incorporation    by Reference
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Exhibit
         <br/>
         Number
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Description
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Exhibit
         <br/>
         Number
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Filing
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         Filing    Date
        </b>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <b>
         File    No.
        </b>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        2.1^
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218015405/ex2-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Agreement and Plan of Merger dated November 7, 2018, among Registrant, Patrick Merger Sub, Inc. and Asterias Biotherapeutics, Inc. (“Asterias”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        2.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    8, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218006559/ex3-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Restated Articles of Incorporation, as amended
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        May    10, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219012036/ex3-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Certificate of Ownership
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    12, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219012036/ex3-2.htm" style="-sec-extract: exhibit" tabindex="18">
         Amended and Restated Bylaws
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        3.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    12, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        4.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Specimen    of Common Share Certificate
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        S-1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        December    18, 1991
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        033-44549
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        4.2*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex4-2.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Description of Capital Stock of the Registrant
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000087634308000014/ex10_23.htm" style="-sec-extract: exhibit" tabindex="18">
         Employment Agreement dated October 10, 2007, between Registrant and Michael D. West (“West Employment Agreement”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.23
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-KSB
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        April    14, 2008
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1(a)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036115043247/ex10_1.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment to West Employment Agreement dated November 24, 2015
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        December    1, 2015
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218013401/ex10-3.htm" style="-sec-extract: exhibit" tabindex="18">
         Transition Agreement dated September 17, 2018, between Registrant and Michael D. West
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        September    18, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036108000966/ex10_1.htm" style="-sec-extract: exhibit" tabindex="18">
         Commercial License and Option Agreement between Registrant and Wisconsin Alumni Research Foundation (“WARF Agreement”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        January    9, 2008
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.3(a)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000087634309000009/ex10_38.htm" style="-sec-extract: exhibit" tabindex="18">
         First Amendment of WARF Agreement dated March 11, 2009
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.38
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    23, 2009
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036115027545/ex4_1.htm" style="-sec-extract: exhibit" tabindex="18">
         Lineage Cell Therapeutics 2012 Equity Incentive Plan, as amended July 2015 (“2012 Plan”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        4.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        S-8
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        July    15, 2015
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        333-205661
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(a)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315217007613/ex4-2.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment to 2012 Plan effective June 2017
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        4.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        S-8
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        July    7, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        333-219204
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(b)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219011912/ex99-3.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment to 2012 Plan effective July 2019
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        99.3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        S-8
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    8, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        333-233132
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(c)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219016930/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment to 2012 Plan effective August 2019
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(d)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036113041885/ex10_7.htm" style="-sec-extract: exhibit" tabindex="18">
         2012 Plan Form of Employee Incentive Stock Option Agreement
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.7
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(e)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036113041885/ex10_8.htm" style="-sec-extract: exhibit" tabindex="18">
         2012 Plan Form of Non-employee Director Stock Option Agreement
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.8
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(f)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219016930/ex10-2.htm" style="-sec-extract: exhibit" tabindex="18">
         2012 Plan Stock Option Grant Agreement
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        000-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4(g)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/ex10-6.htm" style="-sec-extract: exhibit" tabindex="18">
         2012 Plan Form of Restricted Stock Unit
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.6
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    12, 2020
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.5+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036117012402/ex10_38.htm" style="-sec-extract: exhibit" tabindex="18">
         Cell Cure Neurosciences Ltd. Share Option Plan
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.38
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    16, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.5(a)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036117012402/ex10_39.htm" style="-sec-extract: exhibit" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Form of Cell Cure Neurosciences Ltd. Share Option Plan Option Agreement
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.39
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    16, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.6+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/ex10-18.htm" style="-sec-extract: exhibit" tabindex="18">
         Inducement Stock Option Agreement between Registrant and Brian Culley
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.38
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    14, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.7+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036115011259/ex10_64.htm" style="-sec-extract: exhibit" tabindex="18">
         Employment Agreement dated December 29, 2014, between Registrant and Aditya Mohanty (“Mohanty Employment Agreement”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.64
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2015
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.7(a)+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036115043247/ex10_2.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment of Mohanty Employment Agreement dated November 24, 2015
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        December    1, 2015
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.8+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218013401/ex10-2.htm" style="-sec-extract: exhibit" tabindex="18">
         Transition Agreement dated September 17, 2018, between Registrant and Aditya P. Mohanty
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        September    18, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.10†
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036117030912/ex10_2.htm" style="-sec-extract: exhibit" tabindex="18">
         Second Amended and Restated License Agreement dated June 15, 2017, between Cell Cure Neurosciences, Ltd. and Hadasit Medical Research Services and Development Ltd. (“Hadasit License”)
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    9, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 127 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        125
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 9%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.10(a)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 42%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218003416/ex10-38.htm" style="-sec-extract: exhibit" tabindex="18">
         Amendment to Hadasit License dated January 8, 2018
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 7%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.38
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 6%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 16%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    15, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 10%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.11†
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036117030912/ex10_3.htm" style="-sec-extract: exhibit" tabindex="18">
         Debt and Note Purchase Agreement dated June 16, 2017, as amended June 29, 2017, between Registrant and HBL-Hadasit Bio-Holdings Ltd.
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.3
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    9, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.12†
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000114036117030912/ex10_4.htm" style="-sec-extract: exhibit" tabindex="18">
         Share Purchase and Transfer Agreement dated June 16, 2017, by and among Registrant and HBL-Hadasit Bio-Holdings Ltd. and Cell Cure Neurosciences Ltd
        </a>
        .
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    9, 2017
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.13+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315218013401/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Employment Agreement effective September 17, 2018, between Registrant and Brian Culley
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        8-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        September    18, 2018
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.14+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/ex10-38.htm" style="-sec-extract: exhibit" tabindex="18">
         Employment Agreement effective January 7, 2019, between Registrant and Brandi Roberts
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.38
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    14, 2019
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.15*+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex10-15.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Separation and Consulting Agreement dated January 20, 2021 between Registrant and Brandi Roberts
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.16+
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/ex10-25.htm" style="-sec-extract: exhibit" tabindex="18">
         Employment Agreement effective May 20, 2019, between Registrant and Chase Leavitt
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.25
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-K
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    12, 2020
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.17
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/1572552/000114036113031873/ex10_6.htm" style="-sec-extract: exhibit" tabindex="18">
         Royalty Agreement dated October 1, 2013, between Asterias and Geron Corporation
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.6
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    S-1/A
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    13, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        333-187706
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.18
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/1572552/000114036113031873/ex10_7.htm" style="-sec-extract: exhibit" tabindex="18">
         Exclusive Sublicense Agreement between Geron Corporation and Asterias
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.7
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    S-1/A
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    13, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        333-187706
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.19
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/1572552/000114036113041879/ex10_4.htm" style="-sec-extract: exhibit" tabindex="18">
         Exclusive License Agreement dated February 20, 2003, and First Amendment thereto dated September 7, 2004, between The Regents of the University of California and Geron Corporation
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.4
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        000-55046
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.20†
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/1572552/000114036113041879/ex10_5.htm" style="-sec-extract: exhibit" tabindex="18">
         Non-exclusive License Agreement dated October 7, 2013, between WARF and Asterias
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.5
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        November    12, 2013
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        000-55046
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.21†
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/1572552/000114036115001602/ex10_1.htm" style="-sec-extract: exhibit" tabindex="18">
         Clinical Trial and Option Agreement dated September 8, 2014, between Asterias and Cancer Research UK and Cancer Research Technology Limited
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Asterias    10-Q/A
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        January    13, 2015
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-36646
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.22(a)
        <span style="background-color: white">
         ††
        </span>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315220014858/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18">
         Second Amendment to Clinical Trial and Option Agreement dated May 6, 2020 between Cancer Research UK, Cancer Research Technology Limited, Asterias Biotherapeutics, Inc. and Registrant
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.1
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    6, 2020
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.23
        <span style="background-color: white">
         ††
        </span>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315220014858/ex10-2.htm" style="-sec-extract: exhibit" tabindex="18">
         Agreement dated May 6, 2020 between CRT and Registrant
        </a>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10.2
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        10-Q
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        August    6, 2020
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        001-12830
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        21.1*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex21-1.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         List of Subsidiaries
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        23.1*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex23-1.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Consent of OUM &amp; Co. LLP
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        31.1*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex31-1.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Certification of Chief Executive Officer and Interim Chief Financial Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        32.1#
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <a href="https://www.sec.gov/Archives/edgar/data/876343/000149315221005814/ex32-1.htm" tabindex="18">
        <span style="font: 10pt Times New Roman, Times, Serif">
         Certification of Chief Executive Officer and Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
        </span>
       </a>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Interactive    Data File
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.INS*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Instance Document
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.SCH*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Taxonomy Extension Schema
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.CAL*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Taxonomy Extension Calculation Linkbase
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.DEF*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Taxonomy Extension Definition Document
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.LAB*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Taxonomy Extension Label Linkbase
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        101.PRE*
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        XBRL    Taxonomy Extension Presentation Linkbase
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     ^The schedules and exhibits to the merger agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of anyomitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     *Filed herewith
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     #Furnished herewith
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     +Indicates management contract or compensatory plan
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     †
    </span>
    <span style="font: 10pt Times New Roman, Times, Serif">
     Portions of this exhibit have been omitted pursuantto a request for confidential treatment
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif; background-color: white">
     ††Portions of this exhibit have been omitted because the omitted information is: (i) not material; and (ii) would likely cause competitiveharm to the registrant if publicly disclosed.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_025">
      </span>
      ITEM16. FORM 10-K SUMMARY
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    <span style="font: 10pt Times New Roman, Times, Serif">
     None
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 128 -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        126
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <div style="break-before: page; margin-top: 6pt">
    <p style="margin: 0pt">
    </p>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
     <b>
      <span id="a_026">
      </span>
      SIGNATURES
     </b>
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
     Pursuantto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this reporton Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 11
     <sup>
      th
     </sup>
     day of March 2021.
    </span>
   </p>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        LINEAGE    CELL THERAPEUTICS, INC.
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        By:
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Brian M. Culley
        </i>
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Brian    M. Culley
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chief    Executive Officer
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <tbody>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Signature
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 36%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Title
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Date
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Brian M. Culley
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Chief    Executive Officer and Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        BRIAN    M. CULLEY
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (Principal    Executive and Financial Officer)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Alexandra Hernandez
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Senior    Director, Finance
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ALEXANDRA    HERNANDEZ
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        (Principal    Accounting Officer)
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Deborah Andrews
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        DEBORAH    ANDREWS
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Don M. Bailey
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        DON    M. BAILEY
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Neal C. Bradsher
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        NEAL    C. BRADSHER
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Alfred D. Kingsley
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ALFRED    D. KINGSLEY
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Michael H. Mulroy
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        MICHAEL    H. MULROY
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        <i>
         /s/    Angus C. Russell
        </i>
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        Director
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">
       <span style="font: 10pt Times New Roman, Times, Serif">
        March    11, 2021
       </span>
      </td>
     </tr>
     <tr style="font: 10pt Times New Roman, Times, Serif">
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ANGUS    C. RUSSELL
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
      <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </td>
     </tr>
    </tbody>
   </table>
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
   <!-- Field: Page; Sequence: 129; Options: Last -->
   <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
     <tbody>
      <tr style="vertical-align: top; text-align: left">
       <td style="text-align: center; width: 100%">
        <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
        127
        <!-- Field: /Sequence -->
       </td>
      </tr>
     </tbody>
    </table>
   </div>
   <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    <span style="font: 10pt Times New Roman, Times, Serif">
    </span>
   </p>
  </div>
 </div>
</body>